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Elucidating the Genetic Basis of Canine Progressive Retinal              
Atrophies in Several Breeds of Dog 
Rebekkah Hitti-Malin 
Canine progressive retinal atrophies (PRA) are a group of hereditary diseases characterised by 
rod and cone photoreceptor cell death in the retina. This study sought to elucidate novel PRA-
associated variants of distinct forms of PRA in three breeds of dog: the Lhasa Apso (LA), Giant 
Schnauzer (GS) and Shetland Sheepdog (SS).  
A genome-wide association study identified a 1.3 Mb disease-associated region on canine 
chromosome 33 in LA dogs. Whole genome sequencing (WGS) analysis of a PRA-affected LA 
revealed a long interspersed nuclear element-1 (LINE-1) insertion in the predicted promoter 
region of the retinal candidate gene, IMPG2. Validation of the LINE-1 insertion determined it 
segregated with disease and was likely to be private to LA dogs.  
Comprehensive WGS analyses alone were utilised to determine PRA-associated mutations in a 
family of GS dogs, and in a single SS. For the GS breed, WGS was performed on two affected siblings 
and both non-affected parents. Successive filtering, for autosomal recessive deleterious variants, 
against 568 canine genomes identified a single nucleotide variant (SNV) in the gene encoding 
NECAP endocytosis associated 1 (NECAP1): c.544G>A (p.G182R). Screening 5,130 canids revealed 
only the three PRA-affected GS were homozygous for the SNV, yet heterozygotes were identified 
in the GS breed and in other breeds of German ancestry. NECAP1 has not previously been 
associated with retinal degeneration; however, these findings, in parallel with known gene 
function, indicate NECAP1 should be considered as a strong candidate for retinal degeneration 
research in other species. Following WGS analysis of the single SS against 176 controls of other 
breeds, a c.1222G>C (p.A408P) SNV in the Bardet-Biedl syndrome 2 gene (BBS2) was identified. 
In addition to PRA, homozygotes exhibited features including an upturned nose, unusual coat and 
dental defects, proposing a novel syndromic form of canine PRA. 
This research has elucidated three novel PRA-associated mutations for which diagnostic DNA 
tests have been developed, offering breeders the opportunity to avoid producing PRA-affected 
dogs. Since PRA shares clinical features to human retinitis pigmentosa (RP) and other 
phenotypically similar retinal diseases, this study may offer novel insights for consideration in 
human as well as canine retinal degeneration research and gene therapies.  
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 Chapter 1 Introduction 
1 
 
Chapter 1 Introduction 
1.1 The origin of domestic dog breeds 
Throughout history, humans have encouraged a mutually beneficial relationship with the dog 
(Canis lupus familiaris), leading to its domestication. Phenotypic diversity of domestic dogs 
suggests a varied genetic heritage, which may have been influenced by interbreeding with wild 
wolf populations (Vila et al, 1997). Ancestry of the modern dog is predominantly European and 
insights into the history of dog domestication in Europe suggest the modern dog population arose 
from a single domestication event occurring between 20,000 - 40,000 years ago from a population 
of grey wolves (Botigué et al, 2017; Parker et al, 2004). Two major bottleneck events throughout 
history are considered to have influenced genetic diversity in the dog genome. The first population 
bottleneck shaped the ancient domestication of the dog from the grey wolf (Savolainen et al, 
2002). The formation of dog breeds over 200 years ago resulted in a second bottleneck when dogs 
were selectively bred for certain purposes, such as herding and hunting, and for desirable 
characteristics and traits including size, shape, coat colour, temperament, and obedience. 
Although individual breeds are genetically distinct populations, they appear to have diverged 
simultaneously (Parker et al, 2004). Today, 352 dog breeds are recognised worldwide (Fédération 
Cynologique Internationale, 2020) with over 200 of these different dog breeds recognised by The 
Kennel Club UK, the largest registration body for dogs in the UK. The population of purebred dogs 
in the UK is ever growing, with over 250,600 dogs registered by The Kennel Club in 2018, an 
increase of 7,300 puppies from 2017 (The Kennel Club UK, 2019a). This number accounts for a 
small portion of the dog population in the UK, with a total of 8.9 million dogs estimated to be 
owned across the UK in 2018 (PFMA, 2019).  
1.2 The canine genome 
Linkage maps of the canine genome (Lingaas et al, 1997; Mellersh et al, 1997; Neff et al, 1999) 
provided a foundation for the development of a complete chromosome map for the dog in 1999, 
comprising 38 autosomes and the sex chromosomes (Breen et al, 1999; Yang et al, 1999). The first 
high-quality draft (7.5X) canine genome sequence was published in 2005 using a Boxer dog as the 
reference genome, and is approximately 2.4 gigabases (Gb) in size containing approximately 
19,000 genes, with nearly all genes homologous to known human genes (Lindblad-Toh et al, 
2005). With this, a dense map of single nucleotide polymorphisms (SNPs) across breeds were also 
reported. The paleogenomic study of prehistoric dogs provides evidence that the recent canine 
reference genome, CanFam3.1 (Sept.2011.Broad CanFam3.1/canfam3), shares over 60% of its 
identity to 7,000 year old dog specimens, dated back to Early Neolithic times (Botigué et al, 2017). 
Historical dog domestication and breed creation shaped the haplotype structure of canine breeds, 
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which is reflected in the canine genome where interbreed variation is present. A genetic study of 
85 dog breeds demonstrated that humans and dogs share similar levels of overall nucleotide 
diversity: 8 × 10-4 nucleotide substitutions per base/pair. However, the genetic variation between 
dog breeds (27.5%) is much greater than the variation between human populations (5.4%); as is 
the degree of genetic homogeneity (94.6% in dog breed populations versus 72.5% in human 
populations) (Parker et al, 2004). As a result, high levels of linkage disequilibrium (LD; non-
random association of alleles at different loci) are present within dog breeds, extending over 
several megabases (Mb), in comparison to LD across breeds, which extend over tens of kilobases 
(Kb) (Lindblad-Toh et al, 2005). The unique pattern of LD in dogs provides the opportunity to 
study the molecular basis of inherited traits, facilitating the rapid identification of loci associated 
with complex and Mendelian traits and diseases, relevant to dogs and other species. 
1.3 Genetic implications of intensive breeding 
The dog plays a key role in human lives; however, its domestication and integration into society 
has driven selection for breed-related characteristics. Intensive selection for desired physical or 
behavioural traits and the introduction of closed stud books led to the generation of isolated 
breeding populations, each with a limited number of founders with reduced phenotypic and 
genotypic diversity. The same selective pressures have led to long stretches of DNA in LD 
(Goldstein et al, 2006; Sutter et al, 2004), where inter-breed LD is shorter than LD within breeds. 
As a consequence, there is little genetic variability within breeds, with an increase in 
homozygosity, and relatively large genetic differences between breeds. High levels of 
homozygosity throughout the genome increases the likelihood that a variant that arose 
spontaneously in earlier generations occurs within a region of homozygosity in the current 
population. Breeding closely related dogs that share similar chromosomal DNA sequences 
harbouring trait- and disease-associated variants leads to an increased incidence of inherited 
diseases. Thus, by selecting for a given trait, undesirable disease-causing mutations can also be 
unintentionally inherited. 
Animals with particularly favourable characteristics are often bred repeatedly, where popular 
males in the dog population are often used extensively, commonly known as the popular sire 
effect. This is a problematic breeding practice as extensively breeding with one sire limits the gene 
pool, thereby reducing genetic diversity resulting in an over representation of allelic pools in 
subsequent generations (Parker et al, 2004; Quignon et al, 2007). To maintain favourable traits in 
future offspring, breeders may choose not only to continue to breed with one popular sire but also 
with its close relatives. This, combined with historical genetic bottlenecks and breeding in closed 
populations, increases the incidence of inherited disease in offspring (Mellersh, 2008). Breeding 
of closely related individuals (inbreeding) can cause inbreeding depression, which can incur a 
deleterious effect on a given trait and subsequently increases disease occurrence. In dogs, this is 
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demonstrated in a study in Standard Poodles, where an increased incidence of two autoimmune 
disorders in the breed probably arose due to an artificial genetic bottleneck and inbreeding 
(Pedersen et al, 2015). This suggests that generally a reduction in genetic diversity within a breed 
has a negative impact on canine health, increasing the incidence of deleterious complex disorders 
and recessive traits, including heritable eye conditions. 
1.4 The canine eye 
The eye is a complex organ with specialised structures and functions to provide optimal vision. 
Ocular development is a multifaceted process with various crucial stages, pathways and signalling 
interactions involved. Across mammals, anatomy and function of the eye varies depending on 
species evolution and adaptation in different environments. The anatomy of the canine eye 
(Figure 1.1) and human eye have many similarities, sharing most of their anatomical features. One 
notable difference is the existence of a layer of reflective tissue called the tapetum lucidum in the 
canine eye. This layer serves to reflect light after it has passed through the retina, re-stimulating 
photoreceptor cells of the retina and causing “eyeshine” at night when illuminated, to aid night 
vision. The tapetum lucidum occupies approximately half of the canine fundus and shows 
considerable variation across individuals in terms of its colouration, shape and contour, with both 
age and breed variations (Jacobs et al, 1993). The fundus is the posterior inside of the eye housing 
the retinal neural tissue, upon which ophthalmoscopic examination can reveal retinal 
abnormalities associated with disease.  
 
Figure 1.1: Schematic diagram demonstrating the anatomy of the canine eye. (Adapted from 
CleverPet). 
Most of the canine retina is dominated by rod photoreceptor cells with an uneven distribution of 
cone photoreceptors. The fovea, an area with dense cone photoreceptors, is present in the retinas 
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of many primates and enables high resolution vision and acuity. Historically it was believed that 
canids lack this region, where the fovea is replaced by the ‘area centralis’ within a visual streak: a 
horizontal distribution of high retinal ganglion cell density in the retina (Kemp & Jacobson, 1992). 
This area centralis is located supero-temporal to the optic nerve head and is characterised by a 
high concentration of retinal ganglion cells (Peichl, 1992a). It is believed the visual streak has 
evolved from the wolf retina and provides high visual acuity when looking to the horizon (Peichl, 
1992b). A more recent study has shown the area centralis in the canine retina anatomically 
resembles the primate fovea composed exclusively of cones (Beltran et al, 2014), however, it is 
unclear if this is seen across all dogs or if this is a recent adaptation in the formation of domestic 
breeds. Despite limited studies to define the extent of the area centralis in domestic dogs, there is 
evidence that the visual streak and area centralis vary independently amongst breeds, with 
variation in retinal ganglion cell density and distribution across dog breeds. A study by McGreevy 
et al. (2004) found a negative correlation between the ratio of peak ganglion cell density in the 
area centralis to visual streak and skull length in dogs. This suggests that selective breeding for 
certain skull shapes in dog breeds has resulted in variability in the area centralis in the canine 
retina.  
1.5 The retina 
Forming the inner lining of the posterior globe, the retina is a specialised tissue of the central 
nervous system. In order to transmit signals to the brain via the optic nerve, the retina converts 
light stimuli received through the lens to electrical potentials. This enables information to be 
interpreted as vision. The retina is a multi-layered structure consisting of neural layers, and a 
layer of photoreceptor cells supported by a non-neural layer of pigmented epithelial cells, termed 
the retinal pigment epithelium (RPE) (Figure 1.2).  
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Figure 1.2: Diagram of the layers of the retina (adapted from Purves, 2001). 
Retinal pigment epithelium 
The RPE is a melanin-rich structure situated between the neuroretina and the underlying vascular 
layer known as the choroid. The apical membrane of the RPE faces the outer segments of 
specialised neuron cells called photoreceptors, and its basolateral membrane facing Bruch’s 
membrane (reviewed in Simó et al, 2010), an extracellular matrix located at the innermost layer 
of the choroid. The RPE has many functions essential to maintain retinal integrity. This includes 
the transportation of nutrients from the blood to photoreceptors while removing ions, metabolic 
end products and water from the retina to the blood. The RPE also mediates the visual cycle, 
absorbing excess light entering the eye to protect against photooxidation as well as carrying out 
essential reactions in phototransduction including the re-isomerisation of all-trans-retinal into 
11-cis-retinal (reviewed in Bibliowicz et al, 2011). The RPE also plays a crucial role in supporting 
and nourishing photoreceptor cells, including the phagocytosis of shed photoreceptor outer 
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segments, and stabilizing ion composition within the subretinal space to contribute to maintaining 
photoreceptor excitability (reviewed in Simó et al, 2010). Surrounding the RPE and the 
photoreceptor outer segments is the interphotoreceptor matrix (IPM), a unique extracellular 
complex integral to proper function of retinal photoreceptors (Kuehn et al, 2001; Lazarus & 
Hageman, 1992). The IPM aids in recycling photoreceptor outer segments; facilitates retina-RPE 
adhesion; establishes a suitable milieu for photoreceptor survival; and facilitates the exchange of 
molecular products between the RPE and photoreceptor cells (Acharya et al, 2000; Kuehn & 
Hageman, 1999; Lazarus & Hageman, 1992). 
Photoreceptors 
Two types of photoreceptors are present in the retina, differing in morphology and function: rods 
and cones. Rod and cone photoreceptors are specialised elongated cells that are designed to 
capture and convert light into an electrical signal using specialised ciliary organelles to detect 
light. These organelles, termed photoreceptor outer segments, are derived from microtubule-
based organelles on the cell surface called the primary non-motile cilium: tiny hair-like organelles 
attached to the cell surface involved in signal transduction from the environment or from other 
cells (reviewed in Purves, 2001). 
Rod and cone photoreceptors provide different visual functions and are named after their shapes 
(Figure 1.3). Rod outer segments are cylindrically shaped, function in dim light and lack colour 
perception. Cone outer segments are conical and work in bright light, enabling high-acuity and 
colour vision. Each type also differs in the type of photopigment they contain, arrangement of 
membranous discs, distribution across the retina and pattern of synaptic connections (reviewed 
in Purves, 2001). The photoreceptor layer is dense with rod and cone outer segments closely 
arranged in stacks of flattened membranous discs, in which visual pigments are embedded. 
Rhodopsin, the light-sensitive photopigment present in rod disc membranes, is comprised of the 
light-absorbing molecule 11-cis-retinal bound to a lipoprotein component called ‘opsin’. In 
humans, there are three subclasses of cone photoreceptors for trichromatic colour vision, long- 
(L), medium- (M) or short-wavelength-sensitive (S) cones, each with one of three photopigments 
(red, green or blue, respectively) present in disc membranes. Dogs have dichromatic vision to 
perceive colour with the presence of two subclasses of cone photoreceptors in the canine retina, 
each with its own specific red/green or blue pigment to form visual pigments, collectively called 
‘photopsins’. These are known as long- and medium-wavelength-absorbing cones (L/M cones) 
with a maximum sensitivity of 555 nanometre (nm) and short-wavelength-absorbing cones (S 
cones) of 429 nm sensitivity (Jacobs et al, 1993; Neitz et al, 1989).  
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Figure 1.3: Schematic diagram of a rod and cone photoreceptor. The outer segment includes 
hundreds of tightly packed membranous discs containing visual pigment specific to each 
photoreceptor cell. The inner segment contains the cell’s metabolic machinery including 
subcellular organelles such as mitochondria. The ciliary compartment is made up of three 
subunits: the basal body, connecting cilium and the outer segment. The connecting cilium 
transports proteins specific to the visual system to the outer segment (adapted from Veleri et al, 
2015). 
Rod and cone photoreceptors also differ in phototransduction mechanisms in the 
phototransduction cascade: a series of biochemical pathways in response to light. For example, 
rods respond to a single light-energised photon whereas over 100 photons are required for cones 
to produce a comparable response. This is largely due to differences in the current a single photon 
produces in each receptor type (reviewed in Purves, 2001). Furthermore, the adaptation 
mechanisms of cones are more effective than rods, where even though both adapt to operate 
across a range of illumination levels, cones recover four times faster than rods when exposed to 
bright conditions that produce the maximum change in photoreceptor current (reviewed in 
Purves, 2001).  
Due to its ciliary origin, the photoreceptor outer segment shares basic structural elements and 
common mechanisms for development and maintenance with primary cilia, however there are 
many features that are unique to the outer segment. The outer segment is more elongated than 
primary cilia with a larger ciliary plasma membrane for increased light sensitivity. Furthermore, 
unlike primary cilia, the outer segment undergoes continual renewal, with new discs formed at 
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the base of the outer segment and discs at the distal tip undergo shedding and phagocytosis by 
RPE cells (reviewed in Goldberg et al, 2016).  
The basal body, the connecting cilium and the outer segment are central components located 
within photoreceptors and are collectively termed the ‘ciliary compartment’ (Figure 1.3). The 
localisation of proteins involved in ciliogenesis and trafficking of specific proteins to the outer 
segment occurs within the ciliary compartment (Seo & Datta, 2017). At the base of the ciliary 
compartment lies the basal body, playing a crucial role in microtubule organisation. Primary cilia 
are typically non-motile, with a ciliary axoneme comprising of nine doublet microtubules arising 
from the triplet microtubules of the basal body within the cell. The ciliary microtubules direct the 
trafficking of ciliary cargo from the ciliary base to the tip, including vesicles and organelles 
(reviewed in Mannu, 2014). The targeting and assembly of ciliary cargo is controlled by 
specialised multiprotein complexes within the cilium, including intraflagellar transport (IFT) 
proteins and the BBSome: a stable complex consisting of eight BBS proteins (BBS1, 2, 4, 5, 7, 8, 9 
and BBS18/BBIP10). The connecting cilium acts as a ciliary transition zone and connects the outer 
segment to the inner segment of photoreceptors. The inner segment contains subcellular 
organelles including mitochondria, Golgi apparatus, endoplasmic reticulum and lysosomes, which 
play a role in the metabolic and biosynthetic mechanisms of the cell. Distal to the inner segment 
is the nuclear region housing the nucleus, followed by synaptic terminals branching out to interact 
with horizontal cells, bipolar cells, amacrine cells and ganglion cells across additional retinal 
layers. The arrangement of these cell types and synapses contribute to the different mechanisms 
of rod and cones in light conditions to transmit rod and cone information to ganglion cells 
following phototransduction (reviewed in Purves, 2001).  
The phototransduction cascade 
Retinal photoreceptors contain the proteins required for the phototransduction cascade: a 
process where photoreceptors detect photons and convert light stimuli into cellular signals and 
transmit as a nerve impulse. When light enters the eye, a cascade of chemical conversions and 
photochemical signalling events occur. Unlike in most sensory systems where an action potential 
and transmitter release are stimulated, much of the processing within the retina is mediated by 
graded potentials to initiate a change in the rate of transmitter release onto postsynaptic neurons 
(reviewed in Purves, 2001).  
In darkness, the photoreceptors are active: an abundance of cyclic guanosine monophosphate 
(cGMP) keeps cGMP-gated channels open, allowing the flow of sodium (Na+) and calcium (Ca2+) 
cations into the outer segment, resulting in depolarised photoreceptors that continuously release 
an excitatory neurotransmitter ‘glutamate’ from their synapses (reviewed in Purves, 2001). A 
series of biochemical changes that ultimately lead to a decrease in cGMP levels is initiated when a 
light-energised photon is absorbed by the photopigment. Rod phototransduction is the most well 
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characterised of the sensory transduction pathways. When the photopigment absorbs a light-
energised photon, it undergoes a conformational change: 11-cis-retinal isomerises to all-trans-
retinal and rhodopsin is activated, which in turn catalyses the activation of transducin, a trimeric 
G-protein, enabling the exchange of guanosine diphosphate (GDP) for guanosine triphosphate 
(GTP). This exchange causes the entire alpha (α) subunit of the trimeric transducin molecule to 
dissociate from the rest of the molecule, enabling it to move and interact with a cGMP 
phosphodiesterase enzyme (PDE) to hydrolyse cGMP in the disc membrane, producing GMP. This 
in turn reduces cGMP levels throughout the outer segment and results in fewer cGMP molecules 
available for binding to the cGMP-gated channels in the outer segment membrane, leading to 
closure of these channels and a reduction in the influx of cations (reviewed in Purves, 2001). Light 
exposure therefore leads to a decrease in cGMP levels that initiates closure of the cGMP-gated 
channels, leaving the cell in a hyperpolarised state (Figure 1.4) (reviewed in Purves, 2001). The 
Na+/ Ca2+ influx stops, leading to cell hyperpolarisation and termination of glutamate release from 
the synaptic terminals (reviewed in Gelatt, 2013).  
 
Figure 1.4: An example of light-induced changes in a rod photoreceptor initiated by cyclic GMP-
gated channels in the outer segment membrane. cGMP levels in outer segments are increased in 
the dark and bind to the Na+ membrane channels. This keeps channels open to allow Na+ to enter, 
causing depolarisation of the cell. Light exposure decreases cGMP causing closure of the channels 
(reviewed in Purves, 2001). 
Once a peak light-induced response is reached, the inward current rapidly recovers to the dark 
state. Inactivation of the cascade involves phosphorylation of rhodopsin by the enzyme ‘rhodopsin 
kinase’. This phosphorylation increases the affinity of the capping protein ‘arrestin’ to rhodopsin 
thus blocking further binding and activation of transducin, thus the cascade is unable to continue 
(reviewed in Mannu, 2014). When GTP is hydrolysed to GDP, PDE and transducin are inactivated 
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(reviewed in Burns & Arshavsky, 2005). The concentration of Ca2+ in the outer segment facilitates 
light-induced modulation of photoreceptor sensitivity. The cGMP-gated channels in the outer 
segment are permeable to both Na+ and Ca2+, therefore light-induced closure of these channels 
results in a reduction of Ca2+ concentration in the outer segment. This decrease triggers several 
changes in the phototransduction cascade, all of which tend to reduce the sensitivity of the 
photoreceptor to light. An example of this are regulatory effects of Ca2+ on the cascade, where the 
reduction in Ca2+ concentration in the outer segment results in the activation of retinal guanylate 
cyclase, which in turn catalyses the regeneration of cGMP. Similarly, the reduction in Ca2+ 
concentration increases the affinity of the cGMP-gated channels for cGMP, reducing the impact of 
the light-induced reduction of cGMP levels (Purves, 2001). An eventual increase in cGMP 
concentration causes reopening of the channel and depolarisation of the photoreceptor (reviewed 
in Gelatt, 2013). Figure 1.5 summarises this phototransduction cascade upon a light-energised 
response. This sophisticated process highlights the importance of genes encoding photoreceptor 
proteins and genes involved in phototransduction to convert a light stimulus into vision. 
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Figure 1.5: Schematic summary of the phototransduction cascade in photoreceptors. 
Abbreviations include guanosine diphosphate (GDP), guanosine triphosphate (GTP), cGMP (cyclic 
guanosine monophosphate), PDE (phosphodiesterase enzyme), sodium ions (Na+), calcium ions 
(Ca2+), alpha (α) subunit. Square brackets refer to the concentration of a component. 
The visual cycle 
The phototransduction cascade can only occur if the system can reset itself to allow it to be 
activated again. Following absorption of a photon through phototransduction, the visual cycle is 
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required to regenerate 11-cis-retinal to restore photosensitivity to rhodopsin. Photoactivated 
rhodopsin dissociates to form opsin and all-trans-retinal (reviewed in Lee et al, 2010). The all-
trans-retinal generated in response to a light stimulus is transported to the outer segment in the 
photoreceptor by the retina-specific ATP-binding cassette, subfamily A, member 4 protein 
(ABCA4) (reviewed in Travis et al, 2007). An enzymatic reduction occurs of all-trans-retinal to all-
trans-retinol (vitamin A) by retinol dehydrogenases. Newly formed all-trans-retinol is rapidly 
released by photoreceptor cells to the IPM, where the interphotoreceptor retinoid-binding 
protein (IRBP) secreted by photoreceptors in this extracellular space facilitates binding to the RPE 
(reviewed in Travis et al, 2007). Here, the major retinyl ester synthase in RPE cells, lecithin-retinol 
acyl transferase (LRAT), esterifies all-trans-retinol to a fatty acid and the retinyl ester is 
isomerised and de-esterified by a single protein in the RPE, known as RPE-specific 65-kDa protein 
(RPE65) (reviewed in Travis et al, 2007; Lee et al, 2010). This reaction generates 11-cis retinol, 
which is oxidised to form 11-cis-retinal, which is transported back to the photoreceptor outer 
segment to regenerate rhodopsin (reviewed in Lee et al, 2010). The regeneration of rhodopsin is 
crucial for its role in light activation in the phototransduction pathway, resulting in night vision 
(reviewed in Kijas et al, 2002) and in the renewal of photoreceptor outer segments (Young, 1967). 
1.6 Pathways of photoreceptor degeneration 
Photoreceptor cell development, physiology, maintenance, and the genes implicated in specific 
pathways contributing to these factors can provide further understanding of retinal 
degenerations. Transcriptome studies have revealed that over 10,000 genes (> 35% of the canine 
genome), are expressed in canine retinal tissue (Reddy et al, 2015). These genes are involved in a 
myriad of biological pathways and processes, all of which are necessary to ensure normal 
development and optimal performance of the retina. Thus, mutations in genes involved in vision 
related processes may cause a loss-of-function of these genes and therefore possibly a loss-of-
function in the retina, resulting in retinal dysfunction. However, the complexity of the vertebrate 
retinal structure and function mean that many mechanisms by which mutations lead to 
photoreceptor degeneration and blindness are not completely understood. Broadly, four main 
categories can be defined as mechanisms of degeneration (Pierce, 2001): 
a) Disruption of the photoreceptor outer segment 
b) Metabolic overload 
c) Defects in the RPE  
d) Continuous activation of phototransduction 
Further exploration to increase understanding of these mechanisms may help targeted gene 
therapies for degenerative retinal diseases. 
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Disruption of the photoreceptor outer segment  
As previously described, photoreceptor outer segments are formed from the primary cilia, 
therefore mutations in genes encoding ciliary compartment proteins disrupt photoreceptor 
ciliary function in photoreceptor cells. Examples of this include mutations in the retinitis 
pigmentosa GTPase regulator-interacting protein 1 gene (RPGRIP1), associated with human Leber 
congenital amaurosis (LCA) and retinitis pigmentosa (RP) as well as canine cone-rod dystrophy-
1 (cord1) (Mellersh et al, 2006). RPGRIP1 localises in the connecting cilium of photoreceptors, 
and is required for outer segment development, cilia protein trafficking and disc morphogenesis 
(Boylan & Wright, 2000; Zhao et al, 2003). This is exemplified by histological examination of the 
retinas of Miniature Long-Haired Dachshund dogs with cord1, of which findings included thinning 
of the outer nuclear layer, shortening of the photoreceptor outer segments and defective rod outer 
segment disc development from as early as 10.5 weeks of age (Curtis & Barnett, 1993). Another 
example of abnormal retinal development led by the disruption of photoreceptor outer segment 
morphogenesis is caused by mutations in the rhodopsin gene (RHO) in humans (Dryja et al, 1990; 
Iakhine, 2004; McWilliam et al, 1989) and other species. An accumulation of extracellular vesicles 
around photoreceptors, probably a product of aborted outer segment formation, and attenuation 
of outer segments were observed in RHO-null mice (Li et al, 1996), with some mice showing no 
outer segment formation at all (Lem et al, 1999). Similar findings have been demonstrated in RHO-
null pigs (Ross et al, 2012) and dogs. Electroretinogram (ERG) evaluations of English Mastiff dogs 
harbouring a mutation in RHO exhibited clinical signs similar to that of human autosomal 
dominant RP, with attenuation of rod photoreceptor outer segments (Kijas et al, 2002). 
Furthermore, knockout of the gene encoding tubby-like protein 1 (TULP1) in mice exhibited 
progressive retinal degeneration with a unique feature of accumulation of extracellular vesicles 
in the IPM of the RPE; abundant toward the proximal inner segments and outer segments of 
photoreceptors (Hagstrom et al, 1999). A single defect in complex pathways involved in 
photoreceptor outer segment morphogenesis could affect protein-trafficking regulation resulting 
in these retinal phenotypes described. 
Metabolic overload 
Metabolic overload describes an accumulation of ions within a cell leading to the maintenance of 
a constant electrochemical gradient, which becomes toxic to the cell (Pierce, 2001). In 
photoreceptor cells, this is probably due to a continuous high demand of the cGMP-gated channels 
where a constant influx of Na+ and Ca2+ is directed across the outer segment membrane. As 
observed in canine and murine models, mutations in the gene encoding rod cGMP 
phosphodiesterase beta subunit (PDE6B) lead to excessive cGMP levels, resulting in a loss of 
photoreceptor cells. In Irish Setter dogs with a canine retinal disease, rod-cone dysplasia type 1 
(RCD1), photoreceptor loss is detected as early as postnatal day 10 (Clements et al, 1993; Farber 
& Lolley, 1974; Pittler & Baehr, 1991). High cGMP levels promote the cGMP-gated channels to 
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remain open, allowing an influx of Na+ and Ca2+ through the phototransduction cascade and cause 
metabolic overload in the outer segment (Pierce, 2001; Travis, 1998). Important mutations 
associated with high cGMP levels leading to photoreceptor cell death include genes encoding 
cyclic nucleotide gated (CNG) channels in the outer segment membrane, demonstrating a link 
between Ca2+ influx and rod photoreceptor apoptosis in mutant mice (Paquet-Durand et al, 2011). 
In addition, a mutation in the gene encoding human membrane guanylyl cyclase 1 (GUCY2D) in 
transgenic mice showed increased cGMP binding to CNG channels and therefore depolarisation of 
the outer segment due to an influx of Na+ and Ca2+. Eventual accumulation of Ca2+ concentration 
in mice rod outer segments triggers photoreceptor cell death (Sato et al, 2018).  
Defects in the RPE 
Photoreceptor outer segments shed on a regular basis and undergo phagocytosis by adjacent RPE 
cells, recycling metabolites to photoreceptors. Defects in genes encoding proteins that are 
implicated in the phagocytosis of shed disc tips by RPE cells result in retinal dysfunction in 
rodents, humans and dogs. One example includes the Mer tyrosine kinase proto-oncogene, 
MERTK, whereby mutations in MERTK cause RP through defective outer segment phagocytosis by 
the RPE (D'Cruz et al, 2000; Gal et al, 2000; Everson et al, 2017). This was first demonstrated in a 
rat model of autosomal recessive RP where histological examination of the rat retina displayed 
RPE dysfunction and an abnormal accumulation of photoreceptor outer segment debris between 
the photoreceptors and RPE, resulting in photoreceptor cell death (Dowling & Sidman, 1962; 
Vollrath et al, 2001). Another example of genetic mutations that implicate pathways within the 
RPE include RPE65, where RPE65 is abundant in the RPE and converts all-trans retinyl ester to 
11-cis retinol (Moiseyev et al, 2005), which is essential for normal retinal function. Mutations in 
RPE65 are associated with inherited retinal degenerations in humans (Bowne et al, 2011; Gu et al, 
1997; Marlhens et al, 1997) and dogs (Aguirre et al, 1998; Bechynova et al, 2008; Veske et al, 
1999), resulting in defective RPE cells and photoreceptor apoptosis.  
Continuous activation of phototransduction 
As previously discussed, the phototransduction cascade ensures proper cycling of ions to 
maintain electrochemical homeostasis in the retina. Disruption of proteins triggering these 
pathways and channels can alter the cascade of biochemical reactions, leading to photoreceptor 
apoptosis. Continuous activation of the phototransduction cascade alters the energy utilisation of 
the retina, triggers or inhibits enzyme activity, limits cation entry into photoreceptor outer 
segments and alters the concentration of signalling molecules within the cascade, in particular 
Ca2+ (Fain, 2006). Mutations in genes encoding components of the machinery in the 
phototransduction cascade result in continuous activation of this process and lead to retinal 
degeneration in humans and other species (Chen et al, 1999; Sullivan et al, 2017). Once light 
activates rhodopsin in the phototransduction cascade it must be turned off by two significant 
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proteins: rhodopsin kinase and arrestin. Knockout mouse models of rhodopsin kinase (Chen et al, 
1999) and arrestin (Xu et al, 1997) demonstrates how rods lacking these proteins show altered 
rod light responses and light-induced apoptosis. Both models demonstrate slow retinal 
degeneration that was accelerated by chronic activation of phototransduction when mice are 
exposed to a constant light stimulus. Thus, the arrestin gene, also known as S-antigen visual 
arrestin-1 (SAG), functions in inactivating rhodopsin during the phototransduction cascade. 
Although a mutation in this gene is associated with a late-onset hereditary retinal degeneration in 
Basenji dogs, further study into canine SAG-mutations is required to determine if similar 
mechanisms are affected, as demonstrated in knockout mouse models. 
1.7 Human inherited retinal degenerations (IRDs) 
Human inherited retinal degenerations (IRDs) encompass a diverse group of progressive 
disorders characterised by loss of rod and/or cone photoreceptors eventually leading to visual 
impairment and blindness. They are clinically and genetically heterogeneous, where mutations in 
genes critical to retinal function are responsible for disrupting pathways and mechanisms leading 
to photoreceptor cell death. IRDs can be clinically categorised based on the rate of progression 
and the types of retinal cells that are primarily involved in disease pathogenesis. The wide 
heterogeneity of human IRDs is illustrated by the large number of genetic mutations and number 
of genes associated with IRDs. In addition, there is extensive variation in clinical expression even 
among individuals sharing identical mutations. Despite the identification of 271 genes associated 
with IRDs (RetNet, 2020), many patients still lack a molecular diagnosis indicating that further 
elucidation of genes involved in these diseases is required.  
Retinitis pigmentosa (RP) 
The first form of retinal degeneration in humans was described in 1857 as night blindness, termed 
as retinitis pigmentosa (RP) (Donders, 1857). Today, RP is the most common form of IRD, affecting 
1 in 4,000 people worldwide before middle age (Verbakel et al, 2018). The disease first manifests 
as reduced vision in dim light (nyctalopia) caused by primary depletion in rod photoreceptors. As 
the disease progresses, cone photoreceptors degenerate leading to a gradual reduction in vision 
and total blindness. Typical fundus abnormalities include attenuation of retinal blood vessels, a 
waxy pallor of the optic nerve and mottling and granularity of the RPE. Intraretinal bone-spicule 
pigmentation presents due to pigment migration to and accumulation in the retina, due to 
breakdown of RPE cells. A definitive diagnosis requires an ERG to reveal loss of photoreceptor 
function and to determine the severity in early stages of the disease. RP patients exhibit narrowing 
of the visual field in the dark, therefore typically have reduced vision in dim light or in the dark 
and have a progressive loss of their peripheral vision. Central visual function diminishes 
throughout disease progression. Colour vision generally remains good until visual acuity worsens; 
however, this can deplete if cone dysfunction occurs early in the disease (reviewed in Weleber & 
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Gregory-Evans, 2006). To date, 63 genes have been associated with autosomal recessive RP; 30 
genes associated with autosomal dominant RP; and three genes and loci associated with X-linked 
RP (Appendix 1) (RetNet, 2020). In general, RP-associated genes are known or expected to be 
expressed in retinal photoreceptor cells or the RPE and impact the proper function of the visual 
cycle. 
Leber congenital amaurosis (LCA) 
The most severe human IRD is LCA, primarily affecting both rod and cone photoreceptors 
accompanied by changes in the RPE within the retina. LCA is described as an early-infantile onset 
rod-cone dystrophy, presenting as congenital or within the first few months of life. Early-onset 
severe retinal dystrophy (EOSRD) is considered a milder form of LCA, with clinical signs becoming 
apparent after infancy and usually before the age of five years (Kumaran et al, 2017). Clinical signs 
of LCA include nystagmus (repetitive, uncontrolled eye movement), poor pupillary light response 
and an abnormal fundus appearance, similar to RP. An LCA diagnosis is apparent from 
undetectable ERG responses due to a lack of photoreceptor response whereas EOSRD show 
photoreceptors are less affected with minor ERG signals (Kumaran et al, 2017). There is overlap 
between genes involved in LCA and EOSRD, however, mutations in specific genes are more often 
associated with one disease or the other. To date, three genes have been identified to cause 
autosomal dominant LCA and 23 genes associated with autosomal recessive LCA (Appendix 1) 
(RetNet, 2020). 
Ciliopathies 
Ciliopathies encompass a group of diseases caused by mutations in genes involved in ciliary 
function, leading to ciliary defects. Cilia are a nearly ubiquitous component of all vertebrate cells 
therefore ciliary defects can affect many organ systems. Many ciliary proteins are involved in 
crucial roles in animal physiology, signalling and development, thus cilia-related disorders 
manifest as a wide spectrum of features including retinal degeneration, kidney abnormalities, 
obesity and skeletal dysplasia (Fliegauf et al, 2007; Waters & Beales, 2011). The targeting and 
assembly of ciliary cargo is controlled by specialised multiprotein complexes within the cilium, 
including IFT proteins and, briefly above-mentioned, the BBSome. The BBSome is important in 
regulating protein trafficking in the primary cilium and plays a crucial role in photoreceptor outer 
segment morphogenesis and maintenance (Hsu et al, 2017). Mutations in genes encoding IFT or 
BBS proteins, as well as other cilium associated genes, result in ciliopathies. Specifically, 
mutations in BBSome proteins cause human Bardet-Biedl syndrome (BBS), a ciliopathy where 
patients present with retinal degeneration and additional features including diabetes, obesity, 
polydactyly, renal dysfunction and dental crowding. Currently, BBS-associated variants have been 
identified in 25 genes (Appendix 1) (RetNet, 2020). Other syndromic forms of RP associated with 
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ciliopathies include Usher syndrome, Cohen syndrome, Joubert syndrome, Senior Loken 
syndrome and Sensenbrenner syndrome (Verbakel et al, 2018).  
There are many proteins that localise to the photoreceptor ciliary compartment, e.g. FAM161A, 
NPHP5 and RPGRIP1, and mutations in genes encoding these proteins have been implicated in the 
canine IRD: progressive retinal atrophy (PRA) (Downs & Mellersh, 2014; Goldstein et al, 2013b; 
Mellersh et al, 2006). PRA will be described further below. BBS genes have also been associated 
with canine PRA (Chew et al, 2017; Downs et al, 2014). Studies in humans and animal models have 
shown that ciliary genes are essential for photoreceptor outer segment development, homeostasis 
and photoreceptor survival (Downs et al, 2016; Karlstetter et al, 2014; Won et al, 2009). 
1.8 Canine inherited retinal degenerations (IRDs) 
Canine IRDs present similarly to human forms and represent a group of inherited retinal diseases 
associated with reduced photoreceptor function leading to visual impairment and eventually 
blindness. The first report of a canine IRD by Magnusson (1911) identified it as the canine 
homolog to human RP, sharing similar clinical and genetic features and rates of progression. 
Classifying canine IRDs is complex, however they are typically categorised depending on which 
photoreceptor cells deplete initially, with further classification based on the rate of progression 
and when initial signs of disease present (early- and late-onset). Canine IRDs can be characterised 
into two broad clinical categories: stationary or progressive. 
Stationary IRD 
The first stationary retinal dystrophy to be characterised was congenital stationary night 
blindness (CSNB) in Briard dogs and had similarities to a human CSNB (Narfström et al, 1989). 
Affected dogs displayed congenital night blindness, with normal fundi up to 2-3 years of age and 
reduced ERG responses. Since this initial report, the disease has been further defined and renamed 
as ‘retinal dystrophy’ as progressive changes were apparent (Narfström, 1999). A 4-bp deletion 
in the RPE65 gene has been identified in purebred Briard dogs and Briard crossbreeds presenting 
with CSNB/retinal dystrophy (Aguirre et al, 1998; Veske et al, 1999). However some Briard dogs 
displaying retinal abnormalities consistent with PRA have been identified that do not carry the 
RPE65 mutation, and have no other provocative variants in this region (Aguirre et al, 1998), 
illustrating that this breed segregates two genetically distinct forms of retinal degeneration. 
Cone degeneration is phenotypically similar to a human disease, achromatopsia: a heterogeneous 
autosomal recessive disorder (Dixon, 2016; Seddon et al, 2006). A cone degeneration described 
in Alaskan Malamute dogs specifically affects cone photoreceptors leading to day blindness 
(hemeralopia). Clinically, cone-degenerate puppies develop hemeralopia and light sensitivity 
(photophobia) between 8-12 weeks of age, with normal vision in dim light. ERG readings detect 
loss of cone function from three weeks of age and as affected dogs mature, rod function remains 
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normal. Affected individuals homozygous for mutations in the gene encoding cyclic nucleotide 
gated channel β-3 (CNGB3) have been identified in Alaskan Malamutes and German Shorthaired 
Pointer dogs (Sidjanin et al, 2002). The deletion removing all exons of canine CNGB3 reported 
initially in Alaskan Malamutes was also detected in miniature Australian Shepherd dogs 
(homozygous); and one Siberian Husky and three Alaskan sled dogs were identified as carriers 
(Yeh et al, 2013). Further to this, a mutation in the cyclic nucleotide gated channel α-3 gene 
(CNGA3) was identified in German Shepherd dogs with cone degeneration, presenting the dog as 
a canine model to aid in the identification of human achromatopsia-associated channelopathies 
and treatments (Tanaka et al, 2015). 
Progressive Retinal Atrophy (PRA) 
Canine PRA is the term given to a group of heterogeneous diseases characterised by depletion in 
photoreceptor cells in the retina over time. Progression of the disease is variable, as well as the 
aetiology and age of onset, which can be broadly divided into early- and late-onset. PRA shows 
phenotypic similarities to that of human RP. Clinical signs revealed by ophthalmoscopic 
examination include bilateral vascular attenuation of retinal blood vessels, becoming more 
marked as the severity of the degeneration progresses, and retinal thinning leading to 
hyperreflectivity of the tapetum lucidum. In moderate to advanced stages of disease, 
depigmentation and mottling of the non-tapetal fundus can also be observed. The optic disc 
typically turns pale in colour due to loss of retinal circulation. Typically, nyctalopia is exhibited 
and in many cases bilateral secondary cataracts develop (Parry, 1953; Petersen-Jones, 2005). 
Ophthalmoscopic changes may be supported by ERG readings, measuring the rod and cone 
photoreceptor response. Sophisticated ERG protocols allow the differentiation of progressive rod-
cone degenerations (RCDs) from cone-rod degenerations (CRDs), which can prove difficult using 
ophthalmoscopy alone (Acland, 1988). Where a distinction can be made between RCDs and CRDs, 
RCDs are defined by initial loss of rod photoreceptors responses followed by that of cones. As rod 
photoreceptor cells function in low light conditions, with low spatial acuity, impaired vision in low 
level light and darkness manifest initially in rod led degenerations. Responsible for colour vision, 
cones cells are active at higher levels of light and degeneration of these cells follows rod depletion, 
causing visual impairment in bright light (reviewed in Gelatt, 2013). Forms of RCDs previously 
reported display similar clinical signs, although variability in rates of progression, age of onset 
and aetiology are exhibited across and within breeds. This is shown across previous studies in 
breeds including the Miniature Poodle, Norwegian Elkhound, Briard, Miniature Schnauzer, 
Gordon and Irish Setter, Cardigan Welsh Corgi, Sloughi and Rough and Smooth Collie (Acland & 
Aguirre, 1987; Aguirre et al, 1982; Clements et al, 1993; Dekomien et al, 2000; Downs et al, 2013; 
Kukekova et al, 2009; Millichamp et al, 1988; Parshall et al, 1991; Petersen-Jones et al, 1999). In 
CRDs cones are predominantly affected followed by the depletion of rods. Although clinical 
differences occur, CRDs demonstrate ophthalmoscopic changes that are very similar to those of 
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RCDs. Fewer breeds are affected with CRDs, yet those that are show severe retinal and fundus 
abnormalities and ultimate vision loss (Curtis & Barnett, 1993; Kijas et al, 2004; Ropstad et al, 
2007a; Ropstad et al, 2007b). ERG assessment is not routinely performed in dogs, so 
distinguishing between a rod-cone or cone-rod degeneration is difficult. However, when night 
blindness is the first clinical sign observed, a rod-cone degeneration is considered the most likely 
diagnosis. The lack of ERG assessment in dogs commonly leaves ophthalmoscopic examination as 
the extent of the diagnosis, and has resulted in the use of the umbrella term ‘PRA’ to describe both 
RCDs and CRDs in dogs. 
Early-onset PRA-affected individuals first exhibit clinical signs between six weeks and six months 
of age, typically leading to blindness between the ages of 1-5 years, thus sharing clinical 
similarities with human LCA. Genetically distinct, early-onset forms of RCDs include rod-cone 
dysplasia type-1 (RCD1) (Clements et al, 1993; Dekomien et al, 2000), type-2 (RCD2) (Kukekova 
et al, 2009), type 3 (RCD3) (Petersen-Jones et al, 1999) and early retinal degeneration (ERD) 
(Goldstein et al, 2010). The first canine PRA-associated mutation to be identified was associated 
with a form of RCD in the Irish Setter dog: RCD1 (previously described). Initial presentation of 
RCD1 in Irish Setters demonstrated reduced ERG measurements, with rod responses increasingly 
diminished in the early stages of retinal development and the degree of cone response less so. 
Morphologically, visual cells from the retinas of affected dogs are abnormal with a reduction of 
rods in the photoreceptor layer, short inner segments and fewer visual cells. Cones are affected to 
a lesser extent, still prominent with broad inner segments but abnormal, short outer segments. 
The inner retinal layers appear to remain normal, yet all rod cells degenerate by five months of 
age (Aguirre, 1978). A nonsense mutation in the PDE6B gene was identified as a causative 
mutation of autosomal recessive RCD1, resulting in a loss of function of rod PDE (Clements et al, 
1993).  
A novel PRA in Miniature Long-Haired Dachshund dogs was first clinically characterised as a CRD, 
termed cord1 (Curtis & Barnett, 1993). Histopathology showed the retinas of affected puppies 
were normal at six weeks of age, with retinal abnormalities detected from as early as 10.5 weeks 
of age. This suggested that retinas developed normally, and pathological changes developed after 
retinal maturation, indicative of a retinal degeneration rather than a retinal dysplasia. ERG 
assessment revealed clinical signs of PRA were apparent from as early as six months of age, 
suggesting an early-onset PRA (Curtis & Barnett, 1993). The genetic cause of this form of PRA in 
the Miniature Long-Haired Dachshund was later identified as a 44-bp insertion in exon 2 of the 
RPGRIP1 gene (Mellersh et al, 2006). Despite complete correlation of the RPGRIP1 mutation with 
clinical disease in the initial Miniature Long-Haired Dachshund research colony, additional studies 
in a wider population discovered phenotype-genotype discordance, where vision defects and 
retinal degeneration in dogs developed at varied ages, or not at all within their lifespan (Miyadera 
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et al, 2009), more alike to RPGRIP1 associated human retinopathies. Further ophthalmic studies 
into Miniature Long-Haired Dachshunds homozygous for the RPGRIP1 insertion revealed some 
dogs developed clinical signs later in life, contradicting the previously reported findings of strictly 
an early-onset PRA and demonstrating that the RPGRIP1 mutation alone does not invariably lead 
to an early-onset phenotype (Busse et al, 2011). An age of onset modifier locus was identified on 
canine chromosome 15 (CANFA15) in Miniature Long-Haired Dachshund dogs homozygous for 
the RPGRIP1 mutation, where visual defects presented before the age of four years (Miyadera et 
al, 2012). Further investigation later revealed a mutation in the microtubule-associated protein 9 
(MAP9) gene as the age of onset modifier mutation inherited with the RPGRIP1 insertion in 
Miniature Long-Haired Dachshund dogs with early-onset CRD (Forman et al, 2016).  
Late-onset PRAs are characterised by initial normal retinal development, with photoreceptor 
degeneration occurring from around the age of five years. Dogs inheriting late-onset forms of 
disease show normal ERG responses at a young age, with progressive rod depletion later in their 
lives. As with early-onset RCDs, cones are abnormal and a reduction in cone response follows that 
of rods, although cone degeneration is less severe. Late-onset forms of PRA tend to involve genes 
that are significant for the maintenance and function of photoreceptors throughout life as opposed 
to early-onset forms for which genes necessary for postnatal development are implicated 
(Mellersh, 2014). Perhaps the most common late-onset PRA in dogs is progressive rod-cone 
degeneration (PRCD) a recessively inherited PRA first reported in Miniature Poodles (Aguirre et 
al, 1982) where the disease phenotype was characterised by aberrant photoreceptor structure. A 
single nucleotide substitution in the novel gene PRCD was identified as the causal mutation for 
PRCD initially across 18 breeds (Zangerl et al, 2006). At present, a commercially available DNA 
test is available for 72 dog breeds (Mars Veterinary, UK) with the mutation proving to be shared 
across many diverse breeds and is generally the first PRA-variant excluded when a distinct form 
of PRA is identified in a breed. This suggests that a common ancestral chromosome containing the 
mutant gene was widespread through the development of modern dog breeds. Following variant 
identification in the dog, a human RP patient was identified that was homozygous for the same 
mutation, establishing PRCD as a novel retinal gene causing retinal degeneration in dogs and 
humans (Zangerl et al, 2006).  
In clinical and genetic studies, it is also important to consider the presence of PRA phenocopies: 
eye conditions that are not hereditary but share similar clinical signs to PRA. One example is 
sudden acquired retinal degeneration (SARD): a non-inherited retinal degeneration, where 
ophthalmoscopic signs of retinal degeneration are absent at the onset of blindness and appear 
many weeks following vision loss (Petersen-Jones, 2005). PRA phenocopies can complicate a PRA 
diagnosis and possibly lead to a misdiagnosis. Genetic investigations are reliant on a robust 
clinical diagnosis to ensure the correct disease status is applied to individuals being used for 
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research i.e. cases (affected dogs) and controls (non-affected dogs) for case-control studies. For 
the majority of PRA studies, all dogs selected to contribute to a study have been subject to an eye 
examination by a certified veterinary ophthalmologist, a panellist of the British Veterinary 
Association/Kennel Club/International Sheep Dog Society (BVA/KC/ISDS) Eye Scheme or the 
European equivalent.    
1.9 Identification of disease-associated mutations 
Single-gene diseases, often referred to as Mendelian, are usually inherited in one of several 
patterns depending on the location of the gene and whether one or two normal copies of the gene 
are required for the disease phenotype to manifest. There are five basic modes of inheritance for 
single-gene diseases: autosomal dominant, autosomal recessive, X-linked dominant, X-linked 
recessive, and mitochondrial. In autosomal dominant diseases, each affected individual has one 
copy of the disease-associated mutation inherited from an affected parent. Individuals carrying 
two copies of the disease-causing mutation will be affected with an autosomal recessive disease, 
presenting clinical signs of the disease; both parents are heterozygous (carriers) carrying one 
copy of the mutated gene and are clinically non-affected. In X-linked diseases, the X chromosome 
harbours the causal mutation. Females are more frequently affected in X-linked dominant 
inheritance and, although affected males and females can occur in the same generation, fathers 
cannot pass the trait to male progeny. X-linked recessive diseases present more frequently in 
males, often in each generation. Both parents must carry one affected X chromosome to produce 
affected female offspring, where only a carrier female parent can pass the disease to male 
offspring (a male parent cannot pass an X-linked trait to its male offspring). Mitochondrial 
diseases can affect both males and females, however only female individuals will pass on the 
disease to offspring through maternal inheritance (reviewed in Genetic Alliance, 2010). 
As with many canine Mendelian disorders, the majority of canine PRAs reported are autosomal 
recessive, however, one dominant (Kijas et al, 2002) and four X-linked forms (Kaukonen et al, 
2020; Kropatsch et al, 2016; Vilboux et al, 2008; Zhang et al, 2002) have also been described. 
Canine PRAs are genetically heterogeneous, where multiple mutations exist in individual breeds 
that are deemed disease-causing, though these may not account for all PRA cases in the affected 
breeds. To date, 27 mutations in over 60 breeds are associated with PRA (Appendix 2); with many 
more yet to be elucidated. Although there are PRA-associated mutations that have been detected 
across multiple diverse breeds, e.g. PRCD (Zangerl et al, 2006) identified in at least 65 breeds to 
date and rod-cone degeneration 4 (RCD4) identified in Gordon Setter, Irish Setter, English Setter, 
Tibetan Terrier and Standard Poodle dogs (Downs et al, 2013), the majority of reported canine 
PRAs are often private to individual breeds. Knowledge of the mode of inheritance of a single-gene 
disorder drives the choice of genetic application(s) used in a study. A variety of genetic techniques 
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have been used to identify previously reported causative PRA-variants; some of which will be 
further discussed. 
Linkage analysis 
The fundamental basis of linkage analysis is a family-based analysis, requiring DNA from the 
proband and an informative extended family pedigree with other affected family members. This 
is a genetic mapping approach used to estimate the distance between loci or genes at different 
locations on a chromosome. Linkage analysis was predominantly used prior to high density SNP 
arrays and next-generation sequencing (NGS) technologies to map disease-associated regions. 
Suitable polymorphic markers used in a linkage analysis approach include polymorphic 
microsatellites and SNPs. Microsatellites are short repetitive DNA sequences that vary in length 
and are found interspersed throughout the genome. These range in length from one to six or more 
base pairs that are repeated, however typically consist of di-, tri- and tetra- nucleotide repeats. 
Dinucleotide repeats e.g. (CA)n occur most frequently and are more stable in the canine genome 
than trinucleotide or tetranucleotide repeats (Francisco et al, 1996). These consist of at least 12 
dinucleotide repeats, and longer repeats are associated with greater allelic variation, due to the 
presence of multiple length alleles: the longer the stretch of repeats, the more polymorphic the 
repeat is. The high variability of microsatellites makes them desirable in linkage analysis studies 
as they are highly polymorphic. Another tool used in a linkage analyses are SNP arrays. SNP arrays 
enable genotyping of thousands of polymorphic SNP markers spanning the genome to identify 
those that segregate with a disease in family-based pedigrees to identify disease-associated loci 
and a disease-associated haplotype. During meiosis, the process of recombination occurs during 
which homologous chromosomes align, break to exchange genetic material and re-join in new 
combinations of alleles, different to both parents. Recombination is more likely to occur between 
two markers positioned far apart on different chromosomes, which are independent of one 
another, than between two markers close to each other on the same chromosome. The basis of 
linkage analysis assumes that alleles of markers physically located close together are inherited 
together, and when inherited with a disease can identify the disease-associated locus. Successful 
use of these approaches is demonstrated in a study of Miniature Long-Haired Dachshund dogs 
with a CRD, where a microsatellite-based homozygosity mapping followed by linkage analysis was 
used to identify a disease-associated locus on CANFA15. Further interrogation of the locus 
revealed a 44-bp insertion in exon 2 of RPGRIP1 (Mellersh et al, 2006). 
Candidate gene study 
Knowledge of genes implicated in previous studies of a disease can be adopted for a candidate 
gene study where there is previous evidence that a gene is associated with a disease of interest, 
often in another breed or species. This can be used in conjunction with a linkage approach, where 
selecting polymorphic markers that are located as close as possible to a gene of interest will 
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determine if both are in LD and are within a disease-associated region. In some instances, 
candidate genes are canine homologues of those implicated in similar human diseases, but genes 
can also be selected if they fall within chromosomal regions that are homologous between species. 
For example, canine X-linked PRA (XLPRA) is akin to a human X-linked RP (RP3) and maps to the 
same chromosomal location in the X chromosome (Zeiss et al, 2000; Zhang et al, 2001). A study 
by Zhang et al. (2002) employed a linkage analysis approach to map two canine XLPRAs to the 
region and identified mutations associated with XLPRA type-1 (XLPRA1) in the Siberian Husky 
and Samoyed dogs, and XLPRA type-2 (XLPRA2) in mongrel-derived dogs. The previously 
discussed PRCD mutation is another example of how canine research has informed human 
medicine in retinal degeneration. After the mutation in PRCD was initially detected in dogs the 
gene was screened in unresolved human RP cases, and a patient with the identical mutation was 
subsequently identified (Zangerl et al, 2006). RetNet, the Retinal Information Network (RetNet, 
2020), is an online database summarising all genes and loci identified in human retinal diseases, 
including RP. Thus, many of these genes are candidate genes for canine PRA studies, or 
phenotypically similar diseases. Another reason for a gene to be considered as a candidate for a 
disease is the known function or involvement with relevant biological mechanisms and pathways 
of the encoding protein (examples of such pathways are discussed in section 1.6). This can 
highlight novel candidate genes implicated in disease. Examples of candidate gene studies include 
the identification of a 1-bp deletion in PDE6A in PRA-affected Cardigan Welsh Corgi dogs 
(Petersen-Jones et al, 1999) and an 8-bp deletion in PDE6B in PRA-affected Sloughi dogs 
(Dekomien et al, 2000). Candidate gene approaches were the method of choice prior to the 
availability of genome-wide methods, such as genome-wide association studies. 
Genome-wide association study (GWAS) 
A genome-wide association study (GWAS) employs a large-scale SNP array that genotypes 
hundreds of thousands of SNPs across a genome, and tests these SNPs for statistical associations 
with a trait or disease. The most common approach in the dog utilises a case-control study, where 
the frequency of both alleles at biallelic SNP marker loci is compared between affected individuals 
(cases) and non-affected individuals (controls), and statistical methods are applied to determine 
the likelihood that an observed difference has occurred by chance. A statistically significant 
association between a given disease phenotype and SNP markers suggests that the markers are 
associated with the disease. This can narrow a disease associated region from the entire genome 
down to a small region, in the dog usually a few Mb in size for Mendelian conditions because of 
the aforementioned extensive LD in dog breeds. Various SNP arrays are commercially available to 
genotype SNP markers in many species. For the dog, popular SNP arrays include two Illumina 
CanineHD Whole-Genome Genotyping BeadChips: the 170K chip containing 172,115 highly 
polymorphic SNP markers, based on the earlier CanFam2.0 reference sequence; and the 230K chip 
containing approximately 230,000 SNPs, which is an updated version on the 170K chip. Both these 
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arrays have been successfully used in studies of monogenic diseases, but less so for 
polygenic/complex conditions. More recently, a higher density array has become available: the 
AxiomTM Canine Genotyping Array Set (Thermo Fisher Scientific, Loughborough, UK) includes 
more than 460,000 markers. The increased number of polymorphic markers on this array makes 
it more suitable than the two Illumina arrays for investigating inherited complex conditions where 
multiple more common/ancestral risk factors may be contributing to a disease phenotype. SNPs 
on these dense arrays were selected as they are polymorphic across a variety of dog breeds to 
ensure their utility across breeds. As previously discussed, dog breeds show high levels of LD 
(Sutter et al, 2004) therefore the use of GWAS mapping approaches has proven successful in 
identifying candidate regions and subsequently mutations for hereditary retinal diseases 
(Goldstein et al, 2006). Moreover, the presence of LD blocks and low intrabreed diversity means 
fewer SNP markers and smaller sample sizes can be used in canine GWAS than would be required 
to perform the same experiment in human populations. This has successfully been demonstrated 
in PRA studies using modest numbers of cases and controls (e.g. between 6-27 cases and 3-29 
controls) with a GWAS approach to identify causative mutations (Ahonen et al, 2013; Downs et al, 
2011; Downs et al, 2013; Downs et al, 2014; Downs & Mellersh, 2014; Goldstein et al, 2013a; 
Kropatsch et al, 2010; Murgiano et al, 2018; Wiik et al, 2008; Wiik et al, 2015). Although fewer 
SNP markers might be necessary to identify a region of LD surrounding a disease locus, the region 
of LD will be longer than the equivalent region in the human genome, therefore the fine mapping 
of a disease locus is often more difficult.  
Next-Generation Sequencing 
While Sanger sequencing is considered the gold standard for the identification of disease-
associated variants, this is a laborious and costly method when exploring numerous genes with 
many exons, or an entire genome. High throughput methods have been developed relatively 
recently to sequence more DNA at a reduced cost and faster rate. Next-generation sequencing 
(NGS), also referred to as massively parallel sequencing, is a high-throughput approach to DNA 
sequencing. The emergence of NGS has revolutionised genetic studies, including the identification 
of disease-associated variants, across many species. Two types of NGS applications are often used 
in the study of inherited disease: whole exome sequencing (WES) and whole genome sequencing 
(WGS).  
Whole exome sequencing (WES) 
Whole exome sequencing (WES) targets the protein-coding regions of genomic DNA (gDNA), 
known as the exome. The exome represents an enriched subset of the genome accounting for 
approximately 2% of the canine genome (Broeckx et al, 2014). A WES approach allows an 
inexpensive means of identifying functional variants associated with disease and is based on the 
use of baits to enrich and target specific exonic regions to sequence. As many Mendelian diseases 
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previously reported are caused by variants that disrupt protein-coding or splice site regions, 
several studies have employed WES to identify genes associated with inherited retinal disease, 
when prior mapping information is unknown (Xu et al, 2015; Zuchner et al, 2011). In human IRD 
studies WES is currently a popular method of choice to identify novel genes when a candidate 
gene approach does not yield causative variants (Siemiatkowska et al, 2014). However, WES does 
not detect intronic variation, including structural variants such as inversions where breakpoints 
may be within intronic regions; and deep intronic variants, which may cause aberrant splicing 
events, create cryptic splice sites, or disrupt regulatory elements (Bax et al, 2015; Webb et al, 
2012). For such variants, targeted genomic sequencing or whole genome sequencing (WGS) 
approaches may be more appropriate.  
Whole genome sequencing (WGS) 
During the last decade, WGS is increasingly becoming a popular method in disease variant 
identification, either as a stand-alone method or in combination with other technologies such as 
linkage analysis or GWAS. This is largely due to a decrease in costs over the past five years that 
has enabled multiple genomes to be sequenced for one study and comparisons carried out 
between cases and controls. By sequencing an entire genome, a more comprehensive data set is 
obtained compared to WES where only the coding regions are sequenced. In principle, WGS 
detects all variation, including structural variants and non-coding variants. The caveat of WGS is 
that no positional information can be determined regarding where a causal mutation will lie, 
whereas a GWAS can highlight chromosome(s) harbouring the mutation to further define a 
disease associated region. Despite this, if finances enabled WGS of many cases and controls, WGS 
data could be used for a GWAS by extracting GWAS SNP positions. However, the cost per sample 
of WGS an individual is at least 10 times more than genotyping an individual for a GWAS using the 
aforementioned SNP arrays. Other disadvantages of WGS are the extensive data processing time 
and storage of a large amount of data. In addition, WGS analysis can be susceptible to bias if used 
in conjunction with a candidate gene approach; and non-exonic variants can be difficult to identify. 
With WGS analysis, various filtering steps must be undertaken to strategically decide which 
variants should be under consideration for involvement with the disease to reduce the initial high 
number of variants obtained.  
1.10 The dog as a model for human IRDs 
The study of canine retinal disease offers opportunities for novel target gene discovery in human 
RP and other retinal degenerations, where a large proportion of patients still have an unknown 
molecular diagnosis. Similarities between the human and canine eye morphology and size means 
that many surgical approaches and treatments can be trialled and performed in canine and human 
eyes. In addition, as both species reside in similar environments, the dog eye can be a useful model 
for human retinal research.  
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Naturally occurring canine models exist for several IRDs, some of which have contributed to gene 
augmentation therapies in humans such as the RPE65 model for LCA. RPE65 is expressed in the 
RPE and is a crucial component in the visual cycle, which regenerates visual pigments for 
phototransduction. The retinas of Briard dogs homozygous for a 4-bp deletion in RPE65 show an 
accumulation of lipoidal inclusions within the RPE, with abnormal ERG responses suggesting a 
defect in the phototransduction pathway (Aguirre et al, 1998). This results in a slowly progressive 
photoreceptor degeneration sharing profound visual defects to human LCA. The introduction of 
adeno-associated virus (AAV) vectors carrying the normal RPE65 cDNA enables gene transfer to 
RPE65 mutant dog retinas and demonstrates rescued RPE function and overall retinal function, 
specifically in the visual cycle (Acland et al, 2001). In Briard dogs under observation, ERG 
responses were improved with the therapy providing evidence of long-term improved function of 
photoreceptors (Acland et al, 2005). Following success of canine RPE65 gene therapy studies, 
human clinical trials have shown the same benefits in RPE65 gene therapy using AAV (Bainbridge 
et al, 2008; Russell et al, 2017; Simonelli et al, 2010). This has led to the US Food and Drug 
Administration approving the treatment of patients with RPE65-mediated IRD using this method 
of gene therapy since January 2018. In 2019, this treatment was also recommended for use in the 
NHS in the UK, with the first patient receiving treatment in February 2020 at Moorfields Eye 
Hospital in London. 
Gene therapy for canine models of RP include studies into the PDE6A (Mowat et al, 2017) and 
PDE6B (Petit et al, 2012) autosomal recessive RP phenotypes, and RPGR for X-linked RP (Beltran 
et al, 2012). As with the RPE65 canine model, pre-clinical trials using AAV-mediated gene 
replacement therapy to inject vectors containing normal cDNA into mutant human retinas have 
shown to preserve and rescue photoreceptor function. Further clinical trials in humans are 
underway (Cehajic Kapetanovic et al, 2019). Canine models for human IRDs have provided proof 
of concept for treating human IRD, offering optimistic outlooks for patients with these blinding, 
incurable diseases. 
1.11 Canine DNA testing 
PRA is a canine welfare concern as vision loss is inevitable. Currently there are no treatments 
generally available for PRA in dogs, although, as discussed above, research studies using dogs have 
shown the effectiveness of the use of gene therapy as a treatment for some forms of retinal 
degeneration (Beltran et al, 2012; Lheriteau et al, 2014; Mowat et al, 2017; Occelli et al, 2017; Petit 
et al, 2012). In addition to gene augmentation therapies, cell-replacement therapy for human RP 
patients is being explored using the RNA-guided Cas9 nuclease from the microbial clustered 
regularly interspersed short palindromic repeats (CRISPR/Cas9) system to correct genetic 
mutations in human cell lines (Artero Castro et al, 2019), but these studies are in their relative 
infancy. The development of commercially available DNA tests for PRA-associated mutations 
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therefore plays an important role in controlling the incidence of PRA by enabling dog breeders to 
avoid breeding genetically affected dogs and thereby reduce the incidence of PRA in their breeds. 
Each DNA test is developed to target a specific genetic variant that has supporting evidence to 
cause disease in the breed of interest. For autosomal recessive conditions where two copies of the 
mutant allele are required for an individual to present with clinical signs of disease, genetic assays 
are developed to determine the genotype of each dog, identifying them as either: genetically 
affected (i.e. homozygous for two copies of the mutant allele), a carrier (i.e. heterozygous with one 
copy of the normal allele and one copy of the mutant allele), or genetically clear (i.e. homozygous 
for the wild type allele) of a disease-causing variant. 
Clinical eye screening complements the use of DNA tests, where the former can identify novel or 
emerging eye conditions for which a genetic variant has not yet been discovered, and the latter 
enables dog owners and breeders to use a one-off genetic test to determine their dog’s genotype 
with respect to a specific mutation. This knowledge facilitates informed breeding decisions and 
can detect subclinical cases prior to disease onset. This is especially important for diseases that 
may present as late-onset and past the typical breeding age of the dog. DNA tests can also identify 
non-affected heterozygotes (carriers) for a disease-associated mutation, which a clinical eye 
examination cannot. This is particularly important when considering a hereditary disease with a 
high allele frequency in a population, to ensure carrier dogs are bred appropriately (e.g. to 
genetically clear dogs) to prevent producing affected offspring. It is also important to preserve 
genetic diversity within a dog breed, which in some instances is achieved by keeping carriers in 
the gene pool. For some hereditary diseases, especially where the allele frequency is low, it is 
possible to eliminate the disease allele by eliminating carrier and affected dogs from the breeding 
population. This is not always achievable for numerically small breeds; therefore, breeding 
decisions should be made with caution and tailored to the breed in question. On the other hand, a 
mutation-specific DNA test does not screen for all disease-associated mutations identified in a 
breed. If other forms of ocular disease with unidentified mutations are present in the breed, DNA 
testing will not detect the disease, but clinical screening will.  
1.12 The British Veterinary Association/Kennel Club/International Sheep 
Dog Society (BVA/KC/ISDS) Eye Scheme 
The main purpose of the BVA/KC/ISDS Eye Scheme (https://www.bva.co.uk/Canine-Health-
Schemes/Eye-scheme/) is to identify inherited and non-inherited eye diseases in dogs. Until 
January 2020, the scheme was comprised of two schedules: Schedule A containing breeds with 
confirmed inherited eye diseases and Schedule B containing breeds with eye diseases suspected 
as being inherited and under investigation, based upon the consistent opinion of veterinary 
ophthalmologists in the UK. Recent assessment has updated these to one schedule (Appendix 3) 
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where breeds listed are advised to undergo annual eye examinations carried out by a 
BVA/KC/ISDS panellists, with a result issued as ‘clinically affected’ or ‘clinically unaffected’.  
1.13 Thesis aims 
In this thesis, novel forms of PRA will be explored in the Lhasa Apso (LA), Giant Schnauzer (GS) 
and Shetland Sheepdog (SS) dog breeds, independent of one another. Elucidation of novel PRA-
associated variants aims to improve the understanding of the aetiology of distinct forms of PRA in 
these three breeds. The identification of genes responsible for such afflictions will provide further 
insight into the pathways and interactions involved in retinal function. In addition, the 
identification of PRA-associated variants will enable DNA tests to be developed based on any novel 
mutations identified to offer as a breeding tool, as PRA in many dog breeds continues to burden 
dog breeders. Moreover, identification of novel genes associated with canine PRAs will prompt 
their consideration as candidate genes for RP or other IRDs in humans and other species.  
The major research objectives of this thesis are summarised as below: 
1. Identify breeds affected with PRA for which the causal mutation is unknown. 
2. Elucidate mutations associated with PRA in each breed under investigation, using 
whole genome investigations, including GWAS and WGS technologies, identifying 
the most efficient mutation discovery routes for differently structured proband 
groups. 
3. Develop commercial DNA tests for all mutations identified. 
4. Offer novel insights for consideration in human retinal degeneration research.
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Chapter 2 General Materials and Methods 
2.1 PRA diagnosis and sample collection 
All PRA-affected dogs used in each study were examined by certified veterinary ophthalmologists 
through a clinical referral process or via the BVA/KC/ISDS Eye Scheme in the UK, or the European 
equivalent. Dogs with a PRA diagnosis were defined as “cases” and presented with clinical signs 
consistent with PRA. Dogs clinically clear of PRA were classed as “controls” and were deemed clear 
of inherited eye diseases upon ophthalmoscopic examination after the age of eight years, applying 
the same ophthalmoscopic examination methods as the cases, except where stated. Collection of 
DNA samples from animals using buccal mucosal swabs was approved by the Animal Health Trust 
(AHT) Ethics Committee (ref no. 24-2018E). 
2.2 DNA extraction 
DNA extraction from buccal mucosal swabs 
To extract gDNA from buccal mucosal swabs, the QIAamp DNA Blood Mini or Midi Kits (Qiagen, 
Manchester, UK) were used with a modified and optimised protocol, described below. Kit reagents 
were prepared as per manufacturer’s instructions. Where possible, DNA was extracted from a 
maximum of four buccal swabs obtained from a single dog. Using the QIAamp DNA Mini Kit, a 
maximum of two swabs were transferred into a 2 millilitre (mL) microcentrifuge tube with the 
addition of a lysis mix consisting of 400 microlitres (μL) phosphate buffered saline (PBS; Sigma-
Aldrich Company Ltd., Dorset, UK), 400 μL  AL lysis buffer (Qiagen) and 20 μL protease (Qiagen). 
Tubes were vortexed briefly followed by incubation at 56 °C for 15 minutes. DNA was precipitated 
by adding 400 μL ethanol (Thermo Fisher Scientific) to each tube and mixed by vortexing. The 
swabs and solution were transferred to a 5 mL syringe barrel held in a 15 mL conical tube 
(Falcon™) and centrifuged at 700 times gravity (×g) for 2 minutes. DNA was collected from the 
supernatant by applying 600 μL of sample solution to a QIAamp mini column and centrifuging at 
6,000 ×g for 1 minute, discarding the flow-through. This was repeated until all the DNA-containing 
supernatant had passed through the column. DNA on the filter was purified using 500 μL AW1 
wash buffer (Qiagen) and centrifuged at 20,000 ×g for 2 minutes. The flow-through was discarded 
and the addition of 500 μL AW1 wash buffer (Qiagen) and centrifugation was repeated. A final 
purification step was performed by adding 500 μL AW2 (Qiagen) wash buffer to each column and 
centrifuged for 20,000 ×g for 1 minute. The flow-through was discarded and the final purification 
step repeated. The filter column was placed in a fresh waste collection tube and centrifuged at 
20,000 ×g for 3 minutes to dry the filter. Finally, the filter column was placed in a fresh 1.5 mL 
microcentrifuge tube and 100 μL AE elution buffer (Qiagen) was added to the filter. DNA samples 
were eluted by centrifuging at 6,000 ×g for 1 minute. A second 100 μL volume of AE buffer was 
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applied to each column and centrifuged at 6,000 ×g for 1 minute, resulting in a final volume of 
approximately 200 μL elute containing genomic DNA.  
Where the QIAamp DNA Blood Midi Kit was used, four buccal swabs were suspended in a lysis 
buffer mix of 1,600 μL PBS (Sigma Aldrich), 1,600 μL AL lysis buffer (Qiagen) and 80 μL protease 
(Qiagen) in a 15 mL conical tube. Tubes were briefly vortexed and incubated at 56 °C for 30 
minutes. DNA was precipitated by adding 1,600 μL absolute ethanol stored at -20 °C (Thermo 
Fisher Scientific) and the sample mixed by vortexing. The swabs and solution were transferred to 
a 5 mL syringe barrel held in a 15 mL conical tube and centrifuged at 700 ×g for 1 minute. 
Precipitated DNA was collected on a QIAamp midi column by applying 2.5 mL of the supernatant 
and centrifuging at 1,500 ×g for 3 minutes, discarding the flow-through. This step was repeated 
until all the supernatant had passed through the filter column. A final centrifugation at 2,000 ×g 
for 3 minutes was performed to ensure all solution had passed through the column, and flow-
through discarded. DNA was purified by adding 2 mL AW1 wash buffer (Qiagen) and centrifuging 
at 4,300 ×g for 1 minute, discarding flow thorough. A second wash of 2 mL AW2 buffer (Qiagen) 
was added to the column and centrifuged at 4,300 ×g for 15 minutes, discarding the flow-through. 
DNA was eluted into a fresh 15 mL tube by adding 150 μL AE elution buffer (Qiagen) and 
centrifuging at 4,300 ×g for 1 minute. The elution step was repeated twice, resulting in a final 
volume of approximately 450 μL eluted gDNA.  
DNA extraction from blood 
Genomic DNA was extracted from up to 5 mL residual whole blood samples that were collected 
after clinical testing and preserved in EDTA (ethylenediaminetetraacetic acid) using an adapted 
version of the Nucleon BACC2 protocol (Tepnel Life Sciences, UK). Red blood cells were lysed by 
the addition of 25 mL of nucleon reagent A (see recipe in Chapter 2, section 2.12) to the residual 
blood and mixed by inversion. White blood cells were collected by centrifuging at 4,300 ×g for 10 
minutes and the supernatant removed. Red blood cell lysis and centrifugation was repeated. 
White blood cell lysis was then performed by adding 2 mL nucleon reagent B (see recipe in 
Chapter 2, section 2.12) and the white blood cell pellet fragmented by shaking followed by 
incubation at 37 °C overnight. The cell lysis solution was transferred to a 15 mL conical tube, 800 
μL of 5 molar (M) sodium perchlorate (see recipe in Chapter 2, section 2.12) was added and the 
tube mixed by inversion to achieve protein precipitation. A chloroform wash was performed by 
the addition of 2 mL chloroform (Thermo Fisher Scientific) followed by mixing by inversion for 4 
minutes then centrifugation at 4,300 ×g for 5 minutes to separate aqueous phases. Avoiding 
contact with the middle protein layer, a sterile pipette was used to transfer the upper DNA-
containing aqueous solution to a fresh 15 mL conical tube, leaving the bottom chloroform layer 
for disposal. The chloroform wash was repeated. As before, avoiding contact with the protein 
layer, a sterile Pasteur pipette was used to transfer the top DNA-containing aqueous solution to a 
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new 15 mL tube. DNA was precipitated by adding 5 mL cold absolute ethanol (Thermo Fisher 
Scientific) and slowly inverting the tube to encourage the DNA to spool. A sealed glass hook was 
used to hook out the DNA precipitate and left to air dry for 20 minutes. Finally, the precipitated 
DNA was washed off the glass hook into a 1.5 mL microcentrifuge tube using 300 μL 1× TE buffer 
(10 millimolar (mM) Tris, 0.1mM EDTA, Thermo Fisher Scientific) and left to dissolve at room 
temperature overnight. All extracted DNA samples were stored at -20 °C. 
DNA quantitation and concentration 
DNA concentration and purity were determined using the NanoDrop 1000 spectrophotometer 
(Thermo Fisher Scientific) and/or the Qubit Fluorometer with the Qubit dsDNA broad range (BR) 
Assay Kit (Invitrogen, Renfrewshire, UK). Where possible, DNA samples with low concentrations 
(less than 10 nanograms (ng)/μL) were concentrated using MultiScreen-PCR96 filter plates 
(Merck Millipore, Watford, UK) or Microcon −30 kDa centrifugal filter units with ultracel-30 
membrane (Merck Millipore).  
2.3 DNA amplification 
Oligonucleotide primer and probe design 
Gene annotations were obtained from the online genome browser Ensembl database across the 
human and/or dog genomes (Aken et al, 2016; Zerbino et al, 2018). All primers and custom probe-
based qPCR assays for allelic discrimination assays were designed using Primer3 (Koressaar & 
Remm, 2007; Untergasser et al, 2012), listed in Appendix 4 for all assays, and obtained from 
Integrated DNA Technologies (IDT; Leuven, Belgium). Probes were PrimeTime ZEN double-
quenched qPCR probes containing a 5’ fluorophore, 3’ Iowa Black® FQ (IBFQ) quencher and 
proprietary, internal ZEN™ quencher. For each custom probe-based qPCR assay, primers 
spanning amplicon sizes between 70–150 bp were designed and two probes: a 5′ HEX™ 
fluorophore was used to determine the reference/wild type allele and a FAM™ fluorophore 
(Carboxyfluorescein, 6-FAM) to label the alternate allele. All sequences of each designed primer 
pair were viewed through BLAST on Ensembl (http://www.ensembl.org/Multi/blastview) in the 
Canis familiaris genome CanFam3.1 (Sep.2011. Broad CanFam3.1/canFam3, Ensembl 
(www.ensembl.org; Dog release 89; Aken et al, 2016) to ensure alignment locations were correct 
for efficient amplification. 
Oligonucleotide primer and probe dilution 
All primers arrived as lyophilised primer pellets and were resuspended using ultrapure water 
(ddH2O) to make 100 μM stocks. The 100 μM stock was used to make 20 μM working aliquots by 
combining 20 μL primer and 80 μL ddH2O. Custom probe-based qPCR assays of premixed primers 
and probes (containing a primer pair and a probe labelled with FAM™ or HEX™ fluorophore) for 
allelic discrimination assays were resuspended in ddH2O to a 10X or 40X assay (depending on the 
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amount of assay ordered). Equal quantities of the FAM™ and HEX™ labelled assays were combined 
to obtain a 10X or 40X probe mix. 
Polymerase chain reactions (PCR) 
The polymerase chain reaction (PCR) is a technique used to amplify segments of a DNA sequence 
and generate numerous copies of targeted DNA. The basic principle of PCR involves: 
1. A denaturation step to separate double-stranded DNA to single strands. 
2. An annealing step, usually between 55 °C and 60 °C, to allow binding of sequence-specific 
primers to the complementary sequence on the single-stranded DNA.  
3. An extension stage at approximately 72 °C to allow the DNA polymerase to synthesise 
new strands of complementary DNA from the 3’ end of the annealed primers.  
These steps are typically repeated 30 to 40 times, allowing the DNA target to be exponentially 
amplified. HotStarTaq Plus DNA polymerase (Qiagen) was used for standard PCR and 
PrimeSTAR® GXL DNA Polymerase (Takara Bio Inc., Saint-Germain-en-Laye, France) was used to 
amplify long range templates by PCR. PCR reaction conditions are described in individual 
chapters. 
Quantitative PCR (qPCR) 
Quantitative PCR (qPCR) is a method used to determine the amount of a target sequence present 
in a sample. A custom probe-based qPCR assay was designed, as described above, flanking an exon 
junction to determine gene expression in tissue types of interest and compared to the 
housekeeping TATA box binding protein gene (TBP). Each reaction contained 4 µL Luna universal 
qPCR Master Mix (New England Biolabs (NEB) Ltd., Herts, UK), 1.2 µL ddH2O, 0.8 µL of a 10X target 
assay mix and 2 µL complementary DNA (cDNA). qPCR was performed on a StepOnePlus™ Real-
Time PCR system (Applied Biosystems, Loughborough, UK) using the following cycling conditions: 
95 °C for 5 minutes followed by 40 cycles of 95 °C for 10 seconds and 60 °C for 30 seconds. A 
standard curve was generated using a 1:5 serial dilution of control cDNA and the coefficient of 
correlation (R2) and amplification efficiency were determined. Results were analysed using 
Applied Biosystems StepOne Software v2.3. The R2 value ascertains how well the data points lie 
on a single line, and how effective one value is at predicting another. Where R2 is equal to 1, the 
value of Y (cycle threshold; Ct) can be used to accurately predict the exact value of x (e.g. the 
amount of DNA in the sample). If R2 > 0.99, there is good confidence in correlating two values. 
Efficiency determines the sensitivity of a reaction and where efficiency is equal to 1 (or 100%), 
the fold increase will be 2 at each cycle. (Applied Biosystems, 2020). A qPCR efficiency from 90-
110% is considered acceptable. qPCR efficiency is determined from a standard curve where a 
slope of -3.3 ± 10% reflects an efficiency of 100% ± 10% (Applied Biosystems, 2020). 
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A mean comparative Ct value was calculated between three biological replicates to determine 
expression levels of the targets. Target expression levels were normalised against TBP and 
compared by relative quantification. Normalised reporter (Rn) values were calculated as the ratio 
of the fluorescence of FAM™ dye divided by the fluorescence of ROX dye on the 
StepOnePlus™platform. Delta Rn (∆Rn) values were calculated using the Rn value of the 
experimental reaction minus the Rn value of the baseline signal generated by the StepOnePlus™ 
instrument. 
Agarose gel electrophoresis 
Agarose gel electrophoresis was used to confirm successful PCR amplification and determine DNA 
product sizes. Preparation of 1.5 % agarose gels was done using agarose (Bioline, London, UK), 1X 
TAE buffer (Tris-acetate-EDTA containing 40 mM Tris, 20 mM acetic acid and 1 mM EDTA, Thermo 
Fisher Scientific) and ethidium bromide (EtBr) solution (25 μg; Severn Biotech Ltd, 
Worcestershire, UK). Five μL loading buffer (see recipe in section 2.12) was added to 2 μL PCR 
product and all 7 μL loaded into the gel wells. Five μL of a 2-log DNA ladder (NEB; see recipe in 
section 2.12) was loaded alongside PCR products to measure DNA fragment sizes. DNA was 
separated by electrophoresis at 5 volts per centimetre (V/cm) for 40-60 minutes in a gel tank 
containing 1X TAE buffer (Thermo Fisher Scientific). The gels were visualised on an Alpha 
Innotech AlphaImager 3400 ultraviolet (UV) transilluminator (Alpha Innotech, California, USA) 
and gel images obtained with AlphaImager software. The separation ranges of bands were 
measured against the inserted 2-log DNA ladder (NEB) product image (Figure 2.1) measuring 
DNA fragment size ranges between 0.1-10 Kb. 
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Figure 2.1: 2-Log DNA ladder visualised by EtBr staining on an agarose gel. Mass values indicated 
are for 1 µg/lane. Each separated band represents DNA fragment size within the range of 0.1 – 10 
Kb. Image obtained from 2-log ladder product datasheet (NEB, UK). 
2.4 Purification of PCR products 
2.4.1 Filter plates 
PCR products were purified to remove excess primers and reagents. The PCR product was made 
up to 100 μL using ddH2O and transferred to a MultiScreen PCRμ96 filter plate (Merck Millipore) 
mounted on a vacuum manifold. A vacuum of approximately 15 inches Hg pressure was applied 
for 12 minutes to pass the solution through the filter wells. Resuspension of the purified PCR 
product was performed by the addition of 20 μL ddH2O to each well followed by mixing on a 
rocking platform for 10 minutes. Purified PCR products were transferred to a 96-well PCR plate 
using a pipette for further use and stored at -20 °C.  
2.4.2 Gel extraction 
Where applicable, PCR products were purified following excision from an agarose gel using the 
Monarch® DNA Gel Extraction Kit (NEB), as per manufacturer’s protocols. The desired band was 
excised from the gel using 6.5 x 1 millimetre (mm) gel cutting tips (Alpha Laboratories, Eastleigh, 
UK) with a P1000 pipette and transferred to a 1.5 mL microcentrifuge tube and the gel slice 
weighed. To the gel slice, 4 volumes of Gel Dissolving Buffer (NEB) (relative to the mass of the gel 
slice) were added and the sample incubated at 50 °C with regular vortexing until the gel slice was 
dissolved. For amplicons exceeding 8 Kb, an additional 1.5 volumes of ddH2O was added after the 
gel slice was dissolved to mitigate the tighter binding of larger amplicons. The solute was 
transferred to a column inserted into a collection tube and centrifuged for 1 minute at 16,000 ×g, 
discarding the flow-through. The filter was washed twice by adding 200 μL DNA Wash Buffer 
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(NEB) and centrifuged for 1 minute at 16,000 ×g. The column was transferred to a fresh 1.5 mL 
microcentrifuge tube. Elution was achieved by the addition of 20 μL of DNA Elution Buffer (NEB) 
directly to the filter and left to stand at room temperature for 1 minute before centrifugation at 
16,000 ×g for 1 minute.  
2.5 Sanger sequencing 
Single nucleotide variants (SNV) or small insertions and deletions (INDELs) were confirmed by 
Sanger sequencing. 
Sanger sequencing reaction 
PCR products to be used for Sanger sequencing were purified on a MultiScreen PCRµ96 filter plate 
(Merck Millipore), as described in section 2.4.1, and sequenced using the Sanger method. Each 
reaction contained 2 µL purified PCR product, 0.5 µL BrilliantDye Terminator  v1.1 (Nimagen, 
Nijmegen, NL), 1.2 µL BrilliantDye Terminator Sequencing Buffer (5X) (Nimagen), 1.5 µL ddH2O, 
and  1 µL  1.6 µM oligonucleotide primer (the forward or reverse oligonucleotide primer used in 
PCR amplification). Thermal cycling conditions were as follows: 96 °C for 30 seconds; 44 cycles at 
92 °C for 4 seconds, 55 °C for 4 seconds, and 60 °C for 1 minute 50 seconds.  
Isopropanol precipitation 
Isopropanol precipitation of sequencing reaction products was performed to remove excess 
reagents. Firstly, 60 µL of 80% isopropanol (Thermo Fisher Scientific) was added to each well 
containing sequenced products, followed by centrifugation for 30 minutes at 2,600 ×g. The 
supernatant was discarded by immediate inversion and tapping of the plate upside down on 
tissue. A second addition of 100 µL of 60% isopropanol (Thermo Fisher Scientific) was added to 
each well and the plate centrifuged for 10 minutes at 2,600 ×g. The supernatant was discarded as 
before, and the plate left upside down on clean tissue. The plate was centrifuged upside down at 
160 ×g for 1 minute, transferred the right way up and left covered at room temperature for 20 
minutes to dry. Precipitated DNA was resuspended in 10 µL Hi-Di Formamide (Applied 
Biosystems). Sequencing products were separated on an Applied Biosystems (ABI) 3130xl Genetic 
Analyzer and raw sequence files generated for analysis. 
Sequence data analysis 
Sequence traces were assembled, analysed and compared using Pregap4 and Gap4 in the Staden 
software package (Staden et al, 2000). 
2.6 Next-generation sequencing (NGS) 
All NGS was performed using libraries generated from gDNA and sequenced on Illumina 
sequencing platforms. A standard NGS workflow is shown in Figure 2.2. 
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Figure 2.2: A standard workflow used in NGS analysis. 
Library preparation 
Libraries for amplicon sequencing were generated from 1 ng DNA using the Nextera XT library 
preparation reagents and protocol (Illumina, Cambridge, UK). Briefly, the Nextera transposome, a 
transposase-transposome complex, was used to tagment gDNA by simultaneously fragmenting 
and tagging DNA with adapter sequences (Figure 2.3A and Figure 2.3B). A 12-cycle PCR program 
amplified the tagmented insert DNA using read specific sequencing primers and added Index 1 
(i7) and Index 2 (i5), common adapters (P5 and P7) (Illumina) and sequences required for 
sequencing cluster generation (Figure 2.3C). The addition of index adapters to both ends of the 
DNA enables dual-indexed sequencing of up to 96 DNA libraries in a single pool on an Illumina 
sequencing platform.  
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Figure 2.3: Schematic representation of Nextera XT DNA tagmentation process. (A) An 
engineered transposome with adapters is combined with template genomic DNA approximately 
300-bp in size. (B) Tagmentation to fragment and add adapter sequences in one step. (C) A 
limited-cycle PCR anneals read sequencing primers (Rd1SP and Rd2SP) to add index adapter 
sequences (P5 and P7) to the end of each fragment and amplifies the insert DNA ready for dual-
indexed sequencing (Illumina, 2017). 
A clean-up step using AMPure XP beads (Beckman Coulter, High Wycombe, UK) used bead 
purification to purify amplified libraries. The quality of each individual DNA library was assessed 
by agarose gel electrophoresis and normalised using the Qubit Fluorometer with the Qubit dsDNA 
broad range or high sensitivity Assay Kit (Invitrogen), and then 3 µL of each individual library was 
pooled, thereby ensuring an equal representation of the library in the final pooled library. The 
pooled library was quantified using the KAPA library quantification kit, according to 
manufacturer’s instructions (Kapa Biosystems, Massachusetts, USA) and diluted to a 
concentration of 2 nM. The pooled library was prepared for sequencing by denaturation using 5 
µL DNA library and 5 µL 0.2 normality (N) sodium hydroxide (NaOH), incubating at room 
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temperature for 5 minutes followed by the addition of 990 µL pre-chilled HT1 buffer (Illumina) to 
the denatured library to achieve a concentration of 10 picomoles (pM). A total of 600 µL of 10 pM 
library was loaded into a MiSeq Reagent Kit v2 Nano cartridge (Illumina) to sequence on a MiSeq 
platform (Illumina). 
Cluster generation 
Following loading of the DNA library into a reagent cartridge, cluster generation was performed 
by the sequencing platform to generate clonal clusters on the flow cell in preparation for 
sequencing. Here, each single-stranded DNA fragment binds randomly to oligonucleotides on the 
surface of the flow cell, facilitated by the adapters at each end of the DNA fragment added in the 
library preparation stage (Figure 2.4). In a process called bridge amplification, single-stranded 
molecules flip over to hybridise to adjacent primers and unlabelled nucleotides and polymerase 
enzyme initiate solid-phase amplification, generating double stranded fragments on the flow cell 
surface. This bridge amplification process is repeated until each bound fragment is amplified into 
a clonal cluster creating several million dense clusters in each channel of the flow cell. The double-
stranded bridges are denatured leaving single-stranded templates anchored to the surface of the 
flow cell. Reverse strands are cleaved and washed away, leaving single-stranded DNA molecules 
attached to the flow cell surface. Free 3’ ends of single-stranded DNA are blocked to prevent 
unwanted DNA priming.  
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Figure 2.4: Illustration of cluster amplification in next-generation sequencing. DNA fragments 
from the loaded DNA library are hybridised to the flow cell surface and amplified into a clonal 
cluster through bridge amplification (Illumina, 2017). 
Sequencing 
Sequencing primers hybridise to the single-stranded DNA molecules and other sequencing 
reagents, including four fluorescently labelled nucleotides (A, C, G, T) and DNA polymerase are 
added to the clusters to initiate sequencing. The polymerase adds the first nucleotide to the 
primer, using the single-stranded DNA as a template. The identity of this base is determined by 
imaging of the flow cell flowing laser excitation, capturing the emission wavelength of 
fluorescence from each cluster. This cycle of incorporating the labelled nucleotides, primers and 
DNA polymerase followed by laser excitation and image capturing is repeated ‘n’ times to create 
a sequence read with a length of ‘n’ bases. Reads generated from each cluster are exported to an 
output text file in FASTQ format for data analysis. A schematic of each step in the sequencing 
process is shown in Figure 2.5 
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Figure 2.5: Sequencing of single-stranded DNA molecules following cluster amplification is 
initiated by the addition of sequencing reagents, including fluorescently labelled nucleotides A, C, 
T and G. Sequencing cycles commence and a digital image of the flow cell is captured, with the 
emission of each cluster recorded to identify the base. Reads generated from each cluster are 
exported to an output text file for data analysis (Illumina, 2017).  
Data analysis 
Raw sequencing data files were received in FASTQ file format and were processed through the 
AHT in-house pipeline, based on the Genome Analysis Toolkit (GATK) Best Practices workflow 
(DePristo et al, 2011; Van der Auwera et al, 2013). This NGS pipeline uses a number of analytical 
tools to align sequence files, assess the quality of the sequencing reads to retain high quality data, 
identify sequence variants, make variant effect prediction calls and enable filtering steps to be 
performed; which can be tailored to each study depending on the disease mode of inheritance. 
Alignment of short sequence reads to the canine reference sequence (CanFam3.1) is carried out 
using the BWA (Burrows-Wheeler-Alignment) tool that generates a Sequence Alignment/Map 
(SAM) file (Li & Durbin, 2009). Picard tools (http://broadinstitute.github.io/picard) sorts the 
aligned reads in the SAM file based on chromosomal coordinates and converts it to a Binary 
Alignment/Map (BAM) format whilst adding sequencing read group information to the BAM file. 
BAM files can be manually visualised using Integrative Genomics Viewer (IGV) software 
(Robinson et al, 2011; Thorvaldsdottir et al, 2013) at this point if a region of interest or candidate 
genes are to be interrogated.   
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The Picard ‘ValidateSamFile’ tool reports on the validity of the BAM file relative to the SAM file 
and writes any errors caused by faulty alignment or improper formatting to an output file. The 
SAMtools bioinformatics package is a set of utilities that allows alignment manipulation of SAM 
and BAM files (Li et al, 2009). SAMtools was used to remove PCR duplicate reads, retaining high 
quality read pairs, in addition to indexing the reference FASTA files and read BAM files. GATK is 
an open-source Java framework platform providing tools for NGS analysis including variant 
calling and quality control of high-throughput NGS data (McKenna et al, 2010). GATK is 
incorporated into the in-house pipeline to facilitate variant calling. Variant calls were made using 
HaplotypeCaller (GATK); base quality score recalibration, INDEL realignment and duplicate 
removal were performed (McKenna et al, 2010). SNP and small INDEL discovery were performed 
using standard hard filtering parameters or variant quality score recalibration according to GATK 
Best Practices recommendations (DePristo et al, 2011; Van der Auwera et al, 2013). Genomic 
Variant Call Format (gVCF) files from multiple canine WGS were merged by CombineGVCFs 
(GATK) into a multi-sample Variant Call Format (VCF) file. Cross-genome analysis was conducted 
using Variant Effect Predictor (VEP) provided by Ensembl on a merged VCF file. 
Whole genome sequencing (WGS) 
Whole genome sequencing (WGS) utilises NGS technology to provide a high-resolution, base-by-
base view of an entire genome for further analysis. A large volume of data is obtained where all 
exonic and non-exonic regions of the genome are captured, subject to sufficient coverage over GC-
rich regions or repetitive structures in the DNA due to incorrect assembly over these difficult 
regions.  
To select buccal cheek swab samples for WGS, the extent of bacterial DNA contamination in each 
sample was determined. Libraries were generated from 1 ng DNA using the Nextera XT library 
preparation reagents and protocol (Illumina; described above), and sequenced on the MiSeq 
platform using the MiSeq Reagent Kit v2 Nano cartridge (Illumina). Paired-end reads 50-bp in 
length were generated. Reads were aligned to the canine reference genome using BWA (Li & 
Durbin, 2010) and the percentage of reads aligned were determined using the “flagstat” command 
in SAMtools (Li et al, 2009). Samples with > 80% alignment (i.e. < 20% bacterial content) were 
considered suitable for WGS. Using this method, the number of reads generated per sample 
(14,669-102,068) provides less than 1X coverage, but is sufficient to give an indication of the level 
of non-dog DNA contamination of the DNA sample.  
Genomic DNA samples selected for WGS were normalised to 25 ng/μL, and 1,000 ng was sent for 
sequencing, outsourced to Edinburgh Genomics, UK. Illumina sequencing of a TruSeq Nano library 
on a HiSeq X sequencing platform (Illumina) generated a dataset of approximately 30X coverage 
of the dog genome. Sequencing data were analysed as described above.  
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De novo assembly 
To perform de novo assembly over regions of interest where coverage was low in WGS data or the 
region was unannotated in the canine reference sequence, the presence of DNA sequence from an 
Illumina read visible in IGV in the region of interest at either end of the gap was queried in the 
FASTQ files using an in-house script. The Linux command-line utility ‘grep’ implemented in the 
script searched for a chosen run of nucleotides (20-30 bp), in both the forward and reverse 
orientation, that were present in all of the sequencing reads in the FASTQ file. The perl script used 
for this de novo assembly is shown in Appendix 5. An output file was generated that contained a 
list of the FASTQ Illumina reads where the searched run of nucleotides was present. This was 
repeated, each time querying a new run of nucleotides further upstream or downstream of the 
previous sequence queried to walk across the sequence ‘gap’. Each sequence read extracted from 
the FASTQ file was converted to FASTA format and reads were assembled into contigs using 
Pregap4 and Gap4 in the Staden software package (Staden et al, 2000). 
2.7 Exclusion of known retinal mutations 
Previously published retinal mutations were screened in two to three cases prior to further 
sample recruitment and investigation in each breed to exclude them as causal variants of PRA 
(Appendix 2). SNVs or small INDELs were genotyped using a genotyping-by-sequencing method, 
described below. Large INDELs or variants within repetitive regions were genotyped using PCR 
amplification, followed by amplified fragment length polymorphism (AFLP) analysis or 
visualisation on an agarose gel using gel electrophoresis. 
To perform genotyping-by-sequencing, primer pairs were designed spanning each mutation to 
amplify DNA fragments between 110–130 bp in size. Primer pairs (Appendix 4, Table A1A) were 
pooled and a multiplex PCR was performed. A primer mix was made by combining 4 μL of each 
100 μM stock primer with 468 μL of ddH2O, achieving a final concentration of 0.2 μM of each 
primer. Each PCR reaction comprised 5 μL primer mix, 2.27 μL deoxyribonucleotide triphosphate 
(dNTP) mix (Thermo Fisher Scientific) at a final concentration of 0.2 mM, 1.7 μL of 10X PCR buffer 
(Qiagen), 1.02 μL MgCl2 (Qiagen) at a final concentration of 1.5 mM, 0.3 μL HotStar Taq (5 units/ 
μL) (Qiagen) and 4.71 μL ddH2O. Thermal cycling conditions for the multiplex PCR are listed in 
Appendix 4. Purification was carried out after each thermal cycling reaction using AMPure XP 
beads (Beckman Coulter), according to manufacturer’s instructions, and using 1:1.75 ratio of 
beads to DNA-containing solution.  
Sequencing libraries were prepared as explained in section 2.6. Five μL of each sample DNA 
library was pooled and quantified using a KAPA library quantification kit, according to the 
manufacturer’s instructions (Kapa Biosystems). The final library was diluted to 15 pM and loaded 
into a 150-bp v3 kit cartridge (Illumina) for single-read sequencing on a MiSeq sequencing 
platform (Illumina). FASTQ files were aligned to the canine genome assembly CanFam3.1 using 
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BWA, producing BAM files. BAM files were visualised in IGV (Robinson et al, 2011; Thorvaldsdottir 
et al, 2013).  
PRA-associated variants that were not included in laboratory screening methods prior to 
undertaking additional genetic analysis (e.g. those within regions difficult to amplify or identified 
after the samples were selected for WGS) were looked for in WGS data of each case to exclude as 
causal for each breed (Appendix 2). 
2.8 Variant filtering 
Effect scores 
An in-house analysis pipeline generated an effect score for each variant based on the predicted 
effect of the variant on the protein sequence i.e. scored whether it is predicted to be deleterious. 
This allows the ranking of all variants. All effect scores and their assignment to sequence ontology 
terms can be found in Appendix 6, as termed by the Ensembl database, and the locations of each 
display term relative to the transcript structure is illustrated in Figure 2.6. As an initial step, 
variant filtering retained only variants with a high effect score (4 and 5), including those resulting 
in premature start/stop codons, splice site variants, nonsense and missense variants, frameshift 
variants, and in-frame INDELs.  
 
Figure 2.6: Effect score sequence ontology terms. A diagram showing the locations of sequence 
ontology terms used to determine effect scores to the relative transcript structure (EMBL-EBI, 
2020). Assigned effect score for the sequence ontology term is in brackets. A full list of terms can 
be found in Appendix 6.  
Segregation scores 
To further aid variant filtering, variants in cases were compared against control dogs in the 
analysis and were assigned in-house segregation scores, calculated as follows: 
Segregation score = Number of samples – Discordant samples 
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Where the ‘Number of samples’ is the count of all the individuals used in the analysis (i.e. the 
number of cases plus the number of controls), and ‘Discordant samples’ is the number of those 
individuals in which the genotype at a particular locus does not match the genotype expected 
based on the mode of inheritance. 
A high segregation score indicates that the variant segregates with disease status. The highest 
possible segregation score is the total number of individuals used in the analysis i.e. in an analysis 
of 1 case versus 199 controls, the highest segregation score assigned is 200. Where a control 
individual shares the same allele at a given position as the affected individual under investigation, 
a lower segregation score is assigned due to the reduced likelihood of a causative variant being 
present in a control dog. Depending on the disease model under investigation, segregation scores 
can be used with effect scores to prioritise candidate variants and filter out variants that are likely 
to be polymorphic, benign, or non-pathogenic.  
OMIM database 
The Online Mendelian Inheritance in Man (OMIM) database (OMIM, 2020) is an online catalogue 
of genes implicated in hereditary disorders in humans. The following list of keywords related to 
PRA were compiled and cross-referenced through the OMIM database to extract genes within a 
candidate list from NGS analysis that were associated with any keywords in the PRA keyword list: 
retina, progressive retinal atrophy, retinitis pigmentosa, rod-cone dysplasia/rod cone dysplasia, 
cone-rod dysplasia/cone rod dysplasia, cone degeneration, retinal degeneration, rod dysplasia, 
photoreceptor, retinal dystrophy, retinal pigment epithelium, nyctalopia, bone spicules, fundus, 
blindness, Leber congenital amaurosis, Bardet-Biedl syndrome/Bardet Biedl syndrome, 
chorioretinal atrophy, chorioretinal degeneration, cone dystrophy, cone-rod dystrophy/cone rod 
dystrophy, rod-cone dystrophy/rod cone dystrophy, congenital stationary night blindness, 
macular degeneration, ocular-retinal developmental disease/ocular retinal developmental 
disease, optic atrophy, Usher syndrome, retinopathy, cilium, ciliopathy. This highlighted genes 
with previous evidence of association with ocular phenotypes and allowed prioritisation of high 
impact variants based on gene function. 
Dog Biomedical Variant Database Consortium 
The AHT Canine Genetics group is a member of the Dog Biomedical Variant Database consortium 
(DBVDC) (Jagannathan et al, 2019), where members are invited to submit canine genomes in the 
form of FASTQ files that are processed into a multi-sample VCF file to be shared with other 
members of the consortium. The multi-sample VCF file was used for additional filtering. Although 
there is usually no phenotype or clinical information submitted with genetic information, 
members can contact owners of genomes for further information if a dog harbours a variant of 
interest to aid in inclusion/exclusion of candidate variants in genetic investigations. 
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2.9 Variant screening 
Screening methods were chosen based on those appropriate for the variant in question. Typically, 
small INDELs were assayed using AFLP analysis and SNVs using allelic discrimination assays. 
Amplified fragment length polymorphism (AFLP) analysis 
AFLP analysis was used for genotyping small INDELs that caused a change in the size of an 
amplicon. PCR products were generated used a specific primer pair, of which one incorporated a 
FAM™ fluorescence (Carboxyfluorescein, 6-FAM). Capillary electrophoresis on a 3130xl genetic 
analyser (Applied Biosystems) was used to separate PCR products and determine allele sizes. This 
technique enables amplicons differing by a single base-pair to be separated and identified, 
distinguishing between wild type and alternate alleles thus also enabling the identification of 
heterozygotes. Each well contained 1 µL PCR product, 9.59 µL Hi-Di formamide (Thermo Fisher 
Scientific,) and 0.41 µL GeneScan™ 400HD ROX or 500 LIZ dye size standards (Thermo Fisher 
Scientific). GeneMapper software (Applied Biosystems) was used to interpret data. 
Allelic discrimination assays 
Allelic discrimination assays were typically employed for genotyping of SNVs at a given position 
in the DNA, using allele-specific fluorescently labelled probes. Forward and reverse primers 
flanking the variant and two allele-specific probes complementary to the two alleles at the variant 
position were designed and prepared as described in section 2.3. Each allele-specific probe is 
labelled with a fluorescent reporter dye (fluorophore FAM™ or HEX™) on the 5’ end and a 
quencher dye (IBFQ) on the 3’ end. When the reporter dye is in close proximity to the quencher, 
the quencher absorbs the energy emitted by the reporter dye causing a reduction in fluorescence. 
Where the allele complementary to the probe is present, probe hybridisation occurs causing the 
quencher to be cleaved by the 5’ to 3’ exonuclease activity of DNA polymerase. Separation of the 
reporter dye from the quencher emits fluorescence. A mismatch between probe and template DNA 
reduces the efficiency of the probe hybridisation and cleavage, and therefore reduces the reporter 
signal of that probe (Livak, 1999). Alleles can be distinguished by determining which reporter dye 
is fluorescing, with an increase in both reporter signals indicating heterozygosity. A real-time PCR 
is used to amplify 2µL template DNA in 0.2 µL of a 10X or 40X assay mix, 4 µL Luna universal qPCR 
Master Mix (NEB) and 1.8 µL ddH2O on a StepOnePlus™ Real-Time PCR system (Applied 
Biosystems). Results were analysed using Applied Biosystems StepOne Software v2.3. 
2.10 Genome-wide association study (GWAS) 
A GWAS approach was used to investigate PRA in the LA using a case-control study design. A flow 
chart illustrating the steps performed in this GWAS approach is shown in Figure 2.7. 
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Figure 2.7: A flowchart illustrating a GWAS study design. 
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SNP genotyping 
Five to twenty micrograms (µg) of DNA was sent externally to GeneSeek (Neogen Europe, Ayr, 
UK) for SNP genotyping, carried out using the 170K Illumina CanineHD array (Illumina, San Diego, 
USA) comprising 172,115 SNPs. Data were returned in GenomeStudio (Illumina) format.  
Quality control and genotyping analysis 
GWAS analysis was conducted using the free open-source toolset PLINK v1.90 
(http://zzz.bwh.harvard.edu/plink/) (Purcell et al, 2007), adapted for use in canine GWAS at the 
AHT. An in-house Perl script termed ‘PLINKDOG’ added the following options in effect to each 
PLINK command: --noweb --dog and --allow-no-sex.  
Genotyping data were exported from GenomeStudio to PED and MAP files. The PED file is a tab 
delimited text file with six mandatory columns: ‘Family ID’, ‘Individual ID’, ‘Paternal ID’, ‘Maternal 
ID’, ‘Sex’ and ‘Phenotype’. Each line in a MAP file describes a single marker and four columns exist: 
‘chromosome’, ‘rs# or SNP identifier’, ‘genetic distance’ (morgans) and ‘base-pair position’ (bp 
units). Instead of assigned Family identity (ID) numbers, each individual was numbered in the 
order they appeared in the file as this was not needed for the GWAS. Individual identity (IID) 
numbers were assigned to each sample from the raw data files using the AHT database number. 
Paternal and Maternal ID were not necessary in this study and therefore were assigned 0 as 
missing. Sex was indicated by 1 (male), 2 (female) or 0 (missing); set as 0 as default. By default, 
the phenotype was missing in the raw PED file and needed to be combined with PED and MAP 
files from GenomeStudio (Illumina) before analysis could be conducted. A phenotype file was 
generated including the family ID (FID) number (assigned by the data file), an IID number and a 
phenotype number: 2 (cases), 1 (controls). This was achieved by using the following PLINK 
command, where X is the file name prefix:  
--plinkdog -–file X –-pheno X.pheno.txt -–keep X.pheno.txt –-recode -–out X 
Genome-wide association mapping was performed by standard allelic association analysis using 
the PED and MAP files using the following command: 
--plinkdog –-file X –-out X –-assoc –-maf 0.05 –-geno 0.03 -–mind 0.1 
This command also includes an initial quality control (QC) filtering for minor allele frequency 
(MAF), missing genotypes per SNP (GENO) and missing genotypes per individual (MIND). SNP 
markers with an allele frequency of less than 5% (MAF 0.05) were excluded, including 
monomorphic SNPs, as they were considered too rare to be informative i.e. where differences 
between the frequency of the allele in cases and controls could be due to chance. SNP markers 
with a genotyping call rate of less than 97% (GENO 0.03) were excluded, based on previous 
analysis within the AHT Canine Genetics research group that showed this threshold was 
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appropriate to preserve high quality data for these arrays. By default, individuals within the 
dataset with more than 10% missing genotypes were omitted (MIND 0.1).  
The above script performs a standard case-control association analysis comprising an unadjusted 
allelic chi-squared (χ2) test for association (1 degree of freedom). This computes the frequency of 
both alleles in cases and controls and performs a χ2 test, obtaining raw p-values (praw). Data from 
a GWAS are typically reported using a Manhattan plot representation, plotting each individual SNP 
using the negative log (-log10) of individual p-values against SNP genomic location. SNPs are 
positioned across the x-axis according to chromosomal position, ordered by ascending genomic 
position (chromosome 1-X). The y-axis represents the -log10 of the SNP’s p-value for association 
with the phenotype. This depicts the strength of associations across the genome, positioning SNPs 
with the lowest p-values, and therefore highest association with disease, higher up on the graph. 
Although the most associated SNP from a GWAS analysis is unlikely to be a causal variant, a 
Manhattan plot highlights genomic regions of interest that can be further interrogated. 
The type I error, also known as the significance level or false positive result, is the probability of 
rejecting the null hypothesis when it is true (Clarke et al, 2011). This incorrectly ascribes scientific 
significance to a statistical test, i.e. assigns significance to a SNP when it is not significant and 
therefore not associated with a disease/trait of interest, which is inappropriate in many cases. . 
Type 2 errors, or false negative results, can occur if the correction for multiple comparisons is too 
stringent or if the power is inadequate (Johnson et al, 2010). To reduce the risk of type 1 and type 
2 errors in canine GWAS analyses, dogs of the same breed should be used considering 
demographic history. Selecting individuals from a varied population, i.e. limiting the number of 
closely related individual dogs within the study cohort, will also help minimise the incidence of 
false positives. In contrast to human GWAS, fewer SNPs are required for canine GWAS to identify 
an association and therefore the risk of type 1 errors is lower. In addition, the canine genome 
shows higher levels of LD. With these long stretches of LD, multiple SNPs will have similar 
statistical significance, which may be correlated with one another, and introduce false negative 
results by reducing the power of true disease associated markers, increasing the risk of type 2 
errors. As hundreds of thousands of statistical tests are performed in GWAS analysis due to the 
extensive number of SNP markers genotyped (known as multiple testing), many of these tests will 
result in a significant p-value (< p = 0.05) by chance. Multiple testing correction is required to 
adjust for the simultaneous testing of multiple hypotheses. Genome-wide significance was defined 
using the Bonferroni correction method to identify significant associations. This is considered the 
most conservative method for selecting a p-value threshold as it assumes independence among 
the association tests (SNPs). A Bonferroni corrected significance threshold was defined by 
dividing the p-value 0.05 by the number of SNPs tested in the GWAS that remained after QC 
filtering, i.e. the number of statistical tests, and represented as a -log10 value on the Manhattan 
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plot. The permutation test, considered the gold standard in adjusting groups of correlated tests 
for multiple testing, accurately takes into account the correlation structure of the genome (Joo et 
al, 2016) and provides evidence that a positive hit from a significant p-value is not likely to be a 
false positive. To adjust for multiple testing, the PLINK Max(T) permutation procedure was 
employed, performing 100,000 permutations (--mperm) (Purcell et al, 2007).  
Population stratification refers to the presence of subpopulations in a group of individuals, most 
likely due to divergent ancestry or relatedness amongst samples. If cases and controls are poorly 
matched based on their ancestry or relatedness or unbalanced between cases and controls, allele 
frequencies could differ between cases and controls because they are not representative of each 
other rather than due to an association with disease (Rogers & Weiss, 2017), potentially giving 
rise to false positive results. The only difference that should exist between cases and controls in 
the study is their phenotype for the disease under investigation, although canine researchers tend 
to favour ‘super controls’ that are over the typical age of onset for the disease under study. 
Diagnostic plots based on GWAS data can be used to assess the presence of population 
substructure. Two main plots are used to visualise GWAS data: multi-dimensional scaling (MDS) 
plots and quantile-quantile (Q-Q) plots. To perform MDS analysis, the following PLINK command 
was executed: 
--plinkdog –-noweb --dog –-allow-no-sex –-nonfounders -–file X -–make-founders  –--cluster –-
mds-plot 2 -–out X 
MDS plots can be used to identify individual outliers in a population due to a difference in ancestry 
or where cases and controls are not representative of each other. Each individual in the PLINK 
MDS output file was assigned a phenotype number of either 1 (control) or 2 (case). Data from this 
file were then plotted as scatter graphs with the first dimension (covariate 1) on the x-axis and 
the second dimension (covariate 2) on the y-axis with each point representing an individual, 
either a case or control. 
Q-Q plots detect inflation of GWAS test statistics by enabling a graphical representation of how 
much the observed p-values deviate from the expected p-values from a hypothetical χ2 
distribution when plotted against one another. The overall degree of stratification, known as the 
inflation factor (lambda, λ), is calculated based on comparing the expected and observed median 
p-values; in the absence of stratification lambda is very close to 1. This occurs when the observed 
values correspond to the expected values until significant true observed associations are 
identified at the top end scale where the two should diverge. Where the majority of observed 
values begin to deviate from the expected throughout, this indicates that many moderately 
significant p-values are reported as more significant than expected under the null hypothesis and 
is likely to be due to the presence of population stratification (Ehret, 2010). Conversely, when only 
 Chapter 2 General Materials and Methods 
50 
 
a few of the most significant observed values deviate from the expected values, it is an indication 
that population stratification is not a factor and the association is real. Q-Q plots were generated 
as follows: 
1. The -log10 p-value was generated for each observed p-values from the PLINK association 
output file. 
2. These -log10 observed p-values were sorted from largest to smallest and assigned a rank 
from 1 to the total number of SNPs i.e. ranked 1 to 108,263. 
3. An expected p-value was calculated by subtracting 0.5 from the rank number and dividing 
by the total number of SNPs tested e.g. for rank 1 value: (1 minus 0.5) divided by 108,263.  
4. A -log10 p-value was generated for each expected p-value.  
5. The expected (x-axis) and observed (y-axis) -log10 p-values were plotted on a graph. The 
baseline representing lambda as 1 was generated by plotting the expected p-value for each 
marker against itself on the x-axis and y-axis. 
6. The genomic inflation factor (lambda) was generated by calculating the median for the 
observed and expected values, and dividing the observed median by the expected median.  
Population stratification and sample relatedness in the GWAS was corrected for using Efficient 
Mixed-Model Association eXpedited (EMMAX) (Kang et al, 2010). This is a statistical test 
performed separatley to PLINK analysis in order to exclude false-positive associations of SNPs 
with the disease phenotype by correcting the PLINK results. The association analysis performed 
with PLINK corrects for population structure but does not account for relatedness in the sample. 
Therefore, EMMAX is used to correct the PLINK result to account for both ancestry and population 
structure. 
2.11 In silico tools 
The Ensembl genome browser (www.ensembl.org; Dog releases 87-98) (Aken et al, 2016) and 
UCSC genome browser (http://genome.ucsc.edu/) (Kent et al, 2002) were used to obtain canine 
reference genome sequence (Sep.2011. Broad CanFam3.1/canFam3) to interrogate regions. All 
features, such as genes, transcripts, exons and proteins, that have been annotated and mapped in 
the genome are given unique identifiers. Where genes have been annotated with known function, 
information or orthology, a gene name (gene symbol) is also assigned. Where a gene name has not 
been assigned in the canine genome, but sequence annotation and chromosomal position is 
known, an Ensembl stable identifier is assigned. In the dog, this is given the prefix ‘ENSCAF’ 
followed by a unique identifier number. The Ensembl BioMart data mining tool (Ensembl Dog 
release 87) (Aken et al, 2016) was used to search for human orthologues of unassigned canine 
gene names (i.e. querying canine ENSCAF numbers) to obtain human gene names. 
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Mutation Analyzer (NCBI Mutation Analyzer, 2017), PolyPhen-2 (Adzhubei et al, 2010) and SIFT 
(Kumar et al, 2009) were used to predict potential impact of amino acid substitutions on the 
structure and function of proteins. Mutation Analyzer uses a BLOSUM62 scoring matrix to 
compare amino acid substitutions, reporting residues that substitute frequently as positive scores 
(coloured green) and those that substitute rarely as negative scores (coloured red). PolyPhen-2 
calculates the probability that a given mutation is damaging, reporting estimates of false positive 
rates (the chance that the mutation is classed as damaging although it is non-damaging) and true 
positive rates (the chance that the mutation is classed as damaging when it is indeed damaging) 
(Adzhubei et al, 2010). PolyPhen-2 also reports qualitative classification of a mutation as benign, 
possibly damaging or probably damaging. A SIFT score is a normalised probability of observing 
the new amino acid at that position, and ranges from 0 to 1 where a value between 0 and 0.05 is 
predicted to affect protein function (Sim et al, 2012). Putative promoter regions were predicted 
using Gene2Promoter (Genomatix software suite, 2017) and PromoterInspector (Scherf et al, 
2000) and transcription factor binding sites (TFBSs) using MatInspector (Cartharius et al, 2005). 
2.12 Buffers and solutions 
Nucleon reagent A 
To make 1 litre (L), 1.576 grams (g) Trizma Hydrochloride (Sigma-Aldrich), 109.53 g Sucrose 
(Sigma-Aldrich), 1.017 g MgCl26H2O (Sigma-Aldrich), 19 mL Triton X-100 (Sigma-Aldrich) and 
900 mL ddH2O were combined. The pH was adjusted to 8.0 with 40% NaOH (Sigma-Aldrich) and 
the solution autoclaved before use. 
Nucleon reagent B 
To make 1 L, 63 g Trizma Hydrochloride (Sigma-Aldrich), 22.3 g EDTA (Sigma-Aldrich), 8.8 g 
sodium chloride (NaCl; Sigma-Aldrich) and 800 mL ddH2O were combined. The pH was adjusted 
to 8.0 with 2M NaOH (Sigma-Aldrich) and the solution volume adjusted to 1 L then 10 g Sodium 
dodecyl sulphate (SDS; Sigma-Aldrich) added. 
Sodium perchlorate solution (5M) 
To make 1 L, 612.2 g sodium perchlorate (5M) was dissolved in ddH2O to a volume of 1 L and 
filtered using a Nalgene sterile single use vacuum driven filter unit (Thermo Fisher Scientific). 
Loading buffer 
Ten mL of glycerol was combined with 4 mL 500 mM EDTA, 1 mL 1 M TRIZMA® Base and 1 mL 
bromophenol blue (all from Sigma-Aldrich). The solution was diluted 1:5 with 1X TAE buffer. 
DNA size marker “2-Log DNA ladder” 
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Forty µL of 2-Log ladder (NEB) was combined with 120 µL loading buffer and 240 µL 1X TAE 
buffer.    
Cell culture growth medium 
The following were added to a 500 mL bottle of Dulbecco's Modified Eagle Medium (DMEM) with 
4.5 g glucose: 10% fetal bovine serum, 2 mM penicillin-streptomycin mix and 2 mM L-glutamine 
(all from Invitrogen) and stored at 4 °C for use within six weeks. 
Lysogeny broth (LB) 
To make 500 mL, 5 g Tryptone, 2.5 g yeast extract and 2.5 g NaCl (all from Sigma-Aldrich) were 
added to 450 mL ddH2O and stirred on an electronic stirring plate using a stirring flea. Once 
dissolved, the volume was made up to a total of 500 mL and autoclaved. If antibiotic was to be 
added, this was done following autoclaving once the liquid had reached a temperature 
approximately under 50 °C to prevent antibiotic degradation and stored at 4 °C for use within six 
weeks. 
Lysogeny broth (LB) agar 
To make 500 mL, 5 g Tryptone, 2.5 g yeast extract and 2.5 g NaCl (all from Sigma-Aldrich) were 
added to 450 mL ddH2O and mixed by inversion by hand. Following this, 7.5 g Bacteriological agar 
(Sigma-Aldrich) was added and the solution stirred on an electronic stirring plate using a stirring 
flea. Once dissolved, the volume was made up to a total of 500 mL and autoclaved.  If antibiotic 
was to be added, this was done following autoclaving once the liquid had reached a temperature 
approximately under 50 °C to prevent antibiotic degradation. Following the addition of antibiotic, 
plates were stored at 4 °C and used within six weeks.  
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Chapter 3 PRA in the Giant Schnauzer 
3.1 Introduction 
The Giant Schnauzer (GS) dog is the largest of three recognised sizes within the Schnauzer group: 
Giant, Standard, and Miniature, and is believed to have originated in Germany. Although the 
precise origins are unclear, it is thought the breed was developed using a variety of breeds 
including the Standard Schnauzer, Rottweiler, Great Dane, German Shepherd, and perhaps 
Bouvier De Flandres (American Kennel Club, 2007). Today, the three breed sizes are recognised 
as distinct breeds by The Kennel Club, UK and do not interbreed. A total of 282 GS were registered 
with The Kennel Club, UK in 2019 and over the last decade, this registration total has not changed 
significantly, with an average of 238 dogs registered per year since 2010 (The Kennel Club UK, 
2020).  
Currently, the GS is recognised by the BVA/KC/ISDS eye scheme to suffer from hereditary 
cataracts (HC). In 2018, 912 GS dogs underwent a BVA/KC/ISDS eye examination of which 16 
were diagnosed as affected HC (British Veterinary Association, 2018). To date, PRA has not been 
listed on the current or previous versions of the eye scheme for the GS and is not considered to be 
seen frequently enough to warrant routine screening of PRA in this breed. 
This chapter describes the identification of a previously unidentified PRA-associated variant in 
perhaps the first reported PRA cases in the UK GS population. The gene implicated has not 
previously been associated with retinal degeneration in any species. Although the small number 
of cases suggests this is a newly emerging form of PRA in the breed, identification of the genetic 
cause will enable further screening in the breed to confirm or exclude this hypothesis and improve 
understanding of the aetiology of this form of PRA.  
A manuscript describing this study was accepted for publication following peer-review in the 
Canine Genetics Special Issue of the journal, Genes in May 2019. Rebekkah Hitti-Malin performed 
all laboratory and in silico experiments, formal analysis, data curation, validation and manuscript 
preparation. The manuscript was reviewed by all authors, with editing contributions from Dr 
Cathryn Mellersh, Dr David Sargan, Dr Tosso Leeb, Dr Louise Burmeister, Dr James Oliver and Dr 
Oliver Forman. Parts of the text here (specifically parts of the methods and results sections) follow 
parts of that manuscript entirely written by Rebekkah Hitti-Malin, with some additions and 
modifications in the text in this thesis. 
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3.2 Materials and methods 
3.2.1 PRA diagnosis and sample collection  
PRA was initially diagnosed in a four-year-old GS male dog at the AHT by a board-certified 
veterinary ophthalmologist who is also a qualified BVA/KC/ISDS eye scheme panellist and a 
diplomate of the European College of Veterinary Ophthalmologists. Ophthalmoscopic examination 
detected widespread tapetal hyperreflectivity, retinal vascular attenuation and atrophy of the 
optic nerve head; consistent with PRA (Figure 3.1). A reduced pupillary light response was also 
observed. Follow-up examination of littermates by separate board-certified veterinary 
ophthalmologists identified two additional male dogs that were affected by PRA; meaning a total 
of three of the seven dogs in the litter, which comprised six males and one female, were affected 
by PRA. The sire and dam were clinically unaffected at eight and eleven years of age, respectively. 
A review of the medical records of each dog showed no history of neurological disease in any dog. 
gDNA was extracted from buccal mucosal swabs following the protocols described previously (see 
section 2.2). 
 
Figure 3.1: Fundus changes observed in GS dogs showing (A) non-affected GS dam at 11 years; 
(B) GS PRA case at five years of age. Observations of PRA cases include bilateral tapetal 
hyperreflectivity and retinal vascular attenuation. 
For the Finnish cohort used for subsequent variant screening, eye examinations were conducted 
by veterinary ophthalmologists board-certified by the European College of Veterinary 
Ophthalmologists; 3 mL EDTA-blood was collected under the permission of animal ethical 
committee of County Administrative Board of Southern Finland (ESAVI/343/04.10.07/2016) and 
DNA was extracted from white blood cells using a semi-automated Chemigen extraction robot 
(PerkinElmer Cheagen Technologie GmbH, Baeswieler, Germany) according to manufacturer’s 
instructions.  
3.2.2 Exclusion of known retinal mutations 
Prior to WGS, 25 previously reported variants associated with retinal disease in the dog were 
excluded as causal in two of the three GS dogs diagnosed with PRA by a veterinary 
 Chapter 3 PRA in the Giant Schnauzer 
55 
 
ophthalmologist and/or a panellist of the BVA/KC/ISDS Eye Scheme. Full materials and methods 
are described in Chapter 2 (section 2.7).  
3.2.3 Whole genome sequencing (WGS) 
DNA from four GS (two PRA cases and both non-affected parents) was prepared for WGS. WGS 
was performed and data were processed and analysed following the protocols described in 
section 2.6. 
3.2.4 Variant filtering 
WGS data of two PRA-affected GS full-siblings were compared with corresponding data of their 
non-affected parents and control dogs. Variants were filtered by the predicted effect of each 
variant on the transcript and protein and then based on those segregating appropriately for:   
1. An X-linked recessive condition i.e. dam is heterozygous, both cases are hemizygous 
(appearing as homozygous on the X chromosome when visualising sequencing reads in 
IGV) and the sire is hemizygous for the alternate allele. 
2. An autosomal recessive mode of inheritance i.e. variants were retained if cases were 
homozygous, parents heterozygous, and controls homozygous for the alternate allele. The 
DBVDC was used for additional variant filtering to screen more canine genomes from 
multiple dog breeds.  
To exclude known canine XLPRA mutations that could not be excluded prior to WGS, sequencing 
reads from the two GS PRA genomes were visualised in IGV and a de novo assembly of sequencing 
reads across the mutation regions was conducted, as described in Chapter 2 (section 2.6). In 
addition, the genome data of six additional genes associated with X-linked retinal diseases in 
humans: RP2 (Bhattacharya et al, 1984; Hardcastle et al, 1999), OFD1 (Coene et al, 2009; 
Hardcastle et al, 2000; Webb et al, 2012), TIMM8A (Jin et al, 1996), CACNA1F (Bech-Hansen et al, 
1998; Strom et al, 1998) and NYX (Bech-Hansen et al, 2000; Gal et al, 1989; Hardcastle et al, 1997) 
were visualised for variants that were heterozygous in the dam, hemizygous (appearing 
homozygous on the X allele in IGV) in both cases and hemizygous for the wild type/common allele 
in the sire. 
3.2.5 Variant screening 
Primers and allelic discrimination probes were designed as described in Chapter 2 (section 2.3). 
Individual custom probe-based assays were resuspended in ddH2O to a 40X mix and combined. 
Allelic discrimination assays were carried out as described in Chapter 2 (section 2.9) using qPCR 
primers and probes and conditions listed in Appendix 4. Results were analysed using Applied 
Biosystems StepOne Software v2.3. 
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For the Finnish cohort, DNA was amplified by PCR using components listed in Table 3.1 and 
primers and conditions listed in Appendix 4. PCR products were sequenced by Sanger sequencing 
as explained in Chapter 2 (section 2.5).  
Table 3.1: PCR components used to amplify the NECAP1 variant in the Finnish cohort. 
Component Volume/reaction (μL) Final concentration 
10X PCR Buffer 1.20 1X 
MgCl2 (50mM) 0.40 0.008 mM 
dNTP (10mM) 0.24 0.024 mM 
Forward primer (5 mM) 1.90 0.380 mM 
Reverse primer (5 mM) 1.90 0.380 mM 
Betaine (5M) 2.00 0.400 mM 
Biotools DNA Polymerase (5 units/ μL) 0.10 0.020 
ddH2O 3.06 - 
Total (μL) 10.8 0.120 
 
3.2.6 In silico protein prediction tools 
To assess the impact of the candidate variant amino acid substitution on gene protein function, 
bioinformatics tools Mutation Analyzer, PolyPhen-2, and SIFT were used to computationally 
predict the effect of the missense variant. 
3.2.7 Comparative species conservation  
The Evolutionary Conserved Region Browser (http://ecrbrowser.dcode.org) and UCSC Genome 
Browser were used to determine the degree of sequence conservation of the NECAP1 gene across 
species. Using the human genome (GRCh37/hg19) as the base genome, NECAP1 human 
coordinates were compared across five species.  
3.2.8 Screening cohorts 
To increase the number of individual dogs that were ultimately screened, collaborators at the 
University of Bern, Switzerland (n = 199); University of Helsinki, Finland (n = 487) and Mars 
Veterinary, UK (n = 3,162), kindly genotyped DNA from dogs of multiple different breeds, 
including mixed breed dogs and dogs of unknown breeds, for the candidate variant. Breed-specific 
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allele frequencies for the candidate variant were determined using cohorts of dogs from the AHT, 
UK; University of Bern, Switzerland and University of Helsinki, Finland because the dogs 
comprising these cohorts were all ‘purebred’ dogs of known breeds. The dataset from Mars 
Veterinary, UK, comprised mixed-breed individuals originally submitted for breed testing on the 
Wisdom Panel platform, a commercially available test used to estimate breed ancestry of mixed 
breed dogs, and these genotyping results did not therefore contribute towards overall breed 
frequency calculations. 
3.2.9 Sanger sequencing of NECAP1 variant 
The candidate SNV was confirmed in all three GS PRA cases by PCR amplification; primers and 
conditions are listed in Appendix 4. PCR products were sequenced using the Sanger sequencing 
method described in Chapter 2 (section 2.5). 
3.2.10 Expression of NECAP1 in canine retina 
RNA sequencing (RNA-seq) data generated from retinal RNA of a PRA non-affected Petit Basset 
Griffon Vendéen control dog for a previous unrelated project (Forman et al, 2015) were used to 
determine gene expression. Using RNA-seq expression data published in GeneCards (Stelzer et al, 
2016), three genes known to be implicated in retinal degeneration and considered to be expressed 
in retinal tissue (RPGRIP1, RHO, and GNAT1) and three genes considered to have low/no 
expression in human retinal tissue (ANXA1, MYH41, MYOT) were selected as control genes to 
evaluate expression in the control retinal RNA-seq data from a Petit Basset Griffon Vendéen dog. 
The total number of reads aligned to each of the six control genes was obtained using BEDTools 
v2.17.0 ‘coverage’ tool (Quinlan & Hall, 2010) and compared to that of NECAP1. An average 
number of reads per exon was calculated for each gene. 
3.2.11 Haplotype analyses 
A total of eight SNVs, four either side of the NECAP1 variant, that were homozygous in the cases 
and heterozygous in the parents were selected for genotyping. SNVs were situated up to 573 Kb 
downstream of the variant and 301 Kb upstream. Primers were designed using Primer3 and 
products amplified using PCR conditions, purification, and Sanger sequencing, as described in 
Chapter 2 (sections 2.3, 2.4 and 2.5), and primers listed in Appendix 4. SNVs surrounding the 
variant were genotyped across two GS PRA cases, both GS parents, one control GS, one 
heterozygous Giant Spitz, six heterozygous Miniature Long-Haired Dachshunds, and a control 
Miniature Long-Haired Dachshund to determine a disease-associated haplotype. 
3.2.12 Autozygosity mapping 
Illumina Canine HD array SNP positions were extracted from the four GS WGS datasets into binary 
files using PLINK2 (www.cog-genomics.org/plink/2.0/) (Chang et al, 2015) and an in-house PERL 
script. PLINK v1.07 (Purcell et al, 2007) was used to identify runs of homozygosity (ROH) using 
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sliding windows across the SNP data using the default values: -homozyg-window-kb 5000 (length 
in Kb of the sliding window); -homozyg-window-snp 50 (minimum number of SNPs that the 
sliding window requires); -homozyg-window-het 1 (allowing 1 heterozygous SNP in a window to 
tolerate genotyping errors); -homozyg-window-missing 5 (allowing up to 5 missing calls in a 
window); -homozyg-window-threshold 0.05 (proportion of overlapping windows required as 
homozygous to define a given SNP in a ROH); -homozyg-snp 100 (sliding window of 100 SNPs); -
homozyg-kb 1000 (sliding window of 1,000 Kb/ 1 Mb); -homozyg-density 50 (minimum density 
of 1 SNP per 50 Kb); and -homozyg-gap 1000 (split a segment into two if the distance between 
two SNPs is > 1,000 Kb, i.e., retaining ROH >1 Mb in size). ROH overlapping with one or both 
parents were removed therefore leaving regions that were homozygous in the cases and 
heterozygous in the parents. Genes within each ROH block were cross-referenced with the RetNet 
database (RetNet, 2020) and RetNet gene regions were visualised in the GS WGS data for high 
impact SNVs or structural variants.  
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3.3 Results 
3.3.1 Variant identification 
Screening for 26 previously published retinal mutations (Chapter 2, section 2.7) revealed all PRA-
affected GS were clear of all these mutations. At the time of study, 118 canine genomes sequenced 
as part of other studies at the AHT were available to use as non-breed matched controls to 
compare against the PRA-affected GS genomes. Of these 118 genomes, 112 were of dogs that were 
recruited for non-PRA studies, considered to be PRA controls for the purposes of this study, 
comprising 110 dogs across 58 different dog breeds and 2 cross breed dogs. Date of births were 
known for 69 of the 112 non-breed matched controls, with dogs ages ranging from 0.1 - 15.4 years 
at the time of DNA submission, with a median age of 6.3 years (interquartile range 1.6 - 8.7 years). 
These dogs were affected with conditions including epilepsy, sensory neuropathy, hereditary 
cataracts, glaucoma and primary lens luxation. WGS data from two PRA-affected full-siblings were 
compared with corresponding data of their non-affected parents and 112 control dogs (a total of 
116 genomes/VCFs in analysis). A total of 25,658,899 variants were detected amongst 116 canine 
genomes of 58 breeds and 2 cross breeds, including the four GS genomes. The DBVDC was used 
for further filtering that, at the time of study, contained 452 WGS, 13 of which were contributed 
by the AHT. 
X-linked recessive model 
As the three PRA-affected GS dogs in the litter were males, and both parents were clinically clear 
of PRA, an X-linked recessive mode of inheritance was considered. Following WGS, previous 
XLPRA mutations (XLPRA1 and XLPRA2; Zhang et al, 2002) were excluded by conducting a de 
novo assembly of sequencing reads across the mutation regions in the RPGR gene. As well as 
manually interrogating the entire RPGR gene in the GS genomes by visualising sequencing reads 
in IGV software, the genome data of six additional genes associated with X-linked retinal diseases 
in humans: RP2, OFD1, TIMM8A, CACNA1F and NYX were visualised for variants that were 
heterozygous in the dam, hemizygous (appearing homozygous on the X allele in IGV) in both cases 
and hemizygous for the wild type/common allele in the sire. No variants segregated in this way. 
WGS analysis filtered for variants predicted to have a high/severe effect on the protein-coding 
sequence and present only on the X chromosome. One variant that had the correct segregation 
pattern for an X-linked recessive disorder also had a high effect score (in-frame insertion): a 9-bp 
insertion (CAGCAGCAG) in exon one of the androgen receptor (AR) gene. Visualisation of this 
insertion in the WGS data in IGV showed this to be within the second of two polymorphic tri-
nucleotide CAG repeats, within exon 1 of the canine AR gene (CANFAX: 51,970,321). Polymorphic 
CAG repeat length variations in AR cause inherited disease in humans, including associations with 
spinal and bulbar muscular atrophy (SBMA) (La Spada et al, 1991), however in humans there is 
only one CAG repeat in a location that is orthologous to the first CAG repeat in the canine genome 
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(Lai et al, 2008). The insertion of three additional CAG repeats in the GS genomes results in an 
increase from 11 to 14 CAG repeats, with previous reports of CAG repeats at this location reported 
in the Single Nucleotide Polymorphism Database (dbSNP) (rs853062526). Expression of AR in 
canine retinal tissue was assessed in RNA-seq data from a Petit Basset Griffon Vendéen dog and 
showed no sequencing reads aligning to the gene, suggesting AR is not expressed in the normal 
canine retina.  
Autosomal recessive model 
As both parents were clinically clear of PRA, and no candidate variants segregating with the 
disease were identified through an X-linked recessive disease model, an autosomal recessive 
model was implemented. Variants predicted to be highly penetrant were prioritised, however 
employing this filtering method has limitations. These include the lack of further prioritisation of 
non-coding variants in known IRD/PRA genes and the possibility of dismissing structural variants 
or non-coding variants in potential novel IRD/PRA genes. Filtering for protein changing variants 
on all chromosomes reduced the initial 25,658,899 variants to 102,716 variants that were 
predicted to have a high/severe effect on coding sequence and alter the protein. These included 
variants that introduced a loss/gain of the start/stop codon, missense variants, in-frame INDELs 
and splice-site variants. Of these, 12 variants had an effect score of 3 and above, were homozygous 
in both cases, heterozygous in both parents and either homozygous for the common allele (n = 5) 
or heterozygous (n = 7) in the initial control set of 112 canine genomes. 
Genomes in the DBVDC, comprising 452 genomes of 94 individual breeds, eight cross breeds, and 
three wolves were used for additional filtering to highlight common variants. Exclusion criteria 
included the presence of dogs that were homozygous for a specific variant and/or more than 10 
heterozygous dogs (that were not GS dogs) identified within the consortium genome bank. 
Genotypes of the initial 12 variants were also extracted from genomes in the DBVDC. This resulted 
in the exclusion of seven variants, which had already been previously excluded using the initial 
control set 112 canine genomes due to the presence of multiple heterozygous individuals of other 
breeds. Details of the seven variants that were excluded are listed in Table 3.2. 
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Table 3.2: Seven variants excluded from filtering analysis.  Further filtering using the DBVDC 
dataset excluded seven of the twelve variants identified through variant filtering based on the 
presence of alleles in additional dogs. 
CanFam3.1 
Chromosomal 
Coordinates 
Gene Variant 
Total number of 
homozygous canids in 
DBVDC 
Total number of 
heterozygotes in 
AHT and DBVDC 
genomes 
23: 5,421,356 ENSCAFG00000010012 Missense 
variant 
Entlebucher 
Sennenhund (n=1) 
and Miniature 
Schnauzer (n=1) 
39 
23: 5,421,500 ENSCAFG00000010012 Missense 
variant 
Miniature Schnauzer 
(n=1) 
40 
27: 40,341,520 RAD51AP1 Missense 
variant 
 Yorkshire Terriers 
(n=3) 
26 
30: 7,520,689 C15orf52 Missense 
variant 
Lagotto Romagnolo 
(n=1), Norwich 
Terrier (n=1), Bichon 
Frise (n=1),  West 
Highland White 
Terrier (n=2),  
23 
8: 62,125,521 CCDC88C Missense 
variant 
Bearded Collie (n=1), 
Golden Retriever 
(n=1), Newfoundland 
(n=1), West Highland 
White Terrier (n=1), 
Yorkshire Terrier 
(n=2) 
47 
23: 9,908,657 RPL14 Splice 
site 
variant 
0 24 
23: 5,421,400 ENSCAFG00000010012 3-bp 
insertion 
Miniature Schnauzer 
(n=1), Yorkshire 
Terrier (n=1) 
39 
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The GATK HaplotypeCaller tool was used to perform a local reassembly and realignment of 
sequencing reads in the GS cases to confirm the five variants of potential interest (Table 3.3). At 
the time of analysis, three variants were situated within a novel gene, ENSCAFG00000030684, for 
which no human homologues existed nor did any annotated genes lie nearby. Since the update of 
a more recent annotation of the CanFam3.1 canine assembly in the Ensembl database (database 
version 100.31), this ENSCAF gene is no longer present in Ensembl, however the addition of a 
nearby gene is present: the HNRNP3 gene located on chromosome 36 between coordinates 
20,974,648-20,980,137. The locations of the three variants identified in the former 
ENSCAFG00000030684 gene were visualised in the updated Ensembl CanFam3.1 canine 
assembly, however none of these variants are located in any newly annotated genes and therefore 
would not have passed the original filtering. HaplotypeCaller local realignments showed both 
cases and parents were in fact heterozygous for two of the variants within the novel gene, as well 
as a variant within the LURAP1L gene. This left a single candidate missense variant in the gene 
NECAP1 encoding the NECAP endocytosis associated 1 protein for which, aside from the two GS 
parents, only one additional heterozygous dog was identified (Giant Spitz breed) in the full dataset 
of 568 genomes (WGS controls and DBVDC cohort). 
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Table 3.3: Variants retained following filtration steps. Variant filtering revealed five variants from 
WGS analysis that were not homozygous in a control set 568 genomes. HaplotypeCaller enabled 
local realignment of sequencing reads to confirm/exclude each variant call from the WGS analysis. 
CanFam3.1 
Chromosomal 
Coordinates 
Gene 
GATK 
analysis 
consequence 
in GS cases 
HaplotypeCaller 
realignment 
consequence in GS 
cases 
Homozygote 
in DBVDC 
11: 33,389,711 LURAP1L 
Homozygous 
missense 
variant 
followed by a 
frameshift 
variant 
Heterozygous 8-bp 
insertion (CAGCAGCA) 
followed by 
heterozygous T/A SNV 
in a repetitive region 
Unable to 
determine 
27: 37,468,611 NECAP1 
Homozygous 
missense 
variant 
Homozygous missense 
variant 
None 
36: 20,974,031 ENSCAFG00000030684 
Homozygous 
missense 
variant 
Homozygous missense 
variant 
Chinese 
Indigenous 
dog (n = 1) 
36: 20,974,357 ENSCAFG00000030684 
Homozygous 
missense 
variant 
Heterozygous missense 
variant 
None 
36: 20,974,370 ENSCAFG00000030684 
Homozygous 
missense 
variant 
Heterozygous missense 
variant 
None 
 
The c.544G>A non-synonymous variant is in exon 6 of 8 in the NECAP1 gene at the following 
coordinates: CANFA27:37,468,611 (CanFam 3.1 assembly; Figure 3.2), and is predicted to cause a 
glycine (G) to arginine (R) amino acid substitution at amino acid position 182 (p.G182R).  
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Figure 3.2: View of the NECAP1 SNV in WGS data in IGV. Two GS PRA cases are homozygous (A,B) 
for the c.544G>A (p.Gly182Arg) SNV in exon 6 of 8 of NECAP1, the PRA non-affected sire (C) and 
dam (D) are heterozygous for the variant, and Vizsla control is homozygous for the wild type allele 
(E). 
Sanger sequencing confirmed all three GS PRA cases were homozygous for the mutant allele 
(A/A), both obligate carrier parents were heterozygous (G/A) and the remaining four PRA non-
affected littermates were either heterozygous or homozygous for the wild type allele (G/G) 
(Figure 3.3, Figure 3.4). 
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Figure 3.3: Sanger sequencing traces of the NECAP1 c.544G>A SNV in NECAP1 in three GS PRA 
cases (A, B, C); the heterozygous non-affected sire (D) and dam (E); a homozygous wild type non-
affected sibling (F), and a heterozygous non-affected sibling (G). 
 
Figure 3.4: Pedigree of the GS family showing NECAP1 genotypes. Male dogs are represented as 
a square symbol and female dogs as a circle symbol. PRA cases were homozygous for the NECAP1 
variant (NECAP1-/-); clinically clear relations were either heterozygous (NECAP1 +/-) or 
homozygous for the wild type allele (NECAP1 +/+). Labels A-G correspond to Sanger sequencing 
traces in Figure 3.3 as follows: three NECAP1-/- PRA cases (A, B, C); the NECAP1 +/- non-affected 
sire (D) and dam (E); a NECAP1 +/+ non-affected sibling (F), and a NECAP1 +/- non-affected sibling 
(G). 
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3.3.2 In silico protein predictions 
To assess whether the c.544G>A; p.G182R amino acid substitution affects protein function, 
bioinformatics tools Mutation Analyzer, PolyPhen-2, Mutation Taster2, and SIFT were used to 
predict the effect of the missense variant. Mutation Analyzer and PolyPhen-2 predicted the amino 
acid change to be rarely tolerated and probably damaging to the protein, respectively. Mutation 
Taster predicted the amino acid substitution to be disease-causing and SIFT predicted the change 
to be deleterious with a SIFT score of 0.03. 
3.3.3 Comparative species conservation 
NECAP1 is conserved across species showing > 80% sequence similarity to the human orthologue. 
The glycine amino acid at amino acid position 182 that is substituted to an arginine in the present 
study is highly conserved across 31 mammals, including humans, mice and rhesus macaques. In 
addition, the GGG codon implicated is well conserved across 37 mammals, including humans. 
Using the human genome (GRCh37/hg19 assembly) as the base genome, the degree of 
evolutionary sequence conservation of NECAP1 was assessed in the zebrafish, chicken, mouse, dog 
(CanFam2.0 assembly) and rhesus macaque (Figure 3.5A). All coding exons were conserved 
across the human, dog and rhesus macaque, sharing the highest degree of NECAP1 sequence 
conservation across the species evaluated. The mouse genome only shared sequence conservation 
across exons 5 and 6 of NECAP1 and the zebrafish and chicken genomes displayed an absence of 
conservation across all exons. There is variability in the conservation of NECAP1 amino acid 
residues across exon 6, however the affected amino acid glycine is highly conserved through 
evolution (Figure 3.5B). 
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Figure 3.5: Display of NECAP1 conservation across species. (A) Evolutionary conserved regions of human NECAP1 (GRCh37; chr12: 8234807-
8250373) are highly conserved across the rhesus macaque and dog (CanFam2 assembly) genomes. The mouse construct shows poorer conservation, 
with only exons 5 and 6 conserved. (B) Evolutionary conservation of the amino acid affected by the canine NECAP1 missense variant (p.G182R; glycine 
boxed in red) and surrounding amino acids across the human, zebrafish, chicken, mouse, dog and rhesus macaque show a high degree of conservation. 
Amino acids numbered are relative to the dog sequence (CanFam2 assembly). 
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3.3.4 NECAP1 c.544G>A screening 
To investigate whether the variant is common in the breed, additional GS dogs were genotyped 
for the c.544G>A variant. Six additional GS heterozygotes were initially found. Screening an 
additional 427 dogs of 122 breeds, including 65 Miniature Schnauzers, identified one Miniature 
Long-Haired Dachshund that was heterozygous for the c.544G>A variant. 
3.3.5 Population screening 
The presence of the NECAP1 variant in GS dogs and dogs of additional breeds led to the screening 
of additional GS dogs, Miniature Long-Haired Dachshunds and varieties of German Spitz dogs. In 
total, the c.544G>A candidate variant was genotyped in 5,130 canids. Where known, 1,974 canids 
were of 173 breeds, 10 cross breed dogs, and 3 wolves, including a total of 323 GS dogs (Appendix 
7).  
Of the GS screened, only the three PRA-affected GS were homozygous for the variant and 19 
heterozygotes were identified, nine of which were closely related (within three generations) to 
the two WGS cases, and ten were either known to be not closely related to the affected dogs based 
on pedigree information, or deemed unknown due to lack of pedigree information. Allele 
frequency in GS dogs, excluding closely related dogs, was 0.015.  
Genotyping cohorts of additional breeds of German origin, including Spitz and Dachshund 
varieties, identified dogs that were heterozygous for the variant. Genotyping data were compiled, 
and allele frequencies determined (Table 3.4). Four PRA affected dogs (two Miniature (Klein) 
Spitz and two Pomeranian Spitz) were included in the testing cohorts. These were homozygous 
for the wild type allele, suggesting their PRA phenotype is due to a different PRA-associated 
variant. Out of the total 5,130 canids genotyped for the NECAP1 variant, the only dogs homozygous 
for the variant were the three GS PRA cases. 
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Table 3.4: Total allele frequency of NECAP1 SNV in multiple breeds of dog. 
Breed 
NECAP1 
+/+ 
NECAP1 
+/− 
NECAP1 
−/− 
Total 
Allele 
Frequency 
Giant Schnauzer (GS) 301 19 3 323 0.039 
GS * 300 9 0 309 0.015 
Giant Spitz 109 7 0 116 0.030 
Medium Spitz 146 5 0 151 0.017 
Miniature Spitz 109 8 0 117 0.034 
Pomeranian Spitz 56 3 0 59 0.025 
Miniature Long-
Haired Dachshund 
160 8 0 168 0.024 
172 other breeds, 
mixed breeds and 
unconfirmed breeds 
4,181 15 0 4,196 - 
* excluding third generation relatives to proband from known pedigree information. 
One of the study cohorts (Mars Veterinary, UK) consisted of a combination of unconfirmed breeds 
and mixed breed dogs (n = 3,162) in which 21 additional heterozygotes were identified. Six 
heterozygotes were purebreds, comprising Miniature Long-Haired Dachshund (n = 2), Standard 
Smooth-Haired Dachshund (n = 1), Miniature Spitz (n = 2), and GS (n = 1); 13 were mixed breed 
dogs for which breed compositions could be estimated (Table 3.5); and breed type could not be 
estimated for two heterozygotes. As this cohort included various mixed breed or unknown breeds 
of dogs, these were excluded from the breed specific allele frequency calculations. 
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Table 3.5: Known breed compositions of mixed breed dogs tested by Mars Veterinary, UK. Breeds 
are known for 13/15 NECAP1 heterozygous mixed breed dogs. 
Dog Breed composition 
1 50% Dachshund mix 
2 50% Pekingese mix, (trace German Spitz) 
3 25 % Poodle, 12.5% Russell Terrier, 12.5 % Vizsla mix (trace German Spitz) 
4 25% Australian Kelpie, 25% Labrador Retriever mix (trace Dachshund) 
5 62.5% Dachshund, 12.5% Brittany Spaniel mix 
6 
37.5% American Staffordshire Terrier, 12.5% Labrador Retriever, 25% Dutch Shepherd 
Dog mix 
7 50% German Shepherd dog mix (trace dachshund) 
8 50% Labrador Retriever mix 
9 75% Pomeranian mix 
10 12.5% Rottweiler, 12.5 % Tibetan Mastiff mix 
11 25% Poodle, 25% Kritikos Lagonikos mix (trace Japanese Spitz) 
12 12.5% Dachshund, 12.5% Pumi, 12.5 % Pekingese mix 
13 
12.5 % Dachshund, 12.5% Rhodesian Ridgeback, 12.5% Kritikos Lagonikos, 12.5% 
Poodle mix 
3.3.6 NECAP1 is expressed in canine retina 
A qualitative measure of expression was observed by extracting the total number of reads per 
exon from retinal RNA-seq data from a PRA non-affected Petit Basset Griffon Vendéen dog and 
calculating a mean number of reads per exon for each gene (Table 3.6). A total of 749 reads aligned 
over all eight exons of NECAP1, with 288 reads aligned specifically over exon 6 (Figure 3.6), 
providing evidence that NECAP1 is expressed in canine retinal tissue to similar levels as RPGRIP1. 
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Table 3.6: Example of genes expressed in control canine retina. The total number of exonic reads 
in three genes considered to be expressed in human retinal tissue (RPGRIP1, RHO and GNAT1)  and 
three genes considered to have low/no expression in human retina (ANXA1, MYH41 and MYOT) 
were extracted and the mean number of reads per exon calculated. Comparison of these six 
control genes and the values generated for NECAP1 using canine RNA-seq data showed reads 
aligning to NECAP1 providing evidence of gene expression in the Petit Basset Griffon Vendéen 
control canine retina. 
Gene CanFam3.1 Chromosomal 
Coordinates 
Total Number of Exonic Reads Mean Number of 
Reads Per Exon 
RPGRIP1 15: 18,316,887-18,387,548 1,458 58 
RHO 20: 5,632,150-5,637,404 461,640 92,328 
GNAT1 20: 39,129,469-39,133,156 118,800 13,200 
ANXA1 1: 84,744,444-84,763,121 120 9 
MYH41 5: 34,748,657-34,767,076 3 0 
MYOT 11: 25,591,798-25,592,328 40 4 
NECAP1 27: 37,460,607-37,506,942 749 94 
 
 
Figure 3.6: IGV display of RNA-seq data from a control canine retina (Petit Basset Griffon Vendéen 
(PBGV) dog) aligned to the CanFam3.1 canine genome show reads mapping to NECAP1. 
3.3.7 Haplotype analyses 
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To establish whether the NECAP1 variant identified in dogs of different breeds is due to recurrent 
independent mutation events or inherited identically by descent, SNVs flanking the variant were 
genotyped in the two GS PRA cases, both GS parents, one control GS, one heterozygous Giant Spitz, 
six heterozygous Miniature Long-Haired Dachshunds, and a control Miniature Long-Haired 
Dachshund. SNVs present as homozygous for the alternate allele in the GS PRA cases and 
heterozygous in the obligate carrier parents were determined. Shorter haplotypes were revealed 
in the Giant Spitz and Miniature Long-Haired Dachshund, with the shortest in the Dachshund, 
compared to that of the GS, suggesting the shared region may be an ancestral and ancient 
haplotype (Figure 3.7). 
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Figure 3.7: Schematic diagram of NECAP1 alleles. To build a disease-associated haplotype, a total of eight SNVs up to 301 Kb upstream and 573 Kb 
downstream of the NECAP1 variant were genotyped in (A) two PRA affected GS NECAP1 homozygotes, both NECAP1+/- non-affected parents, and an 
non-affected NECAP1+/+ GS; (B) one NECAP1+/- Giant Spitz from the DBVDC and (C) six NECAP1+/- Miniature Long-Haired Dachshunds (MLHD) and one 
NECAP1+/+ Miniature Long-Haired Dachshund. A disease associated haplotype (shaded orange) was determined. The reference allele is shaded yellow. 
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3.3.8 Autozygosity mapping 
Concurrently with the variant filtering approach taken, an autozygosity mapping approach was 
also undertaken to identify ROH present in both PRA affected GS dogs. After filtering and quality 
control, 106,298 SNPs were tested through PLINK and identified thirteen ROH that were over 1 
Mb in size and shared exclusively by both GS PRA cases (Table 3.7, Figure 3.8). As initial analysis 
excluded an X-linked mode of inheritance, variants identified on the X chromosome were omitted. 
Table 3.7: ROH identified in GS genomes using PLINK. PLINK analysis identified 13 ROH 
exceeding 1 Mb in size present in both PRA affected GS dogs. The NECAP1 SNV lies within the 9.03 
Mb ROH identified on chromosome 27. 
CanFam3.1 Chromosomal Coordinates Size (Mb) 
1:29,970,719-33,682,751 3.71 
6:33,954,067-39,111,638 5.16 
8:59,486,837-65,640,116 6.15 
10:64,657,382-69,250,914 4.59 
13:58,887,427-60,841,228 1.95 
21:12,842,407-19,235,893 6.39 
23:54,039-17,493,091 17.44 
25:23,239,981-26,009,032 2.77 
27:36,722,004-45,753,342 9.03 
28:13,922,125-15,662,789 1.74 
29:38,572,915-41,054,487 2.48 
30:1,366-26,126,946 26.13 
36:17,518,975-21,096,460 3.58 
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Figure 3.8: Chromosomal positions of ROH greater than 1 Mb in size (blue), on canine autosomes 
in the two GS PRA cases, as obtained through PLINK analysis. The red block indicates the 9 Mb 
ROH on CANFA27 in which the NECAP1 variant lies. 
Eight ROH harboured at least one gene present in the RetNet database (RetNet, 2020) and have 
been previously associated with human retinal disease. Upon visualisation of WGS data from both 
PRA cases and non-affected parents, no structural variants or protein-changing variants were 
detected. The NECAP1 variant identified through the variant filtering process lies within a 9 Mb 
ROH on CANFA27 and remained the most likely variant to be disease-causing. 
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3.4 Discussion 
PRA in GS dogs is not routinely screened for through the BVA/KC/ISDS eye scheme, as currently 
it is not seen frequently enough to be considered problematic in the breed. As a consequence, only 
three PRA cases have been identified in the breed to our knowledge; all siblings and with clinically 
clear parents. DNA samples from both parents, all three PRA cases with a robust PRA diagnosis, 
and four non-affected littermates were submitted for research.  
The litter consisted of six males and one female, with the three PRA affected dogs all males. For 
this reason, an X-linked recessive mode of inheritance was considered. WGS analysis based on an 
X-linked recessive model and screening of six X-linked retinal candidate genes excluded this 
hypothesis. Therefore, a recessive model was adopted where both parents were considered to be 
obligate carriers of a recessive form of PRA. Previous published studies have identified PRA-
associated variants in multiple breeds of dog; but, to date, there is no published evidence of any 
being present in GS dogs. However, a DNA test for PRCD-PRA mutation is commercially offered 
for over 70 breeds, including the GS (Mars Veterinary, UK), suggesting this mutation has been 
previously found in the GS breed. The three PRA cases in the present study were clear of 26 
previously reported retinal mutations, including PRCD-PRA, suggesting the presence of a novel 
PRA-causing variant. Six previously published retinal mutations were not included in the 
screening to exclude known PRA-associated variants. These included three XLPRA mutations 
caused by variants in the RPGR gene (Kropatsch et al, 2016; Zhang et al, 2002) in the Siberian 
Husky, Samoyed, mixed breed dogs and Weimaraner dogs and a variant in the C1orf36 gene 
responsible for rod cone dysplasia type 2 (rcd2) in Collie dogs (Kukekova et al, 2009) all of which 
are within regions of high GC content and were highly technically challenging to assay. De novo 
assembly of WGS reads in both GS cases were able to show that both cases were normal for these 
XLPRA variants. A number of other variants in the following genes were either not published at 
the time of study or were not known of at the time of exclusion screening: SAG (Goldstein et al, 
2013a), NPHP5 (Goldstein et al, 2013b), PPT1 (Murgiano et al, 2018), ABCA4 (Makelainen et al, 
2019) and HIVEP3 (Kaukonen et al, 2020). These regions were subsequently visualised in WGS 
data in both GS cases and were further excluded.  
WGS is increasingly becoming the method of choice, when sample numbers are limited, to identify 
causative mutations associated with Mendelian diseases in many species. Although WGS is used 
for complex disease studies, this is generally alongside other methods such as GWAS. This 
technology has led to success in identifying mutations in canine inherited diseases using a very 
small number of cases and is a cost-effective approach when a GWAS or other positional 
approaches are unattainable due to small sample numbers. For this reason, a comprehensive WGS 
approach was elected for this study. Following WGS a quartet of GS dogs (two full-siblings and 
both parents), variants were firstly filtered for those predicted to have a severe impact on the 
 Chapter 3 PRA in the Giant Schnauzer 
77 
 
protein sequence by the assignment an in-house effect score. This ranks variants by their severity 
i.e. scored on pathogenicity with a score of 1-5; low-high severity, respectively (see Chapter 2, 
section 2.8). Secondly, as both parents were considered obligate carriers, the filtering process 
could be structured to retain variants that were heterozygous in both parents, and homozygous 
for the alternate allele in both PRA cases. All control genomes used in the analysis also aided in 
variant filtering, as they were expected to be either heterozygous for the causal variant, or 
homozygous for the common allele (typically the reference sequence). There is greater variation 
amongst the genomes of different breeds than within breeds, where more than a quarter of 
variation is due to differences between breeds (Parker et al, 2004). Therefore, the addition of WGS 
from both GS parents facilitated variant identification by removing breed specific variants that 
were also homozygous in the parents but absent from all other breeds and reduced the initial 
number of starting variants. A novel candidate missense variant in NECAP1 was eventually 
identified; this gene has not formerly been implicated in retinal degeneration in any species. 
The canine NECAP1 gene on CANFA27 is comprised of eight exons spanning 46 Kb and shares 84% 
identity with the human NECAP1 gene (GRCh38.p13 Ensembl Gene ID ENSG00000089818). In 
humans, the N-terminal region of NECAP1 is located between amino acid residues 1-178 and 
contains the PH fold with ear-like function (PHear) domain (amino acid residues 1-133; Figure 
3.9) (Ritter et al, 2007), a member of the pleckstrin homology (PH) superfamily. NECAP1 encodes 
NECAP endocytosis associated 1, also termed adaptin ear binding coat associated protein 1, a 
subunit of the adaptor protein-2 (AP-2) heterotetrametric protein complex involved with clathrin 
mediated endocytosis (CME) in synapses (Ritter et al, 2003). CME is a vesicular transport event 
from the plasma membrane that primarily initiates the entry of material into cells using clathrin-
coated vesicles (CCVs) that mature from clathrin-coated pits. In addition to clathrin, the coats on 
these CCVs contain a variety of adaptor proteins including AP-1, AP-2 and AP-3 (Mattera et al, 
2004).  
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Figure 3.9: NECAP1 human protein (adapted from Ritter et al., 2013). The N-terminal 
(NECAP1_N) is positioned between amino acid residues 1-178, is highly conserved across species 
(Ritter et al., 2007) and contains the PHear domain (amino acid residues 1-133). The ‘WVQF’ motif 
is located between amino acid residues 272-275, which binds to site on the AP-2 accessory 
protein. The NECAP1 candidate SNV affects amino acid position 182, as highlighted by a red 
asterisk. The nonsense variant in NECAP1 described below, which has previously been associated 
with a recessive early infantile epileptic encephalopathy (EIEE) in humans (Alazami et al, 2014; 
Alsahli et al, 2018), affects amino acid residue 48, as indicated by a red arrow. 
CME is the endocytic portal into eukaryotic cells for cargo molecules and facilitates nutrient 
uptake, signal transduction, neurotransmission, the recycling of receptors and the regulation of 
many plasma membrane events, as well as playing a role in synaptic vesicle reformation 
(McMahon & Boucrot, 2011; Ritter et al, 2004; Takei & Haucke, 2001). Complex endocytic 
machinery organised around AP-2 binds to the clathrin coat membrane and traps various 
transmembrane proteins, including cargo receptors, to enrich CCVs (Ritter et al, 2003). This 
triggers the formation of CCVs at the plasma membrane to engulf cargo molecules and enable the 
release of these into the cell following endocytosis. As clathrin does not directly bind to the plasma 
membrane or to cargo receptors, the ear domains of adaptor protein subunits and complexes such 
as AP-2 serve as a platform to allow numerous endocytic accessory proteins, cargo and clathrin to 
associate with the plasma membrane during CCV formation. This is facilitated via recognition of 
specific sequence motifs, termed ‘endocytic motifs’. Endocytic motifs are specific amino acid 
sequences that recognise target proteins that require endocytosis and work as a signal to bind to 
adaptor proteins. Each endocytic accessory protein contributes to one or more specific roles in 
vesicle formation, including membrane deformation, cargo recruitment and vesicle size facilitated 
by the interaction of these adaptor proteins with domains to target vesicle formation sites 
(McMahon & Boucrot, 2011). One such accessory protein, NECAP1, is a CCV-enriched protein and 
a modulator of AP-1 and AP-2 interactions (Mattera et al, 2004; Ritter et al, 2013). The novel α-
ear-binding endocytic motif ‘WVQF’, representing an amino acid sequence of tryptophan (W), 
valine (V), glutamine (Q) and phenylalanine (F) of NECAP1 (Figure 3.9), binds to sites on AP-2, 
restricting the binding of accessory proteins. When clathrin binds to vesicle formation sites, 
NECAP1 binding is prohibited and results in the formation of a second complex in which NECAP1 
and AP-2 cooperate in accessory protein recruitment, specifically to increase the probability that 
a vesicle will form and to determine vesicle size and cargo content for CME (Ritter et al, 2013). 
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NECAP1 is significant for efficient accessory protein recruitment to vesicle formation sites to 
facilitate CME in normal synaptic cell function. 
While NECAP1 was initially reported to be primarily expressed in brain tissue (Ritter et al, 2003), 
it has also been detected throughout the central nervous system in mice, including the spinal cord 
(Alazami et al, 2014) and retina of mice and beagle dogs (Blake et al, 2017; Paez et al, 2006). 
Retinal RNA-seq data from a PRA non-affected Petit Basset Griffon Vendéen dog revealed that 
NECAP1 is considered to be moderately expressed in canine retinal tissue when compared to 
genes known to be implicated in retinal degeneration and expressed in retinal tissue. There is also 
evidence that NECAP1 (and its family member, NECAP2) interacts with phosphorylated AP-2 in 
human RPE cells where disruption of components involved in the phosphorylation event of AP-2 
impacts clathrin-coated pit maturation, blocking CME (Wrobel et al, 2019). Wrobel et al. (2019) 
showed that phosphorylated AP-2 is present in ~70% of clathrin-coated pits in human RPE cells, 
which increases with clathrin-coated pit maturation, and is important for efficient CME. Previous 
work involving RP mouse models demonstrated that CME is present, albeit playing a minor role, 
in retinal ribbon synapses in photoreceptors and bipolar cells of the retina (Park et al, 2008). Park 
et al. (2008) showed that CME is carried out at the rod bipolar cell axon terminals in the mouse 
retina, suggesting that this process may be important for normal synaptic function in the 
mammalian retina. RP mouse models of early-onset retinal degeneration produced by a mutation 
in the Pde6b gene showed changes in the postsynaptic cells of the rod and cone photoreceptors in 
the retina (Park et al, 2008). Specifically, bipolar cells integrating signals of rod photoreceptor 
cells, involved in the rod neural pathway, generate ribbon synapses that are usually formed by 
postnatal day 14 in mice retinas. Preferential changes in endocytosis at the rod bipolar ribbon 
synapses were reported in mice exhibiting rapid photoreceptor degeneration, including abnormal 
synaptic ribbons in rod bipolar cells where clathrin was no longer expressed in comparison to a 
control mouse retina (Park et al, 2008). Moreover, an example of a gene involved in CME causing 
RP in humans is the receptor expression enhancing protein-6 (REEP6) gene (Arno et al, 2016; 
Veleri et al, 2017). REEP6 is involved in intracellular trafficking of CCVs to membrane sites, and a 
loss of REEP6 function resulted in photoreceptor cell death in mouse models (Veleri et al, 2017).  
Studies using Drosophila as an RP disease model highlight the significance of endocytosis of 
rhodopsin, a light sensitive protein, which is a crucial component of the phototransduction 
cascade triggering vision. Endocytosis of metarhodopsin II, the active form of rhodopsin, in 
rhabdomeres present in Drosophila photoreceptors is essential for photoreceptor maintenance. 
Endocytosis of metarhodopsin is facilitated by the binding of arrestin to AP-2, hence when this 
pathway is compromised, metarhodopsin accumulates in the rhabdomeres and leads to the 
degeneration of photoreceptors (Xiong & Bellen, 2013). Examples of rhodopsin accumulation 
caused by mutations in genes involved in endolysosomal pathways (Chinchore et al, 2009; 
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Dourlen et al, 2012) suggest that reduced endocytosis in photoreceptors lead to an accumulation 
of rhodopsin, resulting in photoreceptor cell death and ultimately retinal degeneration.  
Although there is no direct functional evidence supporting the involvement of NECAP1 in retinal 
function, mutations in endolysosomal trafficking genes with similar molecular mechanisms to 
NECAP1 (discussed above) suggest this is a provocative novel candidate gene for retinal 
degeneration. Studies of mice suggest that CME is essential for processes at the rod bipolar ribbon 
synapses in the mammalian retina (Park et al, 2008; Veleri et al, 2017); therefore, it can be 
ventured that if the expression or function of a gene regulating this process is disrupted, its role 
in maintaining rod bipolar ribbon synapses and subsequently photoreceptor function may be 
compromised. It can be speculated that the NECAP1 glycine to arginine substitution identified in 
GS dogs with PRA impacts protein function, and that potential inactivation of the AP-2 adaptor 
complex could disrupt endocytosis in retinal neurons, such as ribbon synapses in photoreceptor 
and bipolar cells. It is plausible that as a consequence of CME disturbance in the retina, rhodopsin 
accumulates in the photoreceptors, leading to cell death and retinal degeneration.  
Currently, there are no reports of NECAP1 directly implicated in retinal degeneration in any 
species. However, in humans, a c.142C>T; p.R48* nonsense variant in NECAP1 has previously been 
associated with a recessive early infantile epileptic encephalopathy (EIEE) (Alazami et al, 2014; 
Alsahli et al, 2018). Epileptic encephalopathy is a heterogeneous group of neurological disorders 
characterised by intractable epileptic activity and is described as infantile when the age of onset 
is within the first few months of life. Clinical signs of EIEE include severe intractable seizures from 
early infancy with a progressive change in frequency and intensity. Following ERG and neuro-
ophthalmological evaluations, no retinal abnormalities were detected in the patients homozygous 
for the NECAP1 c.142C>T; p.R48* variant (Alazami et al, 2014), however, evidence of retinal 
degeneration has been reported in patients with other forms of EIEE in addition to typical EIEE 
clinical signs (Palmer et al, 2016; Turkdogan et al, 2017). One study described the involvement of 
the ARV1 gene in EIEE, where an infant with a form of autosomal recessive EIEE was found to be 
homozygous for a donor splice site variant resulting in exon skipping and protein truncation with 
the loss of 40 amino acids. Ophthalmoscopic evaluation revealed that at six weeks of age, a 
minimal pupillary response to light was present leading to a diagnosis of an early-onset retinal 
degeneration, consistent with LCA. The patient died at one year of age (Palmer et al, 2016). A 
second study identified a novel 1-bp deletion in GNB5 causing a multisystem syndrome. Patients 
presented with signs of EIEE, as well as retinal degeneration, cardiac abnormalities, severe 
neurological developmental delay, and premature sudden death (Turkdogan et al, 2017). 
Although these discussed forms of EIEE are caused by mutations in different genes, it can be 
speculated that the EIEE patients homozygous for the NECAP1 variant may not have either 
survived long enough to develop retinal changes, or were not old enough at the time of study to 
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exhibit retinal changes, aged seven years and 3.4 years, respectively (Alazami et al, 2014; Alsahli 
et al, 2018). Arguably, patients reported in the aforementioned studies may have had both EIEE 
and retinal degeneration as a result of genetically distinct diseases. In this PRA study in GS dogs, 
no MRI scans or neurological examinations were performed; however no obvious neurological 
abnormalities were noted by the veterinary ophthalmologist(s) or by their owners. Despite the 
absence of any epileptic or neurological signs, this study suggests that NECAP1 is associated with 
retinal degeneration and is the cause of PRA in these GS dogs. Furthermore, it can be hypothesised 
that the predicted premature truncation of the NECAP1 protein by the nonsense mutation 
described by Alazami et al. (2014) has a more extreme consequence on the protein than a 
missense SNV, as in the GS cases, therefore could account for the severity of the disease in humans 
compared with the GS dogs. Given the importance of NECAP1 in the central nervous system, it is 
reasonable to hypothesise that variants in NECAP1 affect retinal function and induce ocular 
phenotypes.  
In the GS family studied, the NECAP1 c.544G>A variant segregates with disease phenotype and is 
detected in a heterozygous state in additional breeds. Sixty-five Miniature Schnauzer dogs were 
genotyped in follow-up validation, in which no copies of the NECAP1 variant were identified. This 
is not inconsistent with what is understood about the history of the Miniature Schnauzer and the 
GS, which are recognised as two distinct breeds and are not interbred. Additional genotyping of 
Standard Schnauzers and other breeds used to develop the GS breed may be more informative; 
however, sample numbers available for these breeds limited this scope. A causal mutation would 
be expected to be flanked by homozygous regions that were inherited with the mutation. 
Haplotype analysis showed that the NECAP1 c.544G>A variant is present on a shared identical 
haplotype in additional breeds, implying that it arose from an ancestral founder mutation event 
and is inherited identically by descent rather than being identical by state. This hypothesis is 
supported by the retrospective autozygosity mapping, which was conducted to support WGS 
findings and showed the NECAP1 variant lies within a ROH unique to the cases. This also suggests 
the c.544G>A SNV is more likely to be identical by descent rather than identical by state and 
provides additional evidence for its association with the disease. It is not uncommon for 
deleterious mutations to be shared across seemingly unrelated breeds, for example the PRCD-PRA 
mutation has been detected in various diverse dog breeds (Zangerl et al, 2006). The GS breed is 
believed to have originated in Germany and both those Dachshund and Spitz varieties carrying 
the NECAP1 variant also appear to be of German ancestry. Shared haplotype analysis identifies 
only the Standard Schnauzer, Airedale Terrier, and Black Russian Terrier as ancestors to the GS, 
however, a study by Parker at al. (2017) examined haplotypes >232 Kb, which are likely to detect 
only more recent events. Parker et al. (2017) did not examine haplotypes in the Giant or Medium 
Spitz, and the NECAP1 haplotype established in the Miniature Long-Haired Dachshund is only half 
the size described in the study. It can be hypothesised that the founding haplotype was present in 
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a dog of German ancestry, most likely ancestors of the Dachshund varieties, and prior to the 
development of these other breeds. Typically, the lengths of common shared ancestral 
chromosomal segments in a population are short due to the occurrence of recombination events 
over time, where the shorter haplotype in the Dachshund indicates increased recombination on 
what once was a longer haplotype. The detected haplotype may have been common in the 
population when the NECAP1 variant arose and, therefore, normal copies of this haplotype were 
also present. The breed allele frequency of 0.015 suggests that this form of PRA in the GS is rare, 
resulting in insufficient cases to conduct a GWAS. Additionally, this low allele frequency provides 
scope for the NECAP1 c.544G>A variant to be eliminated from the breeding GS population in a 
reasonable timeframe. The use of the commercial DNA test launched at the AHT in May 2019, 
termed ‘PRA5’, can prevent this form of PRA becoming widespread in the GS population. 
It is important to note that other inheritance patterns, namely mosaicism and a dominant partially 
penetrant disorder, were not considered in the GS pedigree under investigation, however these 
are plausible forms of inheritance, which may result in the PRA disease phenotype. Germline 
mosaicism occurs in the germ line cell population, and therefore the individual (in the case of the 
GS family, this being both parents) can be unaffected, but its offspring affected. As three out of 
seven littermates were affected, a dominant PRA with partial penetrance could also have been 
considered, where the disease-causing variant is present in individuals with and without clinical 
signs and the disease displaying partial penetrance. Such forms of inheritance should be 
considered in future studies of PRA and other Mendelian disorders. Lastly, an additional limitation 
to this study is that structural variants and low-priority variants were not considered due to the 
supporting evidence of the NECAP1 variant, which remained the most compelling candidate, given 
the caveats. 
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Chapter 4 PRA in the Lhasa Apso 
4.1 Introduction 
PRA has been reported in the Lhasa Apso (LA) dog but, until now, no genetic risk factor has been 
identified (Downs & Mellersh, 2014; Miyadera et al, 2009). In the present study, pedigree analysis 
indicated PRA has autosomal recessive inheritance in LA dogs, however the exact age of onset is 
unknown. The LA is currently listed on the BVA/KC/ISDS Eye Scheme and is advised to have 
annual eye examinations by a panellist, especially when used for breeding.  
This chapter describes the use of multiple genetic technologies to explore a novel form of PRA in 
the LA breed. Utilisation of GWAS and WGS datasets revealed a novel variant that is strongly 
associated with PRA in the LA. A WES dataset that was generated from three LA PRA cases and 
three LA controls for a separate study in our laboratory was also interrogated, however no 
protein-coding mutations were found. The gene implicated is a retinal candidate gene involved in 
human inherited retinal disease. Variant validation facilitated the development of a DNA test, 
which has been utilised for over two years to reduce the prevalence of this form of PRA in the 
breed.  
Findings from this research investigation have been submitted for publication following peer-
review in the journal, BMC Genetics. Rebekkah Hitti-Malin performed all laboratory and in silico 
experiments, formal analysis (with statistical analysis by Dr Tom Lewis), data curation, validation 
and manuscript preparation. The manuscript was reviewed by all authors, with editing 
contributions from Dr Cathryn Mellersh, Dr David Sargan, Dr Sally Ricketts and Dr Tom Lewis. 
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4.2 Materials and methods 
4.2.1 PRA diagnosis and sample collection 
The study cohort consisted of DNA samples submitted to the AHT and to the University of 
Cambridge (Dr David Sargan) for research. Where known, owners of LA dogs included in the study 
resided in the UK, Austria, Germany and The Netherlands. All LA dogs were examined by a 
veterinary ophthalmologist through a clinical referral process or via the BVA/KC/ISDS Eye 
Scheme in the UK, or the European equivalent(s). Ophthalmoscopic examinations of PRA cases 
detected bilateral retinal atrophy, widespread tapetal hyperreflectivity and retinal vascular 
attenuation. In some cases, secondary bilateral cataracts were also observed. The age of diagnosis 
was known for 19 of the 21 cases and ranged from 1.75 - 11.96 years of age with a median age of 
7.11 years (interquartile range 5.01 - 7.99 years). An arbitrary age of eight years or older was 
therefore elected for LA dogs without signs of PRA to be used as “controls” based on this. Buccal 
mucosal cheek swabs were used to collect gDNA from cases and controls. gDNA was extracted 
using protocols described in Chapter 2 (section 2.7). 
4.2.2 Exclusion of known retinal mutations 
Twenty-five previously reported variants associated with retinal disease in the dog were excluded 
as causal in two LA dogs clinically affected with PRA, as determined by a veterinary 
ophthalmologist and/or a panellist of the BVA/KC/ISDS Eye Scheme. Full materials and methods 
are described in Chapter 2 (section 2.7). 
4.2.3 Genome-wide association study (GWAS) 
A GWAS approach was used to investigate PRA in the LA using a case-control study of 44 LA dogs 
(17 PRA cases and 27 controls), as described in Chapter 2 (section 2.10).  
A secondary GWAS analysis was conducted using three LA PRA cases that were genotyped as part 
of the initial GWAS but were not homozygous for the critical region. A new phenotype file was 
generated as before, indicating these three dogs as cases and the remaining control LA from the 
GWAS as controls. New MAP and PED files were also generated as previously described. Due to 
the small number of cases in this analysis, a standard case-control association analysis using a 
Fisher’s exact test was performed using the following command replicating QC parameters from 
the initial analysis and performing 100,000 permutations (--mperm), where X is the file prefix: 
--plinkdog --file X --fisher --geno 0.03 --maf 0.05 --mind 0.1 --mperm 100000 --out X_fisher 
4.2.4 Whole genome sequencing (WGS) 
Whole genome sequencing (WGS) was performed as described in Chapter 2 (section 2.6) of one 
LA PRA case that was included in the GWAS and was homozygous for the critical region. 
Sequencing reads and variants were visualised manually in IGV (Robinson et al, 2011; 
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Thorvaldsdottir et al, 2013) across the defined disease-associated region identified by the GWAS 
analysis and compared to 102 WGS non-breed matched controls. 
4.2.5 Characterisation of the IMPG2 LINE-1 insertion 
The length of the long interspersed nuclear element-1 (LINE-1) insertion was estimated by PCR 
amplification using PrimeSTAR® GXL DNA Polymerase (Takara Bio Europe, Saint-Germain-en-
Laye, France) and primers listed in Appendix 4. Reaction components in Table 4.1 were combined 
and PCR performed as described in Appendix 4. PCR products were separated using agarose gel 
electrophoresis, as described in Chapter 2 (section 2.3). 
Table 4.1: Reaction components to amplify the IMPG2 LINE-1 insertion. 
Component Volume/reaction (μL) Final concentration 
dNTPs (1.5 mM) 4.00 0.20 mM 
PrimeStar GXL 5X buffer 10.00 1X 
Forward Primer (20 μM) 0.75 0.30 μM 
Reverse Primer (20 μM) 0.75 0.30 μM 
PrimeStar GXL polymerase (1.25 units/μL) 1.00 1.25 units/μL 
ddH2O 31.50 - 
Total (μL) 48.00  
 
Long PCR products were generated in the same way for NGS to determine the LINE-1 DNA 
sequence. Long PCR products were purified and prepared for NGS on a MiSeq platform (Illumina) 
using the methods listed in Chapter 2 (section 2.6). De novo assembly was performed using 
SOAPdenovo (Xie et al, 2014). L1Base2 (http://l1base.charite.de/) was used to analyse the LINE-
1 insertion sequence in the dog genome (Penzkofer et al, 2017). 
4.2.6 Variant screening 
Candidate variants within the disease-associated region were genotyped in LA PRA cases and 
controls. Genotyping of the IMPG2 LINE-1 insertion was performed using PCR amplification 
followed by AFLP analysis, as described in Chapter 2 (section 2.9). using reaction components 
listed in Table 4.2 and primers and conditions listed in Appendix 4. 
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Table 4.2: Amplification of IMPG2 LINE-1 insertion for AFLP analysis. 
Component Volume/reaction (μL) Final concentration 
dNTPs (1.5 mM) 1.60 0.20 mM 
HotStarTaq Plus 10X PCR buffer 1.20 1X 
Forward Primer 1 (wild type) (10 μM) 0.11 0.09 μM 
Forward Primer 2 (affected) (10 μM) 0.22 0.18 μM 
Reverse Primer (10 μM) 0.22 0.18 μM 
HotStarTaq Plus Polymerase (5 units/μL) 0.24 0.10 units/μL 
ddH2O 6.42 - 
Total (μL) 10.00  
 
Allelic discrimination assays were performed as described in Chapter 2 (section 2.9) using 
primers and conditions listed in Appendix 4.  
Genotypes for the most associated GWAS SNP (BICF2G630247609) and the CEP97 intronic SNV 
(CANFA33: 8,044,097) were determined by PCR amplification using primers and conditions listed 
in Appendix 4. PCR products were sequenced using the Sanger method as described in Chapter 2 
(section 2.5). 
NNSPLICEv.0.9 (Reese et al, 1997; Berkeley Drosophila Genome Project, 2020) was used to 
evaluate splice site prediction to determine if intronic variants of interest caused disruption or 
introduction of exonic splicing or cryptic splicing 
4.2.7 Predicting the IMPG2 promoter region 
To predict the promoter region of the IMPG2 gene, DNA sequence annotated in the CanFam3.1 
canine genome assembly positioned upstream of the gene was queried through in silico tools 
Gene2Promoter (Genomatix software suite, 2017) and PromoterInspector (Scherf et al, 2000). 
Transcription factor binding sites (TFBSs) located within the sequence were predicted using the 
in silico tool MatInspector (Cartharius et al, 2005). 
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4.2.8 Reporter assay 
Cell culture 
Canine skin fibroblast cells, Madin-Darby canine kidney (MDCK) cells and canine mesenchymal 
stem cells (MSC) cryopreserved in liquid nitrogen were fast-thawed over a period of 3-5 minutes. 
Cells stored in cryovials were removed from liquid nitrogen and left to thaw in a 37 °C water bath 
until a fluid phase was reached. The cell suspension was pipetted to 10 mL cell culture growth 
medium (see recipe in Chapter 2, section 2.12) and immediately centrifuged for 5 minutes at 160 
×g to remove the DMSO containing freezing media. The cell pellet was resuspended in cell culture 
growth medium, plated in a 56.7 cm2 cell culture dish and incubated at 37 °C. 
Cells were observed using a phase contrast microscope (EVOS XL Care, Life Technologies, Thermo 
Fisher Scientific). Once at confluence, media was removed using a pipette and cells were washed 
briefly using PBS (Gibco, Thermo Fisher Scientific). Cells were then detached using Trypsin with 
EDTA 0.5% (1X, Invitrogen, Thermo Fisher Scientific) for 3-5 minutes at room temperature or 
phenol red TrypLE™ Express Enzyme (1X, Invitrogen, Thermo Fisher Scientific) for up to 5 
minutes at 37 °C. Detached cells were resuspended in culture media and centrifuged at 160 ×g for 
5 minutes at room temperature to pellet cells. The cell pellet was resuspended in 1 mL TRI-
Reagent (Sigma-Aldrich) and stored at -80 °C until further use. 
RNA extraction and isolation 
Harvested canine skin fibroblast cells, MDCK and MSCs stored at -80 °C in TRI-Reagent (Sigma-
Aldrich) were thawed on ice and incubated at room temperature for 5 minutes. Phase separation 
was initiated by the addition of 300 µL chloroform (Thermo Fisher Scientific) followed by 
incubation at room temperature for 5 minutes and centrifugation at 12,500 ×g for 15 minutes at 
4 °C. The aqueous phase was removed and combined with 1 volume of 70% ethanol (Thermo 
Fisher Scientific) by pipetting. The solution was transferred to a RNeasy column (Qiagen RNeasy 
kit, Qiagen, Manchester, UK) and centrifugation performed at 13,500 ×g for 15 seconds. The 
optional on-column DNase digestion was performed using the RNeasy kit (Qiagen), following 
manufacturer’s instructions. A wash step was performed using 350 µL Buffer RW1 (Qiagen) and 
centrifuged for 15 seconds, 500 µL Buffer RPE and centrifuged for 15 seconds, and a final addition 
of 500 µL RPE centrifuged for 2 minutes, all at 16,000 ×g. RNA was eluted using 30 µL RNA free 
water and incubated at room temperature for 1 minute before centrifugation at 13,000 ×g for 1 
minute. 
Complementary DNA (cDNA) synthesis 
cDNA was synthesised from RNA using the QuantiTect Reverse Transcription Kit (Qiagen) 
following manufacturer’s instructions.  
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Ascertaining IMPG2 expression  
Target primers for qPCR were designed based on sequence of the experimental reaction spanning 
exons 16-17 of IMPG2 cDNA, and the housekeeping gene TBP using primers and conditions listed 
in Appendix 4. qPCR was performed as described in section 2.3 using retinal cDNA synthesised 
from retinal tissue harvested from a control Golden Retriever dog as the control cDNA.  
Construction of pGL4/IMPG2-promoter plasmid 
To test the impact of the predicted IMPG2 promoter sequence on gene expression, an 
experimental plasmid was constructed, initially using the authentic IMPG2 predicted promoter as 
the insert. The pGL4 mouse interleukin-17 (mIL-17) plasmid containing a 2 Kb mIL-17 promoter 
with an NheI 5′ cloning site (5’-GˇCTAGC-3’) and BglII 3′ cloning site (5’-AˇGATCT-3’) was a gift 
from Warren Strober (Addgene plasmid # 20124; http://n2t.net/addgene:20124; 
RRID:Addgene_20124 (Zhang et al, 2008); Figure 4.1) and was used in this study as residual 
plasmid was available for immediate use from an unrelated study at the AHT. The pGL4 mIL-17 
plasmid also contained the firefly luciferase gene (fluc) with a Simian virus 40 (SV40) poly-A 
signal, an ampicillin resistance gene (AmpR) enabling detection of plasmid-containing bacteria 
when grown on selective media and providing those bacteria with a means of replicating the 
plasmid, and an origin of replication (ori) where the DNA replication begins to allow a plasmid 
reproduction. 
To remove the mIL-17 promoter from the pGL4 mIL-17 plasmid to generate the plasmid backbone 
to use as the vector, a sequential digestion of the pGL4 mIL-17 plasmid was performed initially 
with NheI using 10 μg plasmid, 5 μL NEBuffer2.1 (NEB), 2 μL NheI (NEB) and 33.63 μL ddH2O and 
incubated at 37 °C for 8 hours. The digested product was purified using the Monarch® PCR & DNA 
Cleanup Kit (5 μg) (NEB) according to manufacturer’s instructions and eluted in 6 μL elution 
buffer. Further digestion was performed with 2 μL BglII enzyme (NEB), 5 μL NheI digested vector, 
5 μL NEBuffer 3.1 (NEB), and 38 μL ddH2O and incubated at 37 °C overnight. The resulting product 
was separated on a 0.8% 1:1 low-melting/standard agarose gel and the DNA fragment excised 
under UV light using a gel extractor tip. The pGL4 backbone (vector) was dephosphorylated to 
prevent religation: a mix of 60 μL vector, 2 μL Antarctic phosphatase 10X buffer (NEB) and 1 μL 
Antarctic phosphatase (NEB) was prepared and incubated at 37 °C for 1 hour followed by an 
inactivation step at 80 °C for 2 minutes then held at 4 °C until further use.  
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Figure 4.1: Plasmid map of the 6,231-bp pGL4 mIL-17 plasmid. The mIL-17 2 Kb promoter 
(labelled in pink), that would drive the luciferase gene (orange) under appropriate luciferase 
conditions, was removed by restriction digest at the enzyme cut sites NhelI and BglII (highlighted 
in pink). This generated the 4,231-bp pGL4 backbone (vector) to ligate with the IMPG2-promoter 
sequence (insert). The backbone also contains the luciferase gene with an SV40 poly-A signal, an 
ampicillin resistance gene (AmpR) and an origin of replication (ori). 
The authentic IMPG2 predicted promoter sequence was amplified by PCR in control LA gDNA as 
follows. Removal of the mIL-17 promoter from the pGl4 mIL-17 plasmid resulted in NheI and BglII 
overhangs, however as a BglII restriction enzyme site was also present within the IMPG2 
promoter sequence, the BglII restriction enzyme could not be used to generate the BglII overhang 
necessary to ligate to the pGL4 vector. The BamHI restriction enzyme site shares the same 
overhang as BglII and did not cut any additional sites in the promoter sequence, therefore a BamHI 
restriction enzyme site was used as the overhang generated from the PCR IMPG2 insert clone. A 
6-bp overhang sequence (tagtag) followed by a NheI restriction enzyme site (5’-GˇCTAGC-3’) was 
added to the 5’ end of the forward primer 
(tagtagGCTAGCGGATTTTCAAGAGAAATATGTTTTAGATC) and the 6-bp overhang with a BamHI 
restriction enzyme site (5’-GˇGATCC-3’) to the reverse primer 
(tagtagGGATCCTTGGGCCACAATCAAAGG). Each reaction contained 4 μL dNTP mix (200 μM) 10 
 Chapter 4 PRA in the Lhasa Apso 
90 
 
μL 5X PrimeSTAR® GXL buffer (Takara Bio Inc.), 0.75 μL each primer (0.3 μM), 31.5 μL ddH2O and 
1 μL PrimeSTAR® GXL DNA Polymerase (Takara Bio Inc.). PCR amplification was performed as 
described in Appendix 4. Forty μL PCR product was purified using Monarch® PCR & DNA Cleanup 
Kit (5 μg) (NEB) and the purified product eluted in 20 μL elution buffer.  
The purified PCR product (insert) was digested using NheI and BamHI restriction enzymes (NEB). 
A sequential digest was conducted using 10 μL purified insert (1 μg), 5 μL 10X NEBuffer 2.1 (1X; 
NEB), 1 μL NheI and 34 μL ddH2O and incubated at 37 °C for 15 minutes. To increase the salt 
concentration to match that of the BamHI compatible buffer (NEBuffer 3.1), 1 μL 5M NaCl was 
added followed by 1 μL BamHI (NEB) and incubated at 37 °C for 15 minutes. The digestion was 
loaded into a 2% 1:1 low-melting temperature/ standard agarose gel. Under UV light, the digested 
fragments were excised from the gel and purified as described in Chapter 2 (section 2.4.2). 
Ligation was carried out with 30 ng of the insert, 18 ng of the vector, 2 μL T4 DNA ligation buffer 
(NEB), 1 μL T4 DNA ligase (NEB) and 15 μL ddH2O at room temperature for 1 hour. The ligation 
products were transformed to E. coli DH5α competent cells (Subcloning Efficiency DH5α 
Competent Cells; Thermo Fisher Scientific). Experimental reactions of 5 μL ligation reaction and 
50 μL competent cells and a negative control reaction where no plasmid was added were 
prepared. Reactions were incubated on ice for 10 minutes, transferred to a 42 °C water bath for 
90 seconds followed by a further incubation on ice for 2 minutes and 900 μL Lysogeny broth (LB) 
added (without antibiotic; see recipe in Chapter 2, section 2.12). A 100 μL aliquot of 950 μL 
suspension was cultured on LB-agar plates (recipe in Chapter 2, section 2.12) containing 100 
mg/mL ampicillin. The remaining 850 μL cell suspension was centrifuged at 16,000 ×g for 10 
seconds to pellet the cells and 750 μL  of the supernatant was removed, leaving 100 μL to 
resuspend the cell pellet that was streaked across LB-agar plates containing ampicillin (100 
mg/ml). This resulted in two plates per transformation to improve the chances of obtaining single 
colonies, while allowing all transformants to be recovered. Plates were incubated upside down at 
37 °C overnight.  
The following day, 15 individual colonies were picked from a single plate using the end of a sterile 
10 μL tip and cultured on a single fresh LB-agar plate containing ampicillin (100 mg/ml) at 37 °C 
overnight. To isolate individual clonal populations, 3 of the 15 individual colonies were picked 
using the end of a sterile 10 μL tip and each cultured in 3 mL LB with ampicillin (100 mg/mL) pre-
warmed to 37 °C in a water bath. Cultures were incubated in a shaking incubator at 37 °C at 220 
revolutions per minute (rpm) overnight. Plasmid DNA was isolated from 1.5 mL of each bacterial 
culture using the Monarch® Plasmid Miniprep Kit (NEB), following manufacturer’s instructions 
and eluting in 30 μL elution buffer. The purified plasmid DNA (200-500 ng) was sequenced 
directly by Sanger sequencing (see Chapter 2, section 2.5) using primers listed in Appendix 4 to 
check successful ligation of the vector and the insert and transformation of the constructed 
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plasmid. The remaining 1.5 mL was cultured in 500 mL LB with ampicillin (100 mg/mL) in a 
shaking incubator at 37 °C at 220 rpm overnight. Two of the three overnight cultures in 500 mL 
LB with ampicillin (100 mg/mL), that proved successful in ligation and transformation of the 
plasmid, based on the sequencing results, were removed from the shaking incubator  the following 
day and transferred to plastic flasks. Cultures were centrifuged at 10,000 ×g at 4 °C for 10 minutes 
to pellet the cells. The supernatant was discarded, and plasmid DNA was purified from the cells 
using the HiSpeed Plasmid Maxi Kit (Qiagen), following manufacturer’s protocol and eluting in 1 
mL Buffer TE (Qiagen). A restriction digest was performed to verify correct generation of the 
pGL4/IMPG2-promoter plasmid by digesting 1 μg plasmid DNA with 5 μL 10X CutSmart buffer, 1 
μL NheI and 1 μL PspOMI (all from NEB) and up to 30 μL ddH2O at 37 °C for 2 hours. Digested 
plasmid DNA was evaluated on a 0.8% agarose gel against undigested plasmid to verify an 
expected size of 5,710-bp of the pGL4/IMPG2-promoter plasmid (Figure 4.2). 
 
Figure 4.2: Plasmid map of the pGL4/IMPG2-promoter plasmid. The expected structure and size 
(5,710-bp) of the pGL4/IMPG2-promoter plasmid generated in the current study using the pGL4 
backbone and IMPG2 promoter insert. Restriction cut sites were determined using NEBCutter 
(NEB). 
Control plasmids 
Control plasmids served as experimental controls to the pGL4/IMPG2-promotor plasmid 
(experimental sample) in the luciferase reporter assay. The pGL4.10[luc2] basic vector (Promega 
UK Ltd., Southampton, UK) with no promoter that encodes the luciferase reporter gene (luc2) 
acted as an experimental ‘empty vector’ control to determine background luciferase expression 
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in the luciferase reporter assay (Figure 4.3A). The pGL4 mIL-17 plasmid was considered a suitable 
positive control, where the mIL-17 promoter was expected to drive luciferase expression (Figure 
4.1). The pGL4.73[hRuc/SV40] vector (Promega) encoding the Renilla reniformis luciferase 
reporter gene (hRluc) was used as the internal control, which also contains a SV40 early 
enhancer/promoter to drive expression of hRluc (Figure 4.3B). The use of an internal control 
plasmid was to normalise the values of the experimental plasmids for variation that could be due 
to transfection efficiency and pipetting errors. The pGL4.10 control (4,242-bp) and 
pGL4.73[hRuc/SV40] internal control (3,921-bp) plasmids were chosen based on comparable 
sizes to the constructed pGL4/IMPG2-promoter plasmid (5,710-bp) aiming to eliminate plasmid 
size as a variable in the transfection experiments.  
 
Figure 4.3: Control plasmid maps. (A) pGL4.10[luc2] basic vector (Promega UK Ltd., 
Southampton, UK) with no promoter that encodes the luciferase reporter gene luc2 was used as a 
background control for luciferase expression. (B) pGL4.73[hRuc/SV40] vector (Promega) 
encoding the Renilla reniformis luciferase reporter gene (hRluc) and containing a SV40 early 
enhancer/promoter to drive expression of hRluc was used as the internal control. 
Transfection and cell lysis 
To determine the number of cells to split across 24-well plates, cell numbers were counted 
manually using a haemocytometer (Neubauer chamber). Two lines of canine skin fibroblast cells 
cultured in cell culture growth medium at 37 °C were seeded at 5.5 × 104 cells per well (canine 
skin fibroblast cell line A) and 6.5 × 104 cells per well (canine skin fibroblast cell line B) at passage 
three. Human embryonic kidney 293T (HEK239T) cells cultured in cell culture growth medium at 
37 °C were seeded at 5 × 104 cells per well at passage seven to use as a transfection control. 
Subsequent to transfection optimisation to determine the optimum ratio of FuGENE®6 
transfection reagent (Promega) to DNA, a standard transfection protocol was followed, as 
summarised in Figure 4.4. All cell lines were plated in single wells (1.9 cm2) in a 24-well plate 
using 0.5 mL cell culture growth medium without penicillin and streptomycin in preparation for 
transfection. Confluent cells were co-transfected the following day by combining 20 μL OptiMEM 
reduced serum medium (Thermo Fisher Scientific) and 0.9 μL FuGENE®6 transfection reagent 
(Promega) in a tube and mixed by gently flicking. FuGENE®6 is a lipid-based transfection reagent 
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and should not be pipetted up and down. Plasmid DNAs were diluted to 200 ng/μL and added to 
the FuGENE®6/OptiMEM in a 1:20 ratio of experimental plasmid to internal control plasmid and 
incubated at room temperature for 15 minutes. The FuGENE®6-DNA complex was added to each 
well of the cell culture plate and mixed by gently swirling. Depending on the confluency of each 
well, two or three biological replicates were transfected for each canine skin fibroblast cell line to 
examine after incubation at 37 °C at three time points: 24 hours, 48 hours and 72 hours post-
transfection. Following incubation, cells were lysed using Glo lysis buffer (Promega) following 
manufacturer’s instructions. Each lysate was transferred to an Eppendorf tube and stored at -80 
°C until ready to conduct the luciferase reporter assay.  
                              
Figure 4.4: Schematic diagram showing steps in a standard transfection protocol. 
A green fluorescent protein (GFP) reporter gene control transfection was performed alongside 
experimental transfections to calculate transfection efficiencies in each cell line. At each time 
point, media was removed from each well and cells briefly washed in 500 μL PBS (Gibco, Thermo 
Fisher Scientific). Cells were detached using 250 μL Trypsin with EDTA 0.5% (1X, Invitrogen, 
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Thermo Fisher Scientific) for 3-5 minutes at room temperature followed by the addition of 250 
μL cell culture growth medium without penicillin and streptomycin. To estimate the cell count and 
estimate transfection efficiency of canine skin fibroblast cell line A, GFP positive cells and a total 
cell count were estimated manually using a haemocytometer (Neubauer chamber). To determine 
transfection efficiency of GFP reporter gene transfections by cell quantification using flow 
cytometry on two biological replicates of canine skin fibroblast cell line B and HEK293T cells, 200 
μL of cell lysate was transferred to a 96 well V-bottom assay plate (Corning, Flintshire, UK). In 
each measurement, to allow for all GFP positive cells to be counted, a maximum of 100,000 events 
were recorded on an ACEA NovoSampler Pro 2000R NovoCyte Flow Cytometer (ACEA Biosciences 
Inc., San Diego, USA) equipped with a blue laser (480 nm) and red laser (640 nm) for excitation. 
GFP reporter gene signal was detected using the fluorescein isothiocyanate (FITC) detection 
channel (530/30 nm filter with the pass-band centred on 530 nm, and the width of the pass-band 
is 30 nm) for emission. A medium flow rate was set at a stop condition of 150 μL, and the following 
mixing parameters were used: speed = 1,200 rpm; duration = 10 seconds; acceleration = 3 
seconds. Data were extracted using the ACEA NovoExpress® software (ACEA Biosciences) and 
analysed as follows. Gating was applied manually to the flow cytometry data using forward scatter 
(FSC) versus side scatter (SSC) heights to find viable, single cell events and exclude dead cells. 
Viable events were gated to remove doublets (P1) by forward scatter height (FSC-H) and side 
scatter height (SSC-H). P1 events were gated by FITC height versus SSC-H. Gated events from the 
no template control (NTC) were overlaid with experimental GFP events to determine positive GFP 
cells, where events to the right were considered positive.  
Measuring luminescence 
Frozen lysates were thawed on ice and each fluc and hRluc activity was measured using the Dual-
Glo(R) Luciferase Assay System (Promega) on an EnVision Multilabel Reader (Perkin Elmer, 
Buckinghamshire, UK). The results, measured in relative light units (RLU), were normalised as the 
ratio of fluc activity to hRluc activity by dividing each fluc value by the value for hRluc to obtain 
ratios. Relative fold changes of normalised RLU were calculated to the background control 
plasmid, pGL4.10, by dividing the experiment mean ratio by the mean ratio of pGL4.10 plasmid. 
The standard deviation of both canine skin fibroblast cell lines at each time point was calculated 
using the following formula, where x is the sample mean and n is the sample size (n = 2):  
The standard deviation of canine skin fibroblast cell lines at each time point was calculated and 
the standard error estimated as the sample standard deviation divided by the square root of the 
sample size (i.e. number of observations, n = 2).  
 
 (𝑥 − 𝑥 )2
 𝑛 − 1 
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4.3 Results 
4.3.1 GWAS analysis 
A GWAS was conducted using 17 PRA cases and 27 controls. After QC filtering, 108,263 SNPs were 
included for the analysis of 42 dogs (15 cases and 27 controls; call rate ≥ 97%; MAF ≥ 95%; 
genotype calls ≥ 90%). The level of genome-wide significance, determined by Bonferroni 
correction, was p = 4.6 × 10-7 (-log P = 6.34). Analysis of GWAS data revealed a genome-wide 
significant association on chromosome 33 (CANFA33; -log10 praw = 2.2 × 10-16) (Figure 4.5A). 
Visualisation of the SNPs on CANFA33 revealed that 40 SNPs passed the Bonferroni level of 
genome-wide significance (Figure 4.5B), with a single SNP showing the lowest p-value 
(BICF2G630247609 at position CANFA33: 8,045,162). The signal on CANFA33 remained 
significant after correcting for multiple testing using the max(T) permutation procedure, with 
three SNPs (TIGRP2P385447_RS9043116, BICF2G630247609 and BICF2G630247831) 
positioned under the GWAS signal with identical -log10 p-values (pgenome = 9 × 10-6) (Figure 4.6A; 
Figure 4.6B). The MDS plot showed a similar distribution of cases and controls (Figure 4.7). After 
correcting for population stratification and sample relatedness, the signal on CANFA33 remained 
statistically associated (p = 1.6 × 10-17). Q-Q plots suggested potential population stratification 
with a moderately increased genomic inflation factor (λ = 1.36), which decreased to baseline (λ = 
1.02) following corrections of the PLINK results using EMMAX (Figure 4.8).   
Visualisation of SNPs either side of the most associated SNP (SNP BICF2G630247609; p-value = 
2.2 × 10-16) in cases sharing the disease-associated haplotype identified a disease-associated 
interval 1.3 Mb in size that was homozygous in 12 of the 15 cases (Figure 4.9).  
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Figure 4.5: Results of the LA PRA GWAS. (A) Manhattan plot of unadjusted association analysis 
showed a statistical association on canine chromosome 33 (CANFA33) (praw = 2.2×10-16) in LA 
cases. The level of genome-wide significance, determined by Bonferroni correction, p = 4.6 × 10×7 
(-log P=6.34), is indicated by a red line. (B)A regional plot of SNPs on CANFA33. 
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Figure 4.6: Manhattan plots following correcting for multiple testing. (A) The signal on canine 
chromosome 33 (CANFA33) remained significant after correcting for multiple testing using the 
max(T) permutations procedure (pgenome = 9 × 10-6). (B) Visualisation of SNP associations on 
CANFA33 revealed three SNPs with a -log10 p-value of 9 × 10-6.  
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Figure 4.7: A MDS plot to visualise relatedness between the LA case and control sample sets 
showed a similar distribution of 15 cases and 27 controls analysed in the GWAS. 
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Figure 4.8: Results of the LA PRA GWAS analysis using EMMAX to correct PLINK results . (A) The 
Q-Q plot of the expected and observed –log10 p-values generated from PLINK derived a genomic 
inflation factor, lambda (λ) = 1.36. (B) The Q-Q plot after correcting for population stratification 
using EMMAX showed a decreased inflation factor, λ = 1.02. (C) Manhattan plot of corrected 
association analysis using EMMAX.  
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Figure 4.9: Homozygosity analysis of PRA-affected LA dogs after QC filtering. Homozygosity 
mapping of SNP markers surrounding the most associated SNP from the GWAS (SNP 
BICF2G630247609; text highlighted in red) in LA PRA cases (A1-15) and controls (C1-27) were 
used to define the critical region. The yellow coloured boxes represent the reference alleles, the 
pink coloured boxes highlight the alternate alleles and grey boxes represent missing data. The 1.3 
Mb critical region was homozygous in 12 of the 15 cases used in GWAS analysis, as shown by the 
shaded region between positions CANFA33: 7,465,076-8,738,020. One LA control (C10) is 
heterozygous for this region, as are two of the three cases that are not homozygous for the critical 
region, as marked by asterisks (*). Locations of the four variants later followed up after 
subsequent WGS analysis (LINE-1 insertion, the top associated GWAS SNP (BICF2G630247609), 
and intronic SNVs in IMPG2 and CEP97) are indicated to show where these variants lie within the 
critical region. 
The defined critical region harbours 21 genes, of which 12 are protein-coding (Table 4.3). Two of 
these genes were potential candidates: interphotoreceptor matrix proteoglycan 2 (IMPG2) and 
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centrosomal protein 97 (CEP97). IMPG2 has previously been associated with autosomal recessive 
RP and vitelliform macular dystrophy (VMD) in humans (Bandah-Rozenfeld et al, 2010; Brandl et 
al, 2017) and is therefore a strong candidate gene for canine PRA. CEP97 plays a role in 
centrosome function and cilia formation (Spektor et al, 2007) and although CEP97 has not directly 
been implicated with human retinal degenerations, mutations in other centrosomal protein-
coding genes have been associated with both syndromic and non-syndromic retinal degenerations 
(CEP19, CEP78, CEP164, CEP250 and CEP290) (Baala et al, 2007; Chaki et al, 2012; Chang et al, 
2006; den Hollander et al, 2006; Frank et al, 2008; Fu et al, 2017; Khateb et al, 2014; Menotti-
Raymond et al, 2007; Namburi et al, 2016; Nikopoulos et al, 2016; Valente et al, 2006; Yıldız 
Bölükbaşı et al, 2018).  
Table 4.3: Protein-coding genes situated within the 1.3 Mb critical region. An asterisk (*) 
highlights genes previously associated with, or within a gene family associated with retinal 
degeneration in humans. 
Gene Name Abbreviation 
ABI family member 3 binding protein AB13BP 
Interphotoreceptor matrix proteoglycan 2 IMPG2* 
SUMO1/sentrin specific peptidase 7 SENP7 
tRNA methyltransferase 10C, mitochondrial RNase P subunit TRMT10C 
PEST proteolytic signal containing nuclear protein PCNP 
Zinc finger and BTB domain containing 11 ZBTB11 
Centrosomal protein 97 CEP97* 
Neurexophilin and PC-esterase domain family member 3 NXPE3 
NFKB inhibitor zeta NFKBIZ 
Zona pellucida like domain containing 1 ZPLD1 
ENSCAFG00000009584 N/A; no human orthologue 
Ribosomal protein L24 RPL24 
 
A weak signal on chromosome 8 was also present in the GWAS Manhattan plot (Figure 4.5), 
although this is below the level of genome-wide significance. Visualisation of SNPs spanning the 
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most associated SNP on chromosome 8 (CANFA8: 10,117,864) showed a small region of 
homozygosity upstream of the top SNP position (CANFA8: 9,927,621-10,117,864) in four cases, 
which were also homozygous for the disease-associated region on CANF33, however the 
homozygous region on CANFA8  was also present in four control dogs. As the cases that were not 
homozygous for the disease-associated region on CANFA33 could not be accounted for by the 
chromosome 8 signal, the possibility of this region as another possible PRA locus was excluded. 
4.3.2 Secondary GWAS analysis 
A secondary GWAS analysis was performed using three LA PRA cases, that were not homozygous 
for the critical region, and 27 controls. QC filtering resulted in the inclusion of 106,299 SNPs for 
the analysis of 30 dogs (call rate ≥ 97%; MAF ≥ 95%; genotype calls ≥ 90%). GWAS analysis 
revealed no genome-wide significant association, as expected due to low statistical power, 
however, indicative signals on canine chromosome 1 (top SNP BICF2P1007300 at position 
CANFA1 :66,635,731, chromosome 7 (top SNP BICF2S23052355 at position CANFA7 :70,561,883) 
and the X chromosome (top SNP BICF2P332508 at position CANFAX :32,952,883) were observed 
(Figure 4.10). After correcting for multiple testing using the max(T) permutations procedure for 
100,000 permutations, these signals remained but were not significant. Further exploration of the 
genomic regions surrounding these SNPs revealed no suggestive loci associated with disease. 
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Figure 4.10: Manhattan plots representing -log10 of p-values of LA PRA GWAS using 3 cases and 
27 controls showed no statistical associations although weak signals on canine chromosomes 1, 7 
and X were observed (A). The level of genome-wide significance, determined by Bonferroni 
correction, p= 4.6 × 10×7 (-log P = 6.34), is indicated by a red line. (B) The non-significant signals 
on chromosomes 1, 7 and X remained after correcting for multiple testing using the max(T) 
permutations procedure remained weak.
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4.3.3 Identification of candidate causal variants underlying the GWAS signal 
From examination of WES data previously generated in our laboratory for three LA PRA cases and 
three LA controls, no exonic or splice site variants that segregated with PRA could be identified. 
Of these LA dogs used for exome analysis, DNA from one control and all three PRA cases were 
used for the GWAS in this study. The LA PRA case selected for WGS was also one of the cases in 
the exome study. The 1.3 Mb homozygous interval was therefore manually interrogated in WGS 
data of the PRA case using IGV software. A LINE-1 insertion was identified within the critical 
region in this PRA case, inserted 181-bp upstream of the IMPG2 gene at CANFA33:7,785,491-
7,785,492 (Figure 4.11, track A). The 17-bp target repeat sequence flanking the LINE-1 spans the 
following coordinates: CANFA33: 7,785,475 - 7,785,491. This insertion was not visible in the WES 
data of the same PRA case used for WGS analysis (Figure 4.11, track B). In control genomes, the 
insertion was not present.  
Variant filtering of WGS data was performed to highlight additional SNPs and INDELs to consider 
as candidate variants, intending to highlight those that may be stronger candidates than the LINE-
1 insertion. This filtering identified two intronic SNVs situated in retinal candidate genes within 
the critical region: one in IMPG2 (G/T SNV; CANFA33:7,717,298) and one in CEP97 (A/G SNV; 
CANFA33:8,044,097). The locations of these two intronic SNVs within the defined homozygous 
critical region are highlighted in Figure 4.9. As this WGS variant filtering prioritised those variants 
predicted to be highly penetrant, limitations include no further prioritisation of non-coding 
variants in known IRD/PRA genes, SVs and non-coding variants in potential new candidate genes. 
The LINE-1 insertion was absent in WGS data from 102 individuals of 52 other breeds and 2 
crossbreeds; WGS data from a Hungarian Vizsla dog is shown to illustrate (Figure 4.11, track C). 
The sequence at each position of the intronic variants were visualised in WGS data from the same 
102 canine genomes to determine genotypes. The IMPG2 intronic SNV was absent in all 102 
individuals and the CEP97 intronic SNV absent in 101 individuals, with one Welsh Springer 
Spaniel dog identified as heterozygous for the SNV.   
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Figure 4.11: IGV display of the LINE-1 insertion upstream of IMPG2. WGS (track A) and WES (track B) alignments over a 722-bp region on CANFA33 
from a LA PRA case compared to control WGS data from a PRA non-affected Hungarian Vizsla dog (example, track C).  The identified LINE-1 insertion 
is upstream of the retinal candidate gene IMPG2.  Grey sequencing reads show those aligning normally to the CanFam3.1 canine reference genome at 
this position. Coloured reads indicate that one of the paired sequencing reads aligns to this region on CANFA33, and the mate in this pair of sequencing 
reads aligns to another chromosome (each colour represents alignment to a different chromosome), consistent with the presence of a repetitive 
element insertion. 
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4.3.4 Sequencing the LINE-1 insertion  
Amplification by PCR across the LINE-1 insertion in three LA PRA cases and three LA controls 
suggested a size of 1.5-2 Kb (Figure 4.12). NGS of the LINE-1 region confirmed an insertion of at 
least 1,600-bp (Appendix 8). The exact length of the poly-A tail could not be determined due to 
the low complexity of the short sequencing reads generated from the Illumina sequencing. 
Analysis in L1Base2 (Penzkofer et al, 2017) of the LINE-1 insertion sequence obtained from de 
novo assembly of NGS reads confirmed a partial transposable element where the sequence 
partially aligns to open reading frame (ORF) 2 of the L1_cf sequence. As the IMPG2 gene is located 
on the reverse DNA strand, WGS alignment shows the LINE-1 sequence has been inserted in the 
reverse orientation to the IMPG2 gene, comprising the 17-bp target site duplication 
AAAAATGGTGTCCTTC (Figure 4.13), a truncated 5’ end with a partial 1,629-bp ORF2 and a poly-
A tail. 
 
 
Figure 4.12: Agarose gel electrophoresis of DNA from three LA PRA cases (lanes 2-4), three LA 
controls (lanes 5-7), a negative control (lane 8) and a 2-log ladder (lanes 1 and 9) (NEB). The 
expected PCR product size in control LA dogs is 1,606-bp. The product containing the LINE-1 
insertion is ~3.5 Kb on the gel, suggesting the LINE-1 insertion is ~1.9 Kb in size. 
 Chapter 4 PRA in the Lhasa Apso 
107 
 
 
 
Figure 4.13: Illustration of Illumina sequencing reads in IGV of the LINE-1 insertion in the IMPG2 gene present in a LA PRA case. The 17-base pair (bp) 
duplication is highlighted in purple, soft-clipped bases in sequence reads at the start and end of the LINE-1 insertion are boxed in pink and the poly-A 
tail boxed in grey. The dashed line joining these two sequences represents the remaining 1,472-bp of LINE-1 insertion sequence. The LINE-1 insertion 
is inserted in the reverse orientation to the IMPG2 gene, which is located 181-bp downstream of the insertion. Sequence annotation of the LINE-1 
insertion is in the forward orientation. 
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4.3.5 Variant screening  
To assess the concordance of the LINE-1 insertion with PRA, an AFLP assay was used to genotype 
447 dogs of 123 breeds (Appendix 9) in addition to the cases and controls in the GWAS. Of the 
individuals in the GWAS dataset analysed, all 12 LA cases that were homozygous for the defined 
critical region were homozygous for the LINE-1 insertion. In the control set, one heterozygote was 
present, and the LINE-1 insertion was absent in the other 26 control dogs. In addition, PRA cases 
of breeds related to the LA (five Shih Tzu dogs, seven Tibetan Spaniels and two Tibetan Terriers), 
were homozygous for the wild type allele. 
Four out of the seventeen PRA-affected individuals included in the original GWAS dataset pre-QC 
filtering were not homozygous for the 1.3 Mb defined critical region. A secondary GWAS analysis 
did not yield any suggestive associations. Five additional PRA cases that were not included in the 
GWAS dataset were available to genotype for the LINE-1 insertion, the top associated SNP from 
the GWAS (BICF2G630247609) and both intronic SNVs in IMPG2 and CEP97. NNSPLICEv.0.9 
(Reese et al, 1997; Berkeley Drosophila Genome Project, 2020) concluded that neither the IMPG2 
or CEP97 intronic SNVs are located within predicted donor or acceptor splice sites or nearby any 
splice site predictions, nor do they introduce novel splice sites. In total, 63 LA dogs comprising 22 
PRA cases and 41 controls were genotyped for these four variants in an attempt to assess which 
variant showed the strongest segregation with PRA (Table 4.4). Figure 4.14 shows a schematic 
diagram of these four variant genotypes across the 63 LA dogs. Five PRA cases (four individuals 
A13-A16 from the GWAS and individual A22) were either homozygous for the wild type allele or 
heterozygous across all four variants. Presuming a single-gene disorder model, these five 
individuals were surmised to be suffering from a genetically different PRA. 
Table 4.4: Genotype distributions of the four variants of interest in LA PRA cases and controls. 
‘Ref’ refers to the reference/wild type allele; ‘Alt’ refers to the alternate allele. 
Variant LA cases LA controls  
 Alt/Alt Alt/Ref Ref/Ref Alt/Alt Alt/Ref Ref/Ref  
IMPG2 intronic SNV (chr33:7,717,298) 17 2 3 0 6 35  
IMPG2 LINE-1 insertion 17 2 3 0 6 35  
CEP97 intronic SNV (chr33:8,044,097) 17 3 2 0 8 33  
BICF2G630247609 top GWAS SNP 17 3 2 0 8 33  
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Figure 4.14: Variant genotypes in LA PRA cases and controls. (A) A schematic diagram showing genotypes for four variants across 22 LA PRA cases 
(A1-22) and (B) 41 LA controls (C1-41) LA: homozygous alternate allele (coloured pink), homozygous wild type/reference allele (coloured yellow) or 
heterozygous (coloured pink and yellow). 
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4.3.6 Promoter and transcription factor binding site (TFBS) predictions 
To investigate whether the LINE-1 insertion may disrupt regulation of the IMPG2 gene, in silico 
analyses of the region surrounding the insertion were performed to search for putative regulatory 
sequences and promoter sequences.  The Gene2Promoter tool suggested that a promoter region 
exists within 1.5 Kb of the upstream DNA sequence of IMPG2. However, when using the 
PromoterInspector tool to predict eukaryotic Pol II promoter regions in mammalian genome 
sequences, no such promoter regions were predicted. Analysis of 1.5 Mb upstream and 
downstream of the LINE-1 insertion breakpoints using the MatInspector tool identified 1,275 
matches to putative TFBSs of which 162 were within 150-bp upstream and 150-bp downstream 
of the LINE-1 breakpoints. Forty-three of these were associated with eye tissue (Appendix 10) 
including three photoreceptor conserved element 1 TFBSs, one cone-rod homeobox-containing 
TFBS and one pituitary homeobox 1 TFBS. These five photoreceptor-specific TFBSs belong to the 
“vertebrates bicoid-like homeodomain transcription factor matrix” family in MatInspector 
(matrix symbol = V$BCDF) and are located within very close proximity to the LINE-1 insertion 
(Figure 4.15). All bicoid-like homeodomain TFBSs within this matrix family ‘V$BCDF’ in the dog 
are listed in Table 4.5. 
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Figure 4.15: Predicted TFBSs surrounding the LINE-1 insertion position. TFBSs within the ‘V$BCDF’ matrix family from MatInspector within a 2,989-
bp region over the LINE-1 insertion are shown in a LA PRA case. Within this matrix family are five photoreceptor conserved element 1 TFBS, one cone-
rod homeobox-containing transcription factor/otx-like homeobox TFBS and one pituitary homeobox 1 TFBS.
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Table 4.5: Genes encoding transcription factors binding to the TFBSs surrounding the LINE-1 
insertion. TFBSs of the ‘V$BCDF’ matrix family closely situated to the IMPG2 LINE-1 insertion were 
identified using MatInspector.
Organism Genes encoding Transcription Factors 
Dog CRX, DMBX1, GSC2, OTX1, OTX2, PITX1, PITX2, PITX3 
Human CRX, DMBX1, GSC, GSC2, OTX1, OTX2, PITX1, PITX2, PITX3 
4.3.7 Luciferase reporter assay 
Given that the LINE-1 insertion is upstream of the IMPG2 gene, within the predicted promoter, it 
was hypothesised that the insertion may cause PRA through dysregulation of IMPG2 expression. 
To assess this, a luciferase reporter assay was attempted, initially optimising the assay using the 
non-interrupted IMPG2 predicted promoter sequence as a positive control to establish that the 
predicted promoter drives luciferase expression in the generated plasmid when transfected into 
a canine cell line. 
Cell line selection 
To determine which cell type to use for the reporter assay, qPCR was conducted using cDNA 
synthesised from canine skin fibroblast cells, MDCK cells and MSCs, and IMPG2 expression in these 
cell types was compared to retinal cDNA synthesised from a control Golden Retriever dog with no 
ocular phenotypes. The IMPG2 target expression level was normalised against a housekeeping 
gene, TBP, which is ubiquitously expressed across tissues. R2 and amplification efficiency values 
determined from standard curves of each target in control canine retinal cDNA are listed in Table 
4.6. qPCR analysis indicated similar levels of IMPG2 expression in canine skin fibroblast cells, 
MDCK and MSCs (Figure 4.16), albeit at a much lower expression to that of IMPG2 in retina (Table 
4.7; Figure 4.17). As no retinal cell lines were available for use at the time of study, canine skin 
fibroblast cells were the cell of choice to perform luciferase reporter assays and assess if the LINE-
1 insertion affects IMPG2 promotor activity. 
Table 4.6: Standard curves of qPCR targets ascertained using control canine retinal cDNA. 
Target Slope R2 Efficiency (%) 
TBP -3.11 0.994 98.379 
IMPG2 -3.41 0.996 96.471 
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Table 4.7: Expression fold changes of IMPG2 in various canine cell types. Expression fold change 
calculated using the delta-delta Ct method (2^-ΔΔCt) of IMPG2 target versus TBP target in canine 
skin fibroblast cells, canine kidney (MDCK) cells and canine mesenchymal stem cells (MSC). 
Cell/Tissue Expression Fold Change (2^-ΔΔCt) 
MSC 0.00055 
MDCK 0.00060 
Canine Skin Fibroblast cells 0.00033 
Retina (Control) 1 
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Figure 4.16: IMPG2 expression in various cell types. A graph to show ΔRn (change in fluorescence) against cycle number for expression of IMPG2. 
cDNA synthesised from RNA extracted from canine retinal tissue was used as a positive control, with IMPG2 known to be highly expressed in the retina. 
cDNA synthesised from RNA extracted from MSC, MDCK and canine skin fibroblast cells were assessed for IMPG2 expression in comparison to the 
canine cDNA from retinal tissue. MSC, MDCK and canine skin fibroblast cells expressed IMPG2, but with very low efficiency, thus canine skin fibroblast 
cells were chosen to utilise for further reporter assays.
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Figure 4.17: Expression fold changes of IMPG2 in various cell types. (A) Expression fold change 
(2^-ΔΔCt) of IMPG2 target versus TBP target in canine skin fibroblast cells, canine kidney (MDCK) 
cells, and canine mesenchymal stem cells (MSC). The retinal cDNA extracted from retinal tissue of 
a control Golden Retriever dog was used as the baseline value (n = 1). (B) Zoom in of canine MSC, 
MDCK and skin fibroblast cells for expression fold change (2^-ΔΔCt) values. 
Generation of the pGL4/IMPG2-promoter plasmid 
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The mIL-17 promoter was removed from the pGL4 mIL-17 plasmid (Figure 4.18), resulting in the 
pGL4 backbone for the IMPG2 promoter insert to be incorporated. Restriction enzymes NheI and 
BglII (both NEB) were used to excise the mIL-17 promoter from the vector. As BglII cut sites were 
present within the IMPG2 insert sequence, the BamHI restriction enzyme (NEB), with the same 
overhang as BglII, was used in restriction digests with the IMPG2 insert to generate sticky ends 
that were compatible with the vector enzyme cut sites for ligation. The constructed plasmid was 
termed ‘pGL4/IMPG2-promoter’. 
 
Figure 4.18: Agarose gel electrophoresis following plasmid restriction digestion. (A) Pre-excised 
agarose gel of 50 µL digested pGL4 mIL-17 plasmid was loaded in two wells (A3,A4) on an agarose 
gel to determine digestion had resulted in the separation of the pGL4 backbone (4,231-bp) and 
the mouse mIL-17 promoter (2,000-bp). A 2-log ladder (NEB) was run to measure DNA fragment 
sizes (A1, A12). A single digest of the pGL4 mIL-17 plasmid was loaded to show BglII had 
successfully digested the plasmid cutting at one position for a single product. An aliquot of uncut 
pGL4 mIL-17 plasmid was loaded as a control well to show the complete vector in supercoiled and 
open-circular confirmations, as shown by multiple bands (A8). (B) Agarose gel post-excision of 
the 4,231-bp pGL4 backbone. 
To determine successful ligation of the vector and insert, and to verify positive transformation 
and purification of the pGL4/IMPG2-promoter plasmid, a restriction digest and Sanger sequencing 
were performed on two positive colonies from the transformation. A restriction digest using NheI 
and PspOMI on two preparations of the plasmid indicated DNA fragments were within expected 
size ranges (two products expected at 4,143-bp and 1,567-bp) (Figure 4.19). 
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Figure 4.19: Agarose gel electrophoresis to verify plasmids. Two positive colonies from 
transformations that underwent plasmid purification were digested using NheI and PspOMI 
enzymes to ensure correct generation of the pGL4/IMPG2-promoter plasmid. Digested plasmids 
were assessed on a 0.8% agarose gel (wells 3 and 7) against undigested plasmid (wells 5 and 9) 
against a 2-log ladder (wells 1 and 11) indicating DNA fragments within the expected size ranges 
(4,143-bp and 1,567-bp). 
Sanger sequencing (using primers to amplify the entire 5,710-bp plasmid) indicated that the 
IMPG2-promoter sequence had successfully inserted into the pGL4 backbone, generating the 
pGL4/IMPG2-promoter plasmid in the two colonies. As restriction enzymes NheI and BglII/BamHI 
(backbone vector/insert) were used in digestions of the backbone and insert, these restriction 
enzyme site sequences were used to determine positions where the insert sequence and pGL4 
backbone sequence were ligated (Figure 4.20). 
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Figure 4.20: Sanger sequencing chromatograms of the pGL4/IMPG2-promoter plasmid DNA containing the cloned IMPG2-promoter insert in the pGL4 
backbone spanning the positions of ligation at (A) the NheI enzyme cut site and (B) the BamHI/BglII enzyme cut site. As restrictions enzymes NheI 
and BglII/BamHI (backbone vector/insert) were used, these restriction enzyme site sequences could be used to determine positions where the insert 
sequence and pGL4 backbone sequence were ligated. 
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Transfection efficiency 
Alongside experimental transfections, transfections using the GFP reporter gene were performed 
in order to monitor the transfection efficiency of each cell line. In addition to the use of canine skin 
fibroblast cell lines, a highly transfectable cell line (HEK293T) was used as a control to determine 
positive or negative GFP transfection using FuGENE®6 transfection reagent. HEK293T cells have 
shown high transfection efficiencies and high expression levels in luciferase assays using 
FuGENE®6 (technical notes, Promega). GFP detection was monitored manually by cell counting 
for canine skin fibroblast cell line A, and using flow cytometry analyses on canine skin fibroblast 
cell line B and HEK293T cells, using a NTC for each line for normalisation. Transfection efficiencies 
were calculated (Table 4.8) and flow cytometry results for GFP transfections in canine skin 
fibroblast cell line B and HEK293T cells are presented in Figure 4.21. The HEK293T cells showed 
high GFP mean transfection efficiencies: 95.56% and 89.16% at 24 hours and 48 hours post-
transfection, respectively. Mean GFP transfection efficiencies of canine skin fibroblast cells were 
much lower, ranging from 0.89 – 9.47% at 24 hours post-transfection, with the highest GFP 
transfection efficiency of 26.04% in the canine fibroblast cell line B measured at 48 hours post-
transfection.  
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Table 4.8: Transfection efficiencies using the GFP reporter gene. Transfection efficiencies (%) of 
canine skin fibroblast cell line A transfected with GFP plasmid DNA were estimated 24 hours post-
transfection by performing a manual cell count of the number of fluorescent positive cells divided 
by the total cell count estimated using a haemocytometer. GFP transfection efficiencies were 
calculated using flow cytometry in canine skin fibroblast cell line B 24 hours, 48 hours and 72 
hours post-transfection, and 24 hours and 48 hours post-transfection in HEK293T cells. All GFP 
transfections were performed in duplicate using FuGENE®6 transfection reagent (Promega). 
Mean transfection efficiencies were calculated for each cell line and the standard deviation 
reported. 
Replicate Cell count Total number of cells Transfection 
efficiency (%) 
Mean transfection 
efficiency (%) 
Standard deviation 
Canine skin fibroblast cell line A 
24 hrs post transfection 
1 434 80,000 0.54 
  
2 990 80,000 1.24 0.89 0.49 
Canine skin fibroblast cell line B 
24 hrs post transfection 
1 1,376 15,255 9.02 
  
2 1,463 14,737 9.93 9.47 0.64 
48 hrs post transfection 
1 2,264 9,069 24.96 
  
2 1,797 6,628 27.11 26.04 1.52 
72 hrs post transfection 
1 2,772 11,000 25.20 
  
2 3,949 17,885 22.08 23.64 2.21 
HEK293T cells 
24 hrs post transfection 
1 77,029 79,707 96.64 
  
2 67,041 70,951 94.49 95.56 1.52 
48 hrs post transfection 
1 70,618 78,384 90.09 
  
2 60,777 68,890 88.22 89.16 1.32 
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Figure 4.21: Forward and side scatter density plots for GFP transfected cells. Flow cytometry 
analysis for two biological replicates of (i) canine skin fibroblast cell line B and (ii) HEK293T cells 
at three time points post transfection using a GFP reporter gene: (A) 24 hours, (B) 48 hours and 
(C) 72 hours (not applicable for HEK293T cells). P1 indicates gating of the viable events to remove 
doublets by forward scatter height (FSC-H) and side scatter height (SSC-H). P1 events were gated 
by FITC height versus SSC-H. Gated events from the control (NTC; blue dots) were overlaid with 
experimental GFP events (green dots) to determine positive GFP cells, where events to the right 
were considered positive. 
 Chapter 4 PRA in the Lhasa Apso 
122 
 
Dual-luciferase reporter assay 
Luciferase activity was measured on a luminometer in RLU. RLU values were normalised in 
individual wells to obtain ratios. As each construct was assayed in duplicate or triplicate wells, a 
mean normalised fluc/hRluc ratio was determined. The relative expression of fluc to hRluc of the 
background control (pGL4.10) was used as a baseline fold change (n = 1) and other constructs 
compared to the activity of pGL4.10 to determine normalised fold changes in activity. Raw RLU 
results, mean ratios and calculated fold changes for each plasmid and cell line are listed in Table 
4.9 and Table 4.10. For the two canine skin fibroblast cell lines, mean fluc/hRluc ratios were 
calculated and a fold change generated relative to pGL4.10 values for each cell line and each time 
point. A mean fold change for each plasmid experiment, at each time point, for the two canine skin 
fibroblast cell lines and the HEK293T cells was calculated (Table 4.11). The standard deviation of 
canine skin fibroblast cell lines at each time point was calculated, and the standard error 
ascertained from the standard deviation with two incidences (cell line A and cell line B). 
In the canine skin fibroblast cell lines, the pGL4 mIL-17 plasmid shows a higher fold change than 
the control pGL4.10 plasmid. In the HEK293T cells, pGL4 mIL-17 is not highly expressed. The 
pGL4/IMPG2-promoter construct shows a lower fold change relative to pGL4.10 in both canine 
skin fibroblast cell lines (Figure 4.22) and HEK239T cells (Figure 4.23), suggesting that the IMPG2 
promoter is not active in these cell types.  
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Table 4.9: Raw luminometer readings for two lines of canine skin fibroblast cells (line A, line B) transfected with each plasmid measuring firefly (F) 
and Renilla (R) luciferase activity in relative light units (RLU).
pGL4.10 pGL4/IMPG2 pGL4 mIL-17 
Time 
Point 
Test 
Replicate 
Luciferase activity 
(RLU) 
Ratio 
(F/R) 
Relative 
Fold 
Change 
Time 
Point 
Test 
Replicate 
Luciferase activity 
(RLU) 
Ratio 
(F/R) 
Relative 
Fold 
Change 
Time 
Point 
Test 
Replicate 
Luciferase activity 
(RLU) 
Ratio 
(F/R) 
Relative 
Fold 
Change Firefly 
(F) 
Renilla 
(R) 
Firefly 
(F) 
Renilla 
(R) 
Firefly 
(F) 
Renilla 
(R) 
24 hrs Line A 1 4 192 0.021 
 
24 hrs Line A 1 8 460 0.017 
 
24 hrs Line A 1 32 200 0.160 
 
 
Line A 2 8 208 0.038 
  
Line A 2 4 500 0.008 
  
Line A 2 28 264 0.106 
 
 
Line A 3 4 216 0.019 
  
Line A 3 8 452 0.018 
       
  
Mean ratio 0.026 1.00 
  
Mean ratio 0.014 0.55 
  
Mean ratio 0.133 5.13 
 
Line B 1 4 112 0.036 
  
Line B 1 0 76 0.000 
  
Line B 1 24 172 0.140 
 
 
Line B 2 4 124 0.032 
  
Line B 2 4 72 0.056 
  
Line B 2 24 124 0.194 
 
  
Mean ratio 0.034 1.00 
  
Mean ratio 0.028 0.82 
  
Mean ratio 0.167 4.90 
48 hrs Line A 1 44 1080 0.041 
 
48 hrs Line A 1 12 1500 0.008 
 
48 hrs Line A 1 104 1788 0.058 
 
 
Line A 2 36 1240 0.029 
  
Line A 2 20 1632 0.012 
  
Line A 2 92 1576 0.058 
 
 
Line A 3 32 1056 0.030 
  
Line A 3 20 1684 0.012 
   
Mean ratio 0.058 1.75 
  
Mean ratio 0.033 1.00 
  
Mean ratio 0.011 0.32 
      
 
Line B 1 60 1696 0.035 
  
Line B 1 20 1096 0.018 
  
Line B 1 172 1628 0.106 
 
 
Line B 2 80 1568 0.051 
  
Line B 2 32 1160 0.028 
  
Line B 2 176 1336 0.132 
 
  
Mean ratio 0.043 1.00 
  
Mean ratio 0.023 0.53 
  
Mean ratio 0.119 2.75 
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Table 4.9 (continued).  
pGL4.10 pGL4/IMPG2 pGL4 mIL-17 
Time 
Point 
Test 
Replicate 
Luciferase activity 
(RLU) 
Ratio 
(F/R) 
Relative 
Fold 
Change 
Time 
Point 
Test 
Replicate 
Luciferase activity 
(RLU) 
Ratio 
(F/R) 
Relative 
Fold 
Change 
Time 
Point 
Test 
Replicate 
Luciferase activity 
(RLU) 
Ratio 
(F/R) 
Relative 
Fold 
Change Firefly 
(F) 
Renilla 
(R) 
Firefly 
(F) 
Renilla 
(R) 
Firefly 
(F) 
Renilla 
(R) 
72 hrs Line A 1 76 896 0.085 
  
Line A 1 24 860 0.028 
       
 
Line A 2 68 748 0.091 
 
72 hrs Line A 2 28 1208 0.023 
 
72 hrs Line A 1 232 1844 0.126 
 
 
Line A 3 88 1252 0.070 
  
Line A 3 40 1340 0.030 
  
Line A 2 216 1708 0.126 
 
  
Mean ratio 0.082 1.00 
  
Mean ratio 0.027 0.33 
  
Mean ratio 0.126 1.54 
 
Line B 1 108 884 0.122 
  
Line B 1 36 572 0.063 
  
Line B 1 268 1568 0.171 
 
 
Line B 2 108 2076 0.052 
  
Line B 2 32 1284 0.025 
  
Line B 2 316 2188 0.144 
 
  
Mean ratio 0.087 1.00 
  
Mean ratio 0.044 0.50 
  
Mean ratio 0.158 1.81 
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Table 4.10: Raw luminometer readings for transfected HEK293T cells measuring firefly (F) and 
Renilla (R) luciferase activity in relative light units (RLU). 
Time 
Point 
Test 
Replicate 
Luciferase Activity (RLU) Ratio 
(F/R) 
Relative Fold 
Change Firefly (F) Renilla (R) 
pGL4.10 
24 hrs 1 6,936 2,840 2.442  
 2 6,516 2,120 3.074  
   Mean ratio 2.758  
48 hrs 1 11,096 29,872 0.371  
 2 9,924 21,016 0.472  
   Mean ratio 0.422 1.00 
pGL4/IMPG2 
24 hrs 1 2,868 2,148 1.335  
 2 2,780 2,248 1.237  
   Mean ratio 1.286 0.47 
48 hrs 1 5,932 24,816 0.239  
 2 5,868 24,440 0.240  
   Mean ratio 0.240 0.57 
pGL4 mIL-17 
24 hrs 1 14,888 4,148 3.589  
 2 13,856 4,308 3.216  
   Mean ratio 3.403 1.23 
48 hrs 1 15,572 29,620 0.526  
 2 17,428 37,484 0.465  
   Mean ratio 0.495 1.17 
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Table 4.11: Mean fold change calculated from firefly luciferase/Renilla luciferase ratios from RLU 
luminometer readings for canine skin fibroblast cell lines A and B assayed after each time point 
(24 hours, 48 hours and 72 hours) post-transfection, and one line of HEK293T cells assayed 24 
hours and 48 hours post-transfection. Fold change differences are expressed relative to 
background control plasmid, pGL4.10 (fold change = 1). The standard deviation was calculated 
using mean ratios of each canine skin fibroblast cell line at each time point post-transfection (24 
hours, 48 hours and 72 hours). The standard error was ascertained from the standard deviation 
with two incidences (cell line A and cell line B). Standard error values were plotted in fold change 
graphs in Figure 4.22 and Figure 4.23.   
Time point post-
transfection/cell line 
pGL4/IMPG2-promoter fold change 
relative to pGL4.10 
pGL4-mIL17 fold change 
relative to pGL4.10 
Canine skin fibroblast cells 
24 hrs   
Fibroblast line A 0.550 5.130 
Fibroblast line B 0.820 4.900 
Mean fold change 0.690 5.010 
Standard deviation 0.186 0.162 
Standard error 0.132 0.114 
48 hrs   
Fibroblast line A 0.320 1.750 
Fibroblast line B 0.530 2.750 
Mean fold change 0.430 2.250 
Standard deviation 0.148 0.708 
Standard error 0.105 0.500 
72 hrs   
Fibroblast line A 0.330 1.540 
Fibroblast line B 0.500 1.810 
Mean fold change 0.420 1.670 
Standard deviation 0.124 0.192 
Standard error 0.088 0.136 
HEK293T cells 
24 hrs 0.470 1.230 
48hrs 0.570 1.170 
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Figure 4.22: Mean fold changes following a luciferase assay in canine skin fibroblast cells of firefly 
luciferase/Renilla luciferase activity to assess the pGL4/IMPG2-promoter construct and pGL4 
mIL-17 plasmid relative to a background control plasmid, pGL4.10. Data represent two 
independent experiments of two lines of canine skin fibroblast cells with triplicate or duplicate 
measures assessed at 24 hours, 48 hours and 72 hours post transfection. Error bars represent 
standard error. The yellow line represents the pGL4.10 (n = 1) baseline. 
 
Figure 4.23: Mean fold changes following a luciferase assay in HEK293T cells of firefly 
luciferase/Renilla luciferase activity in pGL4/IMPG2-promoter construct and pGL4 mIL-17 
plasmid relative to a background control plasmid pGL4.10 assessed at 24 hours and 48 post-
transfections. The yellow line represents the pGL4.10 (n = 1) baseline. 
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4.3.8 DNA testing 
Validation of the PRA association with the LINE-1 insertion enabled the development of a DNA 
test (termed ‘PRA4’) at the AHT to help reduce the incidence of this form of PRA in the LA. At the 
time of writing, 911 LA dogs from 22 countries (including the UK) have been genotyped for the 
IMPG2 LINE-1 insertion with an allele frequency of 0.11. Genotyping data and allele frequencies 
are summarised in Table 4.12.  
Table 4.12: Total number of LA dogs DNA tested for PRA4 showing genotypes and allele 
frequencies of the LINE-1 insertion. The wild type allele is represented by ‘+’ and the mutant allele 
by ‘-‘.  
Genotype* 
Cohort 
IMPG2 
LINE-1 
-/- 
IMPG2 
LINE-1 
+/- 
IMPG2 
LINE-1 
+/+ 
Total Allele frequency 
Across 22 countries 6 170 735 911 0.11 
UK only 4 107 457 568 0.11 
 
A LA dog identified by the DNA testing service at the AHT as homozygous for the IMPG2 LINE-1 
insertion underwent clinical follow-up at the AHT and was examined by a board-certified 
ophthalmologist/ BVA panellist. Upon ophthalmoscopic evaluation at the age of 2.5 years, the LA 
had early retinal abnormalities consistent with PRA, including tapetal hyperreflectivity, mild 
attenuation of blood vessels in the retina and changes to the optic disc colouration (Figure 4.24). 
 
Figure 4.24: Fundus changes observed in a LA with early stage PRA. (A) An image of the retina in 
the left eye of a LA dog homozygous for the IMPG2 LINE-1 insertion. Bilateral tapetal 
hyperreflectivity was observed as well as mild vascular attenuation and changes to the optic disc 
colouration. (B) An image of the retina of a control dog (GS dog) with a normal fundus (Hitti et al, 
2019).  
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4.4 Discussion 
In this study, a GWAS was performed to identify an interval associated with a novel autosomal 
recessive form of PRA in the LA. A statistically significant association was identified on CANFA33 
that remained significant after correcting for multiple testing and population stratification. 
Analysis of a 1.3 Mb region of homozygosity on CANFA33, which was present in the GWAS PRA 
cases and absent in the controls, identified a LINE-1 insertion located within the predicted 
promoter region of IMPG2. PRA in the LA has not been reported in the literature; however, the 
disease is well recognised anecdotally in the breed and is listed on the BVA/KC/ISDS eye scheme 
in the UK. Pedigree analysis of individuals used in the present study indicated an autosomal 
recessive mode of inheritance.  
The 1.3 Mb disease-associated region identified from GWAS analysis was homozygous in 12 of the 
15 cases that passed QC. Two of the three cases that were not homozygous for the critical region 
were aged 6.3 years and 10 years, with a BVA certificate or veterinary referral letter diagnosing 
PRA, respectively. The third dog had been examined by a certified veterinary ophthalmologist, 
with a diagnosis of suspected PRA at 11 years of age, with additional clinical notes reporting that 
related dogs became blind due to a different eye condition: SARD. A fourth PRA case, submitted 
after the initial GWAS but included in variant follow-up, was also found to be homozygous for the 
wild type allele for all four variants of interest within the critical region, including the LINE-1 
insertion. This case was diagnosed with PRA at the age of 6.8 years by a Member of the Royal 
College of Veterinary Surgeons (MRCVS) and was unable to visit a BVA panellist or a certified 
ophthalmologist to confirm the diagnosis. These four discordant cases are assumed to be affected 
with a genetically distinct form of PRA or a PRA phenocopy. A secondary GWAS analysis was 
conducted with three of the cases that were genotyped for the GWAS but were not homozygous 
for the critical region, using the remaining PRA non-affected LA from the GWAS as control dogs. 
This analysis revealed no suggestive loci. Recruitment of additional LA PRA cases that are clear of 
the IMPG2 LINE-1 insertion may provide scope for future study of a second form of PRA in the 
breed. 
Two retinal candidate genes, IMPG2 and CEP97, are situated within the defined critical region on 
CANFA33. Both genes were manually interrogated in IGV software for potential causal variants 
using WES data generated from LA cases and controls in a previous study in our laboratory, which 
confirmed conclusions drawn from prior analysis of these WES data that no candidate exonic 
variants for PRA in this breed were found across the exome or within the defined critical region. 
This suggested that the PRA-associated variant was within a non-coding region of the genome not 
captured by the WES probes, including upstream promoter regions. WGS was therefore 
performed on one LA PRA case to provide a comprehensive genomic dataset. A PRA case 
homozygous for the critical region was chosen for WGS, to ensure it was representative of the 
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other cases from the GWAS sharing this haplotype. The critical region was explored and a LINE-1 
insertion upstream of the IMPG2 gene was identified. Notably, no strong exonic candidate variants 
were identified in CEP97; however, an intronic variant in CEP97 was considered and genotyped in 
a LA cohort. Given the absence of recombination events between the LINE-1 insertion, the most 
associated GWAS SNP and the two intronic SNVs (in CEP97 and IMPG2), the genotype frequencies 
were compared. Alleles illustrated in Figure 4.9 show that all four variants are in close proximity 
to one another, and indicates recombination events have occurred in two dogs between these 
regions. The LINE-1 insertion was considered the most plausible variant as it was a better 
functional candidate. Although the IMPG2 intronic SNV is as correlated as the LINE-1 insertion, 
predicted pathogenicity and disruption of the IMPG2 promoter region suggested the LINE-1 
insertion as the most likely causal variant of PRA in these dogs.  
Dog breeds exist as isolated populations each with a limited number of founders that has led to 
large regions throughout the genome in LD (Goldstein et al, 2006; Sutter et al, 2004). The 
significant LD that may be present in individual breeds means that it can be impossible to 
statistically refine the number of possible causal variants down to one, where regions of 
homozygosity and variants in LD with one another flank a disease locus. Studying additional 
individuals to continue to monitor genotype-phenotype concordance is important in these 
instances. 
Mutations in IMPG2 cause autosomal recessive RP (Bandah-Rozenfeld et al, 2010) and childhood-
onset rod-cone dystrophy with early macular involvement in humans (Khan & Al Teneiji, 2019). 
Bandah-Rozenfeld et al. (2010) identified seven different mutations in patients with early-onset 
RP (five nonsense mutations and a 1.8 Kb genomic deletion over exon 9) and maculopathy (one 
missense mutation). IMPG2 belongs to a group of glycosylated proteins termed proteoglycans, 
which bind the large carbohydrates (glycosaminoglycans) in neural tissues. The retina consists of 
a neural network of layer-by-layer structures in which proteoglycans are secreted from 
photoreceptor cells and reside in the extracellular matrix bound to the RPE (Inatani & Tanihara, 
2002). The IPM is a unique extracellular complex surrounding retinal photoreceptor outer 
segments and the RPE in the fundus of the eye, and is crucial for supporting normal function of 
retinal photoreceptors (Kuehn et al, 2001; Lazarus & Hageman, 1992). Studies have suggested 
that the IPM plays a role in recycling photoreceptor outer segments; in retina-RPE adhesion; the 
establishment of a milieu suitable for photoreceptor survival; and in the exchange of molecular 
products between the RPE and photoreceptor cells (Acharya et al, 2000; Kuehn & Hageman, 1999; 
Lazarus & Hageman, 1992). The role of IMPG2 in retinal photoreceptors and its association with 
human retinal disease therefore makes it a strong candidate gene for canine retinal disorders. 
Belonging to a group of transposable elements, LINE-1 elements are repetitive sequences present 
throughout mammalian genomes. The majority are inactive, defective elements that vary in size 
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(Ostertag & Kazazian, 2001). Structurally, they contain a 5’ untranslated region (UTR) with 
internal promoter activity, two ORFs, a 3’-UTR and a poly-A tail (Ostertag & Kazazian, 2001). ORF1 
and ORF2 are approximately 1 Kb and 4 Kb in size, respectively (Fanning & Singer, 1987). Agarose 
gel separation and NGS analysis demonstrated that the LINE-1 insertion in the predicted IMPG2 
promoter is a partial transposable element. Analysis of the LINE-1 sequence using in silico 
prediction tools confirmed this, where 5’ truncation results in the total loss of ORF1 and partial 
loss of ORF2, with 1,629-bp aligning to OFR2 of the LINE-1 consensus sequence ‘L1_cf’. There are 
a variety of mechanisms in which LINE-1 insertions can alter gene expression. These include: (i) 
altering gene splicing; (ii) introducing additional genes, regulatory regions, promoter sequence 
and/or alternative splice sites or start sites; and (iii) disruption of existing cis-regulatory elements 
(Belancio et al, 2009; Brooks et al, 2003; Credille et al, 2009; Feschotte, 2008; Ostertag & Kazazian, 
2001; Smith et al, 2011), which in turn could insert or remove exons within genes, or alter 
promoter function and affect the expression of nearby genes.  
Promoter regions are DNA sequences typically located upstream of a gene that, along with 
transcription factors interacting with the promoter region, determine where transcription is 
initiated. Transcription factors recognise short DNA sequences, called cis-regulatory sequences 
(between 100-500 bp in length), which consist of binding sites for sequence-specific transcription 
factors to determine which gene they will transcribe (Cherry et al, 2018). Promoter regions 
upstream of genes define the direction of transcription and indicate which DNA strand will be 
transcribed; therefore, mutations within promoter regions impact transcription regulation and 
are commonly associated with disease (de Vooght et al, 2009). In many eukaryotic genes a 
conserved TATA box promoter sequence (5’-TATAAA-3’) is present and is recognised by 
transcription factors, thereby allowing RNA polymerase to bind and initiate transcription. 
Elongation begins with the addition of nucleotides as RNA polymerase moves along the DNA 
strand until it reaches a terminator to signal transcription to end. Chen et al. (2003) showed that 
regulatory elements excluding the TATA box were present within  100-bp upstream of the 5’ end 
of IMPG2 exon 1 and were 100% conserved in human and mouse. Five regulatory elements 
including pineal regulatory elements (PIREs) were located within this 100-bp upstream region 
and four copies of the PIREs were located between 400-bp and 1,000-bp upstream. Transcription 
is regulated through these additional regulatory elements (Chen et al, 2003). Although, sequence 
obtained through in silico prediction tools shows the presence of a TATA box within the predicted 
promoter region, transcription regulation of the canine IMPG2 gene may mimic human and mice 
regulation using PIREs. Sequence in the IMPG2 predicted promoter sequence, upstream of the 17-
bp target site duplication of the LINE-1 insertion, contains a potential TATA box (5’-TATAAA-3’) 
shortly followed by a run of A nucleotides: CATTATAAATTAGCTTAAATAAAAA, which could be 
involved in transcription regulation. Cone-rod homeobox (CRX), a cone-rod homeobox-containing 
transcription factor/otx-like homeobox protein, is the binding partner of PIRE, inducing 
 Chapter 4 PRA in the Lhasa Apso 
132 
 
transactivation of a PIRE reporter construct (Li et al, 1998), and is expressed in retinal 
photoreceptor cells. In the present study, CRX is also one of the genes encoding transcription 
factors represented by the ‘V$BCDF’ matrix family in the in silico prediction tool ‘MatInspector’ 
(Cartharius et al, 2005). Thus, the presence of PIREs is likely to be important in controlling the 
expression of IMPG2 in photoreceptors in the retina (Chen et al, 2003). Moreover, these TFBS 
elements may be disrupted by the insertion of the LINE-1 sequence in LA PRA cases, which in turn 
may impact IMPG2 transcription and protein function. An example of a LINE-1 element within a 
promoter region associated with disease was described by Davidson et al. (2016) in human 
patients with autosomal dominant corneal endothelial dystrophies. Four mutations within a 
conserved promoter region of the OVOL2 gene were suggested to alter predicted TFBSs. 
Dysregulated OVOL2 expression impacted the function of downstream genes and pathways, 
including transcriptional regulation.  
Transposable elements located in non-exonic regions have been associated with inherited 
diseases in dogs and present compelling cases for causality of their respective conditions. In a 
study investigating an X-linked recessive bleeding disorder, haemophilia B, in German wirehaired 
pointers, an intronic LINE-1 insertion with a 200-bp poly-A tail was detected in affected dogs by 
Southern blot analyses (Brooks et al, 2003). Pedigree information enabled the LINE-1 insertion to 
be traced back through at least five previous generations and it segregated with the disease. An 
intronic LINE-1 insertion in the dystrophin gene was identified in Corgi dogs with Duchenne-like 
muscular dystrophy (Smith et al, 2011). This insertion introduced a new exon with a premature 
stop codon. More specifically, examples of non-exonic insertions of transposable elements have 
been associated with canine retinal diseases. These include a short interspersed nuclear element 
(SINE) insertion identified near the splice acceptor site of FAM161A in PRA-affected Tibetan 
Spaniel and Tibetan Terrier dogs (Downs & Mellersh, 2014); and a retinopathy in Swedish 
Vallhund dogs, where an intronic full LINE-1 insertion in a putative regulatory region of the 
MERTK gene was found to be associated with disease (Everson et al, 2017). In order to determine 
the direct impact of a transposable element on gene regulation or expression, the appropriate 
tissue (or blood if the gene is expressed in blood) from affected individuals is required. Further 
studies comparing retinal tissue between LA PRA cases and controls could shed light on the effect 
of the LINE-1 insertion on IMPG2 expression: 5’RACE (Rapid Amplification of cDNA Ends) would 
confirm whether the insertion changes the 5’-UTR and its TFBSs; and RNA-seq analyses could 
reveal IMPG2 expression and transcription regulation differences. As suitable tissues were not 
available, these experiments could not be undertaken for this study.   
As no retinal (or CRX expressing) tissue was available from any cases in the current study, a 
luciferase assay was attempted using canine skin fibroblast cells, chosen because cell lines were 
available for immediate use. Expression of the IMPG2 gene was confirmed by qPCR prior to 
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commencing plasmid construction and cell transfection for a reporter assay. Despite the 
observation that IMPG2 was expressed in canine skin fibroblast cells, the poor luciferase 
expression observed using a luciferase reporter assay suggests that the IMPG2 promoter inserted 
in the pGL4/IMPG2-promoter plasmid did not act as a promoter in the canine skin fibroblast cells, 
or the HEK293T cells. However, the use of a better positive control with higher RLU readings 
would confirm this assumption. Contrary to initial assumptions, the pGL4 mIL-17 plasmid was not 
a suitable positive control for the experiment as the mouse IL-17 promoter did not prove to be 
active at a high enough level in canine skin fibroblast cells or HEK293T cells. IL-17 is an 
inflammatory cytokine; therefore, the promoter may not be active in these cell lines under the 
normal culture conditions used. An appropriate positive control should result in RLU values and 
relative fold changes much higher than those obtained in the current study, comparable to 
previous IL17-promoter-driven luciferase assays (Chuang et al, 2018; Singh et al, 2018), and 
should be robustly expressed in the cell types under observation. Repeating the transfections with 
a more appropriate positive control containing a promoter that is constitutively expressed at high 
levels in most cell types, such as a cytomegalovirus (CMV) or a SV40 driven promoter, would 
confirm this hypothesis. The GFP reporter gene transfections assessed transfection efficiency in 
the current study and confirmed that a CAG promoter with a CMV enhancer is active in the canine 
skin fibroblast skin cells, as well as the HEK293T cells. Therefore, a plasmid constructed with a 
CMV promoter/enhancer could be explored as a more suitable positive control for future studies. 
In addition, reasonable levels of hRluc were detected in canine skin fibroblast skin and HEK293T 
cells, indicating a vector with a SV40 promoter is active in both cell types. Given that IMPG2 is 
expressed at a low level in the canine skin fibroblast cells, and that transfection efficiencies in 
these cell lines were relatively low in comparison to HEK293T cells, these factors could also have 
contributed to the low values obtained from the luciferase assay. Nevertheless, the hypothesised 
absence of photoreceptor-specific-TFBSs or CRX expression in canine skin fibroblast cells and 
HEK293T cells are probable confounding factors to an unsuccessful luciferase reporter assay. 
Although IMPG2 expression was ascertained in the canine skin fibroblast cells, albeit at a lower 
level than in retinal tissue, it appears that photoreceptor-specific-TFBSs such as CRX are crucial 
for normal IMPG2 promoter activity. Thus, a luciferase reporter assay using retinal cell lines would 
be required to measure IMPG2 promoter activity and the impact of the identified LINE-1 mutation 
on IMPG2 expression. As no retinal cell lines were available to use in a luciferase reporter assay, a 
second assay with a more appropriate positive control was not pursued. Since the hypothesis that 
transcription was disrupted by the LINE-1 element could not be tested either by luciferase assay 
or RNA or protein expression analysis, the effect of the LINE-1 insertion observed in this study on 
the IMPG2 gene can only be speculated.  
DNA tests are used by dog owners and breeders as a tool to avoid producing puppies with a 
particular inherited condition. One outcome of this study has been the development of a DNA test 
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at the AHT, termed ‘PRA4’, to enable LA dogs to be tested for this form of PRA. In the UK LA 
population, tested across a two year duration since the DNA test was made available, the recently 
estimated mutant allele frequency of 0.11 indicates that one in 100 LA dogs are expected to be 
affected with this form of PRA, and 18 in 100 are expected to carry the mutation. Although this 
population will probably include closely related dogs, this value is well within the range presented 
by estimated allele frequencies of other recessive conditions in canine studies (Downs et al, 2011; 
Downs et al, 2013; Zangerl et al, 2006).  
Clinical follow-up of one IMPG2 LINE-1 homozygote provides some evidence that the age of onset 
in the breed may be variable, where clinical signs of retinal changes can be present from as early 
as 2.5 years of age; although examination of additional dogs is required to further characterise an 
age of onset. Where provided with sample clinical information, the age of diagnosis of PRA cases 
homozygous for the disease-associated haplotype from the GWAS varied, ranging from aged 1.75-
10 years. The owner of the LA dog that was identified through the DNA testing service as 
homozygous for the IMPG2 LINE-1 insertion had not noticed behavioural changes or signs that the 
dog’s vision was deteriorating; however, early signs PRA were apparent upon ophthalmoscopic 
examination. Dogs are remarkably good at adapting well to blindness, especially when vision loss 
is gradual. Factors such as the presence of other canine companions in the household and a 
consistent environment can also aid in this adaptation. Continual annual checks of this PRA-
affected LA and other genetically affected LA dogs will help describe the rate of progression of 
PRA in this breed. 
4.5 Conclusion 
Using GWAS and WGS, as well as an existing WES dataset, a LINE-1 insertion upstream of the 
IMPG2 gene that strongly segregates with PRA in LA dogs was identified. Due to the lack of tissue 
from affected dogs or suitable retinal cell lines, no functional analysis or a luciferase reporter 
assay could be conducted to determine the impact of the LINE-1 insertion on the IMPG2 gene. 
However, literature surrounding IMPG2 and its implication in human retinal disease, alongside 
previous studies of transposable elements in non-exonic or gene promoter regions in inherited 
diseases, strongly suggests that the LINE-1 insertion is a causal PRA variant in the LA dogs under 
investigation. Extensive genotyping of this variant in multiple breeds strongly implied that the 
LINE-1 insertion is private to the LA breed, or at least rare amongst other breeds, and was only 
present in PRA-affected LA dogs. Elucidation of this PRA-associated variant facilitated the 
development of a DNA test that, over time, will help reduce the frequency and incidence of this 
mutation in the LA breed worldwide. 
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Chapter 5 PRA in the Shetland Sheepdog 
5.1 Introduction 
The Shetland Sheepdog (SS), also referred to as the Sheltie, is a popular breed in the UK. In 2018, 
it had the third highest registrations with The Kennel Club, UK within the Pastoral group, with 794 
registrations. Population analysis by The Kennel Club, UK of the SS breed between 1980 and 2014 
shows a loss of genetic diversity has occurred, with higher rates of inbreeding due to the use of 
popular sires and a reduced estimated effective population size of 77.6 (a value below 100 
indicates an increase in the rate of loss of genetic diversity within the breed) (The Kennel Club UK, 
2015). Therefore, despite a high number of yearly registrations, many of these SS may be closely 
related and today’s SS population may continue this trend of having high coefficient of inbreeding 
rates and a smaller gene pool. This increases the probability that two copies of the same variant 
in a gene being inherited from an ancestor common to both the sire and dam in their offspring. 
Shelties are known to suffer from two main hereditary ocular conditions: collie eye anomaly (CEA) 
(Parker et al, 2007) and PRA (Wiik et al, 2015). One form of PRA has previously been described in 
the SS, caused by an exonic 4-bp deletion in the cyclic nucleotide gated channel alpha 1 (CNGA1) 
gene, however genetic heterogeneity was indicated in the study cohort (Wiik et al, 2015). Several 
SS that were unrelated to the CNGA1 affected proband were clear of the deletion, suggesting that 
at least one additional form of PRA was segregating in the breed. Prior to these findings, the only 
form of inherited retinal disease for which a disease-associated variant has been reported in the 
SS is CEA (Parker et al, 2007). As of 2018, PRA is no longer listed by the BVA/KC/ISDS eye scheme 
due to no recent cases reported under the scheme (Appendix 3). However, at the time this study 
was initiated, PRA was of concern to the English SS Breed Club in the UK as at least one non-CNGA1 
PRA case was known. Knowledge that non-CNGA1 forms of PRA are present in the breed, with an 
unknown number of carriers in worldwide populations, warranted further study of PRA to 
identify genetically unresolved incidences. The aim of this study was to identify the genetic cause 
of an additional form of PRA, enabling DNA test development for breeders to use as a tool to 
reduce the frequency and eventually eradicate a novel form of PRA from the breed.   
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5.2 Materials and methods 
5.2.1 PRA diagnosis and sample collection 
PRA in the SS is clinically indistinguishable from PRA in other breeds of dog and is diagnosed 
based on ophthalmoscopic evaluation by a board-certified veterinary ophthalmologist or a 
qualified BVA/KC/ISDS eye scheme panellist (or the European equivalent if outside the UK). 
Buccal mucosal cheek swabs were submitted to the AHT from four SS PRA cases, one suspected 
PRA case, and 89 SS PRA controls. Of the 89 controls, 43 SS were aged eight years and over and 
had a clinically clear PRA diagnosis following ophthalmic examination by a veterinary 
ophthalmologist via the BVA/KC/ISDS Eye Scheme in the UK, or the European equivalent(s), and 
were therefore considered to be PRA controls for this study. Of the four PRA cases, two were 
littermates. This litter comprised three SS with one female and one male SS clinically affected with 
PRA (one diagnosed by a BVA/KC/ISDS eye panellist; one diagnosed by a board-certified 
veterinary ophthalmologist), and one male suspected to have PRA.  
The age of diagnosis for the four cases ranged from 1.26 - 8.93 years of age. Where known, owners 
of SS dogs included in the study resided in the UK (n = 73), Jersey (n = 1), The Netherlands (n = 3) 
and Czech Republic (n = 1). DNA was extracted from buccal mucosal cheek swabs using protocols 
described in Chapter 2 (section 2.7). 
5.2.2 Exclusion of known retinal mutations 
Twenty-six previously published mutations, including the CNGA1 variant identified in the SS breed 
(Wiik et al, 2015), were excluded as mutations responsible for this form of PRA in the SS (see 
Chapter 2, section 2.7). 
5.2.3 Whole genome sequencing (WGS) 
gDNA from a PRA-affected SS was prepared for WGS. WGS was performed using protocols 
previously described (see Chapter 2, section 2.6). gVCF files from 186 canine WGS in the AHT 
dataset were merged into a multi-sample VCF file. 
5.2.4 Variant filtering 
Variants were filtered for those with the highest effect scores (4 and 5) (see section 2.8 for effect 
score grading) and for variants segregating as an autosomal recessive disease. An X-linked mode 
of inheritance was also considered by filtering for high impact variants located on the X 
chromosome and by checking for XLPRA mutations previously identified in other breeds that 
could not be excluded prior to WGS. Sequencing reads from WGS data were visualised in IGV to 
determine genotypes of the known XLPRA-associated mutations and a de novo assembly of 
sequencing reads across regions which were unannotated in the reference genome, as described 
in Chapter 2 (section 2.6). In addition, the genome data of six additional genes associated with X-
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linked retinal diseases in humans: RP2 (Bhattacharya et al, 1984; Hardcastle et al, 1999), OFD1 
(Coene et al, 2009; Hardcastle et al, 2000; Webb et al, 2012), TIMM8A (Jin et al, 1996), CACNA1F 
(Bech-Hansen et al, 1998; Strom et al, 1998) and NYX (Bech-Hansen et al, 2000; Gal et al, 1989; 
Hardcastle et al, 1997) were visualised for variants. 
Further variant filtering was conducted using the DBVDC (see Chapter 2 section 2.8) as a genome 
bank. De novo local realignments of sequencing reads were conducted over each filtered variant 
region using HaplotypeCaller (Poplin et al, 2018). 
5.2.5 In silico protein prediction tools 
To assess the impact of the candidate variant amino acid substitution on gene protein function, 
bioinformatics tools Mutation Analyzer, PolyPhen-2, and SIFT were used to computationally 
predict the effect of the missense variant. 
5.2.6 Comparative species conservation  
The Evolutionary Conserved Region Browser (http://ecrbrowser.dcode.org) and UCSC Genome 
Browser were used to determine the degree of sequence conservation of the BBS2 gene across 
species. Using the human genome (GRCh37/hg19) as the base genome, BBS2 human coordinates 
were compared across five species.  
5.2.7 Screening Shetland Sheepdogs  
A cohort of SS controls that were aged eight years or over and diagnosed as clinically clear through 
the BVA/KC/ISDS eye scheme were genotyped for variants highlighted through the variant 
filtering process. Primers were designed around each variant to generate PCR amplicons larger 
than 300-bp in size for Illumina short-read sequencing on a MiSeq platform (Illumina). Primers 
are listed in Appendix 4. A multiplex PCR was conducted as described in Chapter 2 (section 2.7) 
followed by PCR purification, library preparation and data interpretation as described in section 
2.6. The University of Helsinki, Finland, kindly genotyped a cohort of 394 SS dogs including one 
PRA case, two dogs with suspected PRA and two other retinopathy-affected dogs using the allelic 
discrimination assay described below. The Norwegian University of Life Sciences, Norway, also 
kindly sequenced eight PRA cases SS for the BBS2 variant using primers and conditions described 
below. 
5.2.8 Variant validation and genotyping 
The missense BBS2 SNV was confirmed using Sanger sequencing (see section 2.5). An allelic 
discrimination probe-based assay was designed to effectively distinguish between individuals 
homozygous for the SNV (C/C), heterozygous (G/C) or homozygous for the wild type/ common 
allele (G/G). Allelic discrimination assays were performed as described in Chapter 2 (section 2.9) 
using a 40X primer/probe mix and conditions listed in Appendix 4. The CEP290 SNV was 
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genotyped using PCR followed by Sanger sequencing as described in Chapter 2 (sections 2.3, 2.4.1 
and 2.5). Primers and assay conditions are listed in Appendix 4. 
5.2.9 Extracting all variants in BBS-genes 
To highlight additional variants in the SS WGS dataset that were situated in other BBS-associated 
genes, all variants (regardless of their effect score) were extracted from the multi-VCF file into a 
text file. The following ‘grep’ Unix command was used to extract all variants that were situated in 
21 known BBS-genes, including gene synonyms in the search: 
grep -wE 
"(Chr|BBS1|BBS2|ARL6|BBS4|BBS5|MKKS|BBS7|BBS8|TTC8|BBS9|BBS10|TRIM32|BBS12|MKS
1|CEP290|WDPCP|SDCCA8|LZTFL1|BBIP1|IFT27|IFT172|C8orf37|BBIP10)" input_file.txt > 
output_file.txt 
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5.3 Results 
5.3.1 Clinical signs 
PRA diagnosis 
Pedigree information revealed that the SS elected for WGS belonged to a litter consisting of three 
offspring: one female and two males (male A and male B). A PRA diagnosis was confirmed in the 
female SS and one of the male SS dogs (male A) by a BVA/KC/ISDS panellist and/or veterinary 
ophthalmologist. The female SS was 8.7 years at the time the PRA diagnosis was confirmed. The 
same dog had been examined under the BVA/KC/ISDS eye scheme 16 months earlier (aged 7.4 
years), by the same ophthalmologist, and was clinically unaffected at that time; indicating a form 
of PRA with a relatively late age of onset. PRA was diagnosed based on findings of bilateral retinal 
degeneration due to bilateral tapetal hyperreflectivity with retinal vascular attenuation and an 
optic disc pale in colour. Menace and pupillary light responses were present but reduced. No 
cataracts were present. Additional findings were bilateral distichiasis, bilateral nuclear sclerosis 
and asteroid hyalosis. Night blindness had been apparent for four weeks prior to the confirmed 
diagnosis and a noticeable decline in daylight vision followed thereafter. A maze test was 
performed, where the female case collided with obstacles under scotopic conditions but avoided 
obstacles under photopic conditions. An ERG showed depressed rod and cone response. 
Ophthalmoscopic follow-up examination at 11.3 years reported no PRA progression, but cataract 
formation at the equatorial region. Mature cataracts were present bilaterally by the age of 12 
years.  
Veterinary records show that male A was also diagnosed with retinal abnormalities that were 
consistent with PRA by a board-certified veterinary ophthalmologist. This included tapetal 
hyperreflectivity and bilateral retinal blood vessel attenuation at the age of six years. Although 
male B was not formally examined through the BVA/KC/ISDS eye scheme or by a board-certified 
veterinary ophthalmologist, a PRA diagnosis was suspected. The owners of male B reported the 
dog had started to suffer from visual impairment around the age of 9-10 years, initially presenting 
with reduced vision in low light or at night that progressed until his death at the age of 15 years. 
The dam of the litter was examined under the BVA/KC/ISDS scheme at 11.4 years and was 
clinically unaffected at that age. There is no evidence that the sire’s eyes were ever examined by a 
veterinary ophthalmologist. 
For the remaining two confirmed PRA cases, one was diagnosed with early-onset PRA at the age 
of 1.26 years and one was diagnosed with PRA at the age of 8.93 years; both by separate 
BVA/KC/ISDS panellists.  
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Weight 
Veterinary history regarding weight was only available from the age of 11 years for the female SS. 
Weight was recorded from the age of 11 years up until euthanasia at the age of 13.9 years, ranging 
from 5.1 kg – 6.6 kg with the dog on a low-fat diet.  
Male A was obese, weighing 19.5 kg at the age of 5.5 years. The owner reported that the SS had a 
severely increased appetite and described the dog as ‘ravenous’ when offered food. A low-fat diet 
eventually reduced the dog’s weight to 14 kg at the age of 6.4 years, but this was not maintained 
and resulted in subsequent weight gain. A dirlotapide based drug (Slentrol®) was used from the 
age of 5.9 years in an attempt to reduce body weight. No information on male B’s weight was 
available, nor the two remaining PRA cases not in the litter. 
Renal function  
Limited information was available on renal biochemistry for the female SS case, however 
nephroliths were present at 13.3 years of age, and eventually the owner elected for euthanasia at 
13.9 years due to renal failure. In male A, urea and creatine levels were within normal limits at 5.5 
years of age: 7.9 moles per Litre (mol/L) (normal range 2.5- 9.6 mol/L) and 85 mol/L (normal 
range 44-159 mol/L), respectively. When assessed at eight years, these levels had increased (urea 
26.7 mol/L; creatine 160 mol/L). Two months later, urea and creatine levels had significantly 
increased to 35.6 mol/L and 258 mol/L; resulting in a diagnosis of renal failure. The veterinarian 
prescribed a renal diet feed and Fortekor® to aid in the management of chronic renal failure. By 
the age of 9.4 years, kidney disease had progressed with elevated urea and creatine levels (urea 
46.4 mol/L; creatine 444 mol/L) and euthanasia was elected. No information on male B’s renal 
health was available, nor the two remaining PRA cases not in the litter. 
Additional features 
The female SS PRA case showed uncharacteristic features for the breed, including an upturned 
nose, an unusual coat texture and dental abnormalities (Figure 5.1). At the time, the condition was 
deemed purely cosmetic and no further follow-up was carried out. The owner of this dog shared 
speculations that one of the male dogs in the litter (male B) shared the visible uncharacteristic 
features seen in the female (including an upturned nose and unusual coat texture), with the 
female’s distinctive nose shape more pronounced. These features became more noticeable as the 
dog developed, becoming more apparent around the age of six months. In addition to PRA, the 
female SS was diagnosed with distichiasis and struvite urolithiasis had previously been detected, 
which was controlled by an appropriate diet. Veterinary history also noted dental remarks where 
multiple teeth were extracted at the age of 11.9 years. Photographs confirm this female had 
abnormal teeth (Figure 5.1). 
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Figure 5.1: Photographs of the PRA-affected female SS in the initial litter show the 
uncharacteristic wavy coat, upturned nose and dental defects (A-C). 
The only evidence obtained for the physical appearance of male B was the anecdotal evidence that 
it shared the distinctive characteristics of the female. No further information on the physical 
appearance of male A was available, although the dog was reported to have undergone dental 
treatment of three teeth extractions due to resorptive lesions. Photographs of both sire and dam 
show that they did not exhibit the unusual nose shape or coat texture observed in the affected 
offspring (Figure 5.2). Of the two PRA cases not in the litter, the 1.26-year-old SS showed normal 
physical characteristics typical for the breed, and no information on the physical appearance of 
the 8.93-year-old PRA case was available. 
 
Figure 5.2: Photographs of the sire and dam to the PRA-affected SS. Both the sire (A) and dam (B) 
of the original litter of SS in the present study have typical physical characteristics and features 
that adhere to the SS breed standards for nose shape and coat texture. 
5.3.2 Exclusion of known PRA-associated mutations 
Twenty-seven previously published retinal mutations were excluded as the cause of PRA in the 
PRA-affected SS case, in addition to both the NECAP1 and IMPG2 variants identified in this thesis. 
This indicated that a novel PRA-associated mutation was present. Full materials and methods are 
described in Chapter 2 (section 2.7). 
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5.3.3 Variant filtering 
At the time of study, 185 canine genomes that were sequenced as part of other studies at the AHT 
were available to use as non-breed matched controls to compare against the PRA-affected SS 
genome. Of these 185 genomes, 176 were of dogs that were recruited for non-PRA studies and 
were considered to be PRA controls for the purposes of this study. These comprised 87 pure breed 
dogs and 5 cross breed dogs. Date of births were known for 108 of the 176 non-breed matched 
controls, with dogs ages ranging from 0.11 and 15.4 years at the time of DNA submission, with a 
median age of 6.79 years (interquartile range 1.90-9.14). These dogs were affected with 
conditions including epilepsy, sensory neuropathy, hereditary cataracts, glaucoma, Spongiform 
Leukoencephalomyelopathy (SLEM) and primary lens luxation. The DBVDC contained 648 
genomes at the time of study.  
The merged VCF file contained 186 genomes (1 case versus 185 controls) with a total of 
27,611,812 variants amongst all genomes. Filtering for variants with a high effect score (4 and 5) 
retained 136,383 high impact variants. As the litter consisted of one PRA-affected female and at 
least one PRA-affected male, an X-linked dominant mode of inheritance was considered. However, 
as the sire was apparently unaffected and the dam was clinically confirmed as unaffected, an X-
linked dominant PRA was unlikely. Nevertheless, IGV software was used to visualise sequencing 
reads from the SS WGS over the entire RPGR gene, which has previously been implicated in canine 
XLPRA. No variants of interest were present in RPGR. In addition, no high impact variants 
segregated appropriately for an X-linked mode of inheritance (dominant or recessive) or were 
present in six genes associated with X-linked RP in humans: RP2, OFD1, TIMM8A, CACNA1F and 
NYX. Thus, an X-linked model was excluded, and an autosomal recessive mode of inheritance was 
considered most likely. 
Filtering based on an autosomal recessive model, i.e. retaining high effect variants (effect score of 
4 or 5) that were homozygous in the SS case and either heterozygous or homozygous for the 
alternate allele in all 176 non-breed matched controls, resulted in 151 variants. Further exclusion 
of variants located on unknown chromosomes narrowed the variant list down to 134 variants. 
These 134 variants were checked across canine genomes in the DBVDC, which comprised of 648 
genomes at the time of study (32 belonging to the AHT), including three SS genomes. Twelve 
variants were all homozygous in the SS case and absent from all other genomes in the DBVDC. Five 
of these fifteen variants overlap the variants in the final filtering list, described below. 
In parallel with screening the DBVDC, all genes in which the 151 variants were located were 
assessed for their candidacy: comprising 74 annotated genes (80 variants) and 40 Ensembl canine 
stable identifiers (ENSCAF IDs; 71 variants). Of the 40 ENSCAF IDs, human homologues could be 
determined for 10 genes (28 variants). Fifty-seven variants located within ENSCAF IDs of which 
no human orthologous region was present and/or those on unknown chromosomes were 
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excluded. Therefore, a total of 84 gene names (94 variants) were investigated in the OMIM 
database against a list of relevant keywords considered to be associated with PRA phenotypes 
(see Chapter 2, section 2.8). Thirty-eight variants were predicted to be tolerated by SIFT and 36 
variants were homozygous in non-SS or non-Collie breed control genomes in the DBVDC, and were 
therefore excluded. Two of the remaining 20 variants were homozygous in SS genomes or Collie 
breeds. Manual visualisation of these 20 filtered variants in IGV following de novo local 
realignment using HaplotypeCaller (Poplin et al, 2018) confirmed that 15 variants were called 
correctly (Table 5.1). Of these 15 variants, two were highlighted as candidate variants based on 
direct, or indirect, relation to one or more of the PRA-related terms in the keyword list. 
Nevertheless, all 15 variants were investigated further. 
5.3.4 Variant mining 
The 15 variants identified in the variant filtering process were genotyped (by sequencing on the 
Illumina MiSeq) in a cohort of 43 SS control dogs, which were aged eight years or older and 
diagnosed as clinically clear of PRA. PCR amplicons could only be generated for 12 variants, of 
which 11 were homozygous in at least one of the SS control dogs and therefore were excluded as 
causal PRA variants. Table 5.1 summarises the 15 variants and determines whether they could be 
excluded as candidate variants or not. One candidate variant not excluded is a non-synonymous 
missense SNV in the Bardet-Biedl syndrome 2 gene (BBS2) (Figure 5.3); a gene previously 
associated with a ciliopathy termed BBS in humans. 
Sequencing of three variants failed due to difficulty in amplification, probably due to repetitive 
sequence and/or GC-rich sequence. These were variants in the genes GGN, C7 and IRS2. RNA-seq 
data generated for an unrelated study from a PRA non-affected Petit Bassett Griffon Vendéen 
canine retina showed the GGN gene is considered to be expressed at low levels in the retina, 
whereas C7 and IRS2 are considered to be highly expressed. Although genotyping by sequencing 
of the GGN, C7 and IRS2 variants failed, the variants were identified in additional breeds in the 
DBVDC genomes. The GGN 9-bp insertion was heterozygous in an Alaskan Malamute, two Irish 
Terrier dogs and a Wolf, and homozygous in a Chow Chow dog and two Wolf genomes. The C7 SNV 
was present in two SS genomes in the DBVDC: one homozygote and one heterozygote. The DBVDC 
member that owned the SS genome homozygous for the C7 variant confirmed the dog was 
diagnosed with a neurological condition by a neurologist and no ocular phenotypes had been 
reported. The C7 variant was also heterozygous in WGS from a Lancashire Heeler dog included in 
the AHT’s control genomes used in the analysis. Finally, the IRS2 3-bp insertion had poor 
sequencing coverage in the original SS WGS due to a high GC content across this region. When 
screened for in the DBVDC, no sequencing data were available for the IRS2 variant in multiple 
genomes and two Dachshund dogs were heterozygous for the insertion. Although these variants 
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could not be fully excluded using PCR methods, the candidacy of BBS2 SNV warranted 
prioritisation for further exploration. 
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Table 5.1: Fifteen variants identified through WGS were genotyped in a SS cohort. Filtering 
variants from WGS analysis identified 15 variants to follow up in additional SS. Two variants were 
highlighted as candidate variants based direct, or indirect, relation to one or more of the PRA-
related terms in the keyword list, represented by a † symbol. However, only one gene has been 
associated with a retinal phenotype in any other species: BBS2 (highlighted). Variants were 
sequenced in 43 SS controls aged eight years or older and were excluded as variants of interest if 
homozygous in at least one control SS. Variants with low confidence in sequencing reads due to 
low coverage or those where control dogs were only heterozygous or homozygous for the 
alternate allele were not excluded as potential candidate variants.   
CanFam3.1 
Chromosomal 
Position 
Gene/Ensembl Stable 
Identifier 
Variant 
Excluded/Not 
Excluded 
1: 110,147,994 CD3EAP Missense SNV Excluded 
1: 116,038,553 ENSCAFG00000028805  
(no human orthologue) 
Missense SNV Excluded 
1: 119,547,008 ZNF507 1-bp deletion Excluded 
2: 62,484,625 CHD9 Missense SNV Excluded 
15: 52,265,347 FGG Splice site insertion of 
transposable element  
Excluded 
16: 36,561,913 DLC1 Missense SNV Excluded 
16: 44,477,295 F11 Splice site SNV Excluded 
30: 24,115,675 ENSCAFG00000016650  
(human orthologue PSMA1) 
Missense SNV Excluded 
36: 10,135,919 SLC38A11 Missense SNV Excluded 
X: 1,762,952 MXRA5 Missense SNV Excluded 
X: 43,769,675 BMP15 Missense SNV Excluded 
1: 114,617,154 GGN 9-bp insertion Not excluded 
2: 59,693,737 BBS2† Missense SNV Not excluded 
4: 68,451,901 C7 Nonsense SNV Not excluded 
22: 58,226,397 IRS2† 3-bp insertion Not excluded 
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Figure 5.3: IGV display of the BBS2 c.1222G>C SNV in the SS. (A) WGS from a SS PRA case 
homozygous for the BBS2 SNV. (B) WGS from a PRA non-affected control genome (Vizsla dog) is 
homozygous for the wild type allele. BBS2 is expressed in retinal tissue as demonstrated by RNA-
seq alignment from two control dogs: (C) one Dalmatian dog and (D) one Petit Basset Griffon 
Vendéen (PBGV) dog, both of which are also homozygous for the wild type allele at this position. 
5.3.5 Variant identification 
Sanger sequencing confirmed the c.1222G>C missense SNV in exon 11 of 17 of BBS2 (Figure 5.4). 
This non-synonymous variant results in an amino acid change from alanine to proline at amino 
acid position 408 (p.A408P). Unlike the canine BBS2 gene located on the forward strand in the 
CanFam3.1 canine genome annotation, the human BBS2 gene is located on the reverse strand. At 
the homologous position in the human BBS2 gene (GRCh38; chr16:56,501,010), a missense 
variant (G/A) resulting in an alanine to valine amino acid change, has been reported 
(rs1274202413) with a minor allele frequency of < 0.01. No phenotype data are available for this 
variant, which is also absent from the Genome Aggregation Database (gnomAD), nor are any other 
variants at this position in gnomAD. Moreover, alanine and valine are structurally similar amino 
acid residues, therefore the substitution described above may not have a functional effect on the 
human BBS2 protein. Proline, however, is structurally different to alanine and is usually located 
in unstructured regions between secondary structures, and therefore it is important in shaping 
the secondary structure of a protein (Betts & Russell, 2007). This provides support that the 
alanine to proline substitution reported in SS in this study impacts canine BBS2 structure and 
function. 
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Figure 5.4: Sanger sequencing of the BBS2 c.1222G>C variant confirmed the presence of the 
identified SNV in the SS DNA used for whole genome sequencing (A). Two additional dogs (shown 
in Figure 5.10) were also homozygous for the c.1222G>C variant (B, C). SS dogs heterozygous for 
the variant and homozygous for the wild type allele are shown in tracks D and E, respectively. 
5.3.6 In silico protein predictions  
Mutation Analyzer and PolyPhen-2 predicted the c.1222G>C; p.A408P amino acid change in BBS2 
to be rarely substituted and probably damaging to the protein (PolyPhen score 0.993), 
respectively. SIFT predicted the change to be deleterious with a SIFT score of 0.03. 
5.3.7 Comparative species conservation 
BBS2 is conserved across species showing 90% sequence similarity to the human orthologue. 
Additionally, the ‘GCA’ codon implicated is well conserved across 37 mammals, including humans. 
Using the human genome (GRCh37/hg19 assembly) as the base genome, the degree of 
evolutionary sequence conservation of BBS2 was assessed in the zebrafish, chicken, mouse, dog 
(CanFam2.0 assembly), and rhesus macaque genomes (Figure 5.5A). The majority of coding exons 
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were conserved across each species, with the zebrafish and chicken genomes displaying a 
reduction in conservation across all exons and an absence of exons (exons 1, 3, 9, 11 and 12 in the 
zebrafish and exon 1 in the chicken). The rhesus macaque and the dog genomes share the highest 
degree of BBS2 sequence conservation across the species evaluated, closely followed by the mouse 
genome. BBS2 amino acid residues are conserved across this region; specifically, the affected 
amino acid alanine is highly conserved through evolution (Figure 5.5B). 
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Figure 5.5: Display of BBS2 conservation across species. (A) Evolutionary conserved regions of human BBS2 (GRCh37; chr16:56517591-56553340) 
are most highly conserved across the rhesus macaque and dog genomes (CanFam2 assembly) followed by the mouse. The chicken and zebrafish 
constructs show poorer conservation, however the majority of exonic regions are conserved. (B) Evolutionary conservation of the amino acid affected 
by the canine BBS2 missense variant (p.A408P; alanine boxed in red) and surrounding amino acids across the human, zebrafish, chicken, mouse, dog 
and rhesus macaque show a high degree of conservation. Amino acids numbered are relative to the dog sequence to identify the amino acid affected 
by the c.1222G>C; p.A408P SNV.
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5.3.8 BBS2 domains and features 
The canine BBS2 gene encodes a 715 amino acid protein with three domains (Figure 5.6). The N-
terminal is predicted to be positioned from amino acid residues 22-120; a mid-terminal from 159-
266 and a C-terminal from 270-709 (Pfam; El-Gebali et al, 2019) with a putative coiled-coil 
domain between 317–344 amino acid residues (UniProt). The c.1222G>C; p.A408P BBS2 SNV 
identified in the SS PRA case resides within the predicted C-terminal domain. 
 
Figure 5.6: BBS2 dog protein. The N-terminal (BBS2_N) is positioned between amino acid 
residues 22-120. The middle region domain (BBS2_M) is located between amino acids 159-266. 
The C-terminal (BBS2_C) resides between amino acids 270-709 with a putative coiled-coil domain 
(CC) from 317-344 amino acids. The BBS2 candidate SNV affects amino acid position 408, as 
highlighted by a red asterisk.   
5.3.9 BBS2 variant screening 
The BBS2 c.1222G>C SNV was genotyped across 1,386 canids of 155 dog breeds (Appendix 11), 
15 cross breeds and eight wolves (Table 5.2), including 505 SS. Of the 505 SS, 91 were submitted 
to the AHT, of which 78 were homozygous for the wild type allele, 11 were heterozygous and five 
were homozygous for the BBS2 SNV. Three-hundred-and-ninety-four SS were submitted to The 
University of Helsinki, Finland, including one PRA-affected dog, two dogs with suspected PRA and 
two other retinopathy-affected dogs. These comprised six SS heterozygous for the BBS2 
c.1222G>C SNV and 388 homozygous for the wild type allele. Eight SS were submitted to The 
Norwegian University of Life Sciences, Norway, of which two were homozygous for the BBS2 SNV 
and six were homozygous for the wild type allele. Nine of the 505 SS were from The University of 
Pennsylvania, USA (including one PRA-affected SS and eight SS related to this case); all these USA 
samples were homozygous for the wild type allele. Three SS belonged to the DBVDC and were 
homozygous wild type for the BBS2 SNV. Taken together, 14 SS were confirmed PRA cases, of 
which four were homozygous for the BBS2 SNV and ten were homozygous for the wild type allele. 
The four cases homozygous for the SNV included two SS in the original litter, and two SS from the 
Norwegian cohort. Pedigree information from the two dogs from the Norwegian cohort showed 
they were non-related within five generations to the WGS case, and no photographs or 
information were available regarding any additional phenotypic information. Genotypes of SS 
dogs tested for the BBS2 SNV, that were either confirmed PRA cases or PRA controls known to be 
clear of PRA or where a PRA diagnosis was unknown, are summarised in Table 5.3.  
 Chapter 5 PRA in the Shetland Sheepdog 
151 
 
In addition, the 858 dogs of 154 other breeds, including 136 Border Collie dogs (six PRA-affected), 
15 cross breeds and eight wolves that were also genotyped for the BBS2 SNV were homozygous 
for the wild type allele. 
Table 5.2: Allele frequency of BBS2 SNV in multiple breeds of dog. 
Breed BBS2 +/+ BBS2 +/− BBS2 −/− Allele Frequency 
Shetland Sheepdog (SS) 481 17 7 0.031 
SS * 481 13 4 0.021 
Cross breeds 15 0 0 0 
Wolves 8 0 0 0 
154 other breeds 858 0 0 0 
* excluding third generation relatives to probands from known pedigree information. 
Table 5.3: Genotype distribution of the BBS2 SNV in SS confirmed PRA cases and SS PRA controls, 
or SS with an unknown PRA diagnosis. 
Variant SS PRA cases 
SS PRA controls or unknown 
PRA diagnoses 
 
 Alt/Alt Alt/Ref Ref/Ref Alt/Alt Alt/Ref Ref/Ref  
BBS2 c.1222G>C SNV 4 0 10 3 17 471  
 
Genotyping of two SS, aged one year (Figure 5.7) and 7.6 years old (Figure 5.8), that exhibited the 
same distinctive characteristics as the initial case (upturned nose, unusual coat and dental 
defects) revealed that both are homozygous for the SNV. The 7.6-year-old BBS2 homozygote 
underwent ophthalmoscopic examination by a board-certified ophthalmologist (who was also a 
BVA/KC/ISDS panellist), however no clinical signs of PRA were observed. The one-year-old SS did 
not undergo ophthalmic examination. Pedigree information for these two additional BBS2 
homozygotes shows that both dogs share common ancestry to the initial SS litter of three BBS2 
homozygotes (Figure 5.9). The pedigree also highlights third generation relatives to the proband, 
which were excluded in determining allele frequencies to be more representative of the general 
SS population.  
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Figure 5.7:Photographs of the one-year-old SS homozygous for the BBS2 variant displays 
distinctive features akin to the initial female SS PRA case in the study (A-C). 
 
 
Figure 5.8: Photographs of the 7.6-year-old BBS2 homozygote SS showing a wider snout (A), 
slightly wavy coat texture and a slight upturned nose (B, C).  
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Figure 5.9: Pedigree drawing of BBS2 homozygous SS shows that there is shared ancestry between five of the BBS2 homozygotes. Male dogs are shown 
as a square symbol and female dogs as a circle symbol. Individuals coloured pink are related within three generations to the proband sent for WGS.
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Of the seven dogs homozygous for the BBS2 c.1222G>C SNV, photographs that were obtained for 
three dogs show a striking upturned nose (Figure 5.10A, B, C) with two displaying a slightly more 
pronounced nose (Figure 5.10A, C). Comparison of these dogs against a SS that is a half-sibling to 
the initial PRA case; heterozygous for the SNV; and exhibits a typical Sheltie nose shape and coat 
(Figure 5.10D) suggests heterozygotes do not display this disease phenotype. 
 
Figure 5.10: Profile view photographs of SS dogs tested for the BBS2 SNV. SS in photographs (A), 
(B) and (C) are homozygous for the BBS2 c.1222G>C SNV and exhibit an upturned nose. Dog (D) 
is heterozygous for the SNV and was clinically clear of PRA at the age of 9.2 years. 
5.3.10 Additional BBS-gene variants 
The VCF output file for the SS generated 510,752 variants of all effect scores (1-5), of which 174 
variants reside in one of the 21 genes implicated in human BBS (including the BBS2 candidate 
variant). Of the 174 variants, three variants are situated in the 3’-UTR region (of BBS10), 17 are 
intergenic variants and 152 intronic variants. The only exonic variants are the c.1222G>C SNV in 
BBS2, present only in the SS, and a missense variant in CEP290 (c.3011C>T; p.S1003L). In 199 
genomes in the AHT genome bank, the CEP290 variant was homozygous in the SS as well as three 
other breeds (one Border Collie crossbreed, one Bulldog and one Smooth Collie) and heterozygous 
in four additional breeds (one Bulldog, one Bearded Collie, one Rough Collie and a Swedish 
Vallhund dog). In the DBVDC cohort, the CEP290 variant was homozygous in dogs of the following 
breeds: Cardigan Welsh Corgi (n = 1), Collie (n = 1), Scottish Deerhound (n = 2) and SS (n = 2), and 
heterozygous in: American Bulldog (n = 1), French Bulldog (n = 1), German Shepherd cross (n = 
1), Greyhound (n = 1), Irish Wolfhound (n = 1), Malinois (n = 2), Newfoundland (n = 1), Old English 
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Sheepdog (n = 1), Scottish Deerhound (n = 1), Pembroke Welsh Corgi (n = 1), SS (n = 1) and St 
Bernard (n = 1). The CEP290 SNV is present in dbSNP (rs851859358) with a minor allele 
frequency of 0.021, but no phenotype information is available. The variant is tolerated by SIFT 
with a score of 0.26. Five SS homozygous for the BBS2 SNV, one SS heterozygous for the SNV and 
one SS homozygous for the wild type/ common allele were genotyped for the CEP290 c.3011C>T 
SNV. All eight SS were homozygous for the alternate ‘T’ allele at this position. 
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5.4 Discussion 
Using WGS of a single SS PRA-affected dog compared to 176 non-breed matched controls, a SNV 
in the BBS2 gene located on CANFA2 has been identified. BBS2 is a strong candidate gene for 
canine PRA as it has been implicated in the human BBS, of which retinal degeneration is a primary 
clinical sign. The candidate variant was absent from 858 dogs of 154 other breeds, 15 cross breeds 
and eight wolves, indicating that the variant was probably unique to the SS breed. Further to the 
PRA case sent for WGS, six additional SS were homozygous for the SNV, including two full siblings 
to the WGS case. In these additional homozygotes, where available, clinical information and 
photographs confirmed a PRA diagnosis and/or features of an upturned nose, abnormally 
textured coat and dental abnormalities. The involvement of BBS2 in human BBS patients sharing 
similar clinical features presents BBS2 as an interesting gene to consider a syndromic form of PRA 
in the SS.  
Human BBS is classically an autosomal recessive multisystem ciliopathy. There are a wide array 
of clinical manifestations, whereby a BBS diagnosis is based on the presence of at least four 
primary features, or three primary and two (or more) secondary features. In human patients, 
primary features of the condition include retinal degeneration; polydactyly; obesity; genital 
abnormalities; renal abnormalities; and learning difficulties. A diverse spectrum of secondary 
features manifest, including speech and developmental delays, diabetes; dental defects; 
congenital heart disease; brachydactyly; ataxia; and craniofacial abnormalities, described below 
(Forsythe et al, 2018). The most common feature that typically defines BBS is RP, observed in 93% 
of patients (Beales et al, 1999; Forsythe & Beales, 2013) where a cone-rod or rod-cone 
degeneration can be present. The age of diagnosis is variable and, due to a reduction in rod 
photoreceptor response, night blindness is an initial sign typically apparent between the ages of 
5-10 years, although this can present in infancy, with total blindness occurring before the age of 
20 years (Beales et al, 1999; Forsythe et al, 2018). Canine PRA is clinically akin to human retinal 
degeneration, specifically RP. Two out of three SS in the initial litter were diagnosed with bilateral 
retinal degeneration, based on a PRA-like appearance, and additional homozygotes were also 
clinically affected with PRA. Exceptions to this include the third SS in the initial litter, which was 
reported blind with PRA-like symptoms by the owner but was not confirmed by a veterinary 
ophthalmologist, and the two SS unrelated to the initial litter, aged one year and 7.6 years. Where 
a PRA diagnosis was made, the age of onset of PRA varied between the two related SS cases with 
the initial female SS diagnosed within a year of a previous clear eye examination, aged 8.7 years, 
and the second dog in the litter at an earlier diagnosis of 5.5 years. Therefore, the BBS2 c.1222G>C 
homozygote that was clinically clear of PRA at the age of 7.6 years, and the one-year-old 
homozygous SS, will develop this form of PRA within their lifetimes. Routine ophthalmoscopic 
follow-up of BBS2 homozygotes will determine disease age of diagnosis. 
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There is evidence that BBS patients also display unique, subtle craniofacial secondary features 
(Beales et al, 1999; Lorda-Sanchez et al, 2001; Moore et al, 2005; Tobin et al, 2008). These features 
include undeveloped cheek bones (malar hypoplasia); a depressed nasal bridge; deep set eyes 
with short or narrow palpebral fissures; and a wide forehead (Forsythe et al, 2018; Lorda-Sanchez 
et al, 2001; Moore et al, 2005). The lower jaw can be recessed further back than the upper jaw, 
thus causing an overbite (retrognathia), and the lower lip slightly everted (Forsythe et al, 2018). 
Knowledge of these facial features may help facilitate an earlier diagnosis of BBS before other 
primary and secondary features present. Dentofacial defects are also observed in > 50% of 
affected individuals and include dental crowding (~ 46% of cases), a high arched palate (~ 35% 
of cases) and short dental roots (Borgström et al, 1996; Ferreira do Amaral et al, 2014; Panny et 
al, 2017). Photographs of three SS homozygous for the BBS2 SNV in the present study (Figure 
5.10A-C) show a distinctive upturned nose shape that is uncharacteristic of the breed, possibly 
due to a depressed nasal bridge as described in human BBS, and some dental abnormalities, 
potentially with dental crowding. 
Another commonly observed primary feature of BBS is obesity, occurring in approximately 72-
92% of patients (Forsythe & Beales, 2013). Obesity is a result of an imbalance in energy ingested 
and energy expended, where calorie intake exceeds energy expenditure. Energy balance is 
regulated by hormonal and neural signals in the central nervous system through hormones such 
as insulin and leptin acting as adiposity signals, involved in regulating energy intake and 
expenditure (Morton et al, 2006). Leptin originates from the adipose tissue and is released into 
the blood in proportion to body fat mass, i.e. if more adipose tissue is present, more leptin is 
released. Leptin is involved in the neuroendocrine circuit to control appetite and homeostasis, 
interacting with neurons in the brain that decrease food intake such as orexigenic agouti-related 
peptide (AgRP) and proopiomelanocortin (POMC) derived neurons (Cancello et al, 2004; 
Rahmouni et al, 2008). The regulation of POMC and AgRP neurons relies on a functional BBSome 
to maintain energy homeostasis (Guo et al, 2019). Interestingly, mutations in the POMC gene are 
associated with obesity, specifically with increased food motivation, in humans (Challis et al, 
2002; Kühnen et al, 2016; Lee et al, 2006) as well as Labrador Retriever and Flat-Coated Retriever 
dogs (Raffan et al, 2016). There is evidence that BBS-affected individuals have an increased 
visceral adiposity and higher levels of leptin, suggestive of greater leptin resistance and 
hyperleptinemia (Feuillan et al, 2011). Similar findings of leptin resistance associated with obesity 
have also been displayed in BBS1, BBS2, BBS4 and BBS6 mouse models, where BBS-null mice had 
an increased appetite for food consumption, reduced locomotor activity and showed increased 
levels of leptin (Davis et al, 2007; Rahmouni et al, 2008). This led to speculation that leptin 
resistance in human BBS patients may be facilitated by defects in the BBSome that contribute to 
the regulation of leptin receptors and downstream targets (Feuillan et al, 2011). BBS-knockout 
mouse studies established that BBS proteins interact with leptin receptors and play a role in 
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trafficking, thus aberrant leptin receptor trafficking and reduced signalling leads to leptin 
resistance and is a major cause of obesity in BBS (Seo et al, 2009). Furthermore, dysfunction of 
leptin receptor signalling is associated with reduced expression of POMC. POMC neurons in the 
hypothalamus of Bbs2-/-, Bbs4-/- and Bbs6-/- mice do not respond to changes in peripheral energy 
balance, indicating that POMC is regulated by leptin and critical for the control of energy balance. 
Thus, impairment of POMC neurons downstream of leptin receptor signalling is probably the main 
cause of obesity in BBS mice (Seo et al, 2009). Clinical history of two of the three SS in the original 
litter, all of which are homozygous for the BBS2 SNV, revealed that both dogs were on a low-fat 
diet for much of their adult life, with one classed as severely obese. A BBS2 homozygote identified 
through additional genotyping had not started showing signs of PRA at the age of 7.6 years, 
however it had showed signs of an increased motivation for food, described by the owner as a 
having a “voracious” appetite. It is plausible that these dogs have dysregulation of satiety 
hormones such as leptin due to dysfunction of BBS2 in the BBSome, resulting in an increased food 
intake and consequently leading to weight gain or obesity. Due to limited clinical information of 
other SS that are homozygous for the BBS2 SNV, sufficient evidence has yet been found to support 
the hypothesis of an association between the BBS2 SNV and an increased appetite or obesity. To 
determine whether weight is a contributing factor of the BBS2 canine phenotype, or whether these 
homozygotes were overweight due to overfeeding by owners, requires further study of BBS2 
homozygotes. 
Renal involvement is highly variable and is a major contributor to morbidity and mortality in BBS 
patients, with an estimated prevalence of 53-82% (Forsythe et al, 2017; Imhoff et al, 2011). 
Defects include cystic tubular disease, anatomical deformities and renal dysplasia, leading to 
kidney failure. Early signs of kidney dysfunction are polyuria or polydipsia with urinary 
concentration defects and a large proportion of cases exhibit renal lesions (Tieder et al, 1982). 
Variability in renal involvement is highlighted by research exploring the prevalence of chronic 
kidney disease in BBS patients, which indicated those with mutations in BBS2, BBS10 or BBS12 
were more likely to exhibit severe kidney disease than patients with mutations in the BBS1 gene 
(Forsythe et al, 2017). The involvement of renal anomalies in BBS may be due to several processes 
in the renal system, whereby cilia are present and functionally significant. Primary cilia are 
present on the surface of epithelial cells of the nephron and collecting duct in the renal cortex of 
the kidney and play a role in epithelial homeostasis and repair (reviewed in Deane et al, 2013). 
Information on kidney health was not available for all SS dogs in the present study. However, of 
the three SS littermates in the initial litter, two displayed kidney malfunctions in their later years 
of life, most of which were referred to in veterinary records as kidney failure. For one case (female 
SS), renal changes were exhibited at the age of 13.3 years, and later, possible chronic renal 
degeneration was remarked. A second littermate (male A) consistently showed increased levels 
of urea and creatine in the urine with concerns about renal function and chronic renal failure, 
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despite being on a kidney support diet and medication for renal disease.. By the age of 9.3 years, 
kidney disease had progressed significantly and shortly after the owner elected for euthanasia.  
While human BBS phenotypes are characterised by defects in 21 genes, all involved in the 
functioning of primary cilia (Table 5.4), many encoding genes involved in BBS specifically regulate 
the machinery of the multi-subunit complex termed the BBSome. The BBSome consists of eight 
highly conserved proteins: BBS1, BBS2, BBS4, BBS5, BBS7, BBS8, BBS9, and BBS18/BBIP10, which 
function in primary cilium biogenesis (Loktev et al, 2008; Nachury et al, 2007) (Figure 5.11). 
Additional components include the small Arf-like GTPase comprising BBS3/Arl6, which recruits 
the BBSome onto membranes for coat assembly (Jin et al, 2010); LZTFL1/BBS17, which is 
involved in regulating entry of the BBSome into cilia (Seo et al, 2011); and a BBS/CCT (chaperonin 
containing T-complex protein-1) complex comprising BBS6, BBS10 and BBS12, required for 
BBSome assembly (Seo et al, 2010) (Figure 5.11). Other known BBS genes: BBS11, BBS13, BBS15, 
BBS16 and BBS19-21 (Aldahmesh et al, 2014; Chiang et al, 2006; Heon et al, 2016; Kim et al, 2010; 
Leitch et al, 2008; Lindstrand et al, 2016; Otto et al, 2010; Xing et al, 2014) are not as closely 
associated with the BBSome, and their role in cilia is not completely characterised. 
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Figure 5.11: Schematic diagram of the BBSome and interacting components. The BBS/CCT 
complex and additional components shown interact with the BBSome (adapted from Jin & 
Nachury, 2009). 
BBS2, BBS7 and BBS9 form the core of the BBSome, termed the BBSome core complex, important 
in BBSome maturation (Zhang et al, 2012). Structurally, BBS2, BBS7 and BBS9 are homologous 
proteins that share distinct protein folding and domain organisation: a β-propeller fold within the 
N-terminal and a coiled-coil and a γ-adaptin ear (GAE) motif accompanied by an α/ β platform 
domain in their C-terminal domain (Jin et al, 2010). Within the BBS2-7-9 subcomplex, BBS2 is 
located between BBS7 and BBS9 with the α-helical domain of BBS2 in contact with that of BBS9 
(Ludlam et al, 2019). Thus, BBS2 strongly interacts with BBS9 in this complex.  
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Table 5.4: Genes associated with BBS in humans. An asterisk (*) indicates those genes that have 
also been implicated in canine PRAs. 
BBS type Gene Study reference 
BBS1 BBS1 (Mykytyn et al, 2002) 
BBS2  BBS2 (Nishimura et al, 2001) 
BBS3  ARL6 (Chiang et al, 2004) 
BBS4  BBS4* (Mykytyn et al, 2001) 
BBS5  BBS5 (Li et al, 2004) 
BBS6  MKKS (Katsanis et al, 2000; Slavotinek et al, 2000) 
BBS7  BBS7 (Badano et al, 2003) 
BBS8  TTC8* (Ansley et al, 2003) 
BBS9  BBS9 (Nishimura et al, 2005) 
BBS10  BBS10 (Stoetzel et al, 2006) 
BBS11  TRIM32 (Chiang et al, 2006) 
BBS12  BBS12 (Stoetzel et al, 2007) 
BBS13  MKS1 (Leitch et al, 2008) 
BBS14  CEP290 (Leitch et al, 2008) 
BBS15  WDPCP (Kim et al, 2010) 
BBS16 SDCCA8 (Otto et al, 2010) 
BBS17 LZTFL1 (Marion et al, 2012) 
BBS18 BBIP10 (Scheidecker et al, 2014) 
BBS19 IFT27 (Aldahmesh et al, 2014) 
BBS20 IFT172 (Lindstrand et al, 2016) 
BBS21 C8orf37 (Heon et al, 2016) 
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BBS2-associated variants have been identified in patients with BBS type-2 (BBS2) (Beales et al, 
1997; Bee et al, 2015; Castro-Sanchez et al, 2017; Chen et al, 2011; Ece Solmaz et al, 2015; 
Katsanis, 2001; Nishimura et al, 2001) as well as non-syndromic RP cases (Shevach et al, 2015). 
The BBS2 locus was initially mapped in humans to chromosome 16q (Kwitek-Black et al, 1993) 
and led to the identification of a homozygous 1-bp deletion in exon 8 of BBS2 in a family with BBS, 
and a non-synonymous SNV in a second BBS proband (Nishimura et al, 2001). Further to these, 
several novel homozygous and compound heterozygous nonsense, frameshift and missense 
mutations in BBS2 were identified (Katsanis, 2001). Another study utilised WES analysis to 
identify homozygous variants in BBS2 as a genetic diagnosis for two BBS patients presenting with 
clinical features including RP, obesity, polydactyly and craniofacial anomalies (Castro-Sanchez et 
al, 2017). Nonsense variants were revealed in exons 5 and 16, respectively, and were deemed to 
be the cause of their ciliopathy-like phenotypes. An earlier BBS2 mutation identified by Katsanis 
et al. (2001), causing an amino acid substitution of arginine to proline at residue 632 (R632P), 
was also identified in BBS patients in later studies (Bin et al, 2009; Chen et al, 2011). Binding 
experiments to investigate the impact of the R632P substitution revealed that the mutation is 
located in the α-helical domain of BBS2 (Ludlam et al, 2019). Ludlam et al. (2019) demonstrated 
that BBS2 interacts with BBS7, forming a tight dimer that associates with the rest of the BBSome 
hexameric subcomplex (comprised of BBS1, 4, 5, 8, 9, 18). Therefore, the R632P substitution 
disrupts BBS2-BBS9 interaction and, in turn, BBSome assembly, preventing the BBS2-BBS7 dimer 
from associating with the BBSome hexameric subcomplex (Ludlam et al, 2019). Given that the 
BBS2 c.1222G>C; p.A408P SNV in the present study is predicted to be positioned within the C-
terminal of BBS2, and considering the results of aforementioned studies establishing the presence 
of the α-helical domain of BBS2 within the C-terminal, it may be hypothesised that this candidate 
SNV in the SS is detrimental to the role of BBS2 in the canine BBS2-7-9 complex; comparable to 
the human R632P substitution, i.e. that BBSome assembly is disrupted by the BBS2 c.1222G>C; 
p.A408P SNV, which may impact ciliary transport machinery in the complex. 
Although BBS is generally of autosomal recessive inheritance, there have been suggestions that 
the disorder can manifest as an oligogenic disease model, where in some instances BBS is not 
inherited as a simple single-gene Mendelian disorder nor does it fit a complex disease model. 
Instead, an oligogenic phenotype manifests when mutations are present in a small number of 
genes that interact with one another. Triallelic inheritance is an example of an oligogenic model, 
whereby two mutant alleles at one locus and one mutant allele at another locus are required for 
disease manifestation; exemplified by mutations in BBS2 and BBS6. A study by Katsanis et al. 
(2001) found that 47% of patients with BBS2 mutations also harboured a third mutation in a 
second BBS gene. Thus, genetic modifiers may impact homozygous BBS gene mutations and lead 
to variation in BBS phenotypes. To assess the possibility of an oligogenic pattern of inheritance in 
the current study, further exploration of variants in all 21 known BBS genes was conducted in the 
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affected SS WGS. No variants were identified in the BBS6 gene previously demonstrated to be 
involved in triallelic inheritance with BBS2 in humans. Despite the identification of many intronic 
variants across other BBS genes in the PRA-affected SS genome, the only notable exonic variant 
found to segregate, in addition to the BBS2 c.1222G>C; p.A408P SNV, was a c.3011C>T; p.S1003L 
SNV in CEP290. CEP290 is associated with BBS14 in humans. This missense variant is homozygous 
in five SS homozygous for the BBS2 SNV as well as SS heterozygous for the SNV and homozygous 
for the wild type allele. The CEP290 SNV is also present (homozygous and heterozygous) in 
multiple non-breed matched controls. Therefore, while it may not be pathogenic on its own, it 
could be a rare polymorphism that contributes to the BBS phenotype when inherited in 
combination with the BBS2 SNV. This seems unlikely as this SNV is present across multiple dog 
breeds, and as each breed is an isolated breeding population this is more likely to be an ancestral 
polymorphism. Current evidence suggests that the BBS-phenotype in the SS is a single-gene 
recessive disorder caused by the exonic SNV in BBS2. To exclude the involvement of intronic 
variants as potential oligogenic contributors such as triallelic or modifier mutations, targeted 
sequencing of all BBS genes across numerous SS PRA cases homozygous for the BBS2 c.1222G>C; 
SNV and control SS dogs would be required. Furthermore, this study did not assess the functional 
impact of intronic variants including potential intronic cryptic/pseudo splice site variants. 
Studies of Bbs2-null mice show that the absence of BBS2 expression results in retinal 
degeneration, male infertility, renal cysts and obesity. Consistent with the Sheltie BBS2 
homozygotes, normal retina development and function is present in young Bbs2-null mice 
followed by progressive loss of photoreceptors: the primary ciliated cells of the retina (Nishimura 
et al, 2004). Flagella formation during spermatogenesis in Bbs2-null male mice was impaired, a 
feature that was also demonstrated in human BBS-2 patients and Bbs-4 null mice (Mykytyn et al, 
2004). These findings highlight the involvement of motile cilia in addition to primary cilia in BBS 
phenotypes. Nishimura et al. (2004) demonstrated that although Bbs2-null mice can assemble 
primary cilia of renal tubule cells, these cilia are tapered and, as with polycystic kidney disease, 
renal cyst development is likely to be due to signalling defects in primary cilia. Obesity was 
observed in Bbs2-null mice as a result of an increase in food intake due to a defect in satiety 
regulation, which may be due to a greater leptin resistance, as previously discussed in human BBS. 
Further neurological findings included olfactory defects and social dominance deficits, where 
Bbs2-null mice lack social dominance when compared to littermate controls; a similar phenotype 
that was present in other BBS mouse models (Davis et al, 2007; Eichers et al, 2006). These defects 
in social dominance were replicated in a dark environment to show that this feature was not 
exclusively due to reduced vision in Bbs2-null mice. These findings suggest that, while BBS2 (and 
the BBSome) is not crucial for initial cilia assembly, it is indirectly involved in cilia maintenance, 
ciliogenesis and IFT, whereby the absence of BBS2 in knockout mice impacts intracellular 
transport and IFT requirements, which are crucial for the maintenance of photoreceptor outer 
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segments (Nishimura et al, 2004). Since primary and motile cilia lack the machinery to synthesise 
proteins, IFT is the bidirectional transport of multi-subunit protein complexes, such as the 
BBSome, and is crucial in cilia and flagella formation and function. Non-membrane-bound 
particles are transported in an anterograde (forward) direction along the axonemal doublet 
microtubules beneath the cilium or flagellar membrane, carrying materials essential for the 
assembly and maintenance of the flagellar axoneme and membrane. Once these reach the tip of 
the cilium/flagellum, a recycling step is undertaken in a retrograde (backward) direction where 
IFT particle movement reverses to return to the base of the cilium/flagellum amongst IFT 
components in the region surrounding the basal body (Rosenbaum & Witman, 2002). As this IFT 
mechanism is crucial for cilia and flagella formation and maintenance, defects in IFT are 
detrimental to primary cilia, such as those in photoreceptor outer segments and renal tubule cells, 
and motile flagella. The multisystem phenotype demonstrated in SS BBS2 homozygotes may be 
explained by similar mechanisms described in BBS mouse models. 
Previous research demonstrates similarities between BBS-null mice and canine PRA phenotypes, 
specifically in the Hungarian Puli dog where a nonsense SNV in BBS4 causes a novel syndromic 
PRA with phenotypes comparable to Bbs4-null mice (Chew et al, 2017). In addition to PRA, BBS4-
affected Hungarian Puli dogs displayed spermatozoa flagella defects (albeit less severely affected 
than of that observed in Bbs4-null mice) as well as obesity. This was the first implied BBS-like 
phenotype reported in dogs. Prior to this, the only BBS gene implicated in canine PRA was the 
TTC8 gene, also known as BBS8, in Golden Retriever dogs (Downs et al, 2014), which has also been 
implicated in human BBS (Ansley et al, 2003) and non-syndromic RP in humans (Goyal et al, 2016; 
Riazuddin et al, 2010). However, dogs in the TTC8 study were not reported to have any abnormal 
clinical features apart from PRA. There has since been evidence to suggest that the Golden 
Retriever TTC8 variant causes a BBS phenotype in homozygous dogs. A Labrador Retriever that is 
homozygous for the Golden Retriever TTC8 PRA-associated variant displayed clinical signs of PRA 
accompanied with an upturned nose, abnormal coat and obesity; comparable to the BBS2-
homozyous SS in this study (personal communication, Pearce-Kelling, unpublished work). No 
information regarding spermatozoa flagella potency in SS male dogs was available to conclude if 
fertility defects are present. However, for one of the BBS2 homozygous female dogs, the owner did 
report that the bitch did not have a season until much later in life, around the age of five years. 
This provides further exploration in future studies of canine BBS2 models. 
The Kennel Club, UK outlines a breed standard for the Sheltie to maintain certain characteristics 
and traits to ensure new generations are fit for function. The breed standard states: the head 
should be refined with no exaggerated features with a long, blunt wedge tapering from ear to nose 
when viewed from a top or side view. Cheeks should be flat, merging smoothly into a well-rounded 
muzzle and the skull and muzzle to be of equal length. Jaws should be level, clean and strong with 
 Chapter 5 PRA in the Shetland Sheepdog 
165 
 
a well-developed underjaw and lips tight. Upper teeth should closely overlap the lower teeth, 
setting square to the jaws with preferably a full set of 42 properly placed teeth. Breed standard 
recognised coat colours for the SS are sable, tricolour, blue merle, black and white and black and 
tan. The coat should be comprised of a double coat with a soft short undercoat and an outer coat 
of long, harsh-textured and straight hair. The hair around the face should be smooth and the coat 
should fit the body but not detract from the body outline (The Kennel Club UK, 2019b). Findings 
from this present study demonstrate that physical features of SS BBS2 homozygotes do not fit 
within these criteria. It is plausible that the fullness of the coat may make it difficult to see if a SS 
is over- or underweight and to track weight appropriately. There is limited evidence showing the 
prevalence of obesity in SS: one study in the 1980s showed that the UK Shelties were one amongst 
six other breeds to have a pre-disposition to obesity (Edney & Smith, 1986). A later study in 2006 
on the US population indicated that 57% of SS were overweight and an obesity prevalence of 10% 
(Lund et al, 2006). It is not well documented how this currently stands in the UK population of SS. 
As previously discussed, obesity is a secondary feature of BBS, leading to the hypothesis that the 
BBS2 SNV contributes to the regulation of energy expenditure and satiety hormones in BBS2 
homozygotes. This proposed syndromic PRA in the SS presents with distinct physical features. In 
theory, if any breeders regarded this physical look as appealing, deciding to selectively breed for 
this nose shape or coat texture, a PRA-associated phenotype could be inadvertently selected for, 
posing a detrimental effect on breed health. History shows how actively breeding for certain 
characteristics and physical traits has altered the appearance of certain dog breeds, and this is 
apparent when comparing images of certain breeds over the past century. Examples include the 
Bull Terrier, Boxer and Dachshund, where certain physical characteristics have become more 
exaggerated over time, including nose shape, skull morphology and body length. Breeding choices 
based on physical appearance can have implications not only on breeding standards, but breed 
health, as illustrated with brachycephalic breeds. Another example of breeding for a specific 
phenotype that inadvertently has led to a recessive, detrimental mutation is demonstrated in the 
Petit Basset Griffon Vendéen and Shar-Pei dog breeds. Mutations in the ADAMTS17 gene are 
associated with primary open angle glaucoma (POAG), a chronic eye condition characterised by a 
small, sustained rise in intraocular pressure and lens subluxation, in the Petit Basset Griffon 
Vendéen (Forman et al, 2015); and POAG with primary lens luxation in the Shar-Pei (Oliver et al, 
2018). Both breeds are short in stature and an association between height and POAG genotype 
has been identified (Jeanes et al, 2019). Thus, by selecting for dogs that are shorter in height to 
adhere to specific breed standards, breeders have inadvertently led to an increase in ADAMTS17 
mutation frequencies, thereby contributing to an increased incidence of POAG in these breeds. 
As with the BBS4-homozygous Hungarian Puli dogs, it is plausible that the BBS2 SNV in the current 
study causes a syndromic PRA in the SS. Typically, when studying canine PRA, a diagnosis is 
limited to ophthalmoscopic evaluation. Distinguishing between a canine non-syndromic and 
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syndromic condition requires recognition of multiple clinical signs, where additional features can 
be challenging to quantify or assess. Changes in social dominance, olfactory defects and learning 
or developmental delay are some of the behavioural and neurological features displayed in BBS 
human patients and mouse models. Further to this, obesity is a common problem in dogs, whereby 
39-65% of dogs are classified as overweight and between 9-20% are obese (Courcier et al, 2010; 
German et al, 2018), therefore its association with a genetic disorder can easily be overlooked. 
Physical facets including craniofacial or dental features are more obvious; however renal deficits 
would need to be monitored to characterise. In future studies of canine PRA, the involvement of 
BBS genes should be considered, especially when only ophthalmoscopic information is gathered 
for cases and information on physical or additional characteristics is limited. 
As previously discussed, although there are PRA-associated mutations that have been detected 
across multiple diverse breeds e.g. PRCD (Zangerl et al, 2006) and RCD4 (Downs et al, 2013), the 
majority of canine PRAs previously identified are unique to individual breeds. While candidate 
variants cannot be excluded based on their presence in additional breeds alone, the identification 
of a variant across individuals of multiple breeds can aid variant filtration. A variant identified in 
multiple breeds is more likely to be a shared ancestral polymorphism than a causative variant, 
especially when the variant is present in breeds for which there is no evidence that the breed is 
predisposed to PRA. Additional evidence must be gathered to formally include/exclude variants 
from analyses such as the effect on the protein sequence and whether the gene is known to be 
expressed in retinal tissue.  
In the present study, the c.1222G>C SNV is situated in a compelling gene; segregated 
appropriately in the SS breed; has a predicted severe impact on the protein; and is not shared 
amongst multiple breeds, endorsing it as the top candidate variant. Genotyping of dogs across 155 
purebreds revealed that the BBS2 c.1222G>C SNV was only found in SS dogs, suggesting it may be 
private to the SS breed. The allele frequency, excluding third generation relatives to probands 
from known pedigree information, of 0.021 indicates this is a rare variant and at a low frequency 
in the current SS population. Despite this, sample collection shows the variant is still present in 
the current UK population, thus the use of a DNA test (recently launched by the AHT) will aid in 
reducing and eliminating this form of PRA from the gene pool, possibly in the next few 
generations. Use of a DNA test will also provide genetic information on the status of this PRA-
associated mutation in individual dogs before clinical signs present and therefore provide a tool 
for breeding choices before dogs reach breeding age. Finally, the absence of the BBS2 c.1222G>C 
SNV in additional PRA cases in the SS screening cohort suggests at least one other form of PRA in 
the breed remains unresolved. This provides opportunity to further explore PRA in the SS breed.   
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5.5 Conclusion 
This is the third report to-date of a BBS gene associated with canine PRA. This study highlights the 
power of WGS using a single case to identify a PRA-associated variant. Due to the involvement of 
the BBS2 gene in human BBS phenotypes, and knowledge of additional features in BBS2 
homozygotes in the current study, the c.1222G>C; p.A408P SNV is deemed the cause of a 
syndromic PRA, or a form of canine BBS, in the SS breed. Further follow-up of SS BBS2 
homozygotes is required to understand the spectrum and complexity of additional features, 
ideally throughout the dog’s lifetime with the ability to monitor retinal and renal changes as well 
as weight tracking and fertility programs. Availability of a DNA test will raise awareness of this 
form of PRA and encourage owners to utilise the DNA test to reduce allele frequency. Utilisation 
of such a diagnostic test within the SS breeding community will reduce the possibility of future 
generations becoming affected with this form of PRA.  
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Chapter 6 General Discussion 
Despite the identification of 27 canine PRA-associated mutations in more than 100 dog breeds, 
there are still many genetically unresolved cases. This formed the foundation of this thesis, with 
four main aims to: 
1. Identify breeds affected with PRA for which the causal mutation is unknown. 
2. Elucidate mutations associated with PRA in each breed under investigation, using 
whole genome investigations, including GWAS and WGS technologies, identifying 
the most efficient mutation discovery routes for differently structured proband 
groups. 
3. Develop commercial DNA tests for all mutations identified. 
4. Offer novel insights for consideration in human retinal degeneration research. 
These aims have been achieved, identifying three dog breeds affected with PRA (GS, LA and SS) 
and elucidating variants associated with novel forms of PRA in these breeds. DNA tests have been 
developed for each breed under investigation to reduce the incidence of these forms of PRA in 
each dog breed.  
At present, 44 genes are associated with canine IRDs including achromatopsia, congenital 
stationary night blindness, canine multifocal retinopathy, neuronal ceroid lipofuscinosis, and 
canine PRAs. Currently 273 genes have been implicated in various human IRDs, including 
syndromic/systemic retinal diseases, retinopathies, macular degenerations, LCA, BBS and RP; to 
name a few (RetNet, 2020). Of these 273 human IRD genes, 35 genes are shared across human 
and canine IRDs. In canine IRD studies, researchers often look to the human field to aid in mutation 
discovery. Similarly, canine IRD research has the potential to offer novel genes for consideration 
in human IRD research, with nine genes currently known to be associated only with canine IRDs. 
Six of these genes lead to a PRA phenotype: CCDC66 (Dekomien et al, 2010), SLC4A3 (Downs et al, 
2011), STK38L (Goldstein et al, 2010), MAP9 (Forman et al, 2016), HIVEP3 (Kaukonen et al, 2020) 
and, as identified in this thesis, NECAP1 (Hitti et al, 2019). 
6.1 Gene interactions and pathways 
Of the three genes found to be associated with canine PRAs described in these studies, IMPG2 and 
BBS2 have previously been implicated in human IRDs, and NECAP1 is a novel retinal candidate 
gene. The molecular processes in the retina that enable vision, including the phototransduction 
cascade and the visual cycle, involve a myriad of different proteins in many of the cells of the 
retina. Many of these proteins are retina-specific or encode genes that are enriched in the retina, 
therefore mutations in such genes often result in dysfunction of retinal cells and concurrently 
promote a retinal phenotype. The phototransduction cascade, the visual cycle and the ciliary 
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transport system are highly specific and significant to the photoreceptor/RPE complex in the 
retina. As with the majority of IRDs, each gene that harbours a mutation identified in this thesis 
encodes a protein that participates in one of these pathways in retinal function, including 
trafficking in vesicle formation in retinal synapses (NECAP1), regulation of photoreceptors and 
the RPE (IMPG2), and structural organisation of photoreceptor outer segments and trafficking of 
primary cilia (BBS2).  
NECAP1 
The GS PRA study demonstrated that NECAP1 is a plausible candidate gene for retinal disease. 
NECAP1 is expressed in the canine retina and several human tissues including brain and retinal 
tissue, as indicated by the Human Protein Atlas database (Uhlén et al, 2015). The encoding protein, 
NECAP1, localises to clathrin-coated vesicles where it binds components of adapter protein 
complexes, including AP-1 and AP-2, to facilitate clathrin mediated endocytosis (CME). Related 
pathways of NECAP1 include CME and vesicular transportation in synapses. The STRING v11.0 
web server database demonstrates evidence suggesting a functional link between NECAP1 and 
interacting proteins (Szklarczyk et al, 2019). As an accessory protein to adaptor protein 
complexes AP-1 and AP-2, NECAP1 interacts with several proteins related to these adaptor 
protein complexes (AP1G1, AP2M1, AP2A1, AP2A2; Figure 6.1). Previous studies have illustrated 
the importance of adaptor complexes in photoreceptor development and survival in vertebrate 
and invertebrate retinas. In Drosophila (Xiong & Bellen, 2013) and mice (Moaven et al, 2013), 
rhodopsin/arrestin complexes, where arrestin deactivates rhodopsin in the phototransduction 
cascade preventing accumulation of rhodopsin in photoreceptor cells, interact with AP-2 to 
regulate photoreceptor survival. In addition, it has been demonstrated that AP-1 in Drosophila 
plays a crucial role in eye development, where signalling molecules such as Notch are required for 
the specification of photoreceptor cells in the developing eye and depletion of AP-1 affects the 
expression of these signalling molecules (Kametaka et al, 2012). This suggests that AP-1 and AP-
2, and possibly associated accessory proteins including NECAP1, are important in the intracellular 
trafficking of cargo molecules required for eye development and photoreceptor survival, where 
photoreceptor apoptosis results in retinal degeneration. To date, the only reported human disease 
associated with NECAP1 loss of function is EIEE (Alazami et al, 2014; Alsahli et al, 2018). Animal 
IRD models do not always share the phenotype observed in humans where mutations in the same 
gene are implicated. For example, RHO mutations exert different physiological mechanisms in 
humans as well as different animal models including mice (Lem et al, 1999; Li et al, 1996), pigs 
(Ross et al, 2012) and dogs (Kijas et al, 2002). However, previous studies aforementioned 
involving RP mouse models demonstrate that a) CME is present, albeit playing a minor role, in 
retinal ribbon synapses in photoreceptor and bipolar cells of the retina; and b) adaptor complexes 
AP-1 and AP-2, of which NECAP1 is incorporated as an accessory protein to mediate vesicle 
transportation in synapses, are crucial for photoreceptor survival.  
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Figure 6.1: Human NECAP1 protein interaction map in STRING v11.0 (Szklarczyk et al, 2019) 
showing the top 20 interactors with a medium confidence score (0.400). Line colour indicates the 
types of evidence used in predicting the associations: cooccurrence evidence (blue), experimental 
evidence (purple), text mining evidence extracted from published literature (yellow), curated 
database evidence (light blue) and co-expression evidence (black). All underlying evidence can be 
inspected in dedicated viewers that are accessible from the network.  
IMPG2 
Previous reports have identified disease-associated variants in IMPG2 in human patients sharing 
retinal features with those of canine PRA (Bandah-Rozenfeld et al, 2010; Brandl et al, 2017; Khan 
& Al Teneiji, 2019), highlighting the gene as a strong candidate for canine retinal disease studies. 
According to The Human Protein Atlas database, IMPG2 is one of 310 genes with elevated RNA 
expression in the human retina and one of 87 genes with at least four-fold higher mRNA level in 
retina, compared to other tissue types, with known expression in photoreceptor cells (Uhlén et al, 
2015). The encoding protein is localised within the interphotoreceptor matrix (IPM) occupying 
the interface surrounding rod and cone photoreceptors and is a constituent of proteoglycans, 
which are secreted into the IPM and bind to the RPE. The STRING v11.0 web server database 
demonstrates evidence suggesting a functional link between the human IMPG2 protein and other 
proteins involved in the function and maintenance of retinal components including ABCA4, 
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C2ORF71, FAM161A, PRCD and TTC8 (Figure 6.2; Szklarczyk et al, 2019). Canine PRA-associated 
mutations have been identified in the genes encoding these proteins: ABCA4 (Makelainen et al, 
2019), C2ORF71 (Downs et al, 2013), FAM161A (Downs & Mellersh, 2014),  PRCD (Goldstein et al, 
2006; Zangerl et al, 2006) and TTC8 (Downs et al, 2014). All these genes encode proteins that are 
specific to pathways associated with retinal photoreceptor cells and connecting cilium. Human 
and canine photoreceptors share similar anatomical structures despite differences in density 
across areas of the retina, therefore dysfunction of these pathways result in similar retinal 
phenotypes and concomitantly promote progressive retinal degeneration in both species. In 
contrast, NECAP1 interacts with many genes, none of which are known to directly cause a retinal 
phenotype in humans. This could be because NECAP1 is an accessory protein and interacting 
genes in the same pathways can compensate for a defective NECAP1 protein. 
 
Figure 6.2: Human IMPG2 protein interaction map in STRING v11.0 (Szklarczyk et al, 2019). 
showing the top 20 interactors with a medium confidence score (0.400). Line colour indicates the 
types of evidence used in predicting the associations: cooccurrence evidence (blue), experimental 
evidence (purple), text mining evidence extracted from published literature (yellow), curated 
database evidence (light blue) and co-expression evidence (black). All underlying evidence can be 
inspected in dedicated viewers that are accessible from the network. 
The novel LINE-1 insertion identified in LA PRA cases is believed to alter IMPG2 expression in the 
retina and, as IMPG2 is a structural component of the IPM, probably affects the structure and/or 
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function of the IPM surrounding photoreceptor cells. Consequently, visual processes such as 
photoreceptor shedding and RPE phagocytosis may be compromised, resulting in photoreceptor 
degeneration over time.  
BBS2 
BBS2 is one of eight proteins that comprise the BBSome, a protein complex required for 
ciliogenesis. Using the STRING v11.0 web server database to display putative functional protein 
interactions suggests BBS2 interacts with other proteins within the BBSome (Figure 6.3) 
(Szklarczyk et al, 2019).  
 
Figure 6.3: Human BBS2 protein interaction map in STRING v11.0 (Szklarczyk et al, 2019) 
showing the top 20 interactors with a medium confidence score (0.400). Line colour indicates the 
types of evidence used in predicting the associations: cooccurrence evidence (blue), experimental 
evidence (purple), text mining evidence extracted from published literature (yellow), curated 
database evidence (light blue) and co-expression evidence (black). All underlying evidence can be 
inspected in dedicated viewers that are accessible from the network. 
Ciliogenesis occurs in photoreceptors, where connecting cilium link the outer and inner segments 
of photoreceptor cells. BBS proteins control formation of the primary cilia by facilitating the 
movement of cargo between plasma and ciliary membranes, a process that occurs across various 
cell types where primary cilia are present, including the retina and kidneys. Retinal photoreceptor 
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primary cilia and outer segments are essential for phototransduction and maturation of the RPE, 
suggesting the BBS2 SNV present in SS dogs impairs retinal function through dysfunction of the 
phototransduction cascade. Potential renal defects exhibited in affected SS dogs may be explained 
by the presence of ciliogenesis in the kidney, with the BBS2 SNV affecting transcripts encoding 
components of primary cilia. Another notable feature worth considering as a component of the SS 
BBS2 phenotype is an increase in food motivation, suggesting that disruption of BBS2 leads to a 
defect in the transport of leptin receptor to the plasma membrane, resulting in leptin resistance 
and obesity as demonstrated in BBS knockout mouse models (Davis et al, 2007; Rahmouni et al, 
2008). 
6.2 Choice of genetic applications 
GWAS is a powerful tool and has, up until recently, been the method of choice in canine genetic 
studies of Mendelian diseases, provided DNA can be collected from enough cases and controls of 
the same breed and with a robust phenotype defined. In canine studies of single-gene Mendelian 
disorders, a GWAS approach can succeed with a modest number of samples (8 cases and 16 
controls) and as few as 15,000 evenly spaced SNP markers (Lindblad-Toh et al, 2005); a fraction 
of the sample and marker numbers required for human GWAS. This is largely due to dog breeds 
existing as genetically isolated populations with relative genetic homogeneity: long stretches of 
LD and long haplotype blocks are present in the canine genome due to the generation of discreet 
dog breeds being a recent event; within the past few hundred years. Cases and controls for use in 
these genetic studies should ideally be determined by qualified veterinary surgeons to ensure 
well-defined robust sample sets. One of the key features of GWAS is that it is hypothesis free, so 
can uncover novel biology of disease. A benefit of GWAS mapping is that a region associated with 
disease can be highlighted and a candidate region can be defined, ultimately narrowing the search 
from genome-wide to a manageable region sometimes just Kb in size. This limits candidates to a 
small number of genes to manually interrogate within a region with the application of further 
genetic technologies such as WES or WGS for fine-mapping to pinpoint a causal variant. For the 
LA study, DNA from a sufficient number of cases and controls was obtained. For each individual, 
a clinical diagnosis was provided by a veterinary ophthalmologist to support each DNA sample, 
therefore providing a suitable case-control set for a GWAS to be conducted. 
When the number of cases available for research is limited, such as for a newly emerging disease 
in a breed, a GWAS approach is not suitable. In these instances, WES or WGS can be conducted 
using a single case and analysing against control genomes. Using a hypothesis that the disease is 
private to the breed under investigation, WGS analysis can be made more powerful by using  
genomes of dogs affected with other diseases as control dogs to help find mutations associated 
with different disease in other breeds. For example, an epilepsy case can be utilised as a control 
in a PRA research study. The power of using multiple genomes of different breeds means that 
 Chapter 6 General Discussion 
174 
 
filtering analysis extracts benign variation when looking for private high impact variants. In 
contrast to GWAS, knowledge of a disease-associated region is unavailable in WGS data analysis 
(unless GWAS SNP positions are extracted from multiple WGS data to perform GWAS analysis) as 
no mapping experiment has been performed. As shown with the GS and SS studies, only a small 
number of affected dogs were submitted to the AHT research DNA bank and this prohibited a 
GWAS approach. This resulted in WGS analysis with a small number of cases and related 
unaffected family members, using filtering steps based on the severity of the variant on the protein 
implicated and pedigree information to distinguish segregation, ranking variants based on their 
candidacy for a retinal condition. 
6.3 Limitations 
Phenotyping 
Prior to any study of disease, individual phenotypes must be defined by a clinician. For canine 
ocular disease, this means a veterinary ophthalmologist must examine the individual to determine 
a diagnosis. However, qualifications and experience of ophthalmologists can vary (certificates and 
diplomas). In addition, as with many research studies, many individuals within a study cohort are 
typically examined by multiple ophthalmologists as opposed to a single clinician performing all 
ophthalmoscopic examinations. The clinical information collected for each individual is also 
varied, where some cases submitted to research include supporting reports with ophthalmic 
observations, fundus information or photographs, and others simply mention a PRA-diagnosis. 
For this reason, in many investigations of hereditary ocular disease an individual is considered a 
robust case when examined by a certified veterinary ophthalmologist, a European diploma holder 
or a BVA/KC/ISDS eye panellist, where evidence is provided to support the sample with detailed 
information and diagrams of fundus abnormalities, where possible. Researchers rely on an 
accurate diagnosis of PRA, especially where a single case is being analysed, for example using a 
WGS approach, in order to minimise costs and time in identifying a causal PRA-variant. The 
presence of PRA phenocopies that display similar clinical signs to the disease can sometimes 
result in a misdiagnosis. This includes SARD, as exemplified in the LA cohort, which presents 
ophthalmoscopic signs of retinal degeneration that may be mistaken for PRA. Therefore, it is 
important to consider PRA-phenocopies during any molecular or clinical studies. Where multiple 
cases are collected for a larger study, such as a GWAS, including individuals with ambiguous 
phenotypes may reduce the power of a sample set but in turn defining an unnecessarily strict 
phenotype can impede sample collection. 
Age of onset 
For PRA, the age of onset is generally not defined by the age of diagnosis. Determining the exact 
age of onset can be difficult to assess when the disease is progressive, and owners may remain 
unaware their dog is affected until visual impairment becomes severe. Many dogs can adapt to 
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vision loss and compensate with their highly sensitive sense of smell and behavioural changes, 
especially if they share their environment with other dogs or rarely go out of familiar 
surroundings. The lack of detailed ERG evaluation in dogs, which would detect early changes in 
rod and cone function before the dog started showing any behavioural changes, often leaves 
ophthalmoscopic examination as the extent of the diagnosis.  
Confirmation of causality 
The absence of tissue, specifically retina, from affected dogs is a common issue in canine PRA 
investigations, where the majority of affected dogs rarely undergo enucleation on welfare grounds 
and are typically lost to research follow-up. This limits histology, gene expression or protein 
analysis to explore the consequences of the mutations identified. As a result, bioinformatics tools 
are used to predict variant consequence. In silico tools such as SIFT, PolyPhen and MutationTaster 
classify SNVs according to negative, neutral or positive effects on protein structure or function. 
Although these prediction algorithms can be beneficial in shortlisting variants, these tools do not 
confirm the nature of the variant. Comparison with human biology and model organisms can also 
provide supporting evidence of confirmation of causality. 
Structural variation 
WGS analysis used here implements filtration steps to search for SNVs or small INDELs. More 
complex mutations such as inversions, translocations or transposable elements are difficult to 
identify (as discussed further below) and therefore are not included in the current AHT WGS 
analysis pipeline. For this reason, large structural variation cannot be fully excluded in the WGS 
studies undertaken in this thesis. Detection of structural variants from the use of short-read 
sequencing technologies in WGS is onerous. Poor breakpoint resolution is achieved in repetitive 
regions of the genome and the identification of structural variation relies on a combinatorial 
approach using paired-end mapping and read depth analysis on a genome-wide scale. As 
structural variants are extremely diverse in type and size, data analysis does not always produce 
a manageable list to follow up. To overcome these challenges, long-read sequencing technologies, 
such as PacBio or Oxford Nanopore sequencing, could be used alone or in conjunction with short-
read Illumina sequencing to mediate both SNV/INDEL detection and complex structural variant 
identification. Such methods have been utilised in human studies into Mendelian disease, 
including a homozygous deletion-inversion-deletion complex structural variant in the CEP78 gene 
in a patient with cone-rod dystrophy identified using short-read WGS (Sanchis-Juan et al, 2018). 
Due to technical challenges in identification, complex structural variants are often not considered 
during genetic analyses, although they should be considered in future studies, especially for 
unresolved PRA cases. Although the majority of PRA-associated variants identified to date are 
within coding regions, the LINE-1 insertion within the IMPG2 promoter identified in this study 
demonstrates that non-coding variants cannot be excluded as causal in PRA studies. More complex 
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mutations may be causing PRA in unresolved cases, where when a WGS approach is used without 
GWAS, such variants have not been possible to detect with current filtering steps. More efforts 
must be made to validate and implement structural variant tools in analysis pipelines for canine 
genetic studies in order to facilitate structural variant detection in rare diseases. 
Non-coding variants 
Until recently, all reported PRA-associated variants lie within protein-coding regions of genes (or 
promoter regions). The only report-to-date of a regulatory non-coding variant implicated in a 
canine PRA is an intronic SNV in the transcription factor encoding the ortholog of human 
immunodeficiency virus type I enhancer binding protein 3 gene (HIVEP3) in Miniature Schnauzer 
dogs (Kaukonen et al, 2020). Defining the functional consequences of non-coding variants remains 
a challenge, however such variants have been associated with retinal diseases in humans; 
including deep intronic variants that may cause aberrant splicing events, create cryptic splice 
sites, or disrupt regulatory elements (Bax et al, 2015; Fadaie et al, 2019; Webb et al, 2012). In the 
studies described in this thesis candidate variants were identified, which segregated with the 
disease, and evidence of their causality is described. Thus, further analysis of non-coding variants 
was not performed. However, in future PRA studies where initial analysis of WGS data do not 
highlight candidate variants, non-coding variants should also be considered. 
6.4 Future directions 
In each investigation, the PRA-associated variant identified was genotyped across dogs of other 
breeds. Both the LA and SS variants were absent from the individuals tested from other breeds, 
however more extensive genotyping from larger breed cohorts would be required to fully exclude 
the presence of these variants in other breeds, in particular those with shared ancestry. The GS 
NECAP1 SNV was found in Miniature Long-Haired Dachshunds and Spitz varieties, as well as 
mixed-breed dogs sharing a proportion of their ancestry to these breeds. Studying the haplotype 
around the SNV in the GS, Miniature Long-Haired Dachshund and a Giant Spitz showed a shared 
haplotype, with a shorter haplotype in the Miniature Long-Haired Dachshund breed, suggesting 
the variant is inherited identically by descent. Breed histories suggest these breeds are probably 
of German ancestry, proposing that the SNV arose from a common ancestral chromosome 
containing the variant in a single ancestral founder dog predating the formation of each breed. 
There are examples of pathogenic mutations in dogs that are inherited by descent across multiple 
related breeds, including PRCD-PRA (Goldstein et al, 2006; Zangerl et al, 2006) and CEA (Parker 
et al, 2007). Further study of the breeds found to share the NECAP1 SNV is required to determine 
genotype-phenotype correlations and establish whether the mutation is causal across these 
additional breeds.  
The absence of retinal tissue from any individuals in these studies prevented functional follow-up 
work to be performed. For this thesis, RNA-seq analysis would have been favourable for all breeds 
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investigated. RNA-seq data from PRA cases and controls of each breed investigated may have 
facilitated further characterisation of each candidate gene and define whether retinal-specific 
transcripts were present and thus disrupted in PRA-affected individuals. This would be 
particularly advantageous in the GS study where NECAP1, a novel retinal candidate gene, is 
implicated. Alongside previously published transcriptome studies in the dog, analysis of RNA-seq 
data in our laboratory from retinal tissue from a PRA non-affected dog demonstrated that NECAP1 
is expressed in the normal canine retina. Comparison of this with retinal tissue from a PRA-
affected GS would establish if NECAP1 expression is altered in affected dogs. Retinal transcripts 
could also be investigated to determine if there are NECAP1 retinal-specific transcripts in the dog 
compared to humans. As NECAP1 mutations in humans are associated with a neurological disease, 
comparison of RNA-seq data generated from brain tissue and retinal tissue in affected and non-
affected dogs, and comparison to the human transcripts, could provide further insight into why a 
retinal phenotype is associated with NECAP1 in the dog, but not directly in humans. In addition to 
this, retinal cell lines from a LA PRA case and a LA control dog would enable a luciferase assay to 
be optimised and performed, determining the impact the LINE-1 insertion on IMPG2 expression.  
Conducting a clinical study into the BBS2 phenotype may improve our understanding of the 
clinical manifestations observed, providing further disease characterisation and to determine the 
presence of phenotypic variability in the disease onset, progression or severity of secondary 
features across individuals. Ethical concerns must be considered prior to recruiting BBS2 
homozygotes for a clinical study, for example establishing a donor programme to harvest multiple 
tissue types following euthanasia, or establishing a research colony to control environmental 
factors such as age and diet. This would enable histological experiments and RNA analyses to be 
performed, for example to investigate retinal and renal defects, to investigate molecular pathways 
involved in the disease. Another application to consider with the availability of tissue samples are 
immunohistochemistry experiments, ideally comparing tissue sections from a normal canine 
retina and a PRA-affected retina. Immunohistochemistry utilises monoclonal and polyclonal 
antibodies to detect specific antigens in sections of a tissue of interest and requires isolated, 
sectioned tissue and an appropriate antibody. Establishing where in the retina a gene is expressed, 
for example if primarily expressed in photoreceptor cells, would provide additional evidence for 
disease causality. In addition to further exploration of BBS2 phenotypes in SS, this application 
could be considered for future work investigating the NECAP1 variant in GS dogs, subject to tissue 
availability. 
Although beyond the scope of this thesis, hypothetically animal models could be used to provide 
further understanding of the pathogenesis of NECAP1 in ocular disease. Utilisation of mouse or 
zebrafish models as a means of in vivo study of gene function have been used to further elucidate 
the functional effects in genes of interest (Stiebel-Kalish et al, 2012). For NECAP1, no knockout 
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animal models have been reported so far, however implementing this approach by NECAP1 
inactivation may provide insight into mouse or zebrafish phenotypes. Furthermore, studies using 
zebrafish models, specifically in ocular disease studies, have proven successful using the 
CRISPR/Cas9 system to target and repair specific mutations in zebrafish (Irion et al, 2014). 
Showing similarities in eye development, retinal structure and gene orthology to humans, the 
zebrafish is a prominent model organism in the study of human ocular disease (Richardson et al, 
2017). Such an application could be implemented to assess the NECAP1 SNV in a zebrafish model, 
using CRISPR/Cas9 to introduce the mutation and conduct in vivo experiments of the impact of 
the NECAP1 c.544G>A SNV on zebrafish retinal morphology. Finally, these studies can provide a 
framework for further exploration of each variant and its involvement in disease pathogenesis. 
Harvesting canine induced pluripotent skin cells from affected dogs, differentiating into RPE and 
photoreceptor cells and performing in situ gene correction using CRISPR/Cas9 of each mutation 
would provide further understanding of whether these molecular and cellular phenotypes can be 
rescued. 
Finally, there are still dog breeds suffering from PRA for which a molecular diagnosis has not yet 
been found. DNA from PRA cases of other breeds has been collected and stored at the AHT, and 
known retinal mutations have been excluded as causal. Some of these breeds include in the Irish 
Red and White Setter, English Shepherd, Miniature Long-Haired Dachshund, Tibetan Spaniel and 
Tibetan Terrier, and sample numbers range from single to multiple cases per breed. This 
emphasises the genetic heterogeneity of PRA across and within breeds. Discussions with 
individual Breed Clubs, their Breed Health Coordinators and veterinary ophthalmologists to 
define clear phenotypes and collect additional robust cases and controls, along with pedigree 
information, will help decide which genetic techniques will be most appropriate to pursue genetic 
investigations for breeds with unknown molecular diagnoses.  
6.5 Conclusions 
This thesis describes three novel variants in three dog breeds and provides supportive evidence 
for their causality in canine PRA. Within each breed, ophthalmoscopic evaluation by veterinary 
ophthalmologists provided robust cases and controls for each genetic study, highlighting the 
importance of obtaining clear clinical information for canine genetic studies. As demonstrated, 
this is particularly significant in the absence of appropriate tissue to conduct further functional 
analysis for a variant of interest, relying on genotyping large breed cohorts and determining allele 
frequencies to provide additional evidence that a variant is segregating with a disease. This, along 
with the use of bioinformatics in silico prediction tools, provided evidence that each variant 
identified is associated with disease, in the breeds implicated. As a result, diagnostic DNA tests 
have been developed to use as a breeding tool aiming to reduce the frequency of, and eventually 
eradicate, the mutation from each breeding population within a reasonable timeframe. With many 
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unresolved cases for canine PRA, human IRD studies have proven significant in facilitating the 
identification of canine PRA-associated genes. As illustrated, novel gene discovery in canine PRA 
studies can also present genes for consideration in retinal degeneration in humans and other 
species to identify disease-causing variants. Finally, this thesis contributes three novel canine 
PRA-associated mutations to the community, highlighting the potential applications and 
challenges in elucidating the genetic basis of canine PRAs. 
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Appendices 
Appendix 1. Genes from the RetNet database associated with human 
inherited retinal diseases.  
 
Retinitis 
pigmentosa, 
autosomal 
dominant 
Retinitis pigmentosa, 
autosomal recessive 
Retinitis 
pigmentosa, X-
linked 
Leber 
congenital 
amaurosis, 
autosomal 
dominant 
Leber 
congenital 
amaurosis, 
autosomal 
recessive 
Bardet-
Biedl 
syndrome, 
autosomal 
recessive 
ADIPOR1 ABCA4 MAK OFD1 CRX AIPL1 ADIPOR1 
ARL3 AGBL5 MERTK RP2 IMPDH1 CABP4 ARL6 
BEST1 AHR MVK RPGR OTX2 CCT2 BBIP1 
CA4 ARHGEF18 NEK2   CEP290 BBS1 
CRX ARL6 NEUROD1   CLUAP1 BBS2 
FSCN2 ARL2BP NR2E3   CRB1 BBS4 
GUCA1B BBS1 NRL   CRX BBS5 
HK1 BBS2 PDE6A   DTHD1 BBS7 
IMPDH1 BEST1 PDE6B   GDF6 BBS9 
IMPG1 C2orf71 PDE6G   GUCY2D BBS10 
KLHL7 C8orf37 POMGNT1   IFT140 BBS12 
NR2E3 CERKL PRCD   IQCB1 C8orf37 
NRL CLCC1 PROM1   KCNJ13 CEP19 
PRPF3 CLRN1 RBP3   LCA5 CEP290 
PRPF4 CNGA1 REEP6   LRAT IFT172 
PRPF6 CNGB1 RGR   NMNAT1 IFT27 
PRPF8 CRB1 RHO   PRPH2 INPP5E 
PRPF31 CYP4V2 RLBP1   RD3 KCNJ13 
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Appendix 1 (continued). 
Retinitis 
pigmentosa, 
autosomal 
dominant 
Retinitis pigmentosa, 
autosomal recessive 
Retinitis 
pigmentosa, X-
linked 
Leber 
congenital 
amaurosis, 
autosomal 
dominant 
Leber 
congenital 
amaurosis, 
autosomal 
recessive 
Bardet-
Biedl 
syndrome, 
autosomal 
recessive 
PRPH2 DHDDS RP1   RDH12 LZTFL1 
RDH12 DHX38 RP1L1   RPE65 MKKS 
RHO EMC1 RPE65   RPGRIP1 MKS1 
ROM1 EYS SAG   SPATA7 NPHP1 
RP1 FAM161A SAMD11   TULP1 SDCCAG8 
RP9 GPR125 SLC7A14    TRIM32 
RPE65 HGSNAT SPATA7    TTC8 
SAG IDH3B TRNT1     
SEMA4A IFT140 TTC8     
SNRNP200 IFT172 TULP1     
SPP2 IMPG2 USH2A     
TOPORS KIAA1549 ZNF408     
 KIZ ZNF513     
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Appendix 2. Mutations associated with canine inherited retinal disease (IRD) and those excluded in the laboratory. 
 
 
IRD/ 
Abbreviation 
Inheritance Gene/ Locus References 
CanFam3 
Position 
Mutation 
Breeds 
identified 
Excluded by 
laboratory 
screening 
Cone-rod degenerations (CRDs) 
1 
Cone-rod 
dystrophy 1 
(CORD1) 
Autosomal 
recessive 
RPGRIP1 
(Mellersh et al, 
2006) 
chr15:18,331,99
5 
44-bp insertion 
Miniature Long-
Haired 
Dachshund 
LA, GS, SS 
2 EORD modifier 
Autosomal 
recessive 
MAP9 
(Forman et al, 
2016) 
chr15:52,907,60
4-52,908,043 
Deletion 
Miniature Long-
Haired 
Dachshund 
LA, GS, SS 
3 
Cone-rod 
dystrophy 3 
(CRD3) 
Autosomal 
recessive 
ADAM9 
(Kropatsch et al, 
2010) 
Approx. 
chr16:26446610-
26469830 
Deletion of 
exons 15 and 16 
Glen of Imaal 
Terrier 
LA, GS, SS 
4 
Cone-rod 
dystrophy (CRD) 
Autosomal 
recessive 
NPHP4 (Wiik et al, 2008) chr5:59,913,209 180-bp deletion 
Standard Wire-
haired 
Dachshund 
LA, GS, SS 
5 
Cone-rod 
dystrophy 1 
(crd1) 
Autosomal 
recessive 
PDE6B 
(Goldstein et al, 
2013b) 
chr3:91747728-
91747730 
3-bp del (AAC) 
American 
Staffordshire 
Terrier 
N/A 
 
 Appendices 
183 
 
 
Appendix 2 (continued). 
 
IRD/ 
Abbreviation 
Inheritance Gene/ Locus References 
CanFam3 
Position 
Mutation 
Breeds 
identified 
Excluded by 
laboratory 
screening 
Progressive retinal atrophies (PRAs) 
6 
Cone-rod 
dystrophy 2 
(crd2) 
Autosomal 
recessive 
IQCB1(NPHP5) 
(Goldstein et al, 
2013b) 
chr33:25078909
-25078910 
1-bp insertion 
(C) 
American Pitbull 
Terrier 
N/A 
7 
Rod-cone 
dystrophy 1 
(RCD1a) 
Autosomal 
recessive 
PDE6B 
(Dekomien et al, 
2000) 
chr3:91747685-
91747686 
8bp insertion 
(TGAAGTCC) 
Sloughi LA, GS, SS 
8 
Rod-cone 
dystrophy 1 
(RCD1) 
Autosomal 
recessive 
PDE6B 
(Clements et al, 
1993; Suber et al, 
1993) 
chr3:91747714 
Missense SNV 
(G/A) 
Irish Setter LA, GS, SS 
9 
Rod cone 
dysplasia type 2 
(rcd2) 
Autosomal 
recessive 
C1orf36 (RD3) 
(Kukekova et al, 
2009) 
Approx. 
chr7:9874987:9
876615 
22-bp insertion Collie N/A 
10 
Rod-cone 
dystrophy 3 
(RCD3) 
Autosomal 
recessive 
PDE6A 
(Petersen-Jones 
et al, 1999) 
chr4:59145361 1-bp deletion (A) 
Cardigan Welsh 
Corgi 
LA, GS, SS 
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Appendix 2 (continued). 
 
IRD/ 
Abbreviation 
Inheritance Gene/ Locus References 
CanFam3 
Position 
Mutation 
Breeds 
identified 
Excluded by 
laboratory 
screening 
11 
Rod-cone 
degeneration 4 
(RCD4) 
Autosomal 
recessive 
C2ORF71 
(Downs et al, 
2013) 
chr17:22907389-
22907390 
1-bp insertion 
(C) 
Gordon Setter, 
Irish Setter, 
English Setter & 
Tibetan Terrier 
LA, GS, SS 
12 
Progressive 
retinal atrophy 3 
(PRA3) 
Autosomal 
recessive 
FAM161A 
(Downs & 
Mellersh, 2014) 
chr10:61,822,33
5-61,822,372 
SINE insertion 
Tibetan Spaniel 
& Tibetan 
Terrier 
LA, GS, SS 
13 
Early retinal 
degeneration 
(ERD) 
Autosomal 
recessive 
STK38L 
(Goldstein et al, 
2010) 
chr27:20,447,81
6 
4-bp deletion in 
exon 3, SINE 
insertion in exon 
4 
Norwegian 
Elkhound 
LA, GS, SS 
14 
Generalized PRA 
(GPRA) 
Autosomal 
recessive 
CCDC66 
(Dekomien et al, 
2010) 
chr20:33,745,44
6-33,745,447 
1-bp insertion 
(A) 
Schapendoes LA, GS, SS 
15 
Progressive 
retinal atrophy 
(PRA) 
Autosomal 
recessive 
CNGB1 
(Ahonen et al, 
2013) 
chr2:58622673; 
chr2:58622676-
58622677 
1-bp deletion 
(A); 6-bp 
insertion 
(AGCTAC) 
Papillion & 
Phalènes 
LA, GS, SS 
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Appendix 2 (continued). 
 
IRD/ 
Abbreviation 
Inheritance Gene/ Locus References 
CanFam3 
Position 
Mutation 
Breeds 
identified 
Excluded by 
laboratory 
screening 
16 
Progressive rod-
cone 
degeneration 
(PRCD) 
Autosomal 
recessive 
PRCD 
(Goldstein et al, 
2006; Zangerl et 
al, 2006) 
chr9:4188663 
Missense SNV 
(G/A) 
72 breeds (i) LA, GS, SS 
17 
Autosomal 
dominant PRA 
(ADPRA) 
Autosomal 
dominant 
RHO 
(Kijas et al, 2002; 
Kijas et al, 2003) 
chr20:5,637,394 
Missense SNV 
(C/G) 
English Mastiff & 
Bull Mastiff 
LA, GS, SS 
18 
Golden Retriever 
PRA 1 
(GR_PRA_1) 
Autosomal 
recessive 
SLC4A3 
(Downs et al, 
2011) 
chr37:26145747
-26145748 
1-bp insertion (C 
ins) 
Golden Retriever LA, GS, SS 
19 
Golden Retriever 
PRA 2 
(GR_PRA_2) 
Autosomal 
recessive 
TTC8 
(Downs et al, 
2014) 
chr8:60090186 1-bp deletion (A) 
Golden Retriever 
and Labrador 
Retriever 
LA, GS, SS 
20 
Progressive 
retinal atrophy 
(PRA) 
Autosomal 
recessive 
CNGA1 (Wiik et al, 2015) 
chr13:43,831,89
6-43,831,900 
4-bp deletion 
Shetland 
Sheepdogs 
LA, GS, SS 
21 
X-linked PRA 
(XLPRA1) 
X-linked 
recessive 
RPGR 
(Zhang et al, 
2002) 
Approx. 
chrX:33,077,524-
33077426 
5-bp deletion 
(GAGAA) 
Siberian Husky & 
Samoyed 
N/A 
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Appendix 2 (continued). 
 
IRD/ 
Abbreviation 
Inheritance Gene/ Locus References 
CanFam3 
Position 
Mutation 
Breeds 
identified 
Excluded by 
laboratory 
screening 
22 
X-linked PRA 
(XLPRA2) 
X-linked 
recessive 
RPGR 
(Zhang et al, 
2002) 
Approx. 
chrX:33,077,524-
33077426 
2-bp del (GA) 
Mongrel dogs 
(mixed breeds); 
Miniature 
Schnauzer 
N/A 
23 X-linked PRA 
X-linked 
recessive 
RPGR 
(Kropatsch et al, 
2016) 
 Large deletion Weimaraner N/A 
24 
Canine Stargardt 
Disease 
Autosomal 
recessive 
ABCA4 
(Makelainen et 
al, 2019) 
chr6:55146549 
1-bp insertion 
(C) 
Labrador 
Retriever 
SS 
25 PRA 
Autosomal 
recessive 
SAG 
(Goldstein et al, 
2013a) 
chr25:44843440 
Missense SNV 
(T/C) 
Basenji N/A 
26 PRA 
Autosomal 
recessive 
PPT1 
(Murgiano et al, 
2018)  
Structural 
variant 
Miniature 
Schnauzer 
N/A 
27 PRA 
Autosomal 
recessive 
HIVEP3 
(Kaukonen et al, 
2020) 
chr15: 1432293 
Intronic SNV 
(G/A) 
Miniature 
Schnauzer 
N/A 
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Appendix 2 (continued). 
 
IRD/ 
Abbreviation 
Inheritance Gene/ Locus References 
CanFam3 
Position 
Mutation 
Breeds 
identified 
Excluded by 
laboratory 
screening 
Other 
N/A 
Photoreceptor 
Dysplasia 
Autosomal 
recessive 
PDC 
(Zhang et al, 
1998) 
chr7:19,499,691 
Missense SNV 
(C/G) 
Miniature 
Schnauzer 
however now 
not believed to 
be a causal 
mutation 
LA, GS, SS 
26 Retinopathy 
Autosomal 
recessive 
MERTK 
(Everson et al, 
2017) 
chr17:36338043
-36338057 
LINE-1 insertion 
Swedish 
Vallhund 
SS 
27 
Achromatopsia 
(ACHM) 
Autosomal 
recessive 
CNGB3 (Yeh et al, 2013) chr29:32837065 
Missense SNV 
(G/A) 
Alaskan 
Malamute, 
German Short-
Haired Pointer 
LA, GS, SS 
28 
Achromatopsia 
(ACHM) 
Autosomal 
recessive 
CNGA3 
(Tanaka et al, 
2015) 
chr10:44234861 
Missense SNV 
(C/T) 
German 
Shepherd 
LA, GS, SS 
29 
Achromatopsia 
(ACHM) 
Autosomal 
recessive 
CNGA3 
(Tanaka et al, 
2015) 
chr10:44234200 3-bp del (TGG) 
Labrador 
Retriever 
LA, GS, SS 
30 
Canine LCA 
(cLCA) 
Autosomal 
recessive 
RPE65 
(Veske et al, 
1999) 
chr6:76893207-
76893210 
4bp deletion 
(AAGA) 
Briard LA, GS, SS 
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Appendix 2 (continued). 
 
IRD/ 
Abbreviation 
Inheritance Gene/ Locus References 
CanFam3 
Position 
Mutation 
Breeds 
identified 
Excluded by 
laboratory 
screening 
31 
Canine 
multifocal 
retinopathy 1 
(cmr1) 
Autosomal 
recessive 
BEST1 
(Guziewicz et al, 
2007) 
chr18:54478586 
Missense SNV 
(C/G) 
Great Pyrenees, 
English Mastiff & 
Bullmastiff 
LA, GS, SS 
32 
Canine 
multifocal 
retinopathy 2 
(cmr2) 
Autosomal 
recessive 
BEST1 
(Guziewicz et al, 
2007) 
chr18:54,476,143 
Missense SNV 
(G/A) 
Coton de Tulear LA, GS, SS 
33 
Canine 
multifocal 
retinopathy 3 
(cmr3) 
Autosomal 
recessive 
BEST1 
(Zangerl et al, 
2010) 
chr18:54,470,587 Deletion (C) 
Lapponian 
Herder 
LA, GS, SS 
(i) American Cocker Spaniel, American Eskimo Dog, American Hairless Terrier, Australian Cattle Dog, Australian Shepherd, Australian Silky Terrier, Australian Stumpy Tail Cattle Dog, Barbet, Black Russian Terrier, Bolognese, Bolonka, 
Chesapeake Bay Retriever, Chihuahua, Chihuahua – Longhaired, Chihuahua - Smooth-haired, Chinese Crested Dog, Coton de Tulear, English Cocker Spaniel, Entlebucher Mountain Dog, Field Spaniel, Finnish Lapphund, Giant Schnauzer, 
Giant Schnauzer – Black, Giant Schnauzer - Pepper and salt, Golden Labrador Retriever, Golden Retriever, Goldendoodle, Karelian Bear Dog, Kuvasz, Labrador Retriever, Lagotto Romagnolo - Romagna Water Dog, Lancashire Heeler, 
Lapponian Herder, Manchester Terrier – Toy, Miniature American Shepherd, Mixed breed, Norrbottenspitz, Norwegian Elkhound, Black,  Norwegian Elkhound, Grey, Nova Scotia Duck Tolling Retriever, Plott, Poodle (AKC), Poodle - 
Medium size (FCI size standard) - Black, brown and white, Poodle - Medium size (FCI size standard) - Grey, apricot and red, Poodle - Miniature (AKC size standard), Poodle - Miniature (FCI size standard) - Black, brown and white, Poodle 
- Miniature (FCI size standard) - Grey, apricot and red, Poodle - Standard (AKC size standard), Poodle - Standard (FCI size standard} - Black, brown and white, Poodle - Standard (FCI size standard) - Grey, apricot and red, Poodle - Toy 
(AKC size standard), Poodle - Toy (FCI size standard), Portuguese Podengo, Portuguese Podengo – Miniature, Portuguese Podengo - Smooth-haired Miniature, Portuguese Podengo - Wirehaired Miniature, Portuguese Water Dog, Rat 
Terrier, Schipperke, Spanish Water Dog, Swedish Elkhound, Swedish Lapphund, Xoloitzcuintle, Yorkshire Terrier 
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Appendix 3. The BVA/KC/ISDS eye scheme listing canine inherited eye diseases and the breeds advised to have annual 
eye examinations (January 2020). 
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Appendix 4. All primers and assay details. 
Table A1: PCR primers used for sequencing amplicons to exclude known canine retinal mutations 
as causal in the PRA- affected Giant Schnauzer (GS), Lhasa Apso (LA) and Shetland Sheepdog (SS) 
dogs under investigation. (B, C) PCR primers used for genotyping seven known canine retinal 
mutations to exclude in the breeds under investigation (by PCR followed by AFLP analysis or by 
visualisation of PCR product on an agarose gel). 
 
Form of retinal 
degeneration 
Locus or 
Abbreviation 
Gene 
involved 
Primer 
sequences 
References 
(A) Pooled for multiplex PCR for amplicon sequencing 
Cone degeneration CD CNGB3 
F-CCCACTTACCATTATGTCTCCTC; 
R-TCAAACACCAGACAACACACA 
(Yeh et al, 
2013) 
Canine achromatopsia ACHM CNGA3 
SNP_F-AGTGGGCGTCCTAATCTTTG; 
SNP_R-CGGAATTGCATGTACTGCTT 
(Tanaka et al, 
2015) 
Canine achromatopsia ACHM CNGA3 
del_F-CCTGATCGACGAGGACGTG; 
del_R-CGTTGTACTCGGCCAGGAG 
(Tanaka et al, 
2015) 
Congenital stationary 
night blindness/retinal 
dystrophy 
CSNB RPE65 
F-GACAATGCCCTTGTTAACGTC; 
R-AGCATTTCGTCCTACCTGCTT 
(Veske et al, 
1999) 
Canine multifocal 
retinopathy 
CMR1 
BEST1/ 
VMD2 
F-CGTCACCTACTCAAGCCAAGT; 
R-TAGCTGAGCAGGAAGATGAGG 
(Guziewicz et 
al, 2007) 
Canine multifocal 
retinopathy 
CMR2 
BEST1/ 
VMD2 
F-GGCCCTCCCCATCCACTG; 
R-CAGGGCACCCAGAACGTGT 
(Guziewicz et 
al, 2007) 
Canine multifocal 
retinopathy 
CMR3 
BEST1/ 
VMD2 
F-AAGGCCTGGGAGATTAAGGAG; 
R-CTGACTGTCCAGATGGGAAGA 
(Zangerl et al, 
2010) 
Generalised PRA GPRA CCDC66 
F-GCTCATACTGCTTAGATGTCTCTTG; 
R-CAATACTTCCAATCAGCCAAA 
(Dekomien et 
al, 2010) 
Progressive retinal 
atrophy 
PRA CNGB1 
F-CCACCCAGGCTCAGCAG; 
R-TCAGGCAGCCCACCAAT 
(Ahonen et al, 
2013) 
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Appendix 4 (continued). 
Form of retinal 
degeneration 
Locus or 
Abbreviation 
Gene 
involved 
Primer 
sequences 
References 
Photoreceptor dysplasia PD PDC 
F-TGTCTATTCCCAGATGAGCATT; 
R-AAACTCAGCTTCTGGTGCATATC 
(Zhang et al, 
1998) 
Progressive rod-cone 
degeneration 
PRCD PRCD 
F-TTTCTCCTGCAGACTCTGTCC; 
R-CAGCTTCTCACGGTTGGA 
(Goldstein et al, 
2006; Zangerl 
et al, 2006) 
Autosomal dominant PRA ADPRA RHO 
F-ACACCCGTCTTGTTGGAGAA; 
R-CCTCAGCAGCACTCTTAGGAC 
(Kijas et al, 
2002; Kijas et 
al, 2003) 
Progressive retinal 
atrophy 
GR_PRA1 SLC4A3 
F-CTGCCCAGGTGAGTGCTAGA; 
R-CACTCCCGTTCAGCTCCAG 
(Downs et al, 
2011) 
Progressive retinal 
atrophy 
GR_PRA2 TTC8 
F-TGGACTTGGCTGCCCTTT; 
R-CCATGTCTAAGCCCTTCACAA 
(Downs et al, 
2014) 
Progressive retinal 
atrophy 
PRA CNGA1 
F-GCAATCGAAGAACAGCCAAT; 
R-GCTTTCCCTTCTCTTCTAGCAT 
(Wiik et al, 
2015) 
Rod-cone dystrophy RCD1 PDE6B 
F-GAAGAGATCCTGCCCATGTT; 
R-TGTCCTCTTGTTGCTGCTTCT 
(Clements et al, 
1993; Suber et 
al, 1993) 
Rod-cone dystrophy RCD1a PDE6B 
F-GAAGAGATCCTGCCCATGTT; 
R-TGTCCTCTTGTTGCTGCTTCT 
(Dekomien et 
al, 2000) 
Rod-cone dystrophy RCD3 PDE6A 
F-CAGGACTGGGTGAGGATGATA; 
R-ACTTGAAATACAGGGCGAGGT 
(Petersen-Jones 
et al, 1999) 
(B) Amplified fragment length polymorphism (AFLP) analysis 
Cone-rod dystrophy CORD1 RPGRIP1 
6FAM-
GAAGAGCACATGTTGGTGAAGG; 
R- TGAGCTTTGTTTGCCTTTGG 
(Mellersh et al, 
2006) 
Cone-rod dystrophy (early 
onset) 
EORD MAP9 
6FAM-GTCGATGGAGGTCTCCGTAT; 
R- AACCTGGACCATGGGCAATA 
(Forman et al, 
2016) 
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Appendix 4 (continued). 
 
  
Form of retinal 
degeneration 
Locus or 
Abbreviation 
Gene 
involved 
Primer 
sequences 
References 
Rod-cone degeneration RCD4 C2ORF71 
6FAM-CCGAGTGCTCCCTCTGTG ; 
R- GGCTGCAGGCCTCGTC 
(Downs et al, 
2013) 
Progressive retinal 
atrophy 
PRA3 FAM161A 
Aff_F- 
GGATCCCTTTATTTGATTTTAGAAAG; 
Nor_F- 
TCCCTTCCTTTTATTTGATTTTAGAAAG; 
R- 6FAM-
CAACAAACACAACCTGAGCAA 
(Downs & 
Mellersh, 2014) 
(C) Agarose gel electrophoresis 
Cone-rod dystrophy CRD3 ADAM9 
Nor_F- AAGTACCTACCCTCCCGTTCA; 
Nor_R- 
GTAGGATGGAGGTCGAAGAGG; 
Aff_F- TTGGAACACCTAAATGCCTTG; 
Aff_R- GTAACCCCAGCCAACACAGTA 
(Kropatsch et 
al, 2010) 
Cone-rod dystrophy CRD NPHP4 
F- AGTTCCTTCAGTTACGTCAACCAT; 
R- CTTCCAACACACAGACAGTACTCC 
(Wiik et al, 
2008) 
Early retinal degeneration ERD STK38L 
F- CAGCCGCACCTAAAATGTAAA; 
R- CTTTATTCTTGGGTGAACTCCA 
(Goldstein et al, 
2010) 
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Table A2: Primers used in Chapter 3.  
Primer Name 
Assay Method 
Used 
Primer Sequence (5’-3’) 
Thermal 
Cycling 
Parameters 
NECAP1 assays 
NECAP1_F 
Allelic 
discrimination 
assay 
CAACCAAGAAGGGAGGTGTT 
Listed in Table A5 
NECAP1_R GAGGATGGTGGGGGAATAGT 
NECAP1_Normal HEX-CACAGGGGCTGGGGGTTTAA-IBFQ 
NECAP1_Alternate FAM-AGACCACAGGGGCTAGGGGTTT-IBFQ 
NECAP1_Finnish_seq_F 
PCR and 
Sequencing 
TGGTTTCTTTCCCCTACTCCC 
Listed in Table A7 
NECAP1_Finnish_seq__R AATGGGTGGTGGAGTGACAT 
NECAP1_seq_F 
PCR and 
Sequencing 
GGCTTCAAGGAAGGACAGACT 
Listed in Table A8 
NECAP1_seq_R GATACGATGATTCCTCAAAGTTAAA 
Haplotype analysis SNV primers 
36894608_F 
PCR and 
Sequencing 
CAGGTGCCCTCAAAGAATCTA 
Listed in Table A8 
36894608_R CAGAGCCTTGCTCTAACTCCA 
37020314_F 
PCR and 
Sequencing 
CTTGGAATGCTCCATCTCAAC 
37020314_R CTGCATACTGGTTGGTCGATT 
37425357_F 
PCR and 
Sequencing 
TTCTTGATCTCCAGGGAGAGAG 
37425357_R TCTTCCCTCTGGAAGAGGTTC 
37467780_F 
PCR and 
Sequencing 
TGGAACTTCCCATTCACTGTT 
37467780_R GGTGCTATGCGTTACCACTGT 
37501948_F 
PCR and 
Sequencing 
CCTTCTAGACTCTTGGTAACCACTG 
37501948_R GGGAATACTGGACAGTTACATGC 
37541149_F 
PCR and 
Sequencing 
AACGTAGGCCCAGTGACCTAT 
37541149_R CCACAAGTGCTGGGAGATTTA 
37644083_F 
PCR and 
Sequencing 
AAGATCCAGTCTCTGGCTGGT 
37644083_R CTCTCATTGCCACACAGTCAA 
37770618_F 
PCR and 
Sequencing 
GCCTATAAAGACAGTTCTCCCAAT 
37770618_R GCACCTGCATTTGGTATCATT 
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Table A3: Primers used in Chapter 4.  
Primer Name Assay Method 
Used 
Primer Sequence (5’-3’) Thermal Cycling 
Parameters 
IMPG2_Long_F PCR and Gel CCAGGCCTCATGTTTAATAGC Listed in Table A9 
IMPG2_Long_R GCACTGTTGGGTTCTTGGATA 
IMPG2_LINE_Normal_F PCR and AFLP GATTTCAGGAAAGAAGTGAGAGG Listed in Table 
A10 
IMPG2_LINE_Alternate_F TCTGAAGAAAGGAAAGGACACCAT 
IMPG2_LINE _R FAM-ACCCAGAGAAATCTTCCCAAA 
IMPG2_intronic_SNV_F Allelic 
discrimination 
assay 
GGGACAAAGGAAACAGGTATCA Listed in Table 
A11 
IMPG2_ intronic_SNV_R GAAGGAGAAGCAGGCTCCAT 
IMPG2_ intronic_SNV_Normal HEX-CCCAGTGGCTCAGCGGTTTAG-IBFQ 
IMPG2_ intronic_SNV_Alternate FAM-CCCAGTGGCTCAGCAGTTTAG-IBFQ 
GWAS_SNP_BICF2G630247609_F PCR and 
Sequencing 
TGAAGGTAAGTGTGTCATTTCTGA Listed in Table 
A10 
GWAS_SNP_BICF2G630247609_R GTTAACCTTAACTACAATGACCAGTTT 
CEP97_intronic_SNV_F PCR and 
Sequencing 
CAATGAAATGTTAGCAGGGCTAC Listed in Table 
A10 
CEP97_intronic_SNV_R GGAGAATCGGAGAATCCAGA 
IMPG2_cDNA_exons16-17_F qPCR GCCTGGTTTCTGCTTGAATG Listed in Table 
A11 
IMPG2_cDNA_exons16-17_R TCACAATGCTTACCTCGGTAC 
IMPG2_cDNA_exons16-17_probe FAM-TGTAGATGCCGGGTAGGTGAGAACT- IBFQ 
TBP_F qPCR AGCGAGGAAATATGCCAGAG Listed in Table 
A12 
TBP_R GGGAACTTCACATCACAGCTC 
TBP_probe FAM-TTCAAGATTCAGAACATGGTGGG- IBFQ 
IMPG2_promoter_F PCR tagtagGCTAGCGGATTTTCAAGAGAAATATGTTTTAGATC Listed in Table 
A13 
IMPG2_promoter_R tagtagGGATCCTTGGGCCACAATCAAAGG 
Primers to verify sequence of the constructed pGL4 IMPG2-promoter plasmid 
RVprimer3_pp1_F  CTAGCAAAATAGGCTGTCCC  Directly Sanger 
sequenced (conditions 
and parameters listed 
in Chapter 2, section 
2.5.) 
pBR322ori-F  AAAGATACCAGGCGTTTCCC 
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Table A3 (continued). 
Primer Name 
Assay Method 
Used 
Primer Sequence (5’-3’) 
Thermal Cycling 
Parameters 
L4440  CTCGCTCACTGACTCGCT 
Directly Sanger 
sequenced (conditions 
and parameters listed 
in Chapter 2, section 
2.5.) 
 
SV40pA-R  GAAATTTGTGATGCTATTGC 
EBV Reverse  GTGGTTTGTCCAAACTCATC  
Seq_plas_1  GCTGAAGCCAGTTACCTTCG 
Seq_plas_2  GCGATCTGCCTATTTCGTTC 
Seq_plas_3  GAATGAGTGCGACACGAAAA 
Seq_plas_4  TACCTACGCCGAGTACTTCG 
Seq_plas_5  CACCTTCGTGACTTCCCATT 
Seq_plas_6  GAGCTATTCTTGCGCAGCTT 
Seq_plas_7  GAGCGGCTACGTTAACAACC 
Seq_plas_8  CGAGAAGGAGATCGTGGACT 
pp1_R  ACCACAATGGGACCAATAAA 
pp2_F  GGATTTTCAAGAGAAATATGTTTTAGATC 
pp2_R  TTAAACATGAGGCCTGGTATG 
pp3_F  TTTCTTGGTTAAGAGTTCTTCATGT 
pp3_R  ACCCTGAGATCACAATCTGG 
pp4_F  TATTCGGTCTGGGCTTACAG 
pp4_R  CAGCTATGAAAGCGGAAGAG 
pp5_F  TGCCAGTTAAAGGCAAAGAA 
pp5_R  TTGGGCCACAATCAAAGG 
pp6_F  TTTGGGAATGCTTGTCTGTT 
pp6_R  CGAAGTACTCGGCGTAGGTA 
pp7_F  CTAACTGGCCGGTACCTGAG 
pp7_R  TTTGGAATCTTGCTTCATTAGC 
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Table A4: Primers used in Chapter 5.  
Primer Name Assay Method Used Primer Sequence (5’-3’) 
Thermal Cycling 
Parameters 
chr30:24115675_F  
Multiplex PCR for NGS 
CCAGAAATGTCAACTCCTTGG 
Listed in Table A6 
chr30:24115675_R  ATGAGCTGAAGCTCTGACTGC 
chr16:36561913_F GCAACACATTGGGTGCATTAT 
chr16:36561913_R GAAAGCAGGCTGAGGTACACA 
chr36:10135919_F GCATGAGGAAGAAACTTGTCC 
chr36:10135919_R GCTTAGGCTTGCATTTGTTTG 
chr39:43769675_F TAAAGGACGCAGGGTTCTACA 
chr39:43769675_R ACTGATGGAAGCTGACTTGGA 
chr1:110147994_F ACTGATCCAGGCCCTGTTACT 
chr1:110147994_R CTTTCTCCTTCCAGCCTCAAT 
chr39:1762952_F ATCCGTCGATGTTGGAAGTG 
chr39:1762952_R CAGTTGGAGGATGTGGGTGT 
chr2:62484625_F GCCTGAGTTTGGAGAAGTCTG 
chr2:62484625_R CTTGACCCAGAAGACCTCCTT 
chr17:40080783_F GGGGCTGGAACTTCACTTTT 
chr17:40080783_R CCTTACCTGGGGCTGGAG 
chr1:119547008_F TTGATAGCGCAAAGGTGAAAC 
chr1:119547008_R GGTTCCAACGACAATGAGAAA 
chr1:114617154_F CCCAAATTTGACTGGGTGAG 
chr1:114617154_R CCAGAGCCGACTTCGAGTG 
chr22:58226397_F ACGGGCATGGACATGGAG 
chr22:58226397_R CACCACCACCTGGTCAACCT 
chr4:68451901_F AGACACAGGCAGAGGGAGAAG 
chr4:68451901_R CCTCAGGCCCTGCTTATTC 
chr1:116038553_F ACTCTAAGGCCAGAGCCACAC 
chr1:116038553_R CGCCAACAGCTTACTTTTCA 
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Table A4 (continued). 
    
Primer Name Assay Method Used Primer Sequence (5’-3’) Thermal Cycling Parameters 
chr16:44477295_F 
Multiplex PCR for NGS 
(continued) 
GGATGGCATCGGTACACATT 
Listed in Table A6 
chr16:44477295_R ACATCTGAAAGCGGATTACCA 
chr15:52265347_F TCAACCTGGATGAGACCTACC 
chr15:52265347_R TTTGGACATCTGTCTCCCACT 
BBS2_F 
Allelic Discrimination 
Assay 
CCATCTTGGACTGGTTCTTG 
Listed in Table A5 
BBS2_R CTGGAAAGGTTGTGAATGCT 
BBS2_Normal HEX- ACACCATCATCCGAGCAGTACTGA - IBFQ 
BBS2_Alternate FAM-ACACCATCATCCGACCAGTACTGA- IBFQ 
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Table A5: Thermal cycling parameters for NECAP1 and BBS2 allelic discrimination assays. 
PCR Stage Temperature Duration Cycles 
Pre-PCR step 25 °C 30 seconds  
Initial Denaturation 95 °C 3 minutes  
Denaturation 95 °C 3 seconds 
35 
Annealing/Extension 60 °C 10 seconds 
Post-PCR 25 °C 30 seconds  
 
Table A6: Thermal cycling parameters for multiplex PCR assays. 
PCR Stage Temperature (°C) Duration Cycles 
Initial Denaturation 95 10 minutes  
Denaturation 95 15 seconds 
25 
Annealing 60 2 minutes 
Extension 60 30 minutes  
 
Table A7: Thermal cycling parameters for PCR amplification of the NECAP1 variant in the Finnish 
cohort to perform Sanger sequencing. 
PCR Stage Temperature (°C) Duration Cycles 
Initial Denaturation 95 5 minutes  
Denaturation 95 30 seconds 
37 Annealing 59 30 seconds 
Extension 72 45 seconds 
Final Extension 72 10 minutes  
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Table A8: Thermal cycling parameters for PCR amplification of the NECAP1 variant in the AHT 
cohort to perform Sanger sequencing. 
PCR Stage Temperature (°C) Duration Cycles 
Initial Denaturation 95 5 minutes  
Denaturation 95 30 seconds 
35 Annealing 58 30 seconds 
Extension 72 30 seconds 
Final Extension 72 5 minutes  
 
Table A9: Thermal cycling parameters for PCR to characterise the IMPG2 LINE-1 insertion. 
PCR Stage Temperature (°C) Duration Cycles 
Denaturation 98 10 seconds 
30 
Annealing 60 15 seconds 
Final Extension 68 8 minutes  
 
Table A10: Thermal cycling parameters for IMPG2 LINE-1 insertion, GWAS Top SNP 
(BICF2G630247609) and CEP97 intronic SNV genotyping assays. 
PCR Stage Temperature (°C) Duration Cycles 
Initial Denaturation 95 5 minutes  
Denaturation 95 30 seconds 
35 Annealing 60 30 seconds 
Extension 72 30 seconds 
Final Extension 72 5 minutes  
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Table A11: Thermal cycling parameters for IMPG2 intronic SNV allelic discrimination assay. 
PCR Stage Temperature Duration Cycles 
Pre-PCR step 25 °C 30 seconds  
Initial Denaturation 95 °C 3 minutes  
Denaturation 95 °C 3 seconds 
40 
Annealing/Extension 60 °C 10 seconds 
Post-PCR 25 °C 30 seconds  
 
Table A12: Thermal cycling parameters for qPCR assay to determine IMPG2 expression. 
PCR Stage Temperature (°C) Duration Cycles 
Initial Denaturation 95 5 minutes  
Denaturation 95 10 seconds 
40 
Annealing/Extension 60 30 seconds 
 
Table A13: Thermal cycling parameters for PCR amplification of the IMPG2 promoter insert. 
PCR Stage Temperature (°C) Duration Cycles 
Denaturation 98 10 seconds 
30 
Annealing 60 15 seconds 
Extension 68 8 minutes  
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Appendix 5. In-house script used for de novo assembly of sequencing reads. 
This script was written by Dr Oliver Forman for use within the AHT Canine Genetics group. 
## Get reads containing substring AAA or its revcomp TTT 
use strict; 
use Getopt::Std ; 
use File::Basename ; 
#################### 
# Define variables # 
#################### 
my $command = ""; 
my $in1  = ""; 
my $in2  = ""; 
my $fastq = ""; 
my $out  = ""; 
system clear; 
use Term::ANSIColor; 
print color "bold cyan"; 
print " \n\n\n\n\n  FASTQ FILTER!\n\n\n"; 
print color "bold white"; 
print "  THIS IS A SHORT SCRIPT TO OUTPUT A SUBSET OF READS CONTAINING A PARTICULAR 
SEQUENCE\n"; 
print color 'reset'; 
print "  Oliver Forman Aug2014\n\n\n\n\n"; 
print "\n\nEnter a short name for this analysis:\n\n    "; 
$out = <STDIN>; 
chomp $out; 
print "\n\nEnter the names of your fastq file including .fastq extention:\n\n    "; 
$fastq = <STDIN>; 
chomp $fastq; 
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Appendix 5 (continued). 
print "\n\nPlease enter the nucleotide sequence you want the reads to contain:\n\n    
"; 
$in1 = <STDIN>; 
chomp $in1; 
print "\n\nPlease enter the reverse complement of the nucleotide sequence:\n\n    "; 
$in2 = <STDIN>; 
chomp $in2; 
print "\n\n\n\nThe program is running, run time is dependant on the FASTQ file 
size...."; 
$command =  "paste - - - - < $fastq|grep -P '^@.*?\t(.*?$in1.*?)|(.*?$in2.*?)\t\+'|tr 
'\t' '\n'print > $out.fastq "; 
system("$command"); 
print "FINISHED!\n\n"; 
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Appendix 6. In-house effect scores assigned to sequence ontology terms 
used to prioritise variant filtration in whole genome sequencing analysis. 
Sequence ontology term Effect 
Score 
5’-UTR premature start codon gain variant 5 
Chromosome number variation 5 
Disruptive in-frame deletion 5 
Disruptive in-frame insertion 5 
Exon loss 5 
Exon loss variant 5 
Frameshift variant 5 
In-frame deletion 5 
In-frame insertion 5 
Initiator codon variant 5 
Initiator codon variant and non-canonical start  
codon 
5 
Missense variant 5 
Protein altering variant 5 
Rare amino acid variant 5 
Splice acceptor variant 5 
Splice donor variant 5 
Start lost 5 
Stop gained 5 
Stop lost 5 
Transcript ablation 5 
3’-UTR truncation 4 
5 ‘-UTR truncation 4 
Non-coding exon variant 4 
Regulatory region ablation 4 
Splice region variant 4 
TFBS ablation 4 
Coding sequence variant 3 
Conserved intergenic variant 3 
Conserved intron variant 3 
  
  
Non-coding RNA transcript variant 3 
3 prime UTR variant 2 
5 prime UTR variant 2 
Exon variant 2 
Feature elongation 2 
Feature truncation 2 
Gene variant 2 
Intron variant 2 
Mature microRNA (miRNA) variant 2 
miRNA 2 
Nonsense mediated decay (NMD) transcript 
variant 
2 
Non-coding transcript exon variant 2 
Non-coding transcript variant 2 
Regulatory region amplification 2 
Regulatory region variant 2 
Start retained 2 
Stop retained variant 2 
TFBS variant 2 
TFBS amplification 2 
Transcript amplification 2 
Transcript variant 2 
Upstream gene variant 2 
Coding sequence variant 1 
Downstream gene variant 1 
Intergenic region 1 
Intergenic variant 1 
Intragenic variant 1 
Synonymous variant 1 
Transcript 1 
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Appendix 7. Breed names known for canids screened for the NECAP1 
variant. 
Breed Number of 
individuals 
genotyped 
Affenpinscher 5 
Afghan Hound 3 
Airedale Terrier 5 
Alaskan Malamute 6 
Alpine Dachsbracke 1 
American Bulldog 5 
American Cocker Spaniel 3 
American Staffordshire Terrier 1 
Australian Cattle Dog 6 
Australian Kelpie 3 
Australian Shepherd 3 
Australian Terrier 1 
Basset Fauve De Bretagne 3 
Basset Hound 8 
Bavarian Hound 1 
Beagle 10 
Bearded Collie 16 
Bedlington Terrier 1 
Belgian Shepherd Dog 
(Groenendael) 1 
Belgian Shepherd Dog (Tervueren) 2 
Berger Blanc Suisse 1 
Berger Picard (Picardy sheepdog) 4 
Bichon Frisé 4 
Bloodhound 4 
Border Collie 44 
Border Terrier 8 
Borzoi 3 
Boston Terrier 3 
Boxer 5 
Briard 2 
Brittany Spaniel 3 
Brussels Griffon 1 
Bull Dog 6 
Bull Terrier 6 
Bullmastiff 2 
Cairn Terrier 2 
Cane Corso 1 
Catalan Sheepdog 3 
Cavalier King Charles Spaniel 7 
Central Asian Shepherd dog 1 
Cesky Terrier 3 
Chesapeake Bay Retriever 4 
Chihuahua 2 
Chinese Crested 1 
Chinese Indigenous dogs 28 
Chow Chow 5 
Cocker Spaniel 4 
Curly Coated Retriever 4 
Dachshund 3 
Dalmatian 7 
Dandie Dinmont Terrier 7 
Doberman 7 
Dogue de Bordeaux 4 
Dutch Shepherd 1 
Elo 1 
English Setter 4 
English Springer Spaniel 10 
Entlebucher Sennenhund 8 
Eurasier 2 
Field Spaniel 4 
Finnish Lapphund 5 
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Appendix 7 (continued). 
Flat-Coated Retriever 6 
French Bull Dog 10 
German Pinscher  3 
German Shepherd 16 
German Spitz (Giant) 116 
German Spitz (Medium) 151 
German Spitz (Miniature) 117 
German Spitz (Pomeranian) 59 
German Wire-Haired Pointer 4 
Giant Schnauzer 323 
Glen of Imaal Terrier 3 
Golden Retriever 9 
Gordon Setter 3 
Grand Basset Griffon Vendéen 3 
Great Dane 4 
Great Pyrenees 1 
Greater Swiss Mountain Dog 7 
Greyhound 5 
Havanese 3 
Heideterrier 1 
Hovawart 4 
Hungarian Vizsla 7 
Hungarian Wire-Haired Vizsla 3 
Icelandic Sheepdog 3 
Irish Red and White Setter 13 
Irish Setter 3 
Irish Soft-Coated Wheaten Terrier 1 
Irish Terrier 3 
Irish Water Spaniel 3 
Irish Wolfhound 8 
Italian Greyhound 4 
Italian Spinone 5 
Jack Russell Terrier 4 
 
  
Jagdterrier 1 
Japanese Akita 4 
Japanese Chin 1 
Japanese Shiba Inu 3 
Karelian Bear Dog 1 
Keeshond 3 
Kerry Blue Terrier 1 
Kromfohrländer 1 
Kunming Dog 10 
Labrador Retriever 18 
Lagotto Romagnolo 9 
Lakeland Terrier 4 
Lancashire Heeler 3 
Landseer 2 
Large Munsterlander 4 
Leonberger 50 
Lhasa Apso 9 
Malinois 6 
Manchester Terrier 3 
Miniature Smooth-Haired 
Dachshund 3 
Miniature Bull Terrier 7 
Miniature Bullterrier 1 
Miniature Long-Haired Dachshund 168 
Miniature Poodle 2 
Miniature Schnauzer 89 
Miniature Wire-Haired Dachshund 3 
Newfoundland 1 
Norfolk Terrier 3 
Northern Inuit 5 
Norwegian Buhund 7 
Norwegian Elkhound 3 
Norwich Terrier 7 
Nova Scotia Duck Tolling Retriever 4 
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Appendix 7 (continued). 
Old English Mastiff 3 
Old English Sheepdog 5 
Otterhound 3 
Parson Russel Terrier 4 
Pembroke Welsh Corgi 3 
Petit Basset Griffon Vendéen 6 
Pharaoh Hound 3 
Polish Lowland Sheepdog 3 
Poodle 19 
Portuguese Water Dog 3 
Pug 21 
Rhodesian Ridgeback 7 
Rottweiler 2 
Rough Collie 3 
Saint Bernard 3 
Saluki 5 
Samoyed 3 
Scottish Deerhound 3 
Scottish Terrier 7 
Shar Pei 3 
Shetland Sheepdog 5 
Shih Tzu 11 
Siberian Husky 8 
Skye Terrier 5 
Sloughi 3 
Soft-Coated Wheaten Terrier 3 
Spanish Water Dog 1 
St. Bernard 2 
Staffordshire Bull Terrier 4 
Standard Long-Haired Dachshund 3 
Standard Poodle 4 
Standard Schnauzer 3 
  
  
  
Standard Smooth-Haired 
Dachshund 4 
Standard Wire-Haired Dachshund  3 
Swedish Vallhund 6 
Tibetan Mastiff 10 
Tibetan Spaniel 10 
Tibetan Terrier 5 
Utonagan 3 
Weimaraner 5 
Welsh Springer Spaniel 9 
West Highland White Terrier 20 
Whippet 5 
White Shepherd 1 
Working Sheepdog 3 
Yorkshire Terrier 67 
Cross breeds 10 
Wolf 3 
Unknown/unconfirmed breeds 3,156 
Total 5,130 
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Appendix 8. IMPG2 LINE-1 insertion sequence. 
GAAATCTTCCCAAAATGAGGAAACATAATCATTTGGGCCACAATCAAAGGAATGAGGAGAAGCCAAAA
TCCTTAACTTGAACAACCCAAAAGGCTTGAAACTTCCAGTAACAAATTATTATAGGAAAGGTCTAACA
TTTAAGAGTTTATGTTTGAGAACAGACAAGCATTCCCAAACCATTATAAATTAGCTTAAATAAAAATG
GTGTCCTTTCCTTTCTTCAGAGAGTTAGAACAAATTATTTTAAGATTTGTGTGGAATCAGAAAAGACC
CCGAATAGCCAGGGGAATTTTAAAAAAGAAAACCATATCTGGGGGCATCACAATGCCAGATTTCAGGT
TGTACTACAAAGCTGTGGTCATCAAGACAGTGTGGTATTGGCACAAAAACAGACACATAGATCAGTGG
AACAGAATAGAGAATCCAGAAGTGGACCCTGAACTTTATGGGCAACTAATATTCGATAAAGGAGGAAA
GACTATCCATTGGAAGAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAATTGGACATCCACATGCA
GAAGAATGAAACTAGACCACTCTCTTTCACCATACACAAAGATAAACTCAAAATGGATGAAAGATCTA
AATGTGAGACAAGATTCCATCAAAATCCTAGAGAAGAACACAGGCAACACCCTTTTTGAACTCGGCCA
TAGTAACTTCTTGCAAGATACATCCACGAAGGCAAAAGAAACAAAAGCAAAAATGAACTATTGGGACT
TCATCAAGATAAGAAGCTTTTGCACAGCAAAGGATACAGTCAACAAAACTCAAAAACAACCTACAGAA
TGGGAGAAGATATTTGCAAATGACATATCAGATAAAGGGCTAGTTTCCAAGATCTATAAAGAACTTAT
TAAACTCAACACCAAAGAAACAAACAATCCAATCATGAAATGGGCAAAAGACATGAACAGAAATCTCA
CAGAGGAAGACATAGACATGGCCAACATGCATATGAGAAAATGCTCTGCATCACTTGCCATCAGGGAA
ATACAAATGAAAACTACAATGAGATACCACCTCACACCAGTGAGAATGGGGAAAATTATCAAGGCAGG
AAACAACAAATGTTGGAGAGGATGCGGAGAAAAGGGAACCCTCTTACACTGTTGGTGGGAATGTGAAC
TGGTGCAGCCACTCTGGAAAACTGTGTGGAGGTTCCTCAAACAGTTAAAAATATACCTGCCCTACGAC
CCAGCAATTGCACTGTTGGGGATTTACCCCAAAGATACAAATGCAATGAAACGCCGGGACACCTGCAC
CCCGATGTTTCTAGCAGCAATGGCCACGATAGCCAAACTGTGGAAGGAGCCTCGGTGTCCAACGAAAG
ATGAATGGATAAAGAAGATGTGGTTTATGTATACAATGGAATATTACTCAGCTATTAGAAATGACAA
ATACCCACCATTTGCTTCAACGTGGATGGAACTGGAGGGTATTATGCTGAGTGAAGTAAGTCAGTCAG
AGAAGGACAAACATTATATGTTCTCATTCATTTGGGGAATATAAATAATAGTGAAAGGGAAAATAAG
GGAAGGGAGAAGAAATGTGTGGGAAATATCAGAAAGGGAGACAGAACATAAAGACTGCTAACTCTGG
GAAACGAACTAGGGGTGGTAGAAGGGGAGGAGGGCGGGGCGTGGGAGTGAATGGGTGACGGGCACTG
GGTGTTATTCTGTATGTTAGTAAATTGAACACCAATAAAAAAATAAATAAAAATAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATGGTGTCCTTTCAAAATACC
TCTCACTTCTTTC 
Flanking IMPG2 sequence  
16 base pair target site duplication 
LINE-1 insertion sequence 
Poly-A tail  
Flanking IMPG2 sequence
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Appendix 9. Breed names for dogs screened for the IMPG2 LINE-1 insertion. 
Breed 
Number of 
individuals 
genotyped 
American Bull Dog 3 
Australian Cattle Dog 3 
American Cocker Spaniel 3 
Affenpinscher 3 
Afghan Hound 3 
Australian Kelpie 3 
Alaskan Malamute 3 
Australian Shepherd 3 
Airedale Terrier 3 
Boxer 3 
Basset Hound 3 
Border Collie 3 
Bulldog 3 
Beagle 3 
Bearded Collie 3 
Basset Fauve De Bretagne 3 
Bloodhound 3 
Border Terrier 3 
Borzoi 3 
Berger Picard (Picardy sheepdog) 3 
Brittany Spaniel 3 
Belgian Shepherd Dog (Tervueren) 2 
Belgian Shepherd Dog (Groenendael) 1 
Boston Terrier 3 
Bull Terrier 3 
  
  
Chesapeake Bay Retriever 3 
Curly Coated Retriever 3 
Cesky Terrier 3 
Chow Chow 3 
Cavalier King Charles Spaniel 3 
Cocker Spaniel 3 
Catalan Sheepdog 3 
Doberman 3 
Dandie Dinmont 3 
Dalmatian 3 
English Setter 3 
English Springer Spaniel 3 
French Bull Dog 3 
Flat-Coated Retriever 3 
Finnish Lapphund 3 
Field Spaniel 3 
Greyhound 3 
Grand Basset Griffon Vendéen 3 
Great Dane 3 
Glen of Imaal Terrier 3 
Gordon Setter 3 
German Pinscher 3 
Golden Retriever 3 
Giant Schnauzer 3 
German Shepherd Dog 3 
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Appendix 9 (continued). 
Greater Swiss Mountain Dog 3 
German Spitz (Klein) 3 
German Wire-Haired Pointer 3 
Havanese 3 
Hovawart 3 
Icelandic Sheepdog 3 
Italian Greyhound 3 
Irish Red and White Setter 3 
Irish Setter 3 
Italian Spinone 3 
Irish Water Spaniel 3 
Japanese Akita 3 
Jack Russell Terrier 3 
Japanese Shiba Inu 3 
Keeshond 3 
Lhasa Apso 63 
Leonberger 3 
Lancashire Heeler 3 
Large Münsterländer 3 
Labrador Retriever 3 
Lagotto Romagnolo 2 
Lakeland Terrier 3 
Miniature Bull Terrier 3 
Miniature Long-Haired Dachshund 3 
Miniature Schnauzer 3 
Miniature Smooth-Haired Dachshund 3 
Manchester Terrier 1 
 
  
Miniature Wire-Haired Dachshund 3 
Norwegian Buhund 3 
Norwegian Elkhound 3 
Northern Inuit 3 
Norfolk Terrier 3 
Nova Scotia Duck Tolling Retriever 3 
Norwich Terrier 3 
Old English Mastiff 3 
Old English Sheepdog 3 
Otterhound 3 
Pharaoh Hound 3 
Polish Lowland Sheepdog 3 
Parson Russell Terrier 3 
Petit Basset Griffon Vendéen  3 
Pug 2 
Pembroke Welsh Corgi 3 
Rough Collie 3 
Rhodesian Ridgeback 3 
Standard Schnauzer 3 
Saluki 3 
Samoyed 3 
Staffordshire Bull Terrier 3 
Scottish Deerhound 3 
Scottish Terrier 3 
Soft-coated Wheaten Terrier 3 
Shar Pei 3 
Siberian Husky 2 
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Appendix 9 (continued). 
Standard Long-Haired Dachshund  3 
Standard Smooth-Haired Dachshund 3 
Standard Poodle 3 
Shetland Sheepdog 3 
Skye Terrier 3 
Saint Bernard 3 
Shih Tzu 20 
Swedish Vallhund 3 
Tibetan Spaniel 10 
Tibetan Terrier 5 
Utonagan 3 
Vizsla (Smooth-Haired) 3 
Vizsla (Wire-Haired) 3 
Weimaraner 3 
Wire-haired Dachshund 3 
West Highland White Terrier 3 
Whippet 3 
Working Sheepdog 3 
Welsh Springer Spaniel 3 
Total 447 
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Appendix 10. Transcription factor binding site predictions known to be essential for normal eye development or function 
and are situated within 150-bp upstream and 150-bp downstream of the IMPG2 LINE-1 breakpoints.  
Five of these transcription factor binding site predictions are specific to photoreceptor cells in the retina (highlighted in orange). 
MatInspector Matrix Family Detailed Family Information Detailed Matrix Information Sequence 
V$HBOX Homeobox transcription factors Homeobox protein engrailed (en-1) tctttgccTTTAactggca 
V$BCDF Bicoid-like homeodomain transcription factors Pituitary Homeobox 1 (Ptx1, Pitx-1) ccagCTAAgctctttat 
V$BCDF Bicoid-like homeodomain transcription factors Cone-rod homeobox-containing transcription factor / otx-like homeobox gene tattcTAATctagccag 
V$CART Cart-1 (cartilage homeoprotein 1) Binding site for S8 type homeodomains taagcTAATtagaacagatgg 
V$BCDF Bicoid-like homeodomain transcription factors Photoreceptor conserved element 1 taagcTAATtagaacag 
V$BRNF Brn POU domain factors POU class 3 homeobox 2 (POU3F2), OTF7 tctgttcTAATtagcttat 
V$HBOX Homeobox transcription factors Homeodomain transcription factor Gsh-2 ataagcTAATtagaacaga 
V$LHXF Lim homeodomain factors LIM homeobox 8 catctgttctAATTagcttatct 
V$PAXH PAX homeodomain binding sites Paired box 4, homeodomain binding site aagctAATTagaaca 
V$BCDF Bicoid-like homeodomain transcription factors Photoreceptor conserved element 1 tgttcTAATtagcttat 
V$BRNF Brn POU domain factors POU class 3 homeobox 2 (POU3F2), OTF7 gataagcTAATtagaacag 
V$HBOX Homeobox transcription factors Homeodomain transcription factor Gsh-2 ctgttcTAATtagcttatc 
V$LHXF Lim homeodomain factors LIM homeobox 6 gagataagcTAATtagaacagat 
V$PAXH PAX homeodomain binding sites Paired box 4, homeodomain binding site gttctAATTagctta 
V$CART Cart-1 (cartilage homeoprotein 1) Binding site for S8 type homeodomains tgttcTAATtagcttatctct 
V$LHXF Lim homeodomain factors LIM-homeodomain transcription factor LHX3 ggaagagataagcTAATtagaac 
V$PAX6 PAX-4/PAX-6 paired domain binding sites PAX6 paired domain and homeodomain are required for binding to this site tcctgaaatCCAGcacagc 
V$FKHD Fork head domain factors Fork head homologous X binds DNA with a dual sequence specificity (FHXA and FHXB) cctttcAAAAtacctct 
V$NR2F Nuclear receptor subfamily 2 factors Chicken ovalbumin upstream promoter transcription factor 2, NR2F2 homodimer, DR1 sites gaggtattttgaaaGGACaccattt 
V$CART Cart-1 (cartilage homeoprotein 1) Prophet of Pit 1, PROP paired-like homeobox 1 tagcttAAATaaaaatggtgt 
V$LHXF Lim homeodomain factors LIM homeobox transcription factor 1, beta caccatttttATTTaagctaatt 
V$LHXF Lim homeodomain factors LIM homeobox transcription factor 1, alpha aaattagcttAAATaaaaatggt 
V$LHXF Lim homeodomain factors LIM-homeodomain transcription factor LHX3 tttttatttaagcTAATttataa 
V$CART Cart-1 (cartilage homeoprotein 1) Aristaless-like homeobox 3 attataAATTagcttaaataa 
V$HBOX Homeobox transcription factors Engrailed homeobox 2 cattataAATTagcttaaa 
V$LHXF Lim homeodomain factors LIM homeobox 6 tatttaagcTAATttataatggt 
V$PAXH PAX homeodomain binding sites Paired box 6, homeodomain binding site ttataAATTagctta 
V$BCDF Bicoid-like homeodomain transcription factors Photoreceptor conserved element 1 taagcTAATttataatg 
V$BRNF Brn POU domain factors POU class 4 homeobox 3 (POU4F3), BRN3C ccattatAAATtagcttaa 
V$HBOX Homeobox transcription factors Homeodomain transcription factor Gsh-2 ttaagcTAATttataatgg 
V$LHXF Lim homeodomain factors LIM homeobox 1 aaccattataAATTagcttaaat 
V$CART Cart-1 (cartilage homeoprotein 1) Phox2a (ARIX) and Phox2b taagcTAATttataatggttt 
V$BRNF Brn POU domain factors Brn-3, POU-IV protein class agctaatttATAAtggttt 
V$FKHD Fork head domain factors HNF-3/Fkh Homolog 1 (FOXQ1) caaacaTAAActcttaa 
V$PAX6 PAX-4/PAX-6 paired domain binding sites Pax-6 paired domain binding site cataaACTCttaaatgtta 
V$FKHD Fork head domain factors Fork head homologous X binds DNA with a dual sequence specificity (FHXA and FHXB) tttcctATAAtaatttg 
V$BRNF Brn POU domain factors Brn-3, POU-IV protein class tttcctaTAATaatttgtt 
V$BRNF Brn POU domain factors Brn-3, POU-IV protein class cctataaTAATttgttact 
V$HBOX Homeobox transcription factors Engrailed homeobox 1 agtaacaAATTattatagg 
V$PAXH PAX homeodomain binding sites Paired box 6, homeodomain binding site taacaAATTattata 
V$BRNF Brn POU domain factors Brn-3, POU-IV protein class cagtaacaaATTAttatag 
V$CART Cart-1 (cartilage homeoprotein 1) HESX homeobox 1, dimeric binding site tataaTAATttgttactggaa 
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Appendix 11. Breed names for canids screened for the BBS2 variant. 
 
Breed 
Number of 
individuals 
genotyped 
Affenpinscher 2 
Airedale Terrier 5 
Alaskan Malamute 4 
Alpine Dachsbracke 2 
American Bull Dog 2 
American Cocker Spaniel 1 
American Staffordshire Terrier 2 
Australian Cattle Dog 5 
Australian Shepherd 3 
Australian Terrier 1 
Basenji 7 
Basset Hound 9 
Bavarian Hound 1 
Beagle 8 
Bearded Collie 13 
Bedlington Terrier 1 
Berger Blanc Suisse 1 
Berger Picard 1 
Bichon Frisé 6 
Black Russian Terrier 1 
Bloodhound 1 
Border Collie 136 
Border Terrier 10 
Boxer 2 
Briard 2 
  
Brussels Griffon 3 
Bull Terrier 3 
Bulldog 3 
Bullmastiff 2 
Cairn Terrier 4 
Cane Corso 5 
Cardigan Welsh Corgi 1 
Cavalier King Charles Spaniel 6 
Central Asian Shepherd Dog 1 
Cesky Terrier 1 
Chesapeake Bay Retriever 1 
Chihuahua 6 
Chinese Crested 3 
Chinese Indigenous Dog 28 
Chow Chow 2 
Cocker Spaniel 1 
Collie 1 
Corgi 1 
Curly Coated Retriever 5 
Dachshund 4 
Dalmatian 4 
Dandie Dinmont Terrier 5 
Doberman Pinscher 5 
Dogue de Bordeaux 6 
Dutch Shepherd 1 
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Appendix 11 (continued). 
Elo 1 
English Bull Dog 1 
English Cocker Spaniel 3 
English Mastiff 2 
English Setter 1 
English Springer Spaniel 3 
Entlebucher Sennenhund 8 
Eurasier 2 
Field Spaniel 1 
Finnish Lapphund 2 
Flat Coated Retriever 4 
French Bull Dog 7 
Friesian Stabyhoun 2 
German Shepherd 20 
German Wirehaired 1 
Giant Schnauzer 3 
Giant Spitz 1 
Glen of Imaal Terrier 1 
Golden Retriever 13 
Grand Basset Griffon Vendéen 1 
Great Dane 2 
Great Pyrenees 1 
Greater Swiss Mountain Dog 6 
Greyhound 7 
Griffon Bruxellois 1 
Havanese 3 
Heideterrier 1 
Hovawart 3 
Hungarian Vizsla 4 
Hungarian Wire-Haired Vizsla 1 
Irish Red and White Setter 4 
Irish Setter 2 
Irish Soft Coated Wheaten Terrier 1 
Irish Terrier 3 
Irish Water Spaniel 1 
Irish Wolfhound 8 
Italian Greyhound 1 
Italian Spinone 2 
Jack Russell Terrier 8 
Jagdterrier 2 
Japanese Akita 1 
Japanese Chin 1 
Karelian Bear Dog 1 
Keeshond 3 
Kerry Blue Terrier 2 
Kromfohrländer 1 
Kunming Dog 10 
Labrador Retriever 14 
Lagotto Romagnolo 10 
Lakeland Terrier 1 
Lancashire Heeler 2 
Landseer 2 
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Appendix 11 (continued). 
Large Münsterländer 1 
Leonberger 55 
Lhasa Apso 1 
Malinois 7 
Maltese 1 
Miniature Bull Terrier 2 
Miniature Long- Haired Dachshund 3 
Miniature Poodle 2 
Miniature Schnauzer 25 
Miniature Wire-Haired Dachshund 1 
Newfoundland 3 
Northern Inuit 2 
Norwegian Buhund 3 
Norwich Terrier 5 
Nova Scotia Duck Tolling Retriever 2 
Old English Sheepdog 2 
Otterhound 2 
Papillon 3 
Pembroke Welsh Corgi 3 
Petit Basset Griffon Vendéen 5 
Pomeranian 4 
Poodle 19 
Portuguese Podengo 1 
Portuguese Water Dog 3 
Pug 22 
Rhodesian Ridgeback 4 
Rottweiler 4 
Rough Collie 1 
Saluki 2 
Scottish Deerhound 3 
Scottish Terrier 6 
Shar Pei 2 
Shetland Sheepdog 505 
Shih Tzu 4 
Siberian Husky 5 
Skye Terrier 2 
Sloughi 3 
Smooth Collie 1 
Soft-Coated Wheaten Terrier 2 
Spanish Water Dog 1 
St. Bernard 2 
Staffordshire Bull Terrier 1 
Standard Poodle 2 
Standard Schnauzer 1 
Swedish Vallhund 3 
Tibetan Mastiff 10 
Tibetan Terrier 3 
Weimaraner 3 
Welsh Springer Spaniel 9 
West Highland White Terrier 20 
Whippet 3 
White Shepherd 1 
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Appendix 11 (continued). 
Yorkshire Terrier 69 
Cross Breed 15 
Wolf 8 
Total 1,386 
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